,PageNo,Text
0,page_1,"['2016N293064 0', 'CONFIDENTIAL', '2018N394263_00', 'GlaxoSmithKline group of companies', '205864', 'TITLE PAGE', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Protocol Number: 205864 Amendment 3', 'Short Title: Danirixin Pilot Study for Disease Progression', 'Compound Number: GSK1325756', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information will be provided in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s): IND:108168', 'Approval Date: 18-MAY-2018', 'Copyright 2018 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']"
1,page_2,"['2018N394263_00', '-', '2016N293064_03', 'CONFIDENTIAL', '205864', 'SPONSOR SIGNATORY', 'PPD', '18 May 2018', 'Aili Lazaar, MD', 'PPD', 'Date', 'Clinical Development Director', 'Respiratory Therapy Are Unit', 'PPD', '2']"
2,page_3,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 3', '18-May-2018', 'Amendment 2', '24-Jul-2017', 'Amendment 1', '17-May-2017', 'Original Protocol', '21-Mar-2017', 'Amendment 1: 17-MAY-2017', 'Overall Rationale for the Amendment: This amendment excludes the enrolment of', 'women of childbearing potential and clarifies the testing required for determination of', 'post menopausal status in specific situations.', 'Section #', 'Description of Change', 'Brief Rationale', 'and Name', 'Table 1 -', 'Remove pregnancy testing', 'Not required as no longer enrolling', 'Schedule of', 'WOCBP', 'Activities', 'Added missing check', 'marks', 'Error in original protocol', 'Updated screening period', 'Required to allow for screening lab', 'tests', 'Section 6.1', 'Update to only allow females to', 'To remove additional burden on female', 'Inclusion', 'participate if they are not women of', 'subjects of childbearing potential requiring', 'Criteria', 'childbearing potential (WOCBP)', 'additional visits for pregnancy testing only.', 'Section 12.2', 'Update Table 6 - Protocol-', 'Removed pregnancy testing based on the', '- Appendix 2', 'Required Safety Laboratory', 'exclusion of WOCBP', 'Clinical', 'Assessments to remove pregnancy', 'Laboratory', 'testing', 'Tests', 'Section 12.5', 'Adding clarification on', 'Current wording in template is not', '- Appendix 5', 'determination of post', 'clear on testing required', 'Contraceptive', 'menopausal state in the', 'absence of 12 months of', 'Clarification of wording', 'Guidance and', 'Collection of', 'amenorrhea', 'Pregnancy', 'Updated wording to be in', 'Information', 'line with exclusion of', 'WOCBP', '3']"
3,page_4,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amendment 2: 24-JUL-2017', 'Overall Rationale for the Amendment:', 'Section #', 'Description of Change', 'Brief Rationale', 'and Name', 'Section 3.3.1', 'Removal of the following text from', 'Additional data available demonstrating', 'Risk', 'the mitigation strategy of the', 'absence of genotoxic effects', 'Assessment', 'reproductive toxicology section:', '""Male participants with female', 'partners of child-bearing', 'potential must comply with the', 'contraception requirements.""', 'Section 7.1.1', 'Update to add mobile spirometer', 'This device is being used in the study and', 'and Section', '(MicroDiary) as a medical device', 'was inadvertently omitted from the', '9.2.8', 'previous versions of the protocol', 'Medical', 'Devices and', 'Medical', 'Device', 'Incidents', 'Section 6.1', 'Removal of requirement for male', 'Additional data available demonstrating', 'and Section', 'contraception with partners of', 'absence of genotoxic effects', '12.5', 'WOCBP', '(Appendix 5)', 'Inclusion', 'Criteria and', 'Contraceptive', 'Guidance and', 'Collection of', 'Pregnancy', 'Information', '4']"
4,page_5,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amendment 3: 18-MAY-2018', 'Overall Rationale for the Amendment:', 'Section #', 'Description of Change', 'Brief Rationale', 'and Name', 'Section 2', 'Updated Smoking history to', 'Correcting error from original version', 'Schedule of', 'reflect that it is captured only', 'and discussion with investigators', 'Activities', 'at V1 and smoking status is', 'captured at both V1 and V2;', 'also updated Screening visit', 'window to up to 32 days', 'Section 4', 'Updated to match the obectives', 'Correcting error from original version', 'Objectives', 'and endpoints in the synopsis', 'and', 'Endpoints', 'Section 5.1', 'Updated screening period from', 'Based on discussion with', 'up to 28 days to up to 32 days', 'investigators', 'Section 6', 'Updated to reflect that cohorts', 'Based on discussion with', 'Study', 'in addition to COPDGene may', 'investigators', 'Population', 'be used to support recruitment.', 'Removed the use of the', 'Random Forest data in patient', 'selection and changed history', 'of lung function decline from', '20mL/yr to 15 mL/yr.', 'Changed inclusion criteria', 'from weight >45kg to body', 'mass index > 21.', 'Appendix 5', 'Removed pregnancy testing', 'Overisight from previous amendment', 'requirements', 'when WOCBP were excluded. No', 'pregnancy testing needed with this', 'exclusion criteria.', '5']"
5,page_6,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '3', '1. SYNOPSIS', '9', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '11', '3. INTRODUCTION', '14', '3.1.', 'Study Rationale', '15', '3.2.', 'Background', '15', '3.3.', 'Benefit/Risk Assessment', '16', '3.3.1.', 'Risk Assessment', '17', '3.3.2.', 'Benefit Assessment', '21', '3.3.3.', 'Overall Benefit:Risk Conclusion', '21', '4.', 'OBJECTIVES AND ENDPOINTS', '22', '5.', 'STUDY DESIGN', '23', '5.1.', 'Overall Design', '23', '5.2.', 'Number of Participants', '23', '5.3.', 'Participant and Study Completion', '23', '5.4.', 'Scientific Rationale for Study Design', '24', '5.5.', 'Dose Justification', '24', '6.', 'STUDY POPULATION', '25', '6.1.', 'Inclusion Criteria', '25', '6.2.', 'Exclusion Criteria', '26', '6.3.', 'Lifestyle Restrictions', '28', '6.3.1.', 'Meals and Dietary Restrictions', '28', '6.3.2.', 'Activity', '28', '6.4.', 'Screen Failures', '28', '7. TREATMENTS', '29', '7.1.', 'Treatments Administered', '29', '7.1.1.', 'Medical Devices', '29', '7.2.', 'Dose Modification', '30', '7.3.', 'Method of Treatment Assignment', '30', '7.4.', 'Blinding', '30', '7.5.', 'Preparation/Handling/Storage/Accountability', '31', '7.6.', 'Treatment Compliance', '31', '7.7.', 'Concomitant Therapy', '32', '7.8.', 'Treatment after the End of the Study', '33', '8.', 'DISCONTINUATION CRITERIA', '33', '8.1.', 'Discontinuation of Study Treatment', '33', '8.1.1.', 'Liver Chemistry Stopping Criteria', '33', '8.1.2.', 'QTc Stopping Criteria', '34', '8.1.3.', 'Neutrophil Stopping Criteria', '35', '8.1.4.', 'Temporary Discontinuation', '35', '8.1.5.', 'Study Treatment Restart', '35', '6']"
6,page_7,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '8.2.', 'Withdrawal from the Study', '35', '8.3.', 'Lost to Follow Up', '36', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', '37', '9.1.', 'Efficacy Assessments', '37', '9.1.1.', 'FEV1', '37', '9.1.1.1.', 'Clinic Spirometry', '37', '9.1.1.2.', 'Mobile Spirometry', '37', '9.1.2.', 'SGRQ-C', '37', '9.1.3.', 'CAT', '38', '9.1.4.', 'COPD Exacerbations', '38', '9.1.5.', 'Patient Global Rating of Severity and Global Rating of', 'Change in Disease Severity', '38', '9.2.', 'Adverse Events', '39', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '39', '9.2.2.', 'Method of Detecting AEs and SAEs', '39', '9.2.3.', 'Follow-up of AEs and SAEs', '39', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '40', '9.2.5.', 'Cardiovascular and Death Events', '40', '9.2.6.', 'Disease-Related Events and/or Disease-Related', 'Outcomes Not Qualifying as SAEs', '40', '9.2.7.', 'Pregnancy', '41', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', '41', '9.2.8.1.', 'Time Period for Detecting Medical Device', 'Incidents', '41', '9.2.8.2.', 'Follow-up of Medical Device Incidents', '42', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents', 'to Sponsor', '42', '9.2.8.4.', 'Regulatory Reporting Requirements for', 'Medical Device Incidents', '42', '9.3.', 'Treatment of Overdose', '43', '9.4.', 'Safety Assessments', '43', '9.4.1.', 'Physical Examinations', '43', '9.4.2.', 'Vital Signs', '43', '9.4.3.', 'Electrocardiograms', '44', '9.4.4.', 'Clinical Safety Laboratory Assessments', '44', '9.4.5.', 'Pneumonia', '44', '9.5.', 'Pharmacokinetics', '45', '9.6.', 'Pharmacodynamics', '45', '9.7.', 'Genetics', '45', '9.8.', 'Biomarkers', '45', '9.9.', 'Health Economics OR Medical Resource Utilization and Health', 'Economics', '46', '10. STATISTICAL CONSIDERATIONS', '46', '10.1.', 'Sample Size Determination', '46', '10.2. Randomization', '49', '10.3.', 'Populations for Analyses', '49', '10.4.', 'Statistical Analyses', '49', '10.4.1.', 'Efficacy Analyses', '49', '10.4.2.', 'Safety Analyses', '51', '7']"
7,page_8,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.4.3.', 'Other Analyses', '51', '10.4.4.', 'Interim Analyses', '51', '11. REFERENCES', '52', '12. APPENDICES', '55', '12.1. Appendix 1: Abbreviations and Trademarks', '55', '12.2.', 'Appendix 2: Clinical Laboratory Tests', '59', '12.3.', 'Appendix 3: Study Governance Considerations', '61', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '65', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', '71', '12.6.', 'Appendix 6: Genetics', '74', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', '75', '12.8.', 'Appendix 8: Medical Device Incidents: Definition and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '78', '12.9. Appendix 9: Neutrophil Safety and Study Treatment Restart', '80', '12.10. Appendix 10: Country-specific requirements', '82', '12.11. Appendix 11 Protocol Amendment History', '83', '8']"
8,page_9,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '1.', 'SYNOPSIS', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Short Title: Danirixin Pilot Study for Disease Progression in COPD', 'Rationale: This is a pilot study to investigate the effect of danirixin hydrobromide (HBr)', '35mg tablets on lung function and health related quality of life (HRQoL) in participants', 'with mild to moderate airflow obstruction and a demonstrated history of decline in FEV1.', 'This study aims to assess whether danirixin has the potential to impact disease', 'progression in participants with COPD and with a demonstrated history of disease', 'progression measured by lung function.', 'Objectives and Endpoints:', 'Objective', 'Endpoint', 'Primary', 'Rate of decline in FEV1', 'To assess whether danirixin HBr 35mg', 'tablets impact disease progression', ""Change from baseline in St. George's"", 'compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'Secondary', 'To further characterize the safety of', 'Adverse events', 'danirixin HBr 35mg tablets compared', 'Vital Signs', 'with placebo in participants with mild', 'ECG', 'to moderate airflow limitation', 'Clinical Laboratory Assessments', '(hematology, clinical chemistry,', 'urinalysis)', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared with placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', '9']"
9,page_10,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Overall Design:', 'This is a Phase 2 study to investigate the potential impact of danirixin HBr 35mg tablets', 'compared with placebo on disease progression in participants with mild to moderate', 'airflow obstruction. The study will also assess the enrichment strategy of enrolling', 'participants identified from the COPDGene study. These participants have been', 'identified by COPDGene investigators based on data collected over the initial 5 year', 'period. The participants were identified based on a Random Forest analysis and a', 'demonstrated decline of at least 20mL/yr over the initial 5 year period.', 'Number of Participants:', 'Approximately 130 participants will be screened to enrol 100 participants in this study. It', 'is anticipated that approximately 85 participants will complete the 52 weeks of treatment', '(assuming a 15% drop out rate).', 'Treatment Groups and Duration:', 'Participants will receive either placebo or danirixin 35mg tablets (as hydrobromide', 'hemihydrate salt) twice daily for 52 weeks (12months).', '10']"
10,page_11,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', 'Table 1', 'Schedule of activities', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'days', 'Visit1a', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-32 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Eligibility', 'Informed Consent', 'X', 'Genetics Informed Consentb', 'X', 'Demography', 'X', 'Inclusion and Exclusion Criteria', 'X', 'Smoking Statusc', 'X', 'Smoking Historyc', 'X', 'Medical Historyd', 'X', 'Full physical', 'Chest X-ray (historical within 1 year', 'acceptable)', 'HIV, Hepatitis B and C screeninge', 'Additional Eligibility and In Study Assessments', 'Verify Eligibility', 'X', 'Brief physical', 'X', 'Laboratory assessments (clinical chemistry,', 'including liver chemistries), hematology,', 'X', 'X', 'X', 'urinalysis', 'Additional Liver chemistries only', 'X', 'X', 'X', 'X', '12 lead ECG', 'X', 'X', 'X', 'Vital Signs', 'X', 'X', '11']"
11,page_12,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'Visit1a', 'days', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-32 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Office spirometry (centralized)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Home spirometry - (weekly)', 'X', 'Randomization', 'Dispense study medication', 'Dispense log pad and provide training', 'X', 'Dispense MDI sensors and provide training', 'Study Treatment', 'Study Treatment Compliance (ediary)', 'Collect IP', 'Collect MDI sensors', 'X', 'Collect log pad', 'AE review', 'SAE review', 'Concomitant medication review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Clinical Outcomes Assessments', 'COPD exacerbation review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Rescue medication Use', 'SGRQ-C', 'X', 'X', 'COPD Assessment Test (CAT)', 'Participant Global Impression of COPD', 'severity', 'Participant Impression of change in COPD', 'severity', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '12']"
12,page_13,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'Visit1a', 'days', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-32 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Genetic, Pharmacokinetic and Biomarker Blood Collections', 'Blood sample for Genetics', 'Blood sample for CRP', 'Blood sample for exploratory biomarkers', 'a', 'Informed consent may be signed prior to screening visit in the case that any changes in medications are necessary', 'b', 'Agreeing to genetic sample consent is not required for study participation', 'C', 'Smoking status/history assessed at screening; smoking status re-checked at Visit 2', 'd', 'Includes substance usage, past and present medical conditions and family history of premature CV disease', 'e', 'Hepatitis B (HBsAg) and Hepatitis C (HepC antibody) testing is required. If testing otherwise performed within 3 months prior to the first dose of study treatment, testing at', 'screening is not required. Hepatitis C RNA testing is optional; however a confirmatory negative Hepatitis C RNA test must be obtained, to be able to enrol participants with', 'positive Hepatitis C antibody due to prior resolved disease.', 'f', ""Participant's clinical status should be reviewed"", 'The timing and number of planned study assessments, including safety and biomarker assessments may be altered during the course of the study based on newly available data to', 'ensure appropriate data collection. Any changes in the timing or addition of time points for any planned study assess must be documented and approved by the relevant study team', 'member and then archived in the sponsor and site study files, but will not constitute a protocol amendment. The IRB/IEC will be informed of any safety issues that require alteration of', 'the safety monitoring scheme or amendment of the ICF.', '13']"
13,page_14,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.', 'INTRODUCTION', 'The inflammation associated with COPD is characterized by a prominent infiltration of', 'neutrophils in lung tissue and the airways. Neutrophils and other inflammatory cells are', 'recruited to the lung in response to various chemotactic factors, including chemokines.', 'Specifically, there is a large body of evidence that the CXCR2 chemokine receptor plays', 'a pivotal role in neutrophil recruitment to the lung. For neutrophils, chemokine binding', 'to the CXCR2 results in chemotaxis and cell activation, ultimately resulting in the release', 'of a number of inflammatory mediators and proteases that are thought to contribute to the', 'progressive fibrosis, airway stenosis, and destruction of the lung parenchyma', 'characteristic of COPD.', 'Selective antagonism of the interaction between CXCR2 and its ligands is a potential', 'strategy for reducing the inflammation in COPD [Chapman, 2009]. A reduction in tissue', 'and airway neutrophilia is expected to result in downstream effects on mucus', 'hypersecretion, lung inflammation, and tissue destruction that are hypothesized to', 'underlie the development and worsening of respiratory symptoms and decline in lung', 'function that occurs in COPD.', 'Molecules with CXCR2 antagonist activity have been shown to reduce the influx of', 'neutrophils into the lungs in healthy participants (e.g. ozone or LPS challenge models)', 'and to reduce sputum and tissue neutrophils in the lungs of patients with severe,', 'neutrophilic asthma, COPD and bronchiectasis in association with improvements in', ""measures of disease activity in some, but not all, studies O'Byrne, 2016; Holz, 2010;"", 'Watz, 2016; Lazaar, 2011; Nair, 2012; Rennard, 2015]. Overall, the results of the', 'reported clinical studies with CXCR2 antagonists suggest that careful selection of the', 'target patient population is important to achieving clinical benefit.', 'Danirixin is a selective CXCR2 antagonist being developed as a potential anti-', 'inflammatory agent for the treatment of COPD and other inflammatory diseases and', 'influenza. Danirixin has demonstrated potent antagonism of CXCR2 activity both in', 'vitro and in vivo in preclinical studies GlaxoSmithKline Document Number', 'YM2010/00163/07]', 'Clinical pharmacology studies in healthy volunteers demonstrated the pharmacodynamic', 'activity of danirixin (inhibition of ex vivo CXCL1-induced CD11b expression on', 'peripheral blood neutrophils). Danirixin has also been tested in a Phase IIa study in', 'symptomatic participants with mild to moderate COPD at risk for exacerbation', '[GlaxoSmithKline Document Number 2013N180289 03 Study ID 200163]. In study', '200163, twice daily dosing with danirixin free base (75 mg bid) or placebo given on top', 'of standard of care inhaled maintenance treatments was tested for one year. Analyses of', 'clinical endpoints from study 200163 demonstrated that danirixin, compared to placebo,', 'reduced respiratory symptoms as measured with E-RS:COPD [Miller, 2016].', '14']"
14,page_15,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.1.', 'Study Rationale', 'This protocol describes a pilot study to investigate the effect of danirixin HBr 35mg', 'tablets on lung function and health related quality of life (HRQoL) in participants with', 'mild to moderate airflow obstruction identified from the COPDGene cohort. Study', 'participants will continue with their standard of care inhaled medications (i.e. long acting', 'bronchodilators with or without inhaled corticosteroids) while receiving study treatment.', 'Specifically, this study aims to assess whether or not danirixin has the potential to impact', 'disease progression in participants with a demonstrated history of decline in FEV1 based', 'on 5 year data from COPDGene and support the conduct of a larger Phase III study for', 'disease progression. In addition to lung function and HRQoL, this study will assess', 'moderate/severe COPD exacerbations, health status (CAT), and rescue medication use.', '3.2.', 'Background', 'COPD is a major cause of disability, morbidity, and mortality, resulting in millions of', 'deaths annually worldwide contributing significantly to health care costs [Mathers, 2006;', 'Lopez-Campos, 2016; Vastava, 2015; GOLD, 2016]. The morbidity and mortality of', 'COPD are continuing to increase and worldwide and, by the year 2020, COPD is', 'expected to be the third leading cause of death and fifth leading cause of disability', '[Mathers, 2006; Lopez-Campos, 2016]. The airflow limitation that characterizes COPD', 'is primarily due to small airways disease and parenchymal destruction associated with an', 'excessive inflammatory response in the lung, mainly caused by cigarette smoking [Celli,', '2004]. COPD is characterized by symptoms of chronic and, in many patients,', 'progressive breathlessness (or dyspnea), cough and sputum production. Many COPD', 'patients also suffer from periodic worsening of their COPD symptoms that is beyond the', 'typical day to day variation [Hurst, 2010]. These episodes of worsening symptoms', '(COPD exacerbations) account for a significant proportion of COPD-related and total', 'health care costs. Despite several available therapies that have been shown to reduce', 'COPD exacerbations and respiratory symptoms, many COPD patients continue to', 'experience a high burden of respiratory symptoms and COPD exacerbations resulting in a', 'continuing unmet medical need [Vestbo, 2016]. Additionally, there is growing', 'recognition that a high percentage of COPD patients with mild airflow limitation as well', 'as smokers with preserved lung function suffer from a high burden of symptoms and', 'COPD exacerbations with a subsequent impact on health status [Woodruff, 2016].', 'Therapies that effectively further reduce COPD exacerbations and improve respiratory', 'symptoms could have a substantial impact on healthcare utilization and most importantly', ""result in an improvement in COPD patients' quality of life."", 'The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the', 'treatment and management of patients with COPD recommend that the management of', 'current respiratory symptoms and subsequent worsening of symptoms resulting in COPD', 'exacerbations should be an important component of COPD patient management [GOLD,', '2016].', 'Danirixin is being evaluated as an addition to standard of care inhaled therapies (i.e. long', 'acting bronchodilators and long acting bronchodilator/corticosteroid combination', '15']"
15,page_16,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'therapies) and is targeting those COPD patients that continue to have a burden of', 'respiratory symptoms and COPD exacerbations despite management with currently', 'available COPD treatments.', '3.3.', 'Benefit/Risk Assessment', 'More detailed information about the potential benefits and risks of danirixin may be', ""found in the danirixin Investigator's Brochure [GlaxoSmithKline Document Number"", 'YM2010/00163/07].', '16']"
16,page_17,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.1.', 'Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', 'No adverse events related to testicular', 'effects have been observed in clinical', 'studies to date.', '17']"
17,page_18,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count < 0.5 X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', 'study in patients with Influenza (GSK Study', '18']"
18,page_19,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', '201682, GlaxoSmithKline Document No.', '2014N205875_00) decreased neutrophil', 'counts have been observed in participants', 'receiving either placebo or danirixin; no', 'instances of danirixin-related neutropenia', 'have been reported in clinical studies to', 'date. In healthy participants, the data are', 'confounded by the observation of low', 'neutrophil counts before dosing or at', 'follow-up, and were not dose-related, while', 'in patients with influenza, neutrophil counts', 'recovered while receiving danirixin,', 'coincident with resolution of the viral', 'infection. There have been no reports of', 'neutrophil count decreases below the lower', 'limit of normal in patients with COPD who', 'were treated with danirixin for one year.', 'These data support the conclusion that a', 'causal association of neutropenia with', 'danirixin cannot be definitively established.', '19']"
19,page_20,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Study Procedures', 'None', 'Other', 'Not applicable', '20']"
20,page_21,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.2.', 'Benefit Assessment', 'All participants will undergo a thorough medical assessment during the study.', 'Participants will have frequent study clinic visits for the evaluation of their', 'disease symptoms. During these visits, participants will have spirometry, ECG,', 'vital signs monitoring, and physical examinations. Monitoring for worsening of', 'their disease will also take place.', 'Participants may benefit from the knowledge that they are contributing to the', 'process of developing a new treatment in an area of unmet need, even if not', 'directly beneficial for them', 'All participants will continue with changes to their medications, where medically', 'appropriate, to receive established standard of care.', '3.3.3.', 'Overall Benefit:I Risk Conclusion', 'Danirixin has demonstrated potent antagonism of CXCR2 activity both in vitro and in', 'vivo in preclinical and clinical studies. Its potency and duration of action supports its', 'potential use as an oral, anti-inflammatory agent in the treatment of COPD with', 'anticipated potential for bringing benefit to a serious condition that affects the lives of', 'millions and contributes to significant morbidity and mortality.', 'In clinical trials completed to date danirixin has been well-tolerated and most adverse', 'events (AEs) were mild to moderate in intensity. The most commonly observed AEs', 'have been nasopharyngitis, headache and diarrhea following administration of danirixin', 'or placebo. There have been no treatment related clinically significant changes in vital', 'signs or ECG at any dose of danirixin.', 'Taking into account the measures taken to minimize risks to participants in this study, the', 'potential risks identified in association with danirixin are justified by the anticipated', 'benefits that may be afforded to participants with COPD.', '21']"
21,page_22,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '4.', 'OBJECTIVES AND ENDPOINTS', 'Objectives', 'Endpoints', 'Primary', 'To assess whether danirixin HBr', 'Rate of decline in FEV1', '35mg tablets impacts disease', ""Change from baseline in St. George's"", 'progression compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'Secondary', 'To further characterize the safety of', 'Adverse events (AE), clinical', 'danirixin HBr 35mg tablets compared', 'laboratory values, vital signs,', 'with placebo in participants with mild', 'electrocardiogram (ECG), and/or other', 'to moderate airflow limitation', 'safety biomarkers', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared to placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Exploratory', 'To characterize the effect of', 'Blood/serum/plasma biomarkers that', 'danirixin on lung matrix', 'are indicative of extracellular matrix', 'destruction/remodelling and', 'turnover/remodelling (e.g. elastin and', 'inflammation', 'collagen neo-epitopes) and', 'inflammation (e.g. CRP)', 'Further characterize efficacy of', 'danirixin', 'Global assessment of COPD severity', '22']"
22,page_23,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.', 'STUDY DESIGN', '5.1.', 'Overall Design', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days - -32', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', 'Up to', '52 weeks', '32 days', 'Placebo (n=50)', 'R', '1', 'Screening', 'Follow-up 2', 'Danirixin, 35mg', '(n=50)', '1', 'If changes to medication are required, consent must be signed prior to any', 'changes being made and may occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', '5.2.', 'Number of Participants', 'Approximately 130 participants will be screened to achieve 100 randomized in this study.', 'It', 'is anticipated that approximately 85 participants will complete the 12 months of', 'treatment (assuming a 15% drop out rate).', 'For the analysis of study assessments, several analysis populations are defined in Section', '10.3.', '5.3.', 'Participant and Study Completion', 'A participant is considered to have completed the study if he/she has completed all', 'planned study visits including the last study visit and the last scheduled procedure shown', 'in the Schedule of Activities (Table 1).', 'The end of the study is defined as the date of the last visit of the last participant in the', 'study.', '23']"
23,page_24,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.4.', 'Scientific Rationale for Study Design', 'This study will use a multicenter, randomized, parallel-group design. This is a well', 'established design to evaluate the efficacy and safety of an investigational drug. With the', 'use of an enriched population, it is anticipated that one year of treatment will be sufficient', 'to detect a trend in altering disease progression. Danirixin has already been clinically', 'investigated over one year treatment duration (GlaxoSmithKline Document Number', '2013N180289_03 Study ID 200163).', 'The data from this study will provide useful information in determining whether or not to', 'progress to a Phase III study to explore an indication for slowing disease progression.', '5.5.', 'Dose Justification', 'One dose of danirixin is proposed for this study, 35mg tablets BID. This dose was', 'selected based on integrating information on:', 'Dose-exposure-biomarker response using inhibition of ex vivo CXCL1-induced', 'CD11b expression on peripheral blood neutrophils over the dose range of 0-400mg', '(free base tablet) in healthy volunteers (GSK Study No. CX3 112483).', 'Evidence of reduced respiratory symptoms and improvement in health status in mild', 'to moderate COPD participants from interim data in the Phase IIa study (GSK Study', 'No. 200163).', 'Relative bioavailability study comparing danirixin free base VS HBr (GSK Study No.', '201037).', 'In the previous clinical studies, danirixin was administered as a free base tablet, whereas', 'the danirixin formulation to be used in this study will be a hydrobromide salt tablet.', 'The hydrobromide tablet has approximately twice the bioavailability of the free base', 'tablet in healthy elderly participants (GlaxoSmithKline Document Number', '2015N248339 00, Study ID 201037). Thus the danirixin (hydrobromide tablet) 35mg', 'BID dose for investigation in this study is expected to provide steady-state systemic', 'exposure approximately equivalent to the 75mg BID (free base tablet) used in Study', '200163. Predicted steady-state exposures and multiples of blood ex vivo CXCL1-induced', 'CD11b pharmacology at the proposed danirixin doses are presented in Table 2.', 'Table 2', 'Predicted steady state systemic exposure and multiples of blood ex', 'vivo CXCL1-induced pharmacology following twice daily of', 'administration of danirixin', 'Dose', 'Predicted# steady-state median (5th, 95th', 'Cavg', 'Cmin', '(mg)', 'percentile)', 'multiple of', 'multiple of', 'AUC(0-24)', 'Cavg', 'Cmin', 'IC50*', 'IC50*', 'steady-state', '(ng/mL)', '(ng/mL)', '(ug.h/mL)', '35', '9.59', '399', '192', '5.1', '2.4', '(4.70, 19.3)', '(196, 806)', '(47.6,630)', '24']"
24,page_25,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '#Model derived based on PK data in healthy elderly participants from GSK Study No. 201037', '(GlaxoSmithKline Document Number. 2015N248339_00).', '*Model predicted population mean IC50=78.5 ng/mL (95% CI: 37.3, 120), sigmoidal Emax model of DNX', 'PK-ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils in healthy participants.', '6.', 'STUDY POPULATION', 'This study will identify specific COPD patients most likely to decline from well', 'established cohorts like COPDGene [NCT00608764]. This study will be an ancillary', 'study within COPDGene and any other relevant cohort investigating the enrichment', 'strategy for assessing disease progression. These potential participants will be identified', 'by COPDGene investigators based on data collected over the initial 5 year period. The', 'participants were identified based on a demonstrated decline of at least 15mL/yr over the', 'initial 5 year period. Once participants are identified from the COPDGene dataset, the', 'following criteria will be verified at initial study visit following signing of consent.', 'Equivalent cirteria may be identified within other cohorts if necessary to broaden', 'recruitment pool.', 'Prospective approval of protocol deviations to recruitment and enrolment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '6.1.', 'Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria', 'apply:', 'Age', '1. Participant must be 40 to 76 years of age inclusive, at the time of signing the', 'informed consent.', 'Type of Participant and Disease Characteristics', '2.', 'At the screening visit, the subject must have an FEV1 >40% of the predicted', 'normal.', '3.', 'Participants with a prior history of asthma are eligible if they have a current', 'diagnosis of COPD', 'Weight', '4.', 'Body Mass Index > 21', '5.', 'Sex', 'Male or female', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', '25']"
25,page_26,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Informed Consent', '6. Capable of giving signed informed consent as described in Section 12.3 (Appendix 3)', 'which includes compliance with the requirements and restrictions listed in the', 'informed consent form (ICF) and in this protocol.', '6.2.', 'Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', 'Medical Conditions', '1. Diagnosis of other clinically relevant lung disease (other than COPD), e.g.', 'sarcoidosis, tuberculosis, pulmonary fibrosis, severe bronchiectasis or lung cancer', '2. COPD due to alpha-l-antitrypsin deficiency', '3. Pulse oximetry < 88% at rest at screening. Participants should be tested while', 'breathing room air. However, participants living at high altitudes (above 5000 ft or', '1500 m above sea level) who are receiving supplemental oxygen can be included', 'provided they are receiving the equivalent of < 4L/min and screening oximetry is', 'measured while on their usual settings.', '4. Less than 14 days have elapsed from completion of a course of antibiotics or oral', 'corticosteroids for a recent COPD exacerbation', '5. Participants with a peripheral blood neutrophil count < 1 X 109/L', '6. Diagnosis of pneumonia (chest X-ray or CT confirmed) within the 3 months prior to', 'screening', '7. Chest X-ray (posterior with lateral) or CT scan reveals evidence of a clinically', 'significant abnormality not believed to be due to the presence of COPD (historic data', 'up to 1 year may be used).', '8. History or current evidence of clinically significant renal disease, diabetes', 'mellitus/metabolic syndrome, hypertension, or any other clinically significant', 'cardiovascular, neurological, immunological, endocrine, or haematological', 'abnormality that is uncontrolled on permitted therapies. Significant is defined as any', 'disease that, in the opinion of the Investigator, would put the safety of the participants', 'at risk through study participation, or which would affect the safety analysis or other', 'analysis if the disease/condition exacerbated during the study.', '9. History of sensitivity to any of the study medications, or components thereof or a', 'history of drug or other allergy that, in the opinion of the investigator of GSK medical', 'monitor, contraindicates their participation.', '10. Current or chronic history of liver disease, or known hepatic or biliary abnormalities', ""(with the exception of Gilbert's syndrome or asymptomatic gallstones)."", '11. Abnormal and clinically significant 12-lead ECG finding. The investigator will', 'determine the clinical significance of each abnormal ECG finding in relation to the', ""subject's medical history and exclude participants who would be at undue risk by"", 'participating in the trial. An abnormal and clinically significant finding that would', '26']"
26,page_27,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'preclude a subject from entering the trial is defined as a 12-lead tracing that is', 'interpreted as, but not limited to, any of the following:', '- AF with rapid ventricular rate > 120 bpm;', '- sustained or non-sustained VT', '- second degree heat block Mobitz type II and third degree heart block (unless', 'pacemaker or defibrillator has been implanted)', '- QTcF > 500 msec in patients with QRS < 120 msec and QTcF > 530 msec in', 'patients with QRS > 120 msec', '12. Previous lung surgery (e.g. lobectomy, pneumonectomy) or lung volume reduction', 'procedure.', 'Prior/Concomitant Therapy', '13. Current or expected chronic use of macrolide antibiotics during the study period for', 'the prevention of COPD exacerbations. Examples of chronic use include, but are not', 'limited to, daily or two to three times per week use for at least 3 months.', '14. Oral or injectable CYP3A4 or BRCP (breast cancer resistance protein) substrates with', 'a narrow therapeutic index (CYP3A4 substrates include, but are not limited to,', 'alfenatil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,', 'quinidine, sirolimus, tacrolimus, and theophylline; BCRP substrates include, but are', 'not limited to, topotecan.) The Investigator should consult with the Medical Monitor', 'if necessary.', '15. Current or expected use of phosphodiesterase-4 inhibitors (e.g. roflumilast).', 'Participants currently receiving roflumilast may be included if they are able to', 'discontinue use from 30 days prior to screening through the completion of the follow', 'up visit.', 'Prior/Concurrent Clinical Study Experience', '16. Participation in a previous clinical trial and has received an investigational product', 'within any of the following time periods prior to the first dosing day in the current', 'study: 30 days, 5 half lives, or twice the duration of the biological effect of the', 'investigational product (whichever is longer).', '17. Participation in a previous clinical trial with danirixin within 1 year prior to the first', 'dosing day in the current study', '18. Exposure to more than four investigational products within 1 year prior to the first', 'dosing day in the current study.', 'Diagnostic assessments', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN) and bilirubin', '>', '1.5xULN (isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and', 'direct bilirubin <35%).', '20. A positive test for HIV antibody.', '27']"
27,page_28,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening. Note:', '22. Participants with positive Hepatitis C antibody due to prior resolved disease can be', 'enrolled, only if a confirmatory negative Hepatitis C RNA PCR test is obtained.', 'Other Exclusions', '23. Pulmonary rehabilitation: Participants who have taken part in the acute phase of a', 'pulmonary rehabilitation program within 4 weeks prior to screening or participants', 'who plan to enter the acute phase of a pulmonary rehabilitation program during the', 'study. Participants who are in the maintenance phase of a pulmonary rehabilitation', 'program are not excluded.', '24. A history of allergy or hypersensitivity to any of the ingredients in the study', 'treatment.', '25. A known or suspected history of alcohol or drug abuse within the 2 years prior to', 'screening.', '26. Inability to read: in the opinion of the Investigator, any participant who is unable to', 'read and/or would not be able to complete study related materials.', '27. Affiliation with the study site: study investigators, sub-investigators, study', 'coordinators, employees of a study investigator, sub-investigator or study site, or', 'immediate family member of any of the above that are involved with the study.', '6.3.', 'Lifestyle Restrictions', '6.3.1.', 'Meals and Dietary Restrictions', 'No meal or dietary restrictions are required for participation in this study. Danirixin must', 'be taken with food. Specific dosing instructions will be provided in the Study Reference', 'Manual (SRM) and will be provided to all study participants.', '6.3.2.', 'Activity', 'Participants should abstain from strenuous exercise for 24 hours before each blood', 'collection for clinical laboratory tests.', '6.4.', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study', 'but are not subsequently randomized in the study. A minimal set of screen failure', 'information is required to ensure transparent reporting of screen failure participants to', 'meet the Consolidated Standards of Reporting Trials (CONSORT) publishing', 'requirements and to respond to queries from regulatory authorities. Minimal information', 'includes demography, screen failure details, eligibility criteria and any serious adverse', 'events (SAEs).', 'Individuals who do not meet the criteria for participation in this study (screen failure)', 'may not be rescreened unless discussed with the medical monitor.', '28']"
28,page_29,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment(s), marketed product(s)', 'placebo, or medical device(s) intended to be administered to a study participant according', 'to the study protocol.', '7.1.', 'Treatments Administered', 'Study Treatment Name:', 'Danirixin', 'Placebo', '(GSK1325756H, the', 'hydrobromide', 'hemihydrate salt)', 'Dosage formulation:', 'White Film coated', 'White Film coated', 'tablets (oval shaped).', 'tablets (oval shaped).', 'Refer to', ""Refer to Investigator's"", 'Brochure for', ""Investigator's"", 'Brochure for', 'presentation and', 'presentation and', 'excipients', 'excipients', 'Unit dose strength(s)/Dosage level(s):', '35mg tablets (of free', 'N/A', 'base equivalent)', 'Route of Administration', 'Oral', 'Oral', 'Dosing instructions:', 'One tablet to be', 'One tablet to be taken', 'taken twice daily', 'twice daily with food', 'with food', 'Packaging and Labeling', 'Study Treatment will', 'Study Treatment will', 'be provided in a', 'be provided in a HDPE', 'HDPE bottle with', 'bottle with desiccant.', 'desiccant. Each', 'Each bottle will be', 'bottle will be labeled', 'labeled as required per', 'as required per', 'country requirement.', 'country requirement.', 'Manufacturer', 'GSK', 'GSK', '7.1.1.', 'Medical Devices', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', '29']"
29,page_30,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Mobile spirometers (MicroDiary, manufactured by and purchased from CareFusion) are', 'also being provided by GSK for this study. These devices allow participants to conduct', 'spirometry assessments at home. The MicroDiary has US FDA 510(k) clearance to', 'market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices and', 'mobile spirometers are provided in the SRM.', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '7.2.', 'Dose Modification', 'No individual participant dose modifications or adjustments are allowed.', '7.3.', 'Method of Treatment Assignment', 'This study will use an Interactive Web Response System (IWRS). All', 'participants will be centrally randomized using the IWRS. Before the study is', 'initiated, the log in information and directions for the IWRS will be provided to', 'each site.', 'Participant randomization will be stratified by smoking status (i.e. current', 'smoker or former smoker).', 'Study treatment will be dispensed to participants at the study visits summarized', 'in the SOA.', 'Returned study treatment should not be re-dispensed to any participant.', '7.4.', 'Blinding', 'This will be a double-blind study. Study participants, all study site staff, and all members', 'of the GSK study team will be blinded to individual participant treatment assignment.', ""A participant will be withdrawn if the participant's treatment code is unblinded by the"", 'investigator or treating physician. The primary reason for discontinuation (the event or', 'condition which led to the unblinding) will be recorded in the CRF.', ""GSK's Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the"", 'treatment assignment for any participant with an SAE. If the SAE requires that an', 'expedited regulatory report be sent to one or more regulatory agencies, a copy of the', ""report, identifying the participant's treatment assignment, may be sent to investigators in"", 'accordance with local regulations and/or GSK policy.', '30']"
30,page_31,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.5.', 'Preparation/Handling/StoragelAccountability', 'The investigator or designee must confirm and document appropriate temperature', 'conditions have been maintained during transit for all study treatment received', 'and any discrepancies are reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study', 'treatments must be stored in a secure, environmentally controlled, and monitored', '(manual or automated) area in accordance with the labeled storage conditions', 'with access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (ie, receipt, reconciliation, and final disposition of records).', 'Further guidance and information for the final disposition of unused study', 'treatment are provided in the SRM.', 'Precaution will be taken to avoid direct contact with the study treatment. Under', 'normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. In the case of unintentional', 'occupational exposure notify the monitor, Medical Monitor and/or GSK study', 'contact.', 'A Material Safety Data Sheet (MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '7.6.', 'Treatment Compliance', 'When participants are dosed at the site, they will receive study treatment directly', 'from the investigator or designee, under medical supervision. The date and time of', 'each dose administered in the clinic will be recorded in the source documents. The', 'dose of study treatment and study participant identification will be confirmed at the', 'time of dosing by a member of the study site staff other than the person', 'administering the study treatment.', 'When participants self-administer study treatment(s) at home, compliance with study', 'treatment administration will be assessed through querying the participant during the', 'site visits and documented in the source documents and CRF. In addition,', 'participants will be asked to confirm study administration each day in the daily', 'ediary.', 'Study participants who are not compliant with study treatment administration', 'requirements should be re-educated on the importance of treatment compliance.', 'Every effort should be made to keep participants in the study. Participants who', 'continue to be non-compliant after several attempts to re-educate may be', 'discontinued after consultation with the GSK study team.', '31']"
31,page_32,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.7.', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) that the participant is receiving at the time of', 'enrolment or receives during the study must be recorded along with:', 'reason for use', 'dates of administration including start and end dates', 'dosage information including dose and frequency', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', 'The following COPD medications are permitted during the study, at the discretion of the', 'GSK Medical Monitor and/or Investigator:', 'Inhaled COPD maintenance medications (e.g. long acting bronchodilator', 'medications (i.e. LAMA, LABA) and long-acting bronchodilator combination', 'therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled steroid', 'combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)', 'Short courses of oral corticosteroids and/or antibiotics (including macrolides)', 'are permitted for the acute treatment of exacerbations of COPD and should not', 'exceed 21 days. This use must be recorded as an HCRU exacerbation event.', 'The following medications are prohibited from the screening visit until after completion', 'of the follow up visit:', 'Chronic use of macrolide antibiotics for the prevention of COPD exacerbations.', 'Examples of chronic use include daily or two-three times per week for at least', '3', 'months.', 'Oral or injectable CYP3A4 or BCRP substrates with narrow therapeutic index', '(CYP3A4 substrates include, but are not limited to, alfentanil, cyclosporine,', 'dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus,', 'tacrolimus, and theophylline; BCRP substrates include, but are not limited to,', 'topotecan.', 'Phosphodiesterase-4 inhibitors (e.g. roflumilast)', 'Broad spectrum phosphodiesterase inhibitors (e.g. theophylline)', 'GSK will not supply rescue medication. Participants may continue to use and should', 'obtain rescue medication(s) through via their usual route. The following rescue', 'medications may be used:', 'Short acting beta agonists (SABA)( (e.g., albuterol/salbutamol)', 'Short acting muscarinic antagonists (SAMA)(e.g., ipratropium)', '32']"
32,page_33,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb,', 'Combivent)', 'The use of rescue medications is allowable at any time during the study. Participants', 'should record in the daily e-diary the number of puffs of rescue medication(s) over each', '24 hour period. Data from the MDI sensor device will be electronically captured and', 'transmitted to GSK.', 'Annual influenza vaccine is recommended for patients with COPD but is not required for', 'participation in this study. Influenza vaccination is permitted during the study and should', 'be based on applicable local or national guidelines. Pneumococcal vaccine may also be', 'administered, when indicated, based on applicable local or national guidelines.', 'Additional vaccinations may be administered when indicated. Any vaccination', 'administered during the study should be recorded as a concomitant therapy.', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', 'study care of the participant.', 'GSK will not provide post-study treatment. There are no plans to provide the study', 'treatment for compassionate use following study completion.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', '8.1.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to assure', 'participant safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance). These protocol guidelines are in alignment', 'with FDA premarketing clinical liver safety guidance [FDA, 2009].', 'Discontinuation of study treatment for abnormal liver tests should be considered by the', 'investigator when a participant meets one of the conditions outlined in the algorithm', 'below or if the investigator believes that it is in the best interest of the participant.', '33']"
33,page_34,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If subject to be monitored weekly mustrefer to Liver Safety Required Actions and Follow up', 'Assessments section in the Appendix', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin>2x', 'Yes', 'No', 'ULN (>35%', 'ALT23xULN', 'ALT>3xULN', 'ALT>3xULN', 'direct)', 'Plus', 'Yes', 'No', 'No', 'No', 'but able to', 'Yes', 'persist for', 'ALT>3xULN', 'orplus', 'Symptoms of', 'ALT>5xULN', 'monitor', '4 weeks or', 'INR>1.5, if', 'liverinjury', 'weekly for', 'stopping', 'measured*', 'or', '4 weeks', 'criteria', 'Possible', 'hypersensitivity', 'met', ""Hy's Law"", 'Yes', 'Yes', 'No', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', ""Reportas an SAE if possible Hy's Law case: ALT23xULNand Bilirubin>2xULN (>35% direct) or"", 'INR>1.5, if measured*', '*INR value not applicable to subjects on anticoagulants', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Appendix 7: Liver Safety: Required Actions and Follow-up Assessments).', '8.1.2.', 'QTc Stopping Criteria', 'The same QT correction formula must be used for each individual participant to', 'determine eligibility for and discontinuation from the study. This formula may', 'not be changed or substituted once the participant has been enrolled.', 'For example, if a participant is eligible for the protocol based on QTcB, then', 'QTcB must be used for discontinuation of this individual participant as well.', ""Once the QT correction formula has been chosen for a participant's eligibility,"", 'the same formula must continue to be used for that participant for all QTc data', 'being collected for data analysis. Safety ECGs and other non-protocol specified', 'ECGs are an exception.', 'The QTc should be based on single or averaged QTc values of triplicate', 'electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period.', 'A participant who meets either bulleted criteria based on the average of triplicate ECG', 'readings will be withdrawn from study treatment:', 'QTc > 500 msec OR Uncorrected QT > 600 msec', 'Change from baseline of QTc > 60 msec', '34']"
34,page_35,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'For patients with underlying bundle branch block, follow the discontinuation criteria', 'listed below:', 'Baseline QTc with Bundle Branch Block', 'Discontinuation QTc with Bundle', 'Branch Block', '< 450 msec', '> 500 msec', '450 - 480 msec', '> 530 msec', 'See the SoA (Table 1) for data to be collected at the time of treatment discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.1.3.', 'Neutrophil Stopping Criteria', 'A participant with a peripheral blood neutrophil count < 0.5 X 109/L that is confirmed on', 'repeat testing will be instructed to suspend dosing. The neutrophil count should be', 'monitored daily until it returns to within the baseline value, as detailed in Appendix 9.', '8.1.4.', 'Temporary Discontinuation', 'Temporary discontinuation of study treatment is allowed for up to 14 days when', 'medically necessary, e.g. for hospitalization for a COPD exacerbation, other medical', 'condition requiring hospitalization, or reduction in peripheral blood neutrophil counts', '0.5 X 109/L. Temporary discontinuation for any other reason should be discussed with', 'the GSK Medical Monitor.', '8.1.5.', 'Study Treatment Restart', 'Study treatment restart after liver chemistry stopping criteria are met by any participant in', 'this study is not allowed. Refer to Appendix 7 (Section 12.7) for full guidance for', 'required actions and follow-up assessments to undertake if liver stopping criteria are met.', 'Study treatment restart after neutrophil stopping criteria are met can be considered once', 'the neutrophil count has returned to within baseline and provided that no more than 14', 'days have elapsed since study medication was halted. The Investigator must obtain', 'approval from the GSK Medical Monitor prior to restarting study treatment. See', 'Appendix 9 for the procedure to be followed for study treatment restart after neutrophil', 'stopping criteria are met.', '8.2.', 'Withdrawal from the Study', 'A participant may withdraw from the study at any time at his/her own request,', 'or may be withdrawn at any time at the discretion of the investigator for safety,', 'behavioural, compliance or administrative reasons.', 'If the participant withdraws consent for disclosure of future information, the', 'sponsor may retain and continue to use any data collected before such a', 'withdrawal of consent.', '35']"
35,page_36,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If a participant withdraws from the study, he/she may request destruction of any', 'samples taken and not tested, and the investigator must document this in the site', 'study records.', 'Refer to the SoA for data to be collected at the time of study discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.3.', 'Lost to Follow Up', 'A participant will be considered lost to follow-up if he or she repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'The following actions must be taken if a participant fails to return to the clinic for a', 'required study visit:', 'The site must attempt to contact the participant and reschedule the missed visit', 'as soon as possible and counsel the participant on the importance of maintaining', 'the assigned visit schedule and ascertain whether or not the participant wishes to', 'and/or should continue in the study.', 'Before a participant is deemed lost to follow up, the investigator or designee', 'must make every effort to regain contact with the participant (where possible, 3', ""telephone calls and, if necessary, a certified letter to the participant's last known"", 'mailing address or local equivalent methods). These contact attempts should be', ""documented in the participant's medical record."", 'Should the participant continue to be unreachable, he/she will be considered to', 'have withdrawn from the study with a primary reason of lost to follow-up.', '36']"
36,page_37,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA (Table 1)', 'Protocol waivers or exemptions are not allowed', 'Immediate safety concerns should be discussed with the sponsor immediately', 'upon occurrence or awareness to determine if the participant should continue or', 'discontinue study treatment.', 'Adherence to the study design requirements, including those specified in the', 'SoA, is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that', 'potential participants meet all eligibility criteria. The investigator will maintain a', 'screening log to record details of all participants screened and to confirm', 'eligibility or record reasons for screening failure, as applicable.', ""Procedures conducted as part of the participant's routine clinical management"", '(e.g., blood count) and obtained before signing of ICF may be utilized for', 'screening or baseline purposes provided the procedure met the protocol-', 'specified criteria and was performed within the time frame defined in the SoA.', 'The maximum amount of blood collected from each participant over the', 'duration of the study, including any extra assessments that may be required, will', 'not exceed 500 mL.', 'Repeat or unscheduled samples may be taken for safety reasons or for technical', 'issues with the samples.', '9.1.', 'Efficacy Assessments', '9.1.1.', 'FEV1', '9.1.1.1.', 'Clinic Spirometry', 'Spirometry using FEV1 and FVC measurements (FEV%, and FVC% and FEV1/FVC will', 'be calculated) will be performed in triplicate at time points listed in the SoA (Table 1).', 'Spirometry assessments should be performed in accordance with ATS/ERS guidelines as', 'outlined in the SRM.', '9.1.1.2.', 'Mobile Spirometry', 'Spirometry will also be performed weekly by the participants using a mobile spirometer', 'at home. Details will be outlined in the SRM.', '9.1.2.', 'SGRQ-C', ""The St. George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease"", 'specific tool (SGRQ-C) is a disease-specific questionnaire designed to measure the', ""impact of respiratory disease and its treatment on a COPD patient's HRQoL [Meguro,"", '2007]. As well as producing an overall summary score, scores for the individual domains', '37']"
37,page_38,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'of symptoms, activity and impacts are also produced. The SGRQ-C has been used in', 'numerous previous studies of COPD participants and has been translated and validated', 'for use in most major languages. The SGRQ-C is derived from the original SGRQ and', 'produces SGRQ scores equivalent to the original SGRQ instrument [Jones, 1992].', '9.1.3.', 'CAT', 'The COPD Assessment Test is a short and simple patient completed questionnaire which', 'has been developed for use in routine clinical practice to measure the health status of', 'patients with COPD. The CAT is an 8-item questionnaire suitable for completion by all', 'patients diagnosed with COPD [Jones, 2009; Jones, 2012]. When completing the', 'questionnaire, participants rate their experience on a 6-point scale, ranging from 0', '(maximum impairment) to 5 (no impairment) with a scoring range of 0-40. Higher scores', 'indicate greater disease impact.', '9.1.4.', 'COPD Exacerbations', 'An exacerbation of COPD is defined by a worsening of symptoms requiring additional', 'treatment or hospitalization.', 'Details of an exacerbation should be recorded in the exacerbation page of the eCRF.', 'Exacerbations will not be reported according to the standard process for expedited', 'reporting of SAEs to GSK (even though the event may meet the definition of an SAE) as', 'they are considered Disease Related Events (DREs). Only when the event is, in the', ""Investigator's opinion, of greater intensity, or duration than expected for the individual"", 'participant, or the Investigator considers that there is a reasonable possibility that the', 'event is related to study treatment should it be reported as an SAE (See Section 9.2).', '(Pneumonia must be recorded in the AE or SAE section of the eCRF and on the', 'pneumonia page of the eCRF (See Section 9.4.5)).', 'All medications used for the treatment of exacerbations must be recorded in the source', 'documents and the exacerbation page of the eCRF. If necessary the PI or other health', ""care personnel may stop the participant's study treatment temporarily in order to treat the"", 'COPD exacerbation. The reason for temporarily stopping study treatment and duration', 'should be recorded in the eCRF.', 'The date of onset and the date of resolution will be recorded in the source documents and', ""the eCRF based on the Investigator's judgement."", '9.1.5.', 'Patient Global Rating of Severity and Global Rating of Change in', 'Disease Severity', 'Participants will complete the Global Rating of COPD Severity at randomisation and', 'final study visit or IP Discontinuation Visit. This single global question will ask', 'participants to rate their severity of COPD on a four point scale (mild, moderate, severe,', 'very severe).', 'Participants will complete a Global Rating of Change in COPD (overall disease) question', 'at every visit following randomization (or Early Withdrawal (EW) Visit). Response', '38']"
38,page_39,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'options will be on a 7 point Likert scale ranging from much better to much worse. Asking', 'at each Visit allows for early detection of response as well as continued response.', '9.2.', 'Adverse Events', 'The definitions of an AE or SAE can be found in Appendix 4 (Section 12.4).', 'The investigator and any designees are responsible for detecting, documenting, and', 'reporting events that meet the definition of an AE or SAE and remain responsible for', 'following up AEs that are serious, considered related to the study treatment or the study,', 'or that caused the participant to discontinue the study treatment (see Section 8).', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', 'All SAEs will be collected from the time the informed consent is signed by the', 'participant until the follow up visit at the time points specified in the SoA', '(Table 1).', 'All AEs will be collected from the start of study treatment (randomization visit)', 'until the follow-up visit at the time points specified in the SoA (Table 1).', 'Medical occurrences that begin before the start of study treatment but after', 'obtaining informed consent will be recorded on the Medical History/Current', 'Medical Conditions section of the case report form (CRF) not the AE section.', 'All SAEs must be reported immediately and not more than 24 hrs to the sponsor,', 'as indicated in Appendix 4 (Section 12.4). The investigator will submit any', 'updated SAE data to the sponsor within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'participants. However, if the investigator learns of any SAE, including a death,', 'at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study treatment or study', 'participation, the investigator must promptly notify the sponsor.', 'The method of recording, evaluating, and assessing causality of AEs and SAEs', 'and the procedures for completing and transmitting SAE reports are provided in', 'Appendix 4 (Section 12.4).', '9.2.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AE and/or SAE. Open-ended and', 'non-leading verbal questioning of the participant is the preferred method to inquire about', 'AE occurrence.', '9.2.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All SAEs will be followed until the event is', 'resolved, stabilized, otherwise explained, or the participant is lost to follow-up (as', '39']"
39,page_40,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'defined in Section 8.3). Further information on follow-up procedures is given in', 'Appendix 4.', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to the sponsor of a SAE is essential', 'so', 'that legal obligations and ethical responsibilities towards the safety of', 'participants and the safety of a study treatment under clinical investigation are', 'met.', 'The sponsor has a legal responsibility to notify both the local regulatory', 'authority and other regulatory agencies about the safety of a study treatment', 'under clinical investigation. The sponsor will comply with country-specific', 'regulatory requirements relating to safety reporting to the regulatory authority,', 'Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and', 'investigators.', 'Investigator safety reports must be prepared for suspected unexpected serious', 'adverse reactions (SUSAR) according to local regulatory requirements and', 'sponsor policy and forwarded to investigators as necessary.', 'An investigator who receives an investigator safety report describing a SAE or', 'other specific safety information e.g., summary or listing of SAE) from the', ""sponsor will review and then file it along with the Investigator's Brochure and"", 'will notify the IRB/IEC, if appropriate according to local requirements.', '9.2.5.', 'Cardiovascular and Death Events', 'For any cardiovascular events detailed in Section 12.4 (Appendix 4) and all deaths,', 'whether or not they are considered SAEs, specific Cardiovascular (CV) and Death', 'sections of the CRF will be required to be completed. These sections include questions', 'regarding cardiovascular (including sudden cardiac death) and non-cardiovascular death.', 'The CV CRFs are presented as queries in response to reporting of certain CV MedDRA', 'terms. The CV information should be recorded in the specific cardiovascular section of', 'the CRF within one week of receipt of a CV Event data query prompting its completion.', '9.2.6.', 'Disease-Related Events and/or Disease-Related Outcomes Not', 'Qualifying as SAEs', 'The following disease related events (DREs) are common in participants with COPD and', 'can be serious/life threatening:', 'COPD exacerbations', 'Because these events are typically associated with the disease under study, they will not', 'be reported according to the standard process for expedited reporting of SAEs to GSK', '(even though the event may meet the definition of an SAE). These events will be', ""recorded on the DRE page in the participant's CRF within 72 hours after the investigator"", 'becomes aware of the event. These DREs will be monitored by the Safety Review Team', '(SRT) on a routine basis as described in Section 12.3 (Appendix 3).', '40']"
40,page_41,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'NOTE: However, if either of the following conditions applies, then the event must be', 'recorded and reported as an SAE (instead of a DRE).', ""The event is, in the investigator's opinion, of greater intensity, frequency, or"", 'duration than expected for the individual participant, or', 'The investigator considers that there is a reasonable possibility that the event', 'was related to treatment with the investigational product', '9.2.7.', 'Pregnancy', 'Details of all pregnancies in female participants and female partners of male', 'participants will be collected after the start of study treatment and until 60', 'hours after the last dose of study treatment.', 'If a pregnancy is reported, the investigator should inform GSK within 24 hours', 'of learning of the pregnancy and should follow the procedures outlined in', 'Section 12.5 (Appendix 5).', 'Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAEs.', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use and measuring spirometry at home. In order to fulfill', 'regulatory reporting obligations worldwide, the investigator is responsible for the', 'detection and documentation of events meeting the definitions of incident or malfunction', 'that occur during the study with such devices.', 'The definition of a Medical Device Incident can be found in Section 12.8 (Appendix 8).', 'NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes', 'outlined in Section 9.2 and Section 12.4 (Appendix 4).', '9.2.8.1.', 'Time Period for Detecting Medical Device Incidents', 'Medical device incidents or malfunctions of the device that result in an incident', 'will be detected, documented, and reported during all periods of the study in', 'which the medical device is used.', 'If the investigator learns of any incident at any time after a participant has been', 'discharged from the study, and such incident is considered reasonably related to', 'a medical device provided for the study, the investigator will promptly notify the', 'sponsor within 24 hours of determining a device-related event.', 'The method of documenting Medical Device Incidents is provided in Section', '12.8 (Appendix 8).', '41']"
41,page_42,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.2.8.2.', 'Follow-up of Medical Device Incidents', 'All medical device incidents involving an AE will be followed and reported in', 'the same manner as other AEs (see Section 9.2). This applies to all participants,', 'including those who discontinue study treatment or the study.', 'The investigator is responsible for ensuring that follow-up includes any', 'supplemental investigations as indicated to elucidate the nature and/or causality', 'of the incident.', 'New or updated information will be recorded on the originally completed form', 'with all changes signed and dated by the investigator.', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents to Sponsor', 'Medical device incidents will be reported to the sponsor within 24 hours after', 'the investigator determines that the event meets the protocol definition of a', 'medical device incident.', 'Complete the Medical Device Incident Form for each participant who has a', 'medical device incident with GSK medical devices provided for use during the', 'study period. All of the header information in the form must be completed', 'before sending to GSK. Original documents should be filed in the site study', 'file. A copy of the form must also be sent to the GKS study monitor. Contact', 'details will be included in the SRM. A copy of the form must also be sent to the', 'GSK study monitor. Contact details will be included in the SRM. For incidents', 'fulfilling the definition of an AE or SAE, the appropriate pages of the CRF must', 'be completed. If there is an SAE, the completed CRF pages should be sent', 'together with the Medical Device Incident From. If the participant is withdrawn', 'due to a medical device incident, ensure the Study Conclusion page is', 'completed.', 'The same individual will be the contact for the receipt of medical device reports', 'and SAEs.', '9.2.8.4.', 'Regulatory Reporting Requirements for Medical Device Incidents', 'The investigator will promptly report all incidents occurring with any medical', 'device provided for use in the study in order for the sponsor to fulfill the legal', 'responsibility to notify appropriate regulatory authorities and other entities about', 'certain safety information relating to medical devices being used in clinical', 'studies.', 'The investigator, or responsible person according to local requirements (e.g., the', 'head of the medical institution), will comply with the applicable local regulatory', 'requirements relating to the reporting of incidents to the IRB/IEC.', '42']"
42,page_43,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.3.', 'Treatment of Overdose', 'For this study, any dose of study treatment 4 tablets in a day will be considered an', 'overdose.', 'GSK does not recommend specific treatment for an overdose.', 'In the event of an overdose, the investigator/treating physician should:', '1. Contact the Medical Monitor immediately.', '2. Closely monitor the participant for AE/SAE and laboratory abnormalities until study', 'treatment can no longer be detected systemically (at least 3 days).', '3. Obtain a plasma sample for PK analysis as soon as possible from the date of the last', 'dose of study treatment if requested by the Medical Monitor (determined on a case-', 'by-case basis).', '4. Document the quantity of the excess dose as well as the duration of the overdosing in', 'the CRF.', 'Decisions regarding dose interruptions or modifications will be made by the investigator', 'in consultation with the Medical Monitor based on the clinical evaluation of the', 'participant.', '9.4.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SoA.', '9.4.1.', 'Physical Examinations', 'A complete physical examination will include, at a minimum, assessments of the', 'skin, cardiovascular, respiratory, gastrointestinal and neurological systems.', 'Height and weight will also be measured and recorded.', 'A brief physical examination will include, at a minimum, assessments of the', 'skin, lungs, cardiovascular system, and abdomen (liver and spleen).', 'Investigators should pay special attention to clinical signs related to previous', 'serious illnesses.', '9.4.2.', 'Vital Signs', 'Vital signs will be measured in a semi-supine position after 5 minutes rest and will', 'include systolic and diastolic blood pressure, pulse, and respiratory rate. Three readings', 'of blood pressure and pulse will be taken. The first reading should be rejected. The', 'second and third readings should be averaged to give the measurement to be recorded in', 'the CRF. A single measurement of respiratory rate is adequate.', '43']"
43,page_44,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.4.3.', 'Electrocardiograms', 'For participant screening and pre-dose on Day 1, triplicate ECG measurements should be', 'collected. For all subsequent ECG assessments, single measurements are to be collected.', '12-lead ECG will be obtained as outlined in the SoA using an ECG machine that', 'automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.', 'Refer to Section 8.1.2 for QTc withdrawal criteria and additional QTc readings that may', 'be necessary.', 'At each time point at which triplicate ECG are required, 3 individual ECG tracings', 'should be obtained as closely as possible in succession, but no more than 2 minutes apart.', 'The full set of triplicates should be completed in less than 10 minutes.', '9.4.4.', 'Clinical Safety Laboratory Assessments', 'Refer to Section 12.2 (Appendix 2) for the list of clinical laboratory tests to be performed', 'and to the SoA for the timing and frequency.', 'The investigator must review the laboratory report, document this review, and record', 'any clinically relevant changes occurring during the study in the AE section of the', 'CRF. The laboratory reports must be filed with the source documents. Clinically', 'significant abnormal laboratory findings are those which are not associated with the', 'underlying disease, unless judged by the investigator to be more severe than', ""expected for the participant's condition."", 'All laboratory tests with values considered abnormal and clinically significant during', 'participation in the study or within 3 days after the last dose of study treatment', 'should be repeated until the values return to normal or baseline or are no longer', 'considered significantly abnormal by the investigator or medical monitor.', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the investigator, the etiology should be identified and the sponsor', 'notified.', 'All protocol-required laboratory assessments, as defined in Section 12.2, must be', 'conducted in accordance with the laboratory manual and the SoA (Table 1).', 'If laboratory values from non-protocol specified laboratory assessments performed at', ""the institution's local laboratory require a change in participant management or are"", 'considered clinically significant by the investigator (e.g., SAE or AE), then the', 'results must be recorded in the CRF.', '9.4.5.', 'Pneumonia', 'All suspected pneumonias will require confirmation as defined by the presence or new', 'infiltrate(s) on chest x-ray AND at least 2 of the following signs and symptoms:', 'Increased cough', 'Increased sputum purulence (colour) or production', 'Auscultatory findings of adventitious sounds (e.g. egophony, bronchial breath', 'sounds, rales, etc.)', '44']"
44,page_45,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Dyspnea or tachypnea', 'Fever (oral temperature > 37.5 °C)', 'Elevated white blood cell count (WBC) (> 10 X 109/L or > 15% immature', 'forms)', 'Hypoxemia (Hb O2 saturation < 88% or at least 2% lower than baseline value)', 'All pneumonias must be captured on the AE/SAE page of the eCRF and on the', 'pneumonia page of the eCRF.', 'The Investigator and site staff should remain vigilant for the possible development of', 'pneumonia in participants as the clinical features of such infections overlap with the', 'symptoms of COPD exacerbations. For all suspected cases of pneumonia, Investigators', 'are strongly encouraged to confirm the diagnosis (this includes obtaining a chest x-ray)', 'and to initiate appropriate therapy as promptly as possible. Any microbiology or virology', 'tests performed to determine etiology should be reported on the pneumonia eCRF page.', 'All diagnoses of pneumonia (radiographically confirmed or unconfirmed) must be', 'reported as an AE or SAE (if applicable).', '9.5.', 'Pharmacokinetics', 'Pharmacokinetic parameters are not evaluated in this study.', '9.6.', 'Pharmacodynamics', 'Pharmacodynamic parameters are not evaluated in this study.', '9.7.', 'Genetics', 'A 6 mL whole blood sample for DNA isolation will be collected from participants who', 'have consented to participate in the genetics analysis component of the study.', 'Participation in the genetics analysis is optional. Participants who do not wish to', 'participate in the genetic research may still participate in the study.', 'See Section 12.6 (Appendix 6) for Information regarding genetic research. Details on', 'procedures for collection and shipment and destruction of these samples can be found in', 'the SRM.', '9.8.', 'Biomarkers', 'Collection of samples for biomarker research is also part of this study. The following', 'samples for biomarker research will be collected from all participants in this study as', 'specified in the SoA:', 'peripheral venous blood samples for the preparation of serum and plasma', 'Samples will be tested for biomarkers that are indicative of inflammation (i.e. CRP),', 'extracellular matrix turnover and remodelling to evaluate their association with the', 'observed clinical responses or to help understand the underlying biological responses to', 'danirixin.', '45']"
45,page_46,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', ""In addition, with the participant's consent, samples will be stored and may be used to"", 'investigate additional biomarkers thought to play a role in COPD disease progression or', 'to evaluate their association with observed clinical responses to danirixin', 'Samples also may be used for research to develop methods or support identification of', 'prognostic/diagnostic biomarkers associated with clinical outcomes in COPD and related', 'diseases.', '9.9.', 'Health Economics OR Medical Resource Utilization and', 'Health Economics', 'Health Economics/Medical Resource Utilization and Health Economics parameters are', 'not evaluated in this study.', '10.', 'STATISTICAL CONSIDERATIONS', 'The objective of this study is to investigate the effect of danirixin HBr 35mg tablets on', 'COPD disease progression. There are no formal hypothesis tests associated with this', 'objective and no formal significance tests. The information acquired from this study will', 'primarily be used to assess whether or not danirixin impacts disease progression and to', 'quantify the effect that danirixin has on disease progression, specifically change in lung', 'function as measured by FEV1 decline and change in health-related quality of life as', 'measured by SGRQ total score to further support disease understanding and future', 'studies.', '10.1.', 'Sample Size Determination', 'Sample size is based primarily on feasibility for this study. Since there is much', 'uncertainty around the magnitude of the difference in the decline in FEV1 and change in', 'SGRQ along with the between-subject variability for the specific patient population, the', 'proposed sample size is unavoidably imprecise. Sample size may be adjusted using the', 'predictions of final study outcome based on simulations and possible interim analyses. It', 'is anticipated that screening 130 participants will allow for approximately 100', 'participants to enrol.', 'In order to observe the effect of different sample sizes, various simulations were done to', 'assess the impact of sample sizes of 50, 100, 150 and 200 with a 1:1 allocation to each', 'treatment group [Table 3]. The assumed variability for rate of decline in FEV1 and', 'change in SGRQ is 25 and 10, respectively. The correlation between rate of decline in', 'FEV1 and change in SGRQ is assumed to be -0.2. [Nagai, 2015]', 'Table 3', 'Assumptions used for the Simulations', 'Treatment Effect Assumptions', 'Variability Assumptions', 'Sample Size', '(ÔFEV1, ÔSGRQ)', '(OFEV1, OSGRQ)', 'Null', '(0,0)', '(25,10)', 'N={50,100,150,200}', 'Alternate 1', '(5,-1)', '(25,10)', 'N=(50,100,150,200}', 'Alternate 2', '(5,0)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 3', '(0,-1)', '(25,10)', 'N={50,100,150,200}', '46']"
46,page_47,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Data from a bivariate normal distribution were simulated under the four different', 'treatment effect assumptions for samples sizes of 50, 100, 150, and 200. The samples', 'from the posterior probability distribution from the MCMC approximation were divided', 'into four regions based on OFEVI and ÔSGRQ treatment effect cut-off values; SFEVI>O and', 'ôSGRQ 0, OFEVI>0 and SSGRQ>0, OFEVI<( and and OFEVI<0 and SSGRQ>0. Based', 'on a 70% threshold, the proportion of the 1000 simulations meeting the requirement', 'P(OFEV1>0 & > 70% were considered a success based on the joint definition', '[Figure 2, Table 4]. If P(OFEV1>0 & ÔSGRQ<0) < 70%, success could further be defined', 'based on each endpoint independently where P(OFEV1 > 0) > 80% or P(6SGRQ VI 0) > 80%.', 'Figure 2', 'Total Probability of Success', '80', 'Alt 1: (5,-1)', '80', 'Alt 2: (5,0)', 'Alt 3: (0,-1)', 'Null: (0,0)', '02', '60', '50', 'of', '30', '50', '100', '150', '200', 'Sample Size', 'Table 4', 'Total Probability of Success (Figure 2)', 'N=50', 'N=100', 'N=150', 'N=200', '(5,-1)', '57.4', '68.5', '75.1', '81.4', '(5,0)', '52.5', '62.6', '67.8', '74.5', '(0,-1)', '42.6', '46.2', '48.9', '53.0', '(0,0)', '34.9', '33.9', '33.3', '31.5', '47']"
47,page_48,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 3', 'Half Width of the 95% Confidence Interval of OFEV1 Point Estimate', 'D', '13.8', '2L', '01', '9,7', '8.0', '8', '6.9', '9', '50', '100', '150', '200', 'Sample Size', 'Figure 4', 'Half Width of the 95% Confidence Interval of 5SGRQ Point Estimate', '6', '5.5', '5', '&', '3,9', 'm', '3.2', '2.7', '2', '50', '100', '150', '200', 'Sample Size', 'Based on the simulations, under the assumption of an expected treatment difference of', '(5,-1) which is the most probable scenario, the marginal increase for the total probability', 'of success is greatest when increasing the sample size from 50 to 100 (Figure 2). The half', 'widths of the 95% CI of the point estimate of the marginal treatment differences for FEV1', '(Figure 3) and SGRQ (Figure 4) have the greatest reduction from a sample size of 50 to', '100. A sample size of 100 will allow for an adequate level of confidence in the study', 'success while also considering the precision of the treatment effect differences.', '48']"
48,page_49,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.2.', 'Randomization', 'Participants will be randomized equally (1:1) to the two treatment arms of placebo and 35', 'mg danirixin HBr. Randomization will be stratified by smoking status (current VS.', 'former).', '10.3.', 'Populations for Analyses', 'For purposes of analysis, the following populations are defined:', 'Population', 'Description', 'All Participants', 'This population will comprise all participants screened and', 'for whom a record exists on the study database and will be', 'used for the tabulation and listing of reasons for withdrawal', 'before randomization and listings of AEs and SAEs for', 'nonrandomized participants.', 'Intent To Treat (ITT)', 'This population will comprise all participants randomized to', 'treatment and who received at least one dose of study', 'medication. This will constitute the primary population for all', 'analyses of efficacy and safety. Outcomes will be reported', 'according to the randomized treatment allocation.', 'Per-Protocol (PP)', 'This population will comprise of all patients in the ITT', 'Population', 'population who are not major protocol violators.', 'Safety', 'All randomized participants who take at least 1 dose of study', 'treatment. Participants will be analyzed according to the', 'treatment they actually received.', '10.4.', 'Statistical Analyses', 'Treatment comparisons using all endpoints will be made using appropriate statistical', 'techniques. Analysis methods for key endpoints are described below. Main analysis will', 'use ITT unless noted. Further details on all analyses will be described in the reporting and', 'analysis plan (RAP).', '10.4.1.', 'Efficacy Analyses', 'The total probability of success will be defined as a combination of a joint and', 'conditional statement. The joint probability of success will be defined as the probability', 'of the difference in the rate of decline in FEV1 between danirixin and placebo is greater', 'than or equal to 0 and the difference in the change in SGRQ total score from baseline', 'between danirixin and placebo is less than or equal to 0 is greater than 70%. If the joint', 'probability of success is less than 70%, success can further be defined based on each', 'endpoint independently, where either the difference in the rate of decline in FEV1 is', '49']"
49,page_50,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'greater than or equal to 0 is greater than 80% or the difference in the change in SGRQ', 'total score is less than or equal to 0 is greater than 80%.', '=', '+', '+P S o) < 70%', 'Endpoint', 'Statistical Analysis Methods', 'Primary', 'Rate of decline in FEV1 and change from baseline in SGRQ total score', 'Exploratory', 'Will be described in detail in the RAP', 'Lung Function Decline: Rate of Decline of FEV1 (mL/yr)', 'The rate of decline of FEV1 will be derived from a repeated measures random', 'coefficients model. Post-baseline FEV1 will be modelled including terms for age, sex,', 'smoking status, FEV, at baseline, and BMI along with treatment group, time and', 'treatment by time interaction as fixed effects. Subject will be a random effect. Time will', 'be defined as the number of days since start of treatment. Only FEV1 values measured', 'after baseline will be used in the model. Based on the results of previous studies, the', 'study team will determine the time point at which post-baseline spirometry assessments', 'will be included in the model to account for the initial treatment response. The estimate', 'of the rate of FEV1 decline will be the slope of the parameter estimate of the treatment by', 'time interaction term in the model. Contrasts will be calculated for the difference in', 'treatment by time interaction between danirixin and placebo treatment groups to estimate', 'the treatment difference.', 'FEV1 = Treatment group + age + sex +smoking status+FEV1_BL+BMI+ time', '+', 'treatment*time', 'The rate of decline for each subject, the estimate of the slope parameter of the treatment', 'by time interaction term, will be used as a co-primary endpoint for the joint analysis', 'using both FEV, and SGRQ.', 'HRQoL: SGRQ', 'A co-primary endpoint of interest is change in SGRQ total score (derived from SGRQ-C)', 'from baseline. Change in SGRQ total scores from baseline will be derived using a mixed', 'model with repeated measures (MMRM) including fixed effects of treatment group, age,', 'sex, smoking status, BMI, baseline SGRQ score, time as a categorical variable and a', 'treatment by time interaction term. Subject will be a random effect. Estimated treatment', 'differences at the end of one year will be obtained. The difference of the least square', 'mean change from baseline at 12 months will be derived. The adjusted SGRQ total score', '50']"
50,page_51,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'change from baseline will used as the other co-primary endpoint for the joint analysis', 'using both FEV1 and SGRQ.', 'Joint Analysis', 'The joint analysis will use the ITT population with all available FEV1 rate of decline and', 'change in SGRQ data.', 'The rate of decline (the slope parameter from the random coefficients model) of FEV1,', 'along with the change in SGRQ from the MMRM model will be extracted for each', 'subject. These values will then be used to obtain MCMC approximations of the joint', 'posterior distribution of the treatment differences between FEV1 decline and change in', 'SGRQ between the danirixin and placebo groups. Based on the samples from the', 'posterior distribution, the proportion of samples falling within certain treatment', 'difference regions will be calculated and the probability of success will be derived.', '10.4.2.', 'Safety Analyses', 'All safety endpoints will be tabulated or plotted by treatment group and will be', 'performed on the Safety Population. Further details will be described in the RAP.', '10.4.3.', 'Other Analyses', 'Exploratory biomarker analyses will be described in the RAP.', '10.4.4.', 'Interim Analyses', 'Conducting an interim analysis or futility assessment may not be practical due to an', 'expected fast recruitment period. By the time enough data will accumulate for any', 'meaningful interim analysis to support changes to the study design, recruitment of all', 'study participants will have concluded. However, if recruitment takes a longer than', 'anticipated, an interim analysis to reassess the variability assumptions, estimate the', 'probability of success at the end of study, and confirm the directionality of the endpoints', 'may be conducted.', 'The RAP will describe the potential interim analyses in greater detail.', '51']"
51,page_52,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '11.', 'REFERENCES', 'Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD.', 'Eur Respir J. 2004;23:932-946.', 'Chapman RW, Philips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2', 'antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009; 121:55-68.', 'FDA. Guidance for Industry. Center for Drug Evaluation and Research, United States', 'Food and Drug Administration; 2009. Drug-induced liver injury: premarketing clinical', 'evaluation.', 'GlaxoSmithKline Document Number 2013N180289 ( 03 Study ID 200163. A two part,', 'phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability,', 'pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin', '(GSK1325756) in symptomatic COPD subjects with mild to moderate airflow limitation', 'at risk for exacerbations. Report Date 05-Aug-2015.', 'GlaxoSmithKline Document Number 2014N205875 00 Study ID 201682. A', 'randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and', 'clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with', 'acute, uncomplicated influenza. Report Date 21-Nov-2014.', 'GlaxoSmithKline Document Number 2015N248339 00 Study ID 201037. A single', 'centre, open-label, 5-period, cross over, randomized study in healthy elderly subjects to', 'evaluate the relative bioavailability of hydrobromide salt and free base immediate release', 'tablet formulations of danirixin in the fed state, and to evaluate the effect of food and', 'gastric acid secretion suppression on danirixin pharmacokinetics following administration', 'of hydrobromide salt tablets. Report Date 01-Jun-2016.', ""GlaxoSmithKline Document Number YM2010/00163/07. Danirixin Investigator's"", 'Brochure, Version 09. Report Date 14-Apr-2016.', 'GOLD. From the Global Strateby for the Diagnosis, Management and Prevention of', 'COPD, Global Initiative for Chronic Obstructive Lung Disease. Global Initiative for', 'Chronic Obstructive Lung Disease, Available from: http://www.copdgold.org; 2016.', 'Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni I P, et al. SCH527123,', 'a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur', 'Respir J. 2010;35:564-570.', 'Hurst JA, Vestbo J, Anzueto A, Locantore N, Mullerova, Tal-Singer R, et al.', 'Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med.', '2010;363:1128-1138.', 'Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first', 'validation of the COPD Assessment Test (CAT). Eur Respir J. 2009;34:648-654.', '52']"
52,page_53,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R et al. Tests of the', 'responsiveness of the chronic obstructive pulmonary disease (COPD) assessment test', '(CAT) following acute exacerbation and pulmonary rehabilitation. Chest. 2012;142:134-', '140.', 'Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health', ""status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev"", 'Respir Dis. 1992;145:1321-1327.', 'Lazaar AL, Sweeney LE, MacDonald AJ et al. SB-656933, a novel CXCR2 selective', 'antagnoist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation', 'in humans. Br J Clin Pharmacol. 2011;72:282-293.', 'Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology.', '2016;21:14-23.', 'Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002', 'to 2030. PLoS Med. 2006;3:e442.', 'Meguro M, Barley EA, Spencer S et al. Development and validation of an improved', 'COPD-specific version of the St. George Respiratory Questionnaire. Chest.', '2007;132:456-463.', 'Miller B, Tal-Singer R, Lazaar A, Leidy N, Watz H, Collins D, et al. Assessing', 'symptoms in COPD: use of the E-RS daily digital diary in early drug development. Eur', 'Respir J.2016;48(S60):PA1047.', 'Nagai, K., Makita, H., Suzuki, M., Shimizu, K., Konno, S., Ito, Y. M., & Nishimura, M.', 'Differential changes in quality of life components over 5 years in chronic obstructive', 'pulmonary disease patients. International Journal of Chronic Obstructive Pulmonary', 'Disease. 2015; 10: 745-757.', 'Nair P, Gaga M, Zervas E et al. Safety and efficacy of a CXCR2 antagnoist in patients', 'with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical', 'trial. Clin Exp Allergy. 2012;42:1097-2103', ""O'Byrne PM, Metev H, Puu M et al. Efficacy and safety of a CXCR2 antagonist,"", 'AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind,', 'placebo-controlled trial. Lancet Respir Med. 2016;4:797-806.', 'Rennard SI, Dale DC, Donohue JF et al. CXCR2 antagonist MK-7123 - a phase 2 proof-', 'of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med.', '2015;191:1001-1011.', 'Vastava S, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and', 'economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoecon.', '2015;33:467-488.', '53']"
53,page_54,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindate S, et al.', 'Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J', 'Med. 2016;375:1253-1260.', 'Watz H, Kirsten A, Pedersen F, Goldmann T, Stellmacher F, Uddin M, et al. Neutrophils', 'in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist', 'AZD5069 - an explorative study in neutrophilic asthma. Eur Respir J.', '2016;48(S60): PA4892.', 'Woodruff PG, Barr RG, Bleecker F, Christenson SA, Couper D, Curtis JL, et al. Clinical', 'significance of symptoms in smokers with preserved pulmonary function. N Engl J Med.', '2016;374:1811-1821.', '54']"
54,page_55,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.', 'APPENDICES', '12.1.', 'Appendix 1: Abbreviations and Trademarks', 'List of Abbreviations', 'AE', 'Adverse Event', 'ALT', 'Alanine Aminotransferase (SGPT)', 'AST', 'Aspartate Aminotransferase (SGOT)', 'ATS', 'American Thoracic Society', 'AUC', 'Area under the concentration-time curve', 'BfS', 'Federal Office of Radiation Protection (Germany)', 'BID', 'Twice daily', 'BRCP', 'Breast cancer resistance protein', 'BUN', 'Blood urea nitrogen', 'CAT', 'COPD Assessment Test', 'CD', 'Cluster of differentiation', 'CFR', 'Code of Federal Regulations (United States)', 'CI', 'Confidence Interval', 'CID', 'Clinically important deterioration', 'CIL', 'Clinical Investigation Leader', 'Cmax', 'Maximum observed concentration', 'CONSORT', 'Consolidated standards of reporting trials', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'CRF', 'Case Report Form', 'CT', 'Computed Tomography', 'CV', 'Cardiovascular', 'CXCR', 'CXC Chemokine Receptor', 'CXR', 'Chest X-Ray', 'dL', 'Deciliter', 'DNA', 'Deoxyribonucleic acid', 'DNX', 'Danirixin', 'DRE', 'Disease Related Event', 'E0', 'Effect at zero concentration', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic Case Report Form', 'ED50', 'Dose causing 50% of the maximum achievable response', '55']"
55,page_56,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'EMA', 'European Medicines Agency', 'Emax', 'Maximum response achievable', 'eMDI', 'Electronic metered dose inhaler', 'EW', 'Early Withdrawal', 'FDA', 'Food and Drug Administation (United States)', 'FEV1', 'Forced Expiratory Volume in one second', 'FVC', 'Forced Vital Capacity', 'FSH', 'Follicle Stimulation Hormone', 'GCP', 'Good Clinical Practice', 'GCSP', 'Global Clinical Safety and Pharmacovigilance', 'GGT', 'Gamma glutamyltransferase', 'GOLD', 'Global Initiative for Chronic Obstructive Lung Disease', 'GSK', 'GlaxoSmithKline', 'HBsAG', 'Hepatitis B surface antigen', 'HCRU', 'Healthcare Resource Utilization', 'hCG', 'Human chorionic gonadotrophin', 'HDPE', 'High density polyethylene', 'Hep B', 'Hepatitis B', 'Hep C', 'Hepatitis C', 'hsCRP', 'High sensitivity C-reactive protein', 'HIV', 'Human immunodeficiency virus', 'HPLC', 'High performance liquid chromatography', 'IB', ""Investigator's Brochure"", 'ICF', 'Informed Consent Form', 'International Conference on Harmonization of Technical', 'ICH', 'Requirements for Registration of Pharmaceuticals for', 'Human Use', 'ICS', 'Inhaled corticosteroid', 'IDMC', 'Independent Data Monitoring Committee', 'IEC', 'Independent Ethics Committee', 'IgG', 'Immunoglobulin G', 'IgM', 'Immunoglobulin M', 'INR', 'International normalized ratio', 'IP', 'Investigational Product', 'IRB', 'Institutional Review Board', 'ITT', 'Intent to treat', '56']"
56,page_57,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'IUD', 'Intrauterine device', 'IUS', 'Intrauterine hormone releasing system', 'IVIVT', 'In vitro In vivo Translation', 'IWRS', 'Interactive Web Response System', 'kg', 'Kilogram', 'L', 'Liter', 'LABA', 'Long acting ß2 receptor agonist', 'LAMA', 'Long acting muscarinic receptor antagonist', 'LH', 'Leutinizing Hormone', 'MCV', 'Mean corpuscular volume', 'MCH', 'Mean corpuscular hemoglobin', 'MCHC', 'Mean corpuscular hemoglobin count', 'MDI', 'Metered dose inhaler', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mg', 'Milligrams', 'mL', 'Millititer', 'MM', 'Medical monitor', 'MSDS', 'Material Safety Data Sheet', 'msec', 'Millisecond', 'NOAEL', 'No observed adverse effect level', 'O2', 'Oxygen', 'PK', 'Pharmacokinetics', 'PR', 'PR interval; duration in milliseconds from the beginning', 'of the P wave to onset of ventricular depolarization (R)', 'PRO', 'Patient Reported Outcome', 'PTS', 'Platform Technology and Science', 'QRS interval; duration in milliseconds of the QRS', 'QRS', 'complex', 'QT interval; duraction in milliseconds between the start', 'QT', 'of the Q wave and the end of the T wave', 'QTcF', 'QT interval corrected for heart rate (Friderica formula)', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cells', 'RNA', 'Ribonucleic acid', 'SABA', 'Short-acting ß2 Receptor Agonist', 'SAE', 'Serious Adverse Event', 'SAMA', 'Short-acting Muscarinic Receptor Agonist', '57']"
57,page_58,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'SGRQ', ""St George's Respiratory Questionnaire"", 'SGRQ-C', 'SGRQ-C for COPD patients', 'SRM', 'Study Reference Manual', 'SRT', 'Safety Review Team', 'SOA', 'Schedule of Activities', 'SUSAR', 'Suspected unexpected serious adverse reaction', 't¹/2', 'Terminal phase half-life', 'tmax', 'Time to reach Cmax', 'TPR', 'Third Party Resourcing', 'ULN', 'Upper limit of normal', 'g', 'Microgram', 'VT', 'Ventricular tachycardia', 'WBC', 'White blood cells', 'WOCBP', 'Women of child bearing potential', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'CAT', 'Combivent', 'Duoneb', '58']"
58,page_59,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.2.', 'Appendix 2: Clinical Laboratory Tests', 'The tests detailed in Table 5 (Protocol-Required Safety Laboratory', 'Assessments) will be performed by the central laboratory, except as noted.', 'Local laboratory results are only required in the event that the central laboratory', 'results are not available in time for either study treatment administration and/or', 'response evaluation. If a local sample is required, it is important that the sample', 'for central analysis is obtained at the same time. Additionally, if the local', 'laboratory results are used to make either a study treatment decision or response', 'evaluation, the results must be entered into the CRF.', 'Protocol-specific requirements for inclusion or exclusion of participants are', 'detailed in Section 6.', 'Additional tests may be performed at any time during the study as determined', 'necessary by the investigator or required by local regulations.', 'Table 5', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Specific gravity', 'Urinalysis', 'pH, glucose, protein, blood, ketones by dipstick', '59']"
59,page_60,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody²', 'All study-required laboratory assessments will be performed by a central', 'laboratory', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Laboratory results that could unblind the study will not be reported to investigative sites', 'or other blinded personnel until the study has been unblinded.', '60']"
60,page_61,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.3.', 'Appendix 3: Study Governance Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with:', 'Consensus ethical principles derived from international guidelines', 'including the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical', 'Guidelines', 'Applicable ICH Good Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other', 'relevant documents (eg, advertisements) must be submitted to an IRB/IEC by', 'the investigator and reviewed and approved by the IRB/IEC before the study is', 'initiated.', 'Any amendments to the protocol will require IEC/IRB approval before', 'implementation of changes made to the study design, except for changes', 'necessary to eliminate an immediate hazard to study participants.', 'The investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC', 'annually or more frequently in accordance with the requirements, policies,', 'and procedures established by the IRB/EC', 'Notifying the IRB/IEC of SAE or other significant safety findings as', 'required by IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 CFR, ICH guidelines, the IRB/IEC, European', 'regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', 'Financial Disclosure', 'Investigators and sub-investigators will provide the sponsor with sufficient, accurate', 'financial information as requested to allow the sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate regulatory authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study.', '61']"
61,page_62,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Informed Consent Process', 'The investigator or his/her representative will explain the nature of the study to', 'the participant or his/her legally authorized representative and answer all', 'questions regarding the study.', 'Participants must be informed that their participation is voluntary. Participants', 'or their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', ""A copy of the ICF(s) must be provided to the participant or the participant's"", 'legally authorized representative.', 'Participants who are rescreened are required to sign a new ICF.', 'The ICF may contain a separate section that addresses the use of remaining', 'mandatory samples for optional exploratory research in accordance with SOP-', 'GSKF-410. The investigator or authorized designee will explain to each', 'participant the objectives of the exploratory research. Participants will be told', 'that they are free to refuse to participate and may withdraw their consent at any', 'time and for any reason during the storage period. A separate signature will be', ""required to document a participant's agreement to allow any remaining"", 'specimens to be used for exploratory research. Participants who decline to', 'participate will not provide this separate signature.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', '62']"
62,page_63,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Committees Structure', 'A study charter will be created to describe important governance aspects while the', 'study is being conducted.', 'The SRT will include the Safety Development Leader, GCSP scientist, MM, CIL', 'and study statistician but will extend to other functions as requied. The SRT will', 'provide a proactive, aggregate and holistic evaluation of the safety data of', 'danirixin. Further details are included in the SRT charter.', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with', 'International Committee of Medical Journal Editors authorship requirements.', 'Dissemination of Clinical Study Data', 'This study will be registered and study information from this protocol will be', 'posted on publicly available clinical trial registers before enrolment of study', 'participants begins.', 'The results summary of this study will be posted to the GSK Clinical Study', 'Register and other publicly available clinical trial registers within 8 months of', 'the primary study completion date.', 'A manuscript reporting the study results will be submitted to a peer reviewed', ""journal within 18 months of the last participant's last visit."", 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic', 'CRF unless transmitted to the sponsor or designee electronically (eg, laboratory', 'data). The investigator is responsible for verifying that data entries are accurate', 'and correct by physically or electronically signing the CRF.', 'The investigator must maintain accurate documentation (source data) that', 'supports the information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', '63']"
63,page_64,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the CRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the investigator for 25 years after study completion', 'unless local regulations or institutional policies require a longer retention period.', 'No records may be destroyed during the retention period without the written', 'approval of the sponsor. No records may be transferred to another location or', 'party without written notification to the sponsor.', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', ""investigator's site."", 'Data reported on the CRF or entered in the eCRF that are transcribed from', 'source documents must be consistent with the source documents or the', 'discrepancies must be explained. The investigator may need to request previous', 'medical records or transfer records, depending on the study. Also, current', 'medical records must be available.', 'Definition of what constitutes source data can be found in the SRM.', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed.', 'The investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the sponsor or investigator may include', 'but are not limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', ""IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines"", 'Inadequate recruitment of participants by the investigator', 'Discontinuation of further study treatment development', '64']"
64,page_65,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', 'Definition of AE', 'AE Definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of a study treatment, whether or not considered related to the', 'study treatment.', 'NOTE: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study treatment.', 'Events Meeting the AE Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)', 'or other safety assessments (eg, ECG, radiological scans, vital signs measurements),', 'including those that worsen from baseline, considered clinically significant in the', 'medical and scientific judgment of the investigator (ie, not related to progression of', 'underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study treatment administration even', 'though it may have been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'treatment or a concomitant medication. Overdose per se will not be reported as an', 'AE/SAE unless it is an intentional overdose taken with possible suicidal/self-', 'harming intent. Such overdoses should be reported regardless of sequelae.', '""Lack of efficacy"" or ""failure of expected pharmacological action"" per se will not be', 'reported as an AE or SAE. Such instances will be captured in the efficacy', 'assessments. However, the signs, symptoms, and/or clinical sequelae resulting from', 'lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE', 'or SAE.', 'The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be', 'reported as AE or SAE if they fulfill the definition of an AE or SAE. Also, ""lack of', 'efficacy"" or ""failure of expected pharmacological action"" constitutes an AE or SAE.', '65']"
65,page_66,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Events NOT Meeting the AE Definition', 'Any clinically significant abnormal laboratory findings or other abnormal safety', 'assessments which are associated with the underlying disease, unless judged by the', ""investigator to be more severe than expected for the participant's condition."", 'The disease/disorder being studied or expected progression, signs, or symptoms of', 'the disease/disorder being studied, unless more severe than expected for the', ""participant's condition."", 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that', 'leads to the procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or', 'convenience admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Definition of SAE', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious', 'conditions are met (eg, hospitalization for signs/symptoms of the disease under study,', 'death due to progression of disease).', 'A SAE is defined as any untoward medical occurrence that, at any dose:', 'a) Results in death', 'b) Is life-threatening', 'The term ""life-threatening\' in the definition of \'serious\' refers to an event in which the', 'participant was at risk of death at the time of the event. It does not refer to an event,', 'which hypothetically might have caused death, if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization', 'In general, hospitalization signifies that the participant has been detained (usually', 'involving at least an overnight stay) at the hospital or emergency ward for observation', ""and/or treatment that would not have been appropriate in the physician's office or"", 'outpatient setting. Complications that occur during hospitalization are AE. If a', 'complication prolongs hospitalization or fulfills any other serious criteria, the event is', 'serious. When in doubt as to whether ""hospitalization"" occurred or was necessary, the AE', 'should be considered serious.', 'Hospitalization for elective treatment of a pre-existing condition that did not worsen from', 'baseline is not considered an AE.', 'Results in persistent disability/incapacity', ""The term disability means a substantial disruption of a person's ability to conduct"", '66']"
66,page_67,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,', 'and accidental trauma (eg, sprained ankle) which may interfere with or prevent', 'everyday life functions but do not constitute a substantial disruption.', 'Is a congenital anomaly/birth defect', 'Other situations:', 'Medical or scientific judgment should be exercised in deciding whether SAE', 'reporting is appropriate in other situations such as important medical events that may', 'not be immediately life-threatening or result in death or hospitalization but may', 'jeopardize the participant or may require medical or surgical intervention to prevent', 'one of the other outcomes listed in the above definition. These events should usually', 'be considered serious.', 'Examples of such events include invasive or malignant cancers, intensive treatment', 'in an emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', 'Definition of Cardiovascular Events', 'Cardiovascular Events (CV) Definition:', 'Investigators will be required to fill out the specific CV event page of the CRF for the', 'following AEs and SAEs:', 'Myocardial infarction/unstable angina', 'Congestive heart failure', 'Arrhythmias', 'Valvulopathy', 'Pulmonary hypertension', 'Cerebrovascular events/stroke and transient ischemic attack', 'Peripheral arterial thromboembolism', 'Deep venous thrombosis/pulmonary embolism', 'Revascularization', '67']"
67,page_68,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Recording AE and SAE', 'AE and SAE Recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (eg, hospital progress notes, laboratory, and diagnostics reports)', 'related to the event.', 'The investigator will then record all relevant AE/SAE information in the CRF', ""It is not acceptable for the investigator to send photocopies of the participant's"", 'medical records to GSK in lieu of completion of the GSK (/AE/SAE CRF page.', 'There may be instances when copies of medical records for certain cases are', 'requested by GSK. In this case, all participant identifiers, with the exception of the', 'participant number, will be redacted on the copies of the medical records before', 'submission to GSK.', 'The investigator will attempt to establish a diagnosis of the event based on signs,', 'symptoms, and/or other clinical information. Whenever possible, the diagnosis (not', 'the individual signs/symptoms) will be documented as the AE/SAE.', 'Assessment of Intensity', 'The investigator will make an assessment of intensity for each AE and SAE reported', 'during the study and assign it to 1 of the following categories:', 'Mild: An event that is easily tolerated by the participant, causing minimal discomfort', 'and not interfering with everyday activities.', 'Moderate: An event that causes sufficient discomfort and interferes with normal', 'everyday activities.', 'Severe: An event that prevents normal everyday activities. An AE that is assessed as', 'severe should not be confused with an SAE. Severe is a category utilized for rating', 'the intensity of an event; and both AE and SAE can be assessed as severe.', 'An event is defined as ""serious\' when it meets at least 1 of the predefined outcomes', 'as described in the definition of an SAE, NOT when it is rated as severe.', 'Assessment of Causality', 'The investigator is obligated to assess the relationship between study treatment and', 'each occurrence of each AE/SAE.', 'A ""reasonable possibility"" of a relationship conveys that there are facts, evidence,', 'and/or arguments to suggest a causal relationship, rather than a relationship cannot', 'be ruled out.', 'The investigator will use clinical judgment to determine the relationship.', '68']"
68,page_69,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other', 'risk factors, as well as the temporal relationship of the event to study treatment', 'administration will be considered and investigated.', ""The investigator will also consult the Investigator's Brochure (IB) and/or Product"", 'Information, for marketed products, in his/her assessment.', 'For each AE/SAE, the investigator must document in the medical notes that he/she', 'has reviewed the AE/SAE and has provided an assessment of causality.', 'There may be situations in which an SAE has occurred and the investigator has', 'minimal information to include in the initial report to GSK. However, it is very', 'important that the investigator always make an assessment of causality for', 'every event before the initial transmission of the SAE data to GSK.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information and send an SAE follow-up report with the updated causality', 'assessment.', 'The causality assessment is one of the criteria used when determining regulatory', 'reporting requirements.', 'Follow-up of AE and SAE', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as medically indicated or as requested by GSK to', 'elucidate the nature and/or causality of the AE or SAE as fully as possible. This may', 'include additional laboratory tests or investigations, histopathological examinations,', 'or consultation with other health care professionals.', 'If a participant dies during participation in the study or during a recognized follow-', 'up period, the investigator will provide GSK with a copy of any post-mortem', 'findings including histopathology.', 'New or updated information will be recorded in the originally completed CRF.', 'The investigator will submit any updated SAE data to GSK within 24 hours of', 'receipt of the information.', 'Reporting of SAE to GSK', 'SAE Reporting to GSK via Electronic Data Collection Tool', 'The primary mechanism for reporting SAE to GSK will be the electronic data', 'collection tool.', 'If the electronic system is unavailable for more than 24 hours, then the site will use', 'the paper SAE data collection tool (see next section).', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', '69']"
69,page_70,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'After the study is completed at a given site, the electronic data collection tool will be', 'taken off-line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated', 'data on a previously reported SAE after the electronic data collection tool has been', 'taken off-line, then the site can report this information on a paper SAE form (see', 'next section) or to the medical monitor/SAE coordinator by telephone.', 'Contacts for SAE reporting can be found in the SRM.', '70']"
70,page_71,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2.', 'Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient and confirmatory testing with additional FSH and', 'estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine or serum pregnancy test', 'Additional pregnancy testing will be performed at approximately monthly intervals', 'during the study treatment period, after the last dose of study treatment and as', 'required locally.', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected', '71']"
71,page_72,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Pregnancy testing, with a high sensitivity test will be performed using the test kit', 'provided by the central laboratory and approved by the sponsor and in accordance', 'with instructions provided in the test kit package insert.', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', 'Investigator will not routinely attempt to collect pregnancy information on any male', ""participant's female partner(s) who becomes pregnant while the male participant is"", 'participating in this study; however, voluntary reports of such incidents will be', 'captured through the GSK standard reporting mechanism. This applies only to male', 'participants who receive double-blind study treatment.', ""If pregnancy information for a male participant's female partner(s) is voluntarily"", 'reported, after obtaining the necessary signed informed consent from the pregnant', 'female partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', ""24 hours of learning of a participant's pregnancy."", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the investigator, will be reported to GSK', 'as described in Appendix 4. While the investigator is not obligated to actively seek', '72']"
72,page_73,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'this information in former study participants, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female participant who becomes pregnant while participating will discontinue', 'study treatment and be withdrawn from the study.', '73']"
73,page_74,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.6.', 'Appendix 6: Genetics', 'USE/ANALYSIS OF DNA', ""Genetic variation may impact a participant's response to therapy, susceptibility,"", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a blood sample will be collected for DNA analysis.', 'DNA samples will be used for research related to danirixin or COPD and related', 'diseases. They may also be used to develop tests/assays including diagnostic tests)', 'related danirixin treatment, and COPD (and related diseases). Genetic research may', 'consist of the analysis of one or more candidate genes or the analysis of genetic', 'markers throughout the genome (as appropriate).', 'DNA samples will be analyzed if it is hypothesized that this may help further', 'understand the clinical data.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to danirixin or study treatments of this class. The results of', 'genetic analyses may be reported in the clinical study report or in a separate study', 'summary.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on danirixin (or study treatments of this', 'class) or COPD (and related diseases) continues but no longer than 15 years or other', 'period as per local requirements.', '74']"
74,page_75,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', 'Phase II liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event etiology', 'Phase II liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria', 'ALT-absolute', 'ALT 5xULN', 'ALT Increase', 'ALT 3xULN persists for >4 weeks', 'Bilirubin1, 2', 'ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin)', 'INR²', 'ALT > 3xULN and INR>1.5, if INR measured', 'Cannot', 'ALT: 3xULN and cannot be monitored weekly for 4 weeks', 'Monitor', 'Symptomatic³', 'ALT 3xULN associated with symptoms (new or worsening) believed', 'to be related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Obtain INR and recheck with each', 'liver chemistry assessment until the', 'Complete the liver event CRF and complete', 'transaminases values show', 'an SAE data collection tool if the event also', 'downward trend', 'meets the criteria for an SAE²', 'Obtain blood sample for', 'Perform liver chemistry event follow up', 'pharmacokinetic (PK) analysis, up', 'assessments', 'to 72 h after last dose5', 'Monitor the participant until liver', 'chemistries resolve, stabilize, or return to', 'Serum creatine phosphokinase', 'within baseline (see MONITORING', '(CPK) and lactate dehydrogenase', '(LDH).', 'below)', 'Fractionate bilirubin, if total', 'Do not restart/rechallenge participant', 'bilirubin 2xULN', 'with study treatment unless allowed per', 'protocol and GSK Medical Governance', 'Obtain complete blood count with', 'approval is granted (see below)', 'differential to assess eosinophilia', 'If restart/rechallenge not allowed per', 'Record the appearance or', 'protocol or not granted, permanently', 'worsening of clinical symptoms of', '75']"
75,page_76,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'discontinue study treatment and continue', 'liver injury, or hypersensitivity, on', 'participant in the study for any protocol', 'the AE report form', 'specified follow up assessments', 'Record use of concomitant', 'medications on the concomitant', 'MONITORING:', 'medications report form including', 'acetaminophen, herbal remedies,', 'For bilirubin or INR criteria:', 'other over the counter medications.', 'Repeat liver chemistries (include ALT,', 'Record alcohol use on the liver', 'AST, alkaline phosphatase, bilirubin) and', 'event alcohol intake case report', 'perform liver event follow up assessments', 'form (CRF) page', 'within 24 hrs', 'Monitor participants twice weekly until', 'liver chemistries resolve, stabilize or return', 'to within baseline', 'For bilirubin or INR criteria:', 'A specialist or hepatology consultation is', 'Anti-nuclear antibody, anti-smooth', 'recommended', 'muscle antibody, Type 1 anti-liver', 'kidney microsomal antibodies, and', 'For All other criteria:', 'quantitative total immunoglobulin', 'Repeat liver chemistries (include ALT,', 'G (IgG) or gamma globulins.', 'AST, alkaline phosphatase, bilirubin) and', 'Serum acetaminophen adduct high', 'perform liver event follow up assessments', 'performance liquid chromatography', 'within 24-72 hrs', '(HPLC) assay (quantifies potential', 'Monitor participants weekly until liver', 'acetaminophen contribution to liver', 'chemistries resolve, stabilize or return to', 'injury in participants with definite', 'within baseline', 'or likely acetaminophen use in the', 'preceding week [James, 2009].', 'Liver imaging (ultrasound,', 'magnetic resonance, or', 'computerised tomography) and /or', 'liver biopsy to evaluate liver', 'disease complete Liver Imaging', 'and/or Liver Biopsy CRF pages.', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that participant if ALT 3xULN and bilirubin 2xULN..', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT > 3xULN and INR>1.5, if INR', ""measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding"", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM);', 'Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable,', 'obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody', '76']"
76,page_77,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '5. PK sample may not be required for participants known to be receiving placebo or non-GSK comparator', 'treatments.) Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the', ""participant's best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot"", 'be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and', 'shipping are in the SRM.', 'Phase II liver chemistry increased monitoring criteria with continued therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'Notify the GSK medical monitor within 24 hours of', 'ALT >3xULN and <5xULN and bilirubin', 'learning of the abnormality to discuss participant', '<2xULN, without symptoms believed to', 'safety.', 'be related to liver injury or', 'Participant can continue study treatment', 'hypersensitivity, and who can be', 'monitored weekly for 4 weeks', 'Participant must return weekly for repeat liver', 'chemistries (ALT, AST, alkaline phosphatase,', 'bilirubin) until they resolve, stabilise or return to', 'within baseline', 'If at any time participant meets the liver chemistry', 'stopping criteria, proceed as described above', 'If, after 4 weeks of monitoring, ALT <3xULN and', 'bilirubin <2xULN, monitor participants twice monthly', 'until liver chemistries normalize or return to within', 'baseline.', 'Reference', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', '77']"
77,page_78,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.8.', 'Appendix 8: Medical Device Incidents: Definition and', 'Procedures for Recording, Evaluating, Follow-up, and', 'Reporting', 'Definition and Documentation of Medical Device Incidents', 'Definitions of a Medical Device Incident', 'The detection and documentation procedures described in this protocol apply to all GSK', 'medical devices provided for use in the study (see Section 7.1.1) for the list of GSK', 'medical devices).', 'Medical Device Incident Definition', 'A medical device incident is any malfunction or deterioration in the characteristics', 'and/or performance of a device as well as any inadequacy in the labeling or the', 'instructions for use which, directly or indirectly, might lead to or might have led to', 'the death of a participant/user/other person or to a serious deterioration in his/her', 'state of health.', 'Not all incidents lead to death or serious deterioration in health. The nonoccurrence', 'of such a result might have been due to other fortunate circumstances or to the', 'intervention of health care personnel.', 'It is sufficient that:', 'An incident associated with a device happened and', 'The incident was such that, if it occurred again, might lead to death or a serious', 'deterioration in health.', 'A serious deterioration in state of health can include any of the following:', 'Life-threatening illness', 'Permanent impairment of body function or permanent damage to body structure', 'Condition necessitating medical or surgical intervention to prevent one of the', 'above', 'Fetal distress, fetal death, or any congenital abnormality or birth defects', '78']"
78,page_79,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Examples of incidents', 'A participant, user, caregiver, or healthcare professional is injured as a result of a', 'medical device failure or its misuse.', ""A participant's study treatment is interrupted or compromised by a medical device"", 'failure.', 'A misdiagnosis due to medical device failure leads to inappropriate treatment.', ""A participant's health deteriorates due to medical device failure."", 'Documenting Medical Device Incidents', 'Medical Device Incident Documenting', 'Any medical device incident occurring during the study will be documented in the', ""participant's medical records, in accordance with the investigator's normal clinical"", 'practice, and on the appropriate form.', 'For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE', 'CRF page will be completed as described in Appendix 4.', 'The form will be completed as thoroughly as possible and signed by the investigator', 'before transmittal to the GSK.', 'It is very important that the investigator provides his/her assessment of causality', '(relationship to the medical device provided by GSK) at the time of the initial report', 'and describes any corrective or remedial actions taken to prevent recurrence of the', 'incident.', 'A remedial action is any action other than routine maintenance or servicing of a', 'medical device where such action is necessary to prevent recurrence of an incident.', 'This includes any amendment to the device design to prevent recurrence.', '79']"
79,page_80,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.9.', 'Appendix 9: Neutrophil Safety and Study Treatment Restart', 'Neutrophil Stopping Criteria: Absolute neutrophil count (ANC) 0.5 X 109 /L', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Record the appearance or', 'worsening of any clinical', 'Report the event to GSK within 24 hours', 'symptoms on the AE report form¹', 'Complete an SAE data collection tool if the', 'event also meets the criteria for an SAE', 'Obtain blood sample for', 'pharmacokinetic (PK) analysis', 'Monitor the participant until neutrophil', 'within 12 hours after last dose²', 'count stabilizes or returns to within', 'Record use of concomitant', 'baseline (see MONITORING below)', 'medications on the concomitant', 'Do not restart participant with study', 'medications report form', 'treatment unless allowed per protocol and', 'GSK Medical Governance approval is', 'granted (see RESTART below)', 'MONITORING:', 'Treatment of any suspected infections¹', 'Repeat CBC within 24 hrs', 'Monitor CBC daily until neutrophil count', 'resolves, stabilizes or returns to within', 'baseline', 'RESTART', 'Restart of study medication must be', 'Check the CBC within 24-48 hours', 'approved by the GSK Medical Monitor', 'after re-starting study medication,', 'Restart may be attempted ONLY if all', 'monitor twice weekly for two', 'three criteria are met:', 'weeks, and monthly thereafter.', 'The neutrophil count is 1.5 X 109/L', 'If the ANC drops below 1.0 X', 'for at least 48 hours', '109/L on restart, the participant', 'At least 7 days have elapsed since the', 'should be permanently', 'suspension of study treatment', 'discontinued from study treatment', 'No sign or symptom of associated', 'and withdrawn from the study.', 'infection has been identified', '80']"
80,page_81,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '1. New or worsening symptoms believed to be related to neutropenia such as (but not limited', 'to): sudden onset of fever or malaise, stomatitis, odynophagia, periodontal infection, skin', 'abscesses, signs or symptoms of sinusitis and otitis, symptoms of pneumonia (eg, cough,', 'dyspnea), perirectal pain and irritation, hypotension or signs of septic shock.', '2.', 'Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is', ""unclear, provide the participant's best approximation. If the date/time of the last dose cannot"", 'be approximated OR a PK sample cannot be collected in the time period indicated above, do', 'not obtain a PK sample. Instructions for sample handling and shipping are in the SRM.', '81']"
81,page_82,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.10.', 'Appendix 10: Country-specific requirements', 'No country specific requirements', '82']"
82,page_83,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.11.', 'Appendix 11 Protocol Amendment History', 'Amendment 1', 'Table 1', 'Schedule of activities', 'Original text:', 'FU', 'Up to', '28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'EW', 'Visit1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', 'days', 'post', 'last', 'dose', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'up to', '0/', '2/', '4/', '8/', '12/', '16 /', '20/', '24', '32', '40 /', '52/', '-7 days', 'D1', 'D14', 'D28', 'D56', 'D84', 'D112', 'D140', '/1168', 'D224', 'D280', 'D364', 'Assessment', '+3d', '+3d', '+3d', '3d', '3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'window', 'Urine or', 'serum', 'X', 'Pregnancy', 'testg', 'HIV,', 'Hepatitis B', 'and C', 'screeninge', 'AE review', 'SAE review', 'Revised text:', 'FU', 'Up to', '28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'EW', 'Visit1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', 'days', 'post', 'last', 'dose', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'up to', '0/', '2/', '4/', '8/', '12/', '16/', '20/', '24', '32', '40/', '52/', '-28 days', 'D1', 'D14', 'D28', 'D56', 'D84', 'D112', 'D140', 'D168', 'D224', 'D280', 'D364', 'Assessment', '+3d', '+3d', '+3d', '+3d', '3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'window', 'HIV,', 'Hepatitis B', 'X', 'and C', 'screeninge', 'AE review', 'SAE review', '83']"
83,page_84,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Section 5.1', 'Overall Design', 'Original text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days - -7 to', '1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Placebo (n=50)', '7 days', 'Follow-up²', 'Screening¹', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', 'Amended text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -28', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', '84']"
84,page_85,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 1', 'Study Schematic', '52 weeks', 'Up to 28', 'Placebo (n=50)', 'days', 'Follow-up2', 'Screening¹', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', 'Section 6.1', 'Inclusion Criteria', 'Original text:', '2', 'Male or female', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'Female participants:', 'A female participant is eligible to participate if she is not pregnant (see Section 12.5;', 'Appendix 5), not breastfeeding, and at least one of the following conditions applies:', 'i. Not a woman of childbearing potential (WOCBP) as defined in Section 12.5', '(Appendix 5)', 'OR', 'ii. A WOCBP who agrees to follow the contraceptive guidance in Section 12.5', '(Appendix 5) during the treatment period and for at least 60 hours after the', 'last dose of study treatment.', '85']"
85,page_86,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Revised text:', '3', 'Male or female', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', 'Section 12.2 Appendix 2:', 'Original text:', 'Table 7', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', '86']"
86,page_87,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as', 'needed for women of childbearing potential²²', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody³', 'All study-required laboratory assessments will be performed by a central', 'laboratory, with the exception of urine testing', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2.', 'Local urine hCG testing will be standard for the protocol unless serum testing is required by local', 'regulation or IRB/IEC.', '3. Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', '87']"
87,page_88,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text:', 'Table 8', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody²', 'All study-required laboratory assessments will be performed by a central', 'laboratory', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', '88']"
88,page_89,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Section 12.5 Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Original text:', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level', 'in the postmenopausal range may be used to confirm a postmenopausal', 'state in women not using hormonal contraception or hormonal', 'replacement therapy (HRT). However, in the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient.', 'Females on HRT and whose menopausal status is in doubt will be', 'required to use one of the non-hormonal highly effective contraception', 'methods if they wish to continue their HRT during the study. Otherwise,', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', '89']"
89,page_90,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Female participants', 'Female participants of childbearing potential are eligible to participate if they agree to', 'use a highly effective method of contraception consistently and correctly as described in', 'Table 6.', 'Table 9', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '90']"
90,page_91,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text:', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level', 'in the postmenopausal range may be used to confirm a postmenopausal', 'state in women not using hormonal contraception or hormonal', 'replacement therapy (HRT). However, in the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient and confirmatory', 'testing with additional FSH and estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be', 'required to use one of the non-hormonal highly effective contraception', 'methods if they wish to continue their HRT during the study. Otherwise,', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', '91']"
91,page_92,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Table 10', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent', 'a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '92']"
92,page_93,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amendment 2', 'Original text:', '3.3.1 Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', '93']"
93,page_94,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'No adverse events related to testicular', 'effects have been observed in clinical', 'studies to date.', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count 0.5', 'X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', '94']"
94,page_95,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', 'study in patients with Influenza (GSK Study', '201682, GlaxoSmithKline Document No.', '2014N205875_00), decreased neutrophil', 'counts have been observed in participants', 'receiving either placebo or danirixin; no', 'instances of danirixin-related neutropenia', 'have been reported in clinical studies to', 'date. In healthy participants, the data are', 'confounded by the observation of low', 'neutrophil counts before dosing or at', 'follow-up, and were not dose-related, while', 'in patients with influenza, neutrophil counts', 'recovered while receiving danirixin,', 'coincident with resolution of the viral', 'infection. There have been no reports of', 'neutrophil count decreases below the lower', 'limit of normal in patients with COPD who', 'were treated with danirixin for one year.', 'These data support the conclusion that a', 'causal association of neutropenia with', 'danirixin cannot be definitively established.', '95']"
95,page_96,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Male participants with female partners of', 'child-bearing potential must comply with', 'the contraception requirements.', 'Study Procedures', 'None', 'Other', 'Not applicable', '96']"
96,page_97,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text:', '3.3.1 Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', 'No adverse events related to testicular', 'effects have been observed in clinical', '97']"
97,page_98,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'studies to date.', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count < 0.5 X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', '98']"
98,page_99,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'study in patients with Influenza (GSK Study', '201682, GlaxoSmithKline Document No.', '2014N205875_00) decreased neutrophil', 'counts have been observed in participants', 'receiving either placebo or danirixin; no', 'instances of danirixin-related neutropenia', 'have been reported in clinical studies to', 'date. In healthy participants, the data are', 'confounded by the observation of low', 'neutrophil counts before dosing or at', 'follow-up, and were not dose-related, while', 'in patients with influenza, neutrophil counts', 'recovered while receiving danirixin,', 'coincident with resolution of the viral', 'infection. There have been no reports of', 'neutrophil count decreases below the lower', 'limit of normal in patients with COPD who', 'were treated with danirixin for one year.', 'These data support the conclusion that a', 'causal association of neutropenia with', 'danirixin cannot be definitively established.', '99']"
99,page_100,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Study Procedures', 'None', 'Other', 'Not applicable', '100']"
100,page_101,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Section 6.1', 'Inclusion Criteria', 'Original text:', 'Sex', '6.', 'Male or female', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', 'Revised text:', '7.', 'Male or female', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', '7.1.1 Medical Devices', 'Original text:', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices are', 'provided in the SRM.', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', 'Revised text:', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', '101']"
101,page_102,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Mobile spirometers (MicroDiary, manusfactured by and purchased from CareFusion) are', 'also being provided by GSK for this study. These devices allow participants to conduct', 'spirometry assessments at home. The MicroDiary has US FDA 510(k) clearance to', 'market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices and', 'mobile spirometers are provided in the SRM.', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '9.2.8 Medical Device Incidents (Including Malfunctions)', 'Original text:', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use. In order to fulfill regulatory reporting obligations', 'worldwide, the investigator is responsible for the detection and documentation of events', 'meeting the definitions of incident or malfunction that occur during the study with such', 'devices.', 'Revised text:', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use and measuring spirometry at home. In order to fulfill', 'regulatory reporting obligations worldwide, the investigator is responsible for the', 'detection and documentation of events meeting the definitions of incident or malfunction', 'that occur during the study with such devices.', '12.5 Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Original text:', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', '102']"
102,page_103,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Table 6', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent', 'a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '103']"
103,page_104,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Revised text:', 'Text deleted.', '12.5 Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Original text:', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', ""Investigator will attempt to collect pregnancy information on any male participant's"", 'female partner of a male study participant who becomes pregnant while participating', 'in this study. This applies only to participants who receive study treatment.', 'After obtaining the necessary signed informed consent from the pregnant female', 'partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure.', 'Revised text:', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', 'Investigator will not routinely attempt to collect pregnancy information on any', ""male participant's female partner(s) who becomes pregnant while the male"", 'participant is participating in this study; however, voluntary reports of such', 'incidents will be captured through the GSK standard reporting mechanism. This', 'applies only to male participants who receive double-blind study treatment.', ""If pregnancy information for a male participant's female partner(s) is voluntarily"", 'reported, after obtaining the necessary signed informed consent from the pregnant', 'female partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', '104']"
104,page_105,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Generally, follow-up will be no longer than 6 to 8 weeks following the', 'estimateddelivery date. Any termination of the pregnancy will be reported', 'regardless of fetal status (presence or absence of anomalies) or indication for', 'procedure.', '105']"
105,page_106,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amendment 03', 'Original text:', 'Schedule of Activities (only section relevant for the change):', 'Screening/', 'Visit', 'Visit1a', '2', 'Week', 'up to', '0/', '-28 days', 'D1', 'Assessment window', '+3d', 'Eligibility', 'Informed Consent', 'X', 'Genetics Informed Consentb', 'Demography', 'Inclusion and Exclusion', 'X', 'Criteria', 'Smoking Statusc', 'Smoking Historyc', 'Amended text:', 'Schedule of Activities (only section relevant for the change):', 'Screening/', 'Visit', 'Visit1a', '2', 'Week', 'up to', '0/', '-32 days', 'D1', 'Assessment window', '+3d', 'Eligibility', 'Informed Consent', 'Genetics Informed Consentb', 'Demography', 'Inclusion and Exclusion', 'Criteria', 'Smoking Statusc', 'X', 'Smoking Historyc', 'Original text:', '3.1', 'Study Rationale', 'This protocol describes a pilot study to investigate the effect of danirixin HBr 35mg', 'tablets on lung function and health related quality of life (HRQoL) in participants with', 'mild to moderate airflow obstruction identified from the COPDGene cohort. Study', 'participants will continue with their standard of care inhaled medications (i.e. long acting', 'bronchodilators with or without inhaled corticosteroids) while receiving study treatment.', '106']"
106,page_107,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Specifically, this study aims to assess whether or not danirixin has the potential to impact', 'disease progression in participants with a COPD progression score indicating they are', 'likely to decline based on 5 year data from COPDGene and support the conduct of a', 'larger Phase III study for disease progression. In addition to lung function and HRQoL,', 'this study will assess moderate/severe COPD exacerbations, health status (CAT), and', 'rescue medication use.', 'Amended text:', '3.1', 'Study Rationale', 'This protocol describes a pilot study to investigate the effect of danirixin HBr 35mg', 'tablets on lung function and health related quality of life (HRQoL) in participants with', 'mild to moderate airflow obstruction identified from the COPDGene cohort. Study', 'participants will continue with their standard of care inhaled medications (i.e. long acting', 'bronchodilators with or without inhaled corticosteroids) while receiving study treatment.', 'Specifically, this study aims to assess whether or not danirixin has the potential to impact', 'disease progression in participants with a demonstrated history of decline in FEV1 based', 'on 5 year data from COPDGene and support the conduct of a larger Phase III study for', 'disease progression. In addition to lung function and HRQoL, this study will assess', 'moderate/severe COPD exacerbations, health status (CAT), and rescue medication use.', 'Original text (relevant section only):', '4.1', 'Objectives and Enppoints', 'Objectives', 'Endpoints', 'Primary', 'To assess whether danirixin HBr', 'Rate of decline in FEV1', '35mg tablets impacts disease', ""Change from baseline in St. George's"", 'progression compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'To further characterize the safety of', 'Adverse events (AE), clinical', 'danirixin HBr 35mg tablets', 'laboratory values, vital signs,', 'compared with placebo in', 'electrocardiogram (ECG), and/or other', 'participants with mild to moderate', 'safety biomarkers', 'airflow limitation', '107']"
107,page_108,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text (relevant section only)', '4.1', 'Objectives and Endpoints', 'Objectives', 'Endpoints', 'Primary', 'To assess whether danirixin HBr', 'Rate of decline in FEV1', '35mg tablets impacts disease', ""Change from baseline in St. George's"", 'progression compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'Secondary', 'To further characterize the safety of', 'Adverse events (AE), clinical', 'danirixin HBr 35mg tablets', 'laboratory values, vital signs,', 'compared with placebo in', 'electrocardiogram (ECG), and/or other', 'participants with mild to moderate', 'safety biomarkers', 'airflow limitation', 'Original text:', '5.1', 'Overall Design', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -28', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', '108']"
108,page_109,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 5', 'Study Schematic', '52 weeks', 'Up to 28', 'Placebo (n=50)', 'days', 'Follow-up2', 'Screening', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2 Follow-up visit to occur within 28days of last dose of study medication', 'Amended text:', '5.1', 'Overall Design', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -32', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', '109']"
109,page_110,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 6', 'Study Schematic', 'Up to', '52 weeks', '32 days', 'Placebo (n=50)', 'R', '2', 'Screening', 'Follow-up', '1', 'Danirixin, 35mg', '(n=50)', '1', 'If changes to medication are required, consent must be signed prior to', 'any changes being made and may occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', 'Original text:', '6', 'Study Population', 'This study will identify specific patients most likely to decline from the well established', 'COPDGene cohort [NCT00608764]. This study will be an ancillary study within', 'COPDGene investigating the enrichment strategy for assessing disease progression.', 'These potential participants have been identified by COPDGene investigators based on', 'data collected over the initial 5 year period. The participants were identified based on a', 'Random Forest analysis and a demonstrated decline of at least 20mL/yr over the initial 5', 'year period. Once participants are identified from the COPDGene dataset, the following', 'criteria will be verified at initial study visit following signing of consent.', 'Amended text:', '6', 'Study Population', 'This study will identify specific COPD patients most likely to decline from well', 'established cohorts like COPDGene [NCT00608764]. This study will be an ancillary', 'study within COPDGene and any other relevant cohort investigating the enrichment', 'strategy for assessing disease progression. These potential participants will be identified', 'by COPDGene investigators based on data collected over the initial 5 year period. The', 'participants were identified based on a demonstrated decline of at least 15mL/yr over the', 'initial 5 year period. Once participants are identified from the COPDGene dataset, the', 'following criteria will be verified at initial study visit following signing of consent.', 'Equivalent cirteria may be identified within other cohorts if necessary to broaden', 'recruitment pool.', '110']"
110,page_111,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Original text:', 'Inclusion Criteria', 'Weight', '4. Body weight >45kg', 'Amended text:', 'Weight', '4, Body Mass Index > 21', 'Original text:', 'Exclusion Criteira', 'Diagnostic assessments', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN); bilirubin > 1.5xULN', '(isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin', '<35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Amended text:', 'Exclusion Criteria', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN) and bilirubin >', '1.5xULN (isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and', 'direct bilirubin <35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Note:', 'Participants with positive Hepatitis C antibody due to prior resolved disease can be', '111']"
111,page_112,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Original text:', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1.', 'Premenarchal', '2.', 'Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3.', 'Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient and confirmatory testing with additional FSH and', 'estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine or serum pregnancy test', 'Additional pregnancy testing will be performed at approximately monthly intervals', 'during the study treatment period, after the last dose of study treatment and as', 'required locally.', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected.', '112']"
112,page_113,"['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Amended text:', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2.', 'Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3.', 'Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient and confirmatory testing with additional FSH and', 'estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', '113']"
113,page_114,"['2016N293064 0', 'CONFIDENTIAL', '2018N394263_00', 'GlaxoSmithKline group of companies', '205864', 'TITLE PAGE', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Protocol Number: 205864 Amendment 2', 'Short Title: Danirixin Pilot Study for Disease Progression', 'Compound Number: GSK1325756', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information will be provided in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s) IND:108168', 'Approval Date: 24-JUL-2017', 'Copyright 2017 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']"
114,page_115,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263 00', '205864', 'SPONSOR SIGNATORY:', 'PPD', '24 July 2017', 'Aili Lazaar, MD', 'PPD', 'Date', 'Clinical Development Director', 'Respiratory Therapy Are Unit', 'PPD', '2']"
115,page_116,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 2', '24-Jul-2017', 'Amendment 1', '17-May-2017', 'Original Protocol', '21-Mar-2017', 'Amendment 1: 17-MAY-2017', 'Overall Rationale for the Amendment: This amendment excludes the enrolment of', 'women of childbearing potential and clarifies the testing required for determination of', 'post menopausal status in specific situations.', 'Section #', 'Description of Change', 'Brief Rationale', 'and Name', 'Table 1 -', 'Remove pregnancy testing', 'Not required as no longer enrolling', 'Schedule of', 'WOCBP', 'Activities', 'Added missing check', 'marks', 'Error in original protocol', 'Updated screening period', 'Required to allow for screening lab', 'tests', 'Section 6.1', 'Update to only allow females to', 'To remove additional burden on female', 'Inclusion', 'participate if they are not women of', 'subjects of childbearing potential requiring', 'Criteria', 'childbearing potential (WOCBP)', 'additional visits for pregnancy testing only.', 'Section 12.2', 'Update Table 6 - Protocol-', 'Removed pregnancy testing based on the', '- Appendix 2', 'Required Safety Laboratory', 'exclusion of WOCBP', 'Clinical', 'Assessments to remove pregnancy', 'Laboratory', 'testing', 'Tests', 'Section 12.5', 'Adding clarification on', 'Current wording in template is not', '- Appendix 5', 'determination of post', 'clear on testing required', 'Contraceptive', 'menopausal state in the', 'absence of 12 months of', 'Clarification of wording', 'Guidance and', 'Collection of', 'amenorrhea', 'Pregnancy', 'Updated wording to be in', 'Information', 'line with exclusion of', 'WOCBP', '3']"
116,page_117,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amendment 2: 24-JUL-2017', 'Overall Rationale for the Amendment:', 'Section #', 'Description of Change', 'Brief Rationale', 'and Name', 'Section 3.3.1', 'Removal of the following text from', 'Additional data available demonstrating', 'Risk', 'the mitigation strategy of the', 'absence of genotoxic effects', 'Assessment', 'reproductive toxicology section:', '""Male participants with female', 'partners of child-bearing', 'potential must comply with the', 'contraception requirements.""', 'Section 7.1.1', 'Update to add mobile spirometer', 'This device is being used in the study and', 'and Section', '(MicroDiary) as a medical device', 'was inadvertently omitted from the', '9.2.8', 'previous versions of the protocol', 'Medical', 'Devices and', 'Medical', 'Device', 'Incidents', 'Section 6.1', 'Removal of requirement for male', 'Additional data available demonstrating', 'and Section', 'contraception with partners of', 'absence of genotoxic effects', '12.5', 'WOCBP', '(Appendix 5)', 'Inclusion', 'Criteria and', 'Contraceptive', 'Guidance and', 'Collection of', 'Pregnancy', 'Information', '4']"
117,page_118,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '3', '1. SYNOPSIS', '8', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '10', '3.', 'INTRODUCTION', '13', '3.1.', 'Study Rationale', '13', '3.2.', 'Background', '14', '3.3.', 'Benefit/Risk Assessment', '15', '3.3.1.', 'Risk Assessment', '16', '3.3.2.', 'Benefit Assessment', '20', '3.3.3.', 'Overall Benefit:Risk Conclusion', '20', '4. OBJECTIVES AND ENDPOINTS', '21', '5.', 'STUDY DESIGN', '22', '5.1.', 'Overall Design', '22', '5.2.', 'Number of Participants', '22', '5.3.', 'Participant and Study Completion', '23', '5.4.', 'Scientific Rationale for Study Design', '23', '5.5.', 'Dose Justification', '23', '6.', 'STUDY POPULATION', '24', '6.1.', 'Inclusion Criteria', '24', '6.2.', 'Exclusion Criteria', '25', '6.3.', 'Lifestyle Restrictions', '27', '6.3.1.', 'Meals and Dietary Restrictions', '27', '6.3.2.', 'Activity', '27', '6.4.', 'Screen Failures', '28', '7. TREATMENTS', '28', '7.1.', 'Treatments Administered', '29', '7.1.1.', 'Medical Devices', '29', '7.2.', 'Dose Modification', '30', '7.3.', 'Method of Treatment Assignment', '30', '7.4.', 'Blinding', '30', '7.5.', 'Preparation/Handling/Storage/Accountability', '30', '7.6.', 'Treatment Compliance', '31', '7.7.', 'Concomitant Therapy', '31', '7.8.', 'Treatment after the End of the Study', '33', '8.', 'DISCONTINUATION CRITERIA', '33', '8.1.', 'Discontinuation of Study Treatment', '33', '8.1.1.', 'Liver Chemistry Stopping Criteria', '33', '8.1.2.', 'QTc Stopping Criteria', '34', '8.1.3.', 'Neutrophil Stopping Criteria', '35', '8.1.4.', 'Temporary Discontinuation', '35', '8.1.5.', 'Study Treatment Restart', '35', '5']"
118,page_119,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '8.2.', 'Withdrawal from the Study', '35', '8.3.', 'Lost to Follow Up', '36', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', '37', '9.1.', 'Efficacy Assessments', '37', '9.1.1.', 'FEV1', '37', '9.1.1.1.', 'Clinic Spirometry', '37', '9.1.1.2.', 'Mobile Spirometry', '37', '9.1.2.', 'SGRQ-C', '37', '9.1.3.', 'CAT', '38', '9.1.4.', 'COPD Exacerbations', '38', '9.1.5.', 'Patient Global Rating of Severity and Global Rating of', 'Change in Disease Severity', '38', '9.2.', 'Adverse Events', '39', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '39', '9.2.2.', 'Method of Detecting AEs and SAEs', '39', '9.2.3.', 'Follow-up of AEs and SAEs', '39', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '40', '9.2.5.', 'Cardiovascular and Death Events', '40', '9.2.6.', 'Disease-Related Events and/or Disease-Related', 'Outcomes Not Qualifying as SAEs', '40', '9.2.7.', 'Pregnancy', '41', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', '41', '9.2.8.1.', 'Time Period for Detecting Medical Device', 'Incidents', '41', '9.2.8.2.', 'Follow-up of Medical Device Incidents', '42', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents', 'to Sponsor', '42', '9.2.8.4.', 'Regulatory Reporting Requirements for', 'Medical Device Incidents', '42', '9.3.', 'Treatment of Overdose', '42', '9.4.', 'Safety Assessments', '43', '9.4.1.', 'Physical Examinations', '43', '9.4.2.', 'Vital Signs', '43', '9.4.3.', 'Electrocardiograms', '43', '9.4.4.', 'Clinical Safety Laboratory Assessments', '44', '9.4.5.', 'Pneumonia', '44', '9.5.', 'Pharmacokinetics', '45', '9.6.', 'Pharmacodynamics', '45', '9.7.', 'Genetics', '45', '9.8.', 'Biomarkers', '45', '9.9.', 'Health Economics OR Medical Resource Utilization and Health', 'Economics', '46', '10. STATISTICAL CONSIDERATIONS', '46', '10.1.', 'Sample Size Determination', '46', '10.2. Randomization', '49', '10.3.', 'Populations for Analyses', '49', '10.4.', 'Statistical Analyses', '49', '10.4.1.', 'Efficacy Analyses', '49', '10.4.2.', 'Safety Analyses', '51', '6']"
119,page_120,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.4.3.', 'Other Analyses', '51', '10.4.4.', 'Interim Analyses', '51', '11. REFERENCES', '52', '12. APPENDICES', '55', '12.1. Appendix 1: Abbreviations and Trademarks', '55', '12.2.', 'Appendix 2: Clinical Laboratory Tests', '59', '12.3.', 'Appendix 3: Study Governance Considerations', '61', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '65', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', '71', '12.6.', 'Appendix 6: Genetics', '74', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', '75', '12.8.', 'Appendix 8: Medical Device Incidents: Definition and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '78', '12.9. Appendix 9: Neutrophil Safety and Study Treatment Restart', '80', '12.10. Appendix 10: Country-specific requirements', '82', '12.11. Appendix 11 Protocol Amendment History', '83', '7']"
120,page_121,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '1.', 'SYNOPSIS', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Short Title: Danirixin Pilot Study for Disease Progression in COPD', 'Rationale: This is a pilot study to investigate the effect of danirixin hydrobromide (HBr)', '35mg tablets on lung function and health related quality of life (HRQoL) in participants', 'with mild to moderate airflow obstruction and a demonstrated history of decline in FEV1.', 'This study aims to assess whether danirixin has the potential to impact disease', 'progression in participants with COPD and with a demonstrated history of disease', 'progression measured by lung function.', 'Objectives and Endpoints:', 'Objective', 'Endpoint', 'Primary', 'Rate of decline in FEV1', 'To assess whether danirixin HBr 35mg', 'tablets impact disease progression', ""Change from baseline in St. George's"", 'compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'Secondary', 'To further characterize the safety of', 'Adverse events', 'danirixin HBr 35mg tablets compared', 'Vital Signs', 'with placebo in participants with mild', 'ECG', 'to moderate airflow limitation', 'Clinical Laboratory Assessments', '(hematology, clinical chemistry,', 'urinalysis)', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared with placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Overall Design:', 'This is a Phase 2 study to investigate the potential impact of danirixin HBr 35mg tablets', 'compared with placebo on disease progression in participants with mild to moderate', '8']"
121,page_122,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'airflow obstruction. The study will also assess the enrichment strategy of enrolling', 'participants identified from the COPDGene study. These participants have been', 'identified by COPDGene investigators based on data collected over the initial 5 year', 'period. The participants were identified based on a Random Forest analysis and a', 'demonstrated decline of at least 20mL/yr over the initial 5 year period.', 'Number of Participants:', 'Approximately 130 participants will be screened to enrol 100 participants in this study. It', 'is anticipated that approximately 85 participants will complete the 52 weeks of treatment', '(assuming a 15% drop out rate).', 'Treatment Groups and Duration:', 'Participants will receive either placebo or danirixin 35mg tablets (as hydrobromide', 'hemihydrate salt) twice daily for 52 weeks (12months).', '9']"
122,page_123,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', 'Table 1', 'Schedule of activities', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'days', 'Visit1a', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Eligibility', 'Informed Consent', 'X', 'Genetics Informed Consentb', 'X', 'Demography', 'X', 'Inclusion and Exclusion Criteria', 'X', 'Smoking Statusc', 'X', 'Smoking Historyc', 'X', 'Medical Historyd', 'X', 'Full physical', 'Chest X-ray (historical within 1 year', 'acceptable)', 'HIV, Hepatitis B and C screeninge', 'Additional Eligibility and In Study Assessments', 'Verify Eligibility', 'X', 'Brief physical', 'X', 'Laboratory assessments (clinical chemistry,', 'including liver chemistries), hematology,', 'X', 'X', 'X', 'urinalysis', 'Additional Liver chemistries only', 'X', 'X', 'X', 'X', '12 lead ECG', 'X', 'X', 'X', 'Vital Signs', 'X', 'X', '10']"
123,page_124,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'Visit1a', 'days', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Office spirometry (centralized)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Home spirometry - (weekly)', 'X', 'Randomization', 'Dispense study medication', 'Dispense log pad and provide training', 'X', 'Dispense MDI sensors and provide training', 'Study Treatment', 'Study Treatment Compliance (ediary)', 'Collect IP', 'Collect MDI sensors', 'X', 'Collect log pad', 'AE review', 'SAE review', 'Concomitant medication review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Clinical Outcomes Assessments', 'COPD exacerbation review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Rescue medication Use', 'SGRQ-C', 'X', 'X', 'COPD Assessment Test (CAT)', 'Participant Global Impression of COPD', 'severity', 'Participant Impression of change in COPD', 'severity', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '11']"
124,page_125,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'Visit1a', 'days', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Genetic, Pharmacokinetic and Biomarker Blood Collections', 'Blood sample for Genetics', 'Blood sample for CRP', 'Blood sample for exploratory biomarkers', 'a', 'Informed consent may be signed prior to screening visit in the case that any changes in medications are necessary', 'b', 'Agreeing to genetic sample consent is not required for study participation', 'C', 'Smoking status/history assessed at screening; smoking status re-checked at Visit 2', 'd', 'Includes substance usage, past and present medical conditions and family history of premature CV disease', 'e', 'Hepatitis B (HBsAg) and Hepatitis C (HepC antibody) testing is required. If testing otherwise performed within 3 months prior to the first dose of study treatment, testing at', 'screening is not required. Hepatitis C RNA testing is optional; however a confirmatory negative Hepatitis C RNA test must be obtained, to be able to enrol participants with', 'positive Hepatitis C antibody due to prior resolved disease.', 'f', ""Participant's clinical status should be reviewed"", 'The timing and number of planned study assessments, including safety and biomarker assessments may be altered during the course of the study based on newly available data to', 'ensure appropriate data collection. Any changes in the timing or addition of time points for any planned study assess must be documented and approved by the relevant study team', 'member and then archived in the sponsor and site study files, but will not constitute a protocol amendment. The IRB/IEC will be informed of any safety issues that require alteration of', 'the safety monitoring scheme or amendment of the ICF.', '12']"
125,page_126,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.', 'INTRODUCTION', 'The inflammation associated with COPD is characterized by a prominent infiltration of', 'neutrophils in lung tissue and the airways. Neutrophils and other inflammatory cells are', 'recruited to the lung in response to various chemotactic factors, including chemokines.', 'Specifically, there is a large body of evidence that the CXCR2 chemokine receptor plays', 'a pivotal role in neutrophil recruitment to the lung. For neutrophils, chemokine binding', 'to the CXCR2 results in chemotaxis and cell activation, ultimately resulting in the release', 'of a number of inflammatory mediators and proteases that are thought to contribute to the', 'progressive fibrosis, airway stenosis, and destruction of the lung parenchyma', 'characteristic of COPD.', 'Selective antagonism of the interaction between CXCR2 and its ligands is a potential', 'strategy for reducing the inflammation in COPD [Chapman, 2009]. A reduction in tissue', 'and airway neutrophilia is expected to result in downstream effects on mucus', 'hypersecretion, lung inflammation, and tissue destruction that are hypothesized to', 'underlie the development and worsening of respiratory symptoms and decline in lung', 'function that occurs in COPD.', 'Molecules with CXCR2 antagonist activity have been shown to reduce the influx of', 'neutrophils into the lungs in healthy participants (e.g. ozone or LPS challenge models)', 'and to reduce sputum and tissue neutrophils in the lungs of patients with severe,', 'neutrophilic asthma, COPD and bronchiectasis in association with improvements in', ""measures of disease activity in some, but not all, studies O'Byrne, 2016; Holz, 2010;"", 'Watz, 2016; Lazaar, 2011; Nair, 2012; Rennard, 2015]. Overall, the results of the', 'reported clinical studies with CXCR2 antagonists suggest that careful selection of the', 'target patient population is important to achieving clinical benefit.', 'Danirixin is a selective CXCR2 antagonist being developed as a potential anti-', 'inflammatory agent for the treatment of COPD and other inflammatory diseases and', 'influenza. Danirixin has demonstrated potent antagonism of CXCR2 activity both in', 'vitro and in vivo in preclinical studies GlaxoSmithKline Document Number', 'YM2010/00163/07]', 'Clinical pharmacology studies in healthy volunteers demonstrated the pharmacodynamic', 'activity of danirixin (inhibition of ex vivo CXCL1-induced CD11b expression on', 'peripheral blood neutrophils). Danirixin has also been tested in a Phase IIa study in', 'symptomatic participants with mild to moderate COPD at risk for exacerbation', '[GlaxoSmithKline Document Number 2013N180289 03 Study ID 200163]. In study', '200163, twice daily dosing with danirixin free base (75 mg bid) or placebo given on top', 'of standard of care inhaled maintenance treatments was tested for one year. Analyses of', 'clinical endpoints from study 200163 demonstrated that danirixin, compared to placebo,', 'reduced respiratory symptoms as measured with E-RS:COPD [Miller, 2016].', '3.1.', 'Study Rationale', 'This protocol describes a pilot study to investigate the effect of danirixin HBr 35mg', 'tablets on lung function and health related quality of life (HRQoL) in participants with', '13']"
126,page_127,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'mild to moderate airflow obstruction identified from the COPDGene cohort. Study', 'participants will continue with their standard of care inhaled medications (i.e. long acting', 'bronchodilators with or without inhaled corticosteroids) while receiving study treatment.', 'Specifically, this study aims to assess whether or not danirixin has the potential to impact', 'disease progression in participants with a COPD progression score indicating they are', 'likely to decline based on 5 year data from COPDGene and support the conduct of a', 'larger Phase III study for disease progression. In addition to lung function and HRQoL,', 'this study will assess moderate/severe COPD exacerbations, health status (CAT), and', 'rescue medication use.', '3.2.', 'Background', 'COPD is a major cause of disability, morbidity, and mortality, resulting in millions of', 'deaths annually worldwide contributing significantly to health care costs [Mathers, 2006;', 'Lopez-Campos, 2016; Vastava, 2015; GOLD, 2016]. The morbidity and mortality of', 'COPD are continuing to increase and worldwide and, by the year 2020, COPD is', 'expected to be the third leading cause of death and fifth leading cause of disability', '[Mathers, 2006; Lopez-Campos, 2016]. The airflow limitation that characterizes COPD', 'is primarily due to small airways disease and parenchymal destruction associated with an', 'excessive inflammatory response in the lung, mainly caused by cigarette smoking [Celli,', '2004]. COPD is characterized by symptoms of chronic and, in many patients,', 'progressive breathlessness (or dyspnea), cough and sputum production. Many COPD', 'patients also suffer from periodic worsening of their COPD symptoms that is beyond the', 'typical day to day variation [Hurst, 2010]. These episodes of worsening symptoms', '(COPD exacerbations) account for a significant proportion of COPD-related and total', 'health care costs. Despite several available therapies that have been shown to reduce', 'COPD exacerbations and respiratory symptoms, many COPD patients continue to', 'experience a high burden of respiratory symptoms and COPD exacerbations resulting in a', 'continuing unmet medical need [Vestbo, 2016]. Additionally, there is growing', 'recognition that a high percentage of COPD patients with mild airflow limitation as well', 'as smokers with preserved lung function suffer from a high burden of symptoms and', 'COPD exacerbations with a subsequent impact on health status [Woodruff, 2016].', 'Therapies that effectively further reduce COPD exacerbations and improve respiratory', 'symptoms could have a substantial impact on healthcare utilization and most importantly', ""result in an improvement in COPD patients' quality of life."", 'The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the', 'treatment and management of patients with COPD recommend that the management of', 'current respiratory symptoms and subsequent worsening of symptoms resulting in COPD', 'exacerbations should be an important component of COPD patient management [GOLD,', '2016].', 'Danirixin is being evaluated as an addition to standard of care inhaled therapies (i.e. long', 'acting bronchodilators and long acting bronchodilator/corticosteroid combination', 'therapies) and is targeting those COPD patients that continue to have a burden of', 'respiratory symptoms and COPD exacerbations despite management with currently', 'available COPD treatments.', '14']"
127,page_128,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.', 'Benefit/Risk Assessment', 'More detailed information about the potential benefits and risks of danirixin may be', ""found in the danirixin Investigator's Brochure [GlaxoSmithKline Document Number"", 'YM2010/00163/07].', '15']"
128,page_129,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.1.', 'Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', 'No adverse events related to testicular', 'effects have been observed in clinical', 'studies to date.', '16']"
129,page_130,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count < 0.5 X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', 'study in patients with Influenza (GSK Study', '17']"
130,page_131,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', '201682, GlaxoSmithKline Document No.', '2014N205875_00) decreased neutrophil', 'counts have been observed in participants', 'receiving either placebo or danirixin; no', 'instances of danirixin-related neutropenia', 'have been reported in clinical studies to', 'date. In healthy participants, the data are', 'confounded by the observation of low', 'neutrophil counts before dosing or at', 'follow-up, and were not dose-related, while', 'in patients with influenza, neutrophil counts', 'recovered while receiving danirixin,', 'coincident with resolution of the viral', 'infection. There have been no reports of', 'neutrophil count decreases below the lower', 'limit of normal in patients with COPD who', 'were treated with danirixin for one year.', 'These data support the conclusion that a', 'causal association of neutropenia with', 'danirixin cannot be definitively established.', '18']"
131,page_132,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Study Procedures', 'None', 'Other', 'Not applicable', '19']"
132,page_133,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.2.', 'Benefit Assessment', 'All participants will undergo a thorough medical assessment during the study.', 'Participants will have frequent study clinic visits for the evaluation of their', 'disease symptoms. During these visits, participants will have spirometry, ECG,', 'vital signs monitoring, and physical examinations. Monitoring for worsening of', 'their disease will also take place.', 'Participants may benefit from the knowledge that they are contributing to the', 'process of developing a new treatment in an area of unmet need, even if not', 'directly beneficial for them', 'All participants will continue with changes to their medications, where medically', 'appropriate, to receive established standard of care.', '3.3.3.', 'Overall Benefit:I Risk Conclusion', 'Danirixin has demonstrated potent antagonism of CXCR2 activity both in vitro and in', 'vivo in preclinical and clinical studies. Its potency and duration of action supports its', 'potential use as an oral, anti-inflammatory agent in the treatment of COPD with', 'anticipated potential for bringing benefit to a serious condition that affects the lives of', 'millions and contributes to significant morbidity and mortality.', 'In clinical trials completed to date danirixin has been well-tolerated and most adverse', 'events (AEs) were mild to moderate in intensity The most commonly observed AEs have', 'been nasopharyngitis, headache and diarrhea following administration of danirixin or', 'placebo. There have been no treatment related clinically significant changes in vital signs', 'or ECG at any dose of danirixin.', 'Taking into account the measures taken to minimize risks to participants in this study, the', 'potential risks identified in association with danirixin are justified by the anticipated', 'benefits that may be afforded to participants with COPD.', '20']"
133,page_134,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '4.', 'OBJECTIVES AND ENDPOINTS', 'Objectives', 'Endpoints', 'Primary', 'To assess whether danirixin HBr', 'Rate of decline in FEV1', '35mg tablets impacts disease', ""Change from baseline in St. George's"", 'progression compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'To further characterize the safety of', 'Adverse events (AE), clinical', 'danirixin HBr 35mg tablets', 'laboratory values, vital signs,', 'compared with placebo in', 'electrocardiogram (ECG), and/or other', 'participants with mild to moderate', 'safety biomarkers', 'airflow limitation', 'Secondary', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared to placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Exploratory', 'To characterize the effect of', 'Blood/serum/plasma biomarkers that', 'danirixin on lung matrix', 'are indicative of extracellular matrix', 'destruction/remodelling and', 'turnover/remodelling (e.g. elastin and', 'inflammation', 'collagen neo-epitopes) and', 'inflammation (e.g. CRP)', 'Further characterize efficacy of', 'danirixin', 'Global assessment of COPD severity', '21']"
134,page_135,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.', 'STUDY DESIGN', '5.1.', 'Overall Design', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -28', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Up to 28', 'Placebo (n=50)', 'days', 'Follow-up2', 'Screening', 'R', 'Danirixin, 35mg', '(n=50)', '1', 'If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', '5.2.', 'Number of Participants', 'Approximately 130 participants will be screened to achieve 100 randomized in this study.', 'It is anticipated that approximately 85 participants will complete the 12 months of', 'treatment (assuming a 15% drop out rate).', 'For the analysis of study assessments, several analysis populations are defined in Section', '10.3.', '22']"
135,page_136,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.3.', 'Participant and Study Completion', 'A participant is considered to have completed the study if he/she has completed all', 'planned study visits including the last study visit and the last scheduled procedure shown', 'in the Schedule of Activities (Table 1).', 'The end of the study is defined as the date of the last visit of the last participant in the', 'study.', '5.4.', 'Scientific Rationale for Study Design', 'This study will use a multicenter, randomized, parallel-group design. This is a well', 'established design to evaluate the efficacy and safety of an investigational drug. With the', 'use of an enriched population, it is anticipated that one year of treatment will be sufficient', 'to detect a trend in altering disease progression. Danirixin has already been clinically', 'investigated over one year treatment duration (GlaxoSmithKline Document Number', '2013N180289_03 Study ID 200163).', 'The data from this study will provide useful information in determining whether or not to', 'progress to a Phase III study to explore an indication for slowing disease progression.', '5.5.', 'Dose Justification', 'One dose of danirixin is proposed for this study, 35mg tablets BID. This dose was', 'selected based on integrating information on:', 'Dose-exposure-biomarker response using inhibition of ex vivo CXCL1-induced', 'CD11b expression on peripheral blood neutrophils over the dose range of 0-400mg', '(free base tablet) in healthy volunteers (GSK Study No. CX3 112483).', 'Evidence of reduced respiratory symptoms and improvement in health status in mild', 'to moderate COPD participants from interim data in the Phase IIa study (GSK Study', 'No. 200163).', 'Relative bioavailability study comparing danirixin free base vs HBr (GSK Study No.', '201037).', 'In the previous clinical studies, danirixin was administered as a free base tablet, whereas', 'the danirixin formulation to be used in this study will be a hydrobromide salt tablet.', 'The hydrobromide tablet has approximately twice the bioavailability of the free base', 'tablet in healthy elderly participants (GlaxoSmithKline Document Number', '2015N248339 00 Study ID 201037). Thus the danirixin (hydrobromide tablet) 35mg', 'BID dose for investigation in this study is expected to provide steady-state systemic', 'exposure approximately equivalent to the 75mg BID (free base tablet) used in Study', '200163. Predicted steady-state exposures and multiples of blood ex vivo CXCL1-induced', 'CD11b pharmacology at the proposed danirixin doses are presented in Table 2.', '23']"
136,page_137,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Table 2', 'Predicted steady state systemic exposure and multiples of blood ex', 'vivo CXCL1-induced pharmacology following twice daily of', 'administration of danirixin', 'Dose', 'Predicted# steady-state median (5th 95th', 'Cavg', 'Cmin', '(mg)', 'percentile)', 'multiple of', 'multiple of', 'AUC(0-24)', 'Cavg', 'Cmin', 'IC50*', 'IC50*', 'steady-state', '(ng/mL)', '(ng/mL)', '(ug.h/mL)', '35', '9.59', '399', '192', '5.1', '2.4', '(4.70,1 19.3)', '(196,806)', '(47.6, 630)', '#Model derived based on PK data in healthy elderly participants from GSK Study No. 201037', '(GlaxoSmithKline Document Number. 2015N248339_00).', '*Model predicted population mean IC50=78.5 ng/mL (95% CI: 37.3, 120), sigmoidal Emax model of DNX', 'PK-ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils in healthy participants.', '6.', 'STUDY POPULATION', 'This study will identify specific patients most likely to decline from the well established', 'COPDGene cohort [NCT00608764] This study will be an ancillary study within', 'COPDGene investigating the enrichment strategy for assessing disease progression.', 'These potential participants have been identified by COPDGene investigators based on', 'data collected over the initial 5 year period. The participants were identified based on a', 'Random Forest analysis and a demonstrated decline of at least 20mL/yr over the initial 5', 'year period. Once participants are identified from the COPDGene dataset, the following', 'criteria will be verified at initial study visit following signing of consent.', 'Prospective approval of protocol deviations to recruitment and enrolment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '6.1.', 'Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria', 'apply:', 'Age', '1.', 'Participant must be 40 to 76 years of age inclusive, at the time of signing the', 'informed consent.', 'Type of Participant and Disease Characteristics', '2.', 'At the screening visit, the subject must have an FEV1 >40% of the predicted normal.', '3.', 'Participants with a prior history of asthma are eligible if they have a current', 'diagnosis of COPD', '24']"
137,page_138,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Weight', '4.', 'Body weight 45 kg', 'Sex', '5.', 'Male or female', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', 'Informed Consent', '6. Capable of giving signed informed consent as described in Section 12.3 (Appendix 3)', 'which includes compliance with the requirements and restrictions listed in the', 'informed consent form (ICF) and in this protocol.', '6.2.', 'Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', 'Medical Conditions', '1. Diagnosis of other clinically relevant lung disease (other than COPD), e.g.', 'sarcoidosis, tuberculosis, pulmonary fibrosis, severe bronchiectasis or lung cancer', '2. COPD due to alpha-l-antitrypsin deficiency', '3. Pulse oximetry < 88% at rest at screening. Participants should be tested while', 'breathing room air. However, participants living at high altitudes (above 5000 ft or', '1500 m above sea level) who are receiving supplemental oxygen can be included', 'provided they are receiving the equivalent of < 4L/min and screening oximetry is', 'measured while on their usual settings.', '4. Less than 14 days have elapsed from completion of a course of antibiotics or oral', 'corticosteroids for a recent COPD exacerbation', '5. Participants with a peripheral blood neutrophil count < 1 X 109/L', '6. Diagnosis of pneumonia (chest X-ray or CT confirmed) within the 3 months prior to', 'screening', '7. Chest X-ray (posterior with lateral) or CT scan reveals evidence of a clinically', 'significant abnormality not believed to be due to the presence of COPD (historic data', 'up to 1 year may be used).', '8. History or current evidence of clinically significant renal disease, diabetes', 'mellitus/metabolic syndrome, hypertension, or any other clinically significant', 'cardiovascular, neurological, immunological, endocrine, or haematological', 'abnormality that is uncontrolled on permitted therapies. Significant is defined as any', 'disease that, in the opinion of the Investigator, would put the safety of the participants', '25']"
138,page_139,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'at risk through study participation, or which would affect the safety analysis or other', 'analysis if the disease/condition exacerbated during the study.', '9. History of sensitivity to any of the study medications, or components thereof or a', 'history of drug or other allergy that, in the opinion of the investigator of GSK medical', 'monitor, contraindicates their participation.', '10. Current or chronic history of liver disease, or known hepatic or biliary abnormalities', ""(with the exception of Gilbert's syndrome or asymptomatic gallstones)."", '11. Abnormal and clinically significant 12-lead ECG finding. The investigator will', 'determine the clinical significance of each abnormal ECG finding in relation to the', ""subject's medical history and exclude participants who would be at undue risk by"", 'participating in the trial. An abnormal and clinically significant finding that would', 'preclude a subject from entering the trial is defined as a 12-lead tracing that is', 'interpreted as, but not limited to, any of the following:', '- AF with rapid ventricular rate > 120 bpm;', '- sustained or non-sustained VT', '- second degree heat block Mobitz type II and third degree heart block (unless', 'pacemaker or defibrillator has been implanted)', '- QTcF 500 msec in patients with QRS < 120 msec and QTcF 530 msec in', 'patients with QRS > 120 msec', '12. Previous lung surgery (e.g. lobectomy, pneumonectomy) or lung volume reduction', 'procedure.', 'Prior/Concomitant Therapy', '13. Current or expected chronic use of macrolide antibiotics during the study period for', 'the prevention of COPD exacerbations. Examples of chronic use include, but are not', 'limited to, daily or two to three times per week use for at least 3 months.', '14. Oral or injectable CYP3A4 or BRCP (breast cancer resistance protein) substrates with', 'a narrow therapeutic index (CYP3A4 substrates include, but are not limited to,', 'alfenatil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,', 'quinidine, sirolimus, tacrolimus, and theophylline; BCRP substrates include, but are', 'not limited to, topotecan.) The Investigator should consult with the Medical Monitor', 'if necessary.', '15. Current or expected use of phosphodiesterase-4 inhibitors (e.g. roflumilast).', 'Participants currently receiving roflumilast may be included if they are able to', 'discontinue use from 30 days prior to screening through the completion of the follow', 'up visit.', 'Prior/Concurrent Clinical Study Experience', '16. Participation in a previous clinical trial and has received an investigational product', 'within any of the following time periods prior to the first dosing day in the current', '26']"
139,page_140,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'study: 30 days, 5 half lives, or twice the duration of the biological effect of the', 'investigational product (whichever is longer).', '17. Participation in a previous clinical trial with danirixin within 1 year prior to the first', 'dosing day in the current study', '18. Exposure to more than four investigational products within 1 year prior to the first', 'dosing day in the current study.', 'Diagnostic assessments', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN); bilirubin > 1.5xULN', '(isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct', 'bilirubin <35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Other Exclusions', '22. Pulmonary rehabilitation: Participants who have taken part in the acute phase of a', 'pulmonary rehabilitation program within 4 weeks prior to screening or participants', 'who plan to enter the acute phase of a pulmonary rehabilitation program during the', 'study. Participants who are in the maintenance phase of a pulmonary rehabilitation', 'program are not excluded.', '23. A history of allergy or hypersensitivity to any of the ingredients in the study', 'treatment.', '24. A known or suspected history of alcohol or drug abuse within the 2 years prior to', 'screening.', '25. Inability to read: in the opinion of the Investigator, any participant who is unable to', 'read and/or would not be able to complete study related materials.', '26. Affiliation with the study site: study investigators, sub-investigators, study', 'coordinators, employees of a study investigator, sub-investigator or study site, or', 'immediate family member of any of the above that are involved with the study.', '6.3.', 'Lifestyle Restrictions', '6.3.1.', 'Meals and Dietary Restrictions', 'No meal or dietary restrictions are required for participation in this study. Danirixin must', 'be taken with food. Specific dosing instructions will be provided in the Study Reference', 'Manual (SRM) and will be provided to all study participants.', '6.3.2.', 'Activity', 'Participants should abstain from strenuous exercise for 24 hours before each blood', 'collection for clinical laboratory tests.', '27']"
140,page_141,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '6.4.', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study', 'but are not subsequently randomized in the study. A minimal set of screen failure', 'information is required to ensure transparent reporting of screen failure participants to', 'meet the Consolidated Standards of Reporting Trials (CONSORT) publishing', 'requirements and to respond to queries from regulatory authorities. Minimal information', 'includes demography, screen failure details, eligibility criteria and any serious adverse', 'events (SAEs).', 'Individuals who do not meet the criteria for participation in this study (screen failure)', 'may not be rescreened unless discussed with the medical monitor.', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment(s), marketed product(s),', 'placebo, or medical device(s) intended to be administered to a study participant according', 'to the study protocol.', '28']"
141,page_142,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.1.', 'Treatments Administered', 'Study Treatment Name:', 'Danirixin', 'Placebo', '(GSK1325756H, the', 'hydrobromide', 'hemihydrate salt)', 'Dosage formulation:', 'White Film coated', 'White Film coated', 'tablets (oval shaped).', 'tablets (oval shaped).', 'Refer to', ""Refer to Investigator's"", 'Brochure for', ""Investigator's"", 'Brochure for', 'presentation and', 'presentation and', 'excipients', 'excipients', 'Unit dose strength(s)/Dosage level(s):', '35mg tablets (of free', 'N/A', 'base equivalent)', 'Route of Administration', 'Oral', 'Oral', 'Dosing instructions:', 'One tablet to be', 'One tablet to be taken', 'taken twice daily', 'twice daily with food', 'with food', 'Packaging and Labeling', 'Study Treatment will', 'Study Treatment will', 'be provided in a', 'be provided in a HDPE', 'HDPE bottle with', 'bottle with desiccant.', 'desiccant. Each', 'Each bottle will be', 'bottle will be labeled', 'labeled as required per', 'as required per', 'country requirement.', 'country requirement.', 'Manufacturer', 'GSK', 'GSK', '7.1.1.', 'Medical Devices', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Mobile spirometers (MicroDiary, manufactured by and purchased from CareFusion) are', 'also being provided by GSK for this study. These devices allow participants to conduct', 'spirometry assessments at home. The MicroDiary has US FDA 510(k) clearance to', 'market (Class II medical device) and European Union CE marking (Class I medical', 'device).', '29']"
142,page_143,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Additional descriptive information and instructions for the eMDI monitoring devices and', 'mobile spirometers are provided in the SRM.', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '7.2.', 'Dose Modification', 'No individual participant dose modifications or adjustments are allowed.', '7.3.', 'Method of Treatment Assignment', 'This study will use an Interactive Web Response System (IWRS). All', 'participants will be centrally randomized using the IWRS. Before the study is', 'initiated, the log in information and directions for the IWRS will be provided to', 'each site.', 'Participant randomization will be stratified by smoking status (i.e. current', 'smoker or former smoker).', 'Study treatment will be dispensed to participants at the study visits summarized', 'in the SOA.', 'Returned study treatment should not be re-dispensed to any participant.', '7.4.', 'Blinding', 'This will be a double-blind study. Study participants, all study site staff, and all members', 'of the GSK study team will be blinded to individual participant treatment assignment.', ""A participant will be withdrawn if the participant's treatment code is unblinded by the"", 'investigator or treating physician. The primary reason for discontinuation (the event or', 'condition which led to the unblinding) will be recorded in the CRF.', ""GSK's Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the"", 'treatment assignment for any participant with an SAE. If the SAE requires that an', 'expedited regulatory report be sent to one or more regulatory agencies, a copy of the', ""report, identifying the participant's treatment assignment, may be sent to investigators in"", 'accordance with local regulations and/or GSK policy.', '7.5.', 'Preparation/Handling/Storage/Accountability', 'The investigator or designee must confirm and document appropriate temperature', 'conditions have been maintained during transit for all study treatment received', 'and any discrepancies are reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study', 'treatments must be stored in a secure, environmentally controlled, and monitored', '30']"
143,page_144,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '(manual or automated) area in accordance with the labeled storage conditions', 'with access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (ie, receipt, reconciliation, and final disposition of records).', 'Further guidance and information for the final disposition of unused study', 'treatment are provided in the SRM.', 'Precaution will be taken to avoid direct contact with the study treatment. Under', 'normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. In the case of unintentional', 'occupational exposure notify the monitor, Medical Monitor and/or GSK study', 'contact.', 'A Material Safety Data Sheet MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '7.6.', 'Treatment Compliance', 'When participants are dosed at the site, they will receive study treatment directly', 'from the investigator or designee, under medical supervision. The date and time of', 'each dose administered in the clinic will be recorded in the source documents. The', 'dose of study treatment and study participant identification will be confirmed at the', 'time of dosing by a member of the study site staff other than the person', 'administering the study treatment.', 'When participants self-administer study treatment(s) at home, compliance with study', 'treatment administration will be assessed through querying the participant during the', 'site visits and documented in the source documents and CRF. In addition,', 'participants will be asked to confirm study administration each day in the daily', 'ediary.', 'Study participants who are not compliant with study treatment administration', 'requirements should be re-educated on the importance of treatment compliance.', 'Every effort should be made to keep participants in the study. Participants who', 'continue to be non-compliant after several attempts to re-educate may be', 'discontinued after consultation with the GSK study team.', '7.7.', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) that the participant is receiving at the time of', 'enrolment or receives during the study must be recorded along with:', 'reason for use', 'dates of administration including start and end dates', '31']"
144,page_145,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'dosage information including dose and frequency', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', 'The following COPD medications are permitted during the study, at the discretion of the', 'GSK Medical Monitor and/or Investigator:', 'Inhaled COPD maintenance medications (e.g. long acting bronchodilator', 'medications (i.e. LAMA, LABA) and long-acting bronchodilator combination', 'therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled steroid', 'combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)', 'Short courses of oral corticosteroids and/or antibiotics (including macrolides)', 'are permitted for the acute treatment of exacerbations of COPD and should not', 'exceed 21 days. This use must be recorded as an HCRU exacerbation event.', 'The following medications are prohibited from the screening visit until after completion', 'of the follow up visit:', 'Chronic use of macrolide antibiotics for the prevention of COPD exacerbations.', 'Examples of chronic use include daily or two-three times per week for at least', '3', 'months.', 'Oral or injectable CYP3A4 or BCRP substrates with narrow therapeutic index', '(CYP3A4 substrates include, but are not limited to, alfentanil, cyclosporine,', 'dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus,', 'tacrolimus, and theophylline; BCRP substrates include, but are not limited to,', 'topotecan.', 'Phosphodiesterase-4 inhibitors (e.g. roflumilast)', 'Broad spectrum phosphodiesterase inhibitors (e.g. theophylline)', 'GSK will not supply rescue medication. Participants may continue to use and should', 'obtain rescue medication(s) through via their usual route. The following rescue', 'medications may be used:', 'Short acting beta agonists (SABA)(e.g., albuterol/salbutamol)', 'Short acting muscarinic antagonists (SAMA)(e.g., ipratropium)', 'Short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb,', 'Combivent)', 'The use of rescue medications is allowable at any time during the study. Participants', 'should record in the daily e-diary the number of puffs of rescue medication(s) over each', '24 hour period. Data from the MDI sensor device will be electronically captured and', 'transmitted to GSK.', 'Annual influenza vaccine is recommended for patients with COPD but is not required for', 'participation in this study. Influenza vaccination is permitted during the study and should', '32']"
145,page_146,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'be based on applicable local or national guidelines. Pneumococcal vaccine may also be', 'administered, when indicated, based on applicable local or national guidelines.', 'Additional vaccinations may be administered when indicated. Any vaccination', 'administered during the study should be recorded as a concomitant therapy.', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', 'study care of the participant.', 'GSK will not provide post-study treatment. There are no plans to provide the study', 'treatment for compassionate use following study completion.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', '8.1.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to assure', 'participant safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance). These protocol guidelines are in alignment', 'with FDA premarketing clinical liver safety guidance [FDA, 2009].', 'Discontinuation of study treatment for abnormal liver tests should be considered by the', 'investigator when a participant meets one of the conditions outlined in the algorithm', 'below or if the investigator believes that it is in the best interest of the participant.', '33']"
146,page_147,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If subject to be monitored weekly mustrefer to Liver Safety Required Actions and Follow up', 'Assessments section in the Appendix', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin>2x', 'Yes', 'No', 'ULN (>35%', 'ALT23xULN', 'ALT>3xULN', 'ALT>3xULN', 'direct)', 'Plus', 'Yes', 'No', 'No', 'No', 'but able to', 'Yes', 'persist for', 'ALT>3xULN', 'orplus', 'Symptoms of', 'ALT>5xULN', 'monitor', '4 weeks or', 'INR>1.5, if', 'liverinjury', 'weekly for', 'stopping', 'measured*', 'or', '4 weeks', 'criteria', 'Possible', 'hypersensitivity', 'met', ""Hy's Law"", 'Yes', 'Yes', 'No', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', ""Reportas an SAE if possible Hy's Law case: ALT23xULNand Bilirubin>2xULN (>35% direct) or"", 'INR>1.5, if measured*', '*INR value not applicable to subjects on anticoagulants', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Appendix 7: Liver Safety: Required Actions and Follow-up Assessments).', '8.1.2.', 'QTc Stopping Criteria', 'The same QT correction formula must be used for each individual participant to', 'determine eligibility for and discontinuation from the study. This formula may', 'not be changed or substituted once the participant has been enrolled.', 'For example, if a participant is eligible for the protocol based on QTcB, then', 'QTcB must be used for discontinuation of this individual participant as well.', ""Once the QT correction formula has been chosen for a participant's eligibility,"", 'the same formula must continue to be used for that participant for all QTc data', 'being collected for data analysis. Safety ECGs and other non-protocol specified', 'ECGs are an exception.', 'The QTc should be based on single or averaged QTc values of triplicate', 'electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period.', 'A participant who meets either bulleted criteria based on the average of triplicate ECG', 'readings will be withdrawn from study treatment:', 'QTc > 500 msec OR Uncorrected QT > 600 msec', 'Change from baseline of QTc > 60 msec', '34']"
147,page_148,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'For patients with underlying bundle branch block, follow the discontinuation criteria', 'listed below:', 'Baseline QTc with Bundle Branch Block', 'Discontinuation QTc with Bundle', 'Branch Block', '< 450 msec', '> 500 msec', '450 - 480 msec', '> 530 msec', 'See the SoA (Table 1) for data to be collected at the time of treatment discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.1.3.', 'Neutrophil Stopping Criteria', 'A participant with a peripheral blood neutrophil count < 0.5 X 109/L that is confirmed on', 'repeat testing will be instructed to suspend dosing. The neutrophil count should be', 'monitored daily until it returns to within the baseline value, as detailed in Appendix 9.', '8.1.4.', 'Temporary Discontinuation', 'Temporary discontinuation of study treatment is allowed for up to 14 days when', 'medically necessary, e.g. for hospitalization for a COPD exacerbation, other medical', 'condition requiring hospitalization, or reduction in peripheral blood neutrophil counts', '0.5 X 109/L. Temporary discontinuation for any other reason should be discussed with', 'the GSK Medical Monitor.', '8.1.5.', 'Study Treatment Restart', 'Study treatment restart after liver chemistry stopping criteria are met by any participant in', 'this study is not allowed. Refer to Appendix 7 (Section 12.7) for full guidance for', 'required actions and follow-up assessments to undertake if liver stopping criteria are met.', 'Study treatment restart after neutrophil stopping criteria are met can be considered once', 'the neutrophil count has returned to within baseline and provided that no more than 14', 'days have elapsed since study medication was halted. The Investigator must obtain', 'approval from the GSK Medical Monitor prior to restarting study treatment. See', 'Appendix 9 for the procedure to be followed for study treatment restart after neutrophil', 'stopping criteria are met.', '8.2.', 'Withdrawal from the Study', 'A participant may withdraw from the study at any time at his/her own request,', 'or may be withdrawn at any time at the discretion of the investigator for safety,', 'behavioural, compliance or administrative reasons.', 'If the participant withdraws consent for disclosure of future information, the', 'sponsor may retain and continue to use any data collected before such a', 'withdrawal of consent.', '35']"
148,page_149,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If a participant withdraws from the study, he/she may request destruction of any', 'samples taken and not tested, and the investigator must document this in the site', 'study records.', 'Refer to the SoA for data to be collected at the time of study discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.3.', 'Lost to Follow Up', 'A participant will be considered lost to follow-up if he or she repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'The following actions must be taken if a participant fails to return to the clinic for a', 'required study visit:', 'The site must attempt to contact the participant and reschedule the missed visit', 'as soon as possible and counsel the participant on the importance of maintaining', 'the assigned visit schedule and ascertain whether or not the participant wishes to', 'and/or should continue in the study.', 'Before a participant is deemed lost to follow up, the investigator or designee', 'must make every effort to regain contact with the participant (where possible, 3', ""telephone calls and, if necessary, a certified letter to the participant's last known"", 'mailing address or local equivalent methods). These contact attempts should be', ""documented in the participant's medical record."", 'Should the participant continue to be unreachable, he/she will be considered to', 'have withdrawn from the study with a primary reason of lost to follow-up.', '36']"
149,page_150,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA (Table 1)', 'Protocol waivers or exemptions are not allowed', 'Immediate safety concerns should be discussed with the sponsor immediately', 'upon occurrence or awareness to determine if the participant should continue or', 'discontinue study treatment.', 'Adherence to the study design requirements, including those specified in the', 'SoA, is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that', 'potential participants meet all eligibility criteria. The investigator will maintain a', 'screening log to record details of all participants screened and to confirm', 'eligibility or record reasons for screening failure, as applicable.', ""Procedures conducted as part of the participant's routine clinical management"", '(e.g., blood count) and obtained before signing of ICF may be utilized for', 'screening or baseline purposes provided the procedure met the protocol-', 'specified criteria and was performed within the time frame defined in the SoA.', 'The maximum amount of blood collected from each participant over the', 'duration of the study, including any extra assessments that may be required, will', 'not exceed 500 mL.', 'Repeat or unscheduled samples may be taken for safety reasons or for technical', 'issues with the samples.', '9.1.', 'Efficacy Assessments', '9.1.1.', 'FEV1', '9.1.1.1.', 'Clinic Spirometry', 'Spirometry using FEV1 and FVC measurements (FEV%, and FVC% and FEV1/FVC will', 'be calculated) will be performed in triplicate at time points listed in the SoA (Table 1).', 'Spirometry assessments should be performed in accordance with ATS/ERS guidelines as', 'outlined in the SRM.', '9.1.1.2.', 'Mobile Spirometry', 'Spirometry will also be performed weekly by the participants using a mobile spirometer', 'at home. Details will be outlined in the SRM.', '9.1.2.', 'SGRQ-C', ""The St. George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease"", 'specific tool (SGRQ-C) is a disease-specific questionnaire designed to measure the', ""impact of respiratory disease and its treatment on a COPD patient's HRQoL [Meguro,"", '2007]. As well as producing an overall summary score, scores for the individual domains', '37']"
150,page_151,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'of symptoms, activity and impacts are also produced. The SGRQ-C has been used in', 'numerous previous studies of COPD participants and has been translated and validated', 'for use in most major languages. The SGRQ-C is derived from the original SGRQ and', 'produces SGRQ scores equivalent to the original SGRQ instrument [Jones, 1992].', '9.1.3.', 'CAT', 'The COPD Assessment Test is a short and simple patient completed questionnaire which', 'has been developed for use in routine clinical practice to measure the health status of', 'patients with COPD. The CAT is an 8-item questionnaire suitable for completion by all', 'patients diagnosed with COPD [Jones, 2009; Jones, 2012]. When completing the', 'questionnaire, participants rate their experience on a 6-point scale, ranging from 0', '(maximum impairment) to 5 (no impairment) with a scoring range of 0-40. Higher scores', 'indicate greater disease impact.', '9.1.4.', 'COPD Exacerbations', 'An exacerbation of COPD is defined by a worsening of symptoms requiring additional', 'treatment or hospitalization.', 'Details of an exacerbation should be recorded in the exacerbation page of the eCRF.', 'Exacerbations will not be reported according to the standard process for expedited', 'reporting of SAEs to GSK (even though the event may meet the definition of an SAE) as', 'they are considered Disease Related Events (DREs). Only when the event is, in the', ""Investigator's opinion, of greater intensity, or duration than expected for the individual"", 'participant, or the Investigator considers that there is a reasonable possibility that the', 'event is related to study treatment should it be reported as an SAE (See Section 9.2).', '(Pneumonia must be recorded in the AE or SAE section of the eCRF and on the', 'pneumonia page of the eCRF (See Section 9.4.5)).', 'All medications used for the treatment of exacerbations must be recorded in the source', 'documents and the exacerbation page of the eCRF. If necessary the PI or other health', ""care personnel may stop the participant's study treatment temporarily in order to treat the"", 'COPD exacerbation. The reason for temporarily stopping study treatment and duration', 'should be recorded in the eCRF.', 'The date of onset and the date of resolution will be recorded in the source documents and', ""the eCRF based on the Investigator's judgement."", '9.1.5.', 'Patient Global Rating of Severity and Global Rating of Change in', 'Disease Severity', 'Participants will complete the Global Rating of COPD Severity at randomisation and', 'final study visit or IP Discontinuation Visit. This single global question will ask', 'participants to rate their severity of COPD on a four point scale (mild, moderate, severe,', 'very severe).', 'Participants will complete a Global Rating of Change in COPD (overall disease) question', 'at every visit following randomization (or Early Withdrawal (EW) Visit). Response', '38']"
151,page_152,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'options will be on a 7 point Likert scale ranging from much better to much worse. Asking', 'at each Visit allows for early detection of response as well as continued response.', '9.2.', 'Adverse Events', 'The definitions of an AE or SAE can be found in Appendix 4 (Section 12.4).', 'The investigator and any designees are responsible for detecting, documenting, and', 'reporting events that meet the definition of an AE or SAE and remain responsible for', 'following up AEs that are serious, considered related to the study treatment or the study,', 'or that caused the participant to discontinue the study treatment (see Section 8).', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', 'All SAEs will be collected from the time the informed consent is signed by the', 'participant until the follow up visit at the time points specified in the SoA', '(Table 1).', 'All AEs will be collected from the start of study treatment (randomization visit)', 'until the follow-up visit at the time points specified in the SoA (Table 1).', 'Medical occurrences that begin before the start of study treatment but after', 'obtaining informed consent will be recorded on the Medical History/Current', 'Medical Conditions section of the case report form (CRF) not the AE section.', 'All SAEs must be reported immediately and not more than 24 hrs to the sponsor,', 'as indicated in Appendix 4 (Section 12.4). The investigator will submit any', 'updated SAE data to the sponsor within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'participants. However, if the investigator learns of any SAE, including a death,', 'at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study treatment or study', 'participation, the investigator must promptly notify the sponsor.', 'The method of recording, evaluating, and assessing causality of AEs and SAEs', 'and the procedures for completing and transmitting SAE reports are provided in', 'Appendix 4 (Section 12.4).', '9.2.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AE and/or SAE. Open-ended and', 'non-leading verbal questioning of the participant is the preferred method to inquire about', 'AE occurrence.', '9.2.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All SAEs will be followed until the event is', 'resolved, stabilized, otherwise explained, or the participant is lost to follow-up (as', '39']"
152,page_153,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'defined in Section 8.3). Further information on follow-up procedures is given in', 'Appendix 4.', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to the sponsor of a SAE is essential', 'so', 'that legal obligations and ethical responsibilities towards the safety of', 'participants and the safety of a study treatment under clinical investigation are', 'met.', 'The sponsor has a legal responsibility to notify both the local regulatory', 'authority and other regulatory agencies about the safety of a study treatment', 'under clinical investigation. The sponsor will comply with country-specific', 'regulatory requirements relating to safety reporting to the regulatory authority,', 'Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and', 'investigators.', 'Investigator safety reports must be prepared for suspected unexpected serious', 'adverse reactions (SUSAR) according to local regulatory requirements and', 'sponsor policy and forwarded to investigators as necessary.', 'An investigator who receives an investigator safety report describing a SAE or', 'other specific safety information e.g., summary or listing of SAE) from the', ""sponsor will review and then file it along with the Investigator's Brochure and"", 'will notify the IRB/IEC, if appropriate according to local requirements.', '9.2.5.', 'Cardiovascular and Death Events', 'For any cardiovascular events detailed in Section 12.4 (Appendix 4) and all deaths,', 'whether or not they are considered SAEs, specific Cardiovascular (CV) and Death', 'sections of the CRF will be required to be completed. These sections include questions', 'regarding cardiovascular (including sudden cardiac death) and non-cardiovascular death.', 'The CV CRFs are presented as queries in response to reporting of certain CV MedDRA', 'terms. The CV information should be recorded in the specific cardiovascular section of', 'the CRF within one week of receipt of a CV Event data query prompting its completion.', '9.2.6.', 'Disease-Related Events and/or Disease-Related Outcomes Not', 'Qualifying as SAEs', 'The following disease related events (DREs) are common in participants with COPD and', 'can be serious/life threatening:', 'COPD exacerbations', 'Because these events are typically associated with the disease under study, they will not', 'be reported according to the standard process for expedited reporting of SAEs to GSK', '(even though the event may meet the definition of an SAE). These events will be', ""recorded on the DRE page in the participant's CRF within 72 hours after the investigator"", 'becomes aware of the event. These DREs will be monitored by the Safety Review Team', '(SRT) on a routine basis as described in Section 12.3 (Appendix 3).', '40']"
153,page_154,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'NOTE: However, if either of the following conditions applies, then the event must be', 'recorded and reported as an SAE (instead of a DRE):', ""The event is, in the investigator's opinion, of greater intensity, frequency, or"", 'duration than expected for the individual participant, or', 'The investigator considers that there is a reasonable possibility that the event', 'was related to treatment with the investigational product', '9.2.7.', 'Pregnancy', 'Details of all pregnancies in female participants and female partners of male', 'participants will be collected after the start of study treatment and until 60', 'hours after the last dose of study treatment.', 'If a pregnancy is reported, the investigator should inform GSK within 24 hours', 'of learning of the pregnancy and should follow the procedures outlined in', 'Section 12.5 (Appendix 5).', 'Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAEs.', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use and measuring spirometry at home. In order to fulfill', 'regulatory reporting obligations worldwide, the investigator is responsible for the', 'detection and documentation of events meeting the definitions of incident or malfunction', 'that occur during the study with such devices.', 'The definition of a Medical Device Incident can be found in Section 12.8 (Appendix 8).', 'NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes', 'outlined in Section 9.2 and Section 12.4 (Appendix 4).', '9.2.8.1.', 'Time Period for Detecting Medical Device Incidents', 'Medical device incidents or malfunctions of the device that result in an incident', 'will be detected, documented, and reported during all periods of the study in', 'which the medical device is used.', 'If the investigator learns of any incident at any time after a participant has been', 'discharged from the study, and such incident is considered reasonably related to', 'a medical device provided for the study, the investigator will promptly notify the', 'sponsor.', 'The method of documenting Medical Device Incidents is provided in Section', '12.8 (Appendix 8).', '41']"
154,page_155,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.2.8.2.', 'Follow-up of Medical Device Incidents', 'All medical device incidents involving an AE will be followed and reported in', 'the same manner as other AEs (see Section 9.2). This applies to all participants,', 'including those who discontinue study treatment or the study.', 'The investigator is responsible for ensuring that follow-up includes any', 'supplemental investigations as indicated to elucidate the nature and/or causality', 'of the incident.', 'New or updated information will be recorded on the originally completed form', 'with all changes signed and dated by the investigator.', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents to Sponsor', 'Medical device incidents will be reported to the sponsor within 24 hours after', 'the investigator determines that the event meets the protocol definition of a', 'medical device incident.', 'Complete the Medical Device Incident Form for each participant who has a', 'medical device incident with GSK medical devices provided for use during the', 'study period. All of the header information in the form must be completed', 'before sending to GSK. Original documents should be filed in the site study', 'file. A copy of the form must also be sent to the GKS study monitor. Contact', 'details will be included in the SRM. A copy of the form must also be sent to the', 'GSK study monitor. Contact details will be included in the SRM. For incidents', 'fulfilling the definition of an AE or SAE, the appropriate pages of the CRF must', 'be completed. If there is an SAE, the completed CRF pages should be sent', 'together with the Medical Device Incident From. If the participant is withdrawn', 'due to a medical device incident, ensure the Study Conclusion page is', 'completed.', 'The same individual will be the contact for the receipt of medical device reports', 'and SAEs.', '9.2.8.4.', 'Regulatory Reporting Requirements for Medical Device Incidents', 'The investigator will promptly report all incidents occurring with any medical', 'device provided for use in the study in order for the sponsor to fulfill the legal', 'responsibility to notify appropriate regulatory authorities and other entities about', 'certain safety information relating to medical devices being used in clinical', 'studies.', 'The investigator, or responsible person according to local requirements (e.g., the', 'head of the medical institution), will comply with the applicable local regulatory', 'requirements relating to the reporting of incidents to the IRB/IEC.', '9.3.', 'Treatment of Overdose', 'For this study, any dose of study treatment > 4 tablets in a day will be considered an', 'overdose.', '42']"
155,page_156,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'GSK does not recommend specific treatment for an overdose.', 'In the event of an overdose, the investigator/treating physician should:', '1. Contact the Medical Monitor immediately.', '2. Closely monitor the participant for AE/SAE and laboratory abnormalities until study', 'treatment can no longer be detected systemically (at least 3 days).', '3. Obtain a plasma sample for PK analysis as soon as possible from the date of the last', 'dose of study treatment if requested by the Medical Monitor (determined on a case-', 'by-case basis).', '4. Document the quantity of the excess dose as well as the duration of the overdosing in', 'the CRF.', 'Decisions regarding dose interruptions or modifications will be made by the investigator', 'in consultation with the Medical Monitor based on the clinical evaluation of the', 'participant.', '9.4.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SoA.', '9.4.1.', 'Physical Examinations', 'A complete physical examination will include, at a minimum, assessments of the', 'skin, cardiovascular, respiratory, gastrointestinal and neurological systems.', 'Height and weight will also be measured and recorded.', 'A brief physical examination will include, at a minimum, assessments of the', 'skin, lungs, cardiovascular system, and abdomen (liver and spleen).', 'Investigators should pay special attention to clinical signs related to previous', 'serious illnesses.', '9.4.2.', 'Vital Signs', 'Vital signs will be measured in a semi-supine position after 5 minutes rest and will', 'include systolic and diastolic blood pressure, pulse, and respiratory rate. Three readings', 'of blood pressure and pulse will be taken. The first reading should be rejected. The', 'second and third readings should be averaged to give the measurement to be recorded in', 'the CRF. A single measurement of respiratory rate is adequate.', '9.4.3.', 'Electrocardiograms', 'For participant screening and pre-dose on Day 1, triplicate ECG measurements should be', 'collected. For all subsequent ECG assessments, single measurements are to be collected.', '12-lead ECG will be obtained as outlined in the SoA using an ECG machine that', 'automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.', 'Refer to Section 8.1.2 for QTc withdrawal criteria and additional QTc readings that may', 'be necessary.', '43']"
156,page_157,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'At each time point at which triplicate ECG are required, 3 individual ECG tracings', 'should be obtained as closely as possible in succession, but no more than 2 minutes apart.', 'The full set of triplicates should be completed in less than 10 minutes.', '9.4.4.', 'Clinical Safety Laboratory Assessments', 'Refer to Section 12.2 (Appendix 2) for the list of clinical laboratory tests to be performed', 'and to the SoA for the timing and frequency.', 'The investigator must review the laboratory report, document this review, and record', 'any clinically relevant changes occurring during the study in the AE section of the', 'CRF. The laboratory reports must be filed with the source documents. Clinically', 'significant abnormal laboratory findings are those which are not associated with the', 'underlying disease, unless judged by the investigator to be more severe than', ""expected for the participant's condition."", 'All laboratory tests with values considered abnormal and clinically significant during', 'participation in the study or within 3 days after the last dose of study treatment', 'should be repeated until the values return to normal or baseline or are no longer', 'considered significantly abnormal by the investigator or medical monitor.', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the investigator, the etiology should be identified and the sponsor', 'notified.', 'All protocol-required laboratory assessments, as defined in Section 12.2, must be', 'conducted in accordance with the laboratory manual and the SoA (Table 1).', 'If laboratory values from non-protocol specified laboratory assessments performed at', ""the institution's local laboratory require a change in participant management or are"", 'considered clinically significant by the investigator (e.g., SAE or AE), then the', 'results must be recorded in the CRF.', '9.4.5.', 'Pneumonia', 'All suspected pneumonias will require confirmation as defined by the presence or new', 'infiltrate(s) on chest x-ray AND at least 2 of the following signs and symptoms:', 'Increased cough', 'Increased sputum purulence (colour) or production', 'Auscultatory findings of adventitious sounds (e.g. egophony, bronchial breath', 'sounds, rales, etc.)', 'Dyspnea or tachypnea', 'Fever (oral temperature > 37.5 °C)', 'Elevated white blood cell count (WBC) (> 10 X 109/L or > 15% immature', 'forms)', 'Hypoxemia (Hb O2 saturation < 88% or at least 2% lower than baseline value)', '44']"
157,page_158,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'All pneumonias must be captured on the AE/SAE page of the eCRF and on the', 'pneumonia page of the eCRF.', 'The Investigator and site staff should remain vigilant for the possible development of', 'pneumonia in participants as the clinical features of such infections overlap with the', 'symptoms of COPD exacerbations. For all suspected cases of pneumonia, Investigators', 'are strongly encouraged to confirm the diagnosis (this includes obtaining a chest x-ray)', 'and to initiate appropriate therapy as promptly as possible. Any microbiology or virology', 'tests performed to determine etiology should be reported on the pneumonia eCRF page.', 'All diagnoses of pneumonia (radiographically confirmed or unconfirmed) must be', 'reported as an AE or SAE (if applicable).', '9.5.', 'Pharmacokinetics', 'Pharmacokinetic parameters are not evaluated in this study.', '9.6.', 'Pharmacodynamics', 'Pharmacodynamic parameters are not evaluated in this study.', '9.7.', 'Genetics', 'A 6 mL whole blood sample for DNA isolation will be collected from participants who', 'have consented to participate in the genetics analysis component of the study.', 'Participation in the genetics analysis is optional. Participants who do not wish to', 'participate in the genetic research may still participate in the study.', 'See Section 12.6 (Appendix 6) for Information regarding genetic research. Details on', 'procedures for collection and shipment and destruction of these samples can be found in', 'the SRM.', '9.8.', 'Biomarkers', 'Collection of samples for biomarker research is also part of this study. The following', 'samples for biomarker research will be collected from all participants in this study as', 'specified in the SoA:', 'peripheral venous blood samples for the preparation of serum and plasma', 'Samples will be tested for biomarkers that are indicative of inflammation (i.e. CRP),', 'extracellular matrix turnover and remodelling to evaluate their association with the', 'observed clinical responses or to help understand the underlying biological responses to', 'danirixin.', ""In addition, with the participant's consent, samples will be stored and may be used to"", 'investigate additional biomarkers thought to play a role in COPD disease progression or', 'to evaluate their association with observed clinical responses to danirixin', 'Samples also may be used for research to develop methods or support identification of', 'prognostic/diagnostic biomarkers associated with clinical outcomes in COPD and related', 'diseases.', '45']"
158,page_159,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.9.', 'Health Economics OR Medical Resource Utilization and', 'Health Economics', 'Health Economics/Medical Resource Utilization and Health Economics parameters are', 'not evaluated in this study.', '10.', 'STATISTICAL CONSIDERATIONS', 'The objective of this study is to investigate the effect of danirixin HBr 35mg tablets on', 'COPD disease progression. There are no formal hypothesis tests associated with this', 'objective and no formal significance tests. The information acquired from this study will', 'primarily be used to assess whether or not danirixin impacts disease progression and to', 'quantify the effect that danirixin has on disease progression, specifically change in lung', 'function as measured by FEV1 decline and change in health-related quality of life as', 'measured by SGRQ total score to further support disease understanding and future', 'studies.', '10.1.', 'Sample Size Determination', 'Sample size is based primarily on feasibility for this study. Since there is much', 'uncertainty around the magnitude of the difference in the decline in FEV1 and change in', 'SGRQ along with the between-subject variability for the specific patient population, the', 'proposed sample size is unavoidably imprecise. Sample size may be adjusted using the', 'predictions of final study outcome based on simulations and possible interim analyses. It', 'is anticipated that screening 130 participants will allow for approximately 100', 'participants to enrol.', 'In order to observe the effect of different sample sizes, various simulations were done to', 'assess the impact of sample sizes of 50, 100, 150 and 200 with a 1:1 allocation to each', 'treatment group [Table 3]. The assumed variability for rate of decline in FEV1 and', 'change in SGRQ is 25 and 10, respectively. The correlation between rate of decline in', 'FEV1 and change in SGRQ is assumed to be -0.2. [Nagai, 2015]', 'Table 3', 'Assumptions used for the Simulations', 'Treatment Effect Assumptions', 'Variability Assumptions', 'Sample Size', '(ÔFEV1, SSGRQ)', '(OFEV1, OSGRQ)', 'Null', '(0,0)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 1', '(5,-1)', '(25,10)', 'N=(50,100,150,200}', 'Alternate 2', '(5,0)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 3', '(0,-1)', '(25,10)', 'N=(50,100,150,200)', 'Data from a bivariate normal distribution were simulated under the four different', 'treatment effect assumptions for samples sizes of 50, 100, 150, and 200. The samples', 'from the posterior probability distribution from the MCMC approximation were divided', 'into four regions based on OFEVI and ôSGRQ treatment effect cut-off values; SFEVI>O and', 'SSGRQ <0, SFEV1>0 and SSGRQ>0, SFEVI<O and SSGRQ0, and SFEVI<0 and Based', 'on a 70% threshold, the proportion of the 1000 simulations meeting the requirement', 'P(OFEV1>0 & SSGRQ<0) > 70% were considered a success based on the joint definition', '46']"
159,page_160,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '[Figure 2, Table 4]. If P(OFEV1>0 & < 70%, success could further be defined', 'based on each endpoint independently where P(ÔFEV1 > 0) > 80% or P(6SGRQ 0) > 80%.', 'Figure 2', 'Total Probability of Success', '90', 'Alt 1: (5,-1)', '80', 'Alt 2: (5, 0)', 'Alt 3: (0,-1)', 'Null: (0,0)', '02', '60', '50', '40', '30', '50', '100', '150', '200', 'Sample Size', 'Table 4', 'Total Probability of Success (Figure 2)', 'N=50', 'N=100', 'N=150', 'N=200', '(5,-1)', '57.4', '68.5', '75.1', '81.4', '(5,0)', '52.5', '62.6', '67.8', '74.5', '(0,-1)', '42.6', '46.2', '48.9', '53.0', '(0,0)', '34.9', '33.9', '33.3', '31.5', '47']"
160,page_161,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 3', 'Half Width of the 95% Confidence Interval of OFEV1 Point Estimate', 'D', '13.8', '2L', '01', '9,7', '8.0', '8', '6.9', '9', '50', '100', '150', '200', 'Sample Size', 'Figure 4', 'Half Width of the 95% Confidence Interval of 5SGRQ Point Estimate', '6', '5.5', '5', '&', '3,9', 'm', '3.2', '2.7', '2', '50', '100', '150', '200', 'Sample Size', 'Based on the simulations, under the assumption of an expected treatment difference of', '(5,-1) which is the most probable scenario, the marginal increase for the total probability', 'of success is greatest when increasing the sample size from 50 to 100 (Figure 2). The half', 'widths of the 95% CI of the point estimate of the marginal treatment differences for FEV1', '(Figure 3) and SGRQ (Figure 4) have the greatest reduction from a sample size of 50 to', '100. A sample size of 100 will allow for an adequate level of confidence in the study', 'success while also considering the precision of the treatment effect differences.', '48']"
161,page_162,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.2.', 'Randomization', 'Participants will be randomized equally (1:1) to the two treatment arms of placebo and 35', 'mg danirixin HBr. Randomization will be stratified by smoking status (current VS.', 'former).', '10.3.', 'Populations for Analyses', 'For purposes of analysis, the following populations are defined:', 'Population', 'Description', 'All Participants', 'This population will comprise all participants screened and', 'for whom a record exists on the study database and will be', 'used for the tabulation and listing of reasons for withdrawal', 'before randomization and listings of AEs and SAEs for', 'nonrandomized participants.', 'Intent To Treat (ITT)', 'This population will comprise all participants randomized to', 'treatment and who received at least one dose of study', 'medication. This will constitute the primary population for all', 'analyses of efficacy and safety. Outcomes will be reported', 'according to the randomized treatment allocation.', 'Per-Protocol (PP)', 'This population will comprise of all patients in the ITT', 'Population', 'population who are not major protocol violators.', 'Safety', 'All randomized participants who take at least 1 dose of study', 'treatment. Participants will be analyzed according to the', 'treatment they actually received.', '10.4.', 'Statistical Analyses', 'Treatment comparisons using all endpoints will be made using appropriate statistical', 'techniques. Analysis methods for key endpoints are described below. Main analysis will', 'use ITT unless noted. Further details on all analyses will be described in the reporting and', 'analysis plan (RAP).', '10.4.1.', 'Efficacy Analyses', 'The total probability of success will be defined as a combination of a joint and', 'conditional statement. The joint probability of success will be defined as the probability', 'of the difference in the rate of decline in FEV1 between danirixin and placebo is greater', 'than or equal to 0 and the difference in the change in SGRQ total score from baseline', 'between danirixin and placebo is less than or equal to 0 is greater than 70%. If the joint', 'probability of success is less than 70%, success can further be defined based on each', 'endpoint independently, where either the difference in the rate of decline in FEV1 is', '49']"
162,page_163,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'greater than or equal to 0 is greater than 80% or the difference in the change in SGRQ', 'total score is less than or equal to 0 is greater than 80%.', '=', '+', '+P ÔSCRQ S o) < 70%', 'Endpoint', 'Statistical Analysis Methods', 'Primary', 'Rate of decline in FEV1 and change from baseline in SGRQ total score', 'Exploratory', 'Will be described in detail in the RAP', 'Lung Function Decline: Rate of Decline of FEV1 (mL/yr)', 'The rate of decline of FEV1 will be derived from a repeated measures random', 'coefficients model. Post-baseline FEV1 will be modelled including terms for age, sex,', 'smoking status, FEV, at baseline, and BMI along with treatment group, time and', 'treatment by time interaction as fixed effects. Subject will be a random effect. Time will', 'be defined as the number of days since start of treatment. Only FEV1 values measured', 'after baseline will be used in the model. Based on the results of previous studies, the', 'study team will determine the time point at which post-baseline spirometry assessments', 'will be included in the model to account for the initial treatment response. The estimate', 'of the rate of FEV1 decline will be the slope of the parameter estimate of the treatment by', 'time interaction term in the model. Contrasts will be calculated for the difference in', 'treatment by time interaction between danirixin and placebo treatment groups to estimate', 'the treatment difference.', 'FEV1 = Treatment group + age + sex +smoking status+FEV1_BL+BMI+ time', '+', 'treatment*time', 'The rate of decline for each subject, the estimate of the slope parameter of the treatment', 'by time interaction term, will be used as a co-primary endpoint for the joint analysis', 'using both FEV, and SGRQ.', 'HRQoL: SGRQ', 'A co-primary endpoint of interest is change in SGRQ total score (derived from SGRQ-C)', 'from baseline. Change in SGRQ total scores from baseline will be derived using a mixed', 'model with repeated measures (MMRM) including fixed effects of treatment group, age,', 'sex, smoking status, BMI, baseline SGRQ score, time as a categorical variable and a', 'treatment by time interaction term. Subject will be a random effect. Estimated treatment', 'differences at the end of one year will be obtained. The difference of the least square', 'mean change from baseline at 12 months will be derived. The adjusted SGRQ total score', '50']"
163,page_164,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'change from baseline will used as the other co-primary endpoint for the joint analysis', 'using both FEV1 and SGRQ.', 'Joint Analysis', 'The joint analysis will use the ITT population with all available FEV1 rate of decline and', 'change in SGRQ data.', 'The rate of decline (the slope parameter from the random coefficients model) of FEV1,', 'along with the change in SGRQ from the MMRM model will be extracted for each', 'subject. These values will then be used to obtain MCMC approximations of the joint', 'posterior distribution of the treatment differences between FEV1 decline and change in', 'SGRQ between the danirixin and placebo groups. Based on the samples from the', 'posterior distribution, the proportion of samples falling within certain treatment', 'difference regions will be calculated and the probability of success will be derived.', '10.4.2.', 'Safety Analyses', 'All safety endpoints will be tabulated or plotted by treatment group and will be', 'performed on the Safety Population. Further details will be described in the RAP.', '10.4.3.', 'Other Analyses', 'Exploratory biomarker analyses will be described in the RAP.', '10.4.4.', 'Interim Analyses', 'Conducting an interim analysis or futility assessment may not be practical due to an', 'expected fast recruitment period. By the time enough data will accumulate for any', 'meaningful interim analysis to support changes to the study design, recruitment of all', 'study participants will have concluded. However, if recruitment takes a longer than', 'anticipated, an interim analysis to reassess the variability assumptions, estimate the', 'probability of success at the end of study, and confirm the directionality of the endpoints', 'may be conducted.', 'The RAP will describe the potential interim analyses in greater detail.', '51']"
164,page_165,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '11.', 'REFERENCES', 'Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD.', 'Eur Respir J. 2004;23:932-946.', 'Chapman RW, Philips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2', 'antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009; 121:55-68.', 'FDA. Guidance for Industry. Center for Drug Evaluation and Research, United States', 'Food and Drug Administration; 2009. Drug-induced liver injury: premarketing clinical', 'evaluation.', 'GlaxoSmithKline Document Number 2013N180289 ( 03 Study ID 200163. A two part,', 'phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability,', 'pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin', '(GSK1325756) in symptomatic COPD subjects with mild to moderate airflow limitation', 'at risk for exacerbations. Report Date 05-Aug-2015.', 'GlaxoSmithKline Document Number 2014N205875 00 Study ID 201682. A', 'randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and', 'clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with', 'acute, uncomplicated influenza. Report Date 21-Nov-2014.', 'GlaxoSmithKline Document Number 2015N248339 00 Study ID 201037. A single', 'centre, open-label, 5-period, cross over, randomized study in healthy elderly subjects to', 'evaluate the relative bioavailability of hydrobromide salt and free base immediate release', 'tablet formulations of danirixin in the fed state, and to evaluate the effect of food and', 'gastric acid secretion suppression on danirixin pharmacokinetics following administration', 'of hydrobromide salt tablets. Report Date 01-Jun-2016.', ""GlaxoSmithKline Document Number YM2010/00163/07. Danirixin Investigator's"", 'Brochure, Version 09. Report Date 14-Apr-2016.', 'GOLD. From the Global Strateby for the Diagnosis, Management and Prevention of', 'COPD, Global Initiative for Chronic Obstructive Lung Disease. Global Initiative for', 'Chronic Obstructive Lung Disease, Available from: http://www.copdgold.org; 2016.', 'Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni I P, et al. SCH527123,', 'a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur', 'Respir J. 2010;35:564-570.', 'Hurst JA, Vestbo J, Anzueto A, Locantore N, Mullerova, Tal-Singer R, et al.', 'Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med.', '2010;363:1128-1138.', 'Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first', 'validation of the COPD Assessment Test (CAT). Eur Respir J. 2009;34:648-654.', '52']"
165,page_166,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R et al. Tests of the', 'responsiveness of the chronic obstructive pulmonary disease (COPD) assessment test', '(CAT) following acute exacerbation and pulmonary rehabilitation. Chest. 2012;142:134-', '140.', 'Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health', ""status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev"", 'Respir Dis. 1992;145:1321-1327.', 'Lazaar AL, Sweeney LE, MacDonald AJ et al. SB-656933, a novel CXCR2 selective', 'antagnoist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation', 'in humans. Br J Clin Pharmacol. 2011;72:282-293.', 'Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology.', '2016;21:14-23.', 'Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002', 'to 2030. PLoS Med. 2006;3:e442.', 'Meguro M, Barley EA, Spencer S et al. Development and validation of an improved', 'COPD-specific version of the St. George Respiratory Questionnaire. Chest.', '2007;132:456-463.', 'Miller B, Tal-Singer R, Lazaar A, Leidy N, Watz H, Collins D, et al. Assessing', 'symptoms in COPD: use of the E-RS daily digital diary in early drug development. Eur', 'Respir J.2016;48(S60):PA1047.', 'Nagai, K., Makita, H., Suzuki, M., Shimizu, K., Konno, S., Ito, Y. M., & Nishimura, M.', 'Differential changes in quality of life components over 5 years in chronic obstructive', 'pulmonary disease patients. International Journal of Chronic Obstructive Pulmonary', 'Disease. 2015; 10: 745-757.', 'Nair P, Gaga M, Zervas E et al. Safety and efficacy of a CXCR2 antagnoist in patients', 'with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical', 'trial. Clin Exp Allergy. 2012;42:1097-2103', ""O'Byrne PM, Metev H, Puu M et al. Efficacy and safety of a CXCR2 antagonist,"", 'AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind,', 'placebo-controlled trial. Lancet Respir Med. 2016;4:797-806.', 'Rennard SI, Dale DC, Donohue JF et al. CXCR2 antagonist MK-7123 - a phase 2 proof-', 'of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med.', '2015;191:1001-1011.', 'Vastava S, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and', 'economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoecon.', '2015;33:467-488.', '53']"
166,page_167,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindate S, et al.', 'Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J', 'Med. 2016;375:1253-1260.', 'Watz H, Kirsten A, Pedersen F, Goldmann T, Stellmacher F, Uddin M, et al. Neutrophils', 'in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist', 'AZD5069 - an explorative study in neutrophilic asthma. Eur Respir J.', '2016;48(S60): PA4892.', 'Woodruff PG, Barr RG, Bleecker F, Christenson SA, Couper D, Curtis JL, et al. Clinical', 'significance of symptoms in smokers with preserved pulmonary function. N Engl J Med.', '2016;374:1811-1821', '54']"
167,page_168,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.', 'APPENDICES', '12.1.', 'Appendix 1: Abbreviations and Trademarks', 'List of Abbreviations', 'AE', 'Adverse Event', 'ALT', 'Alanine Aminotransferase (SGPT)', 'AST', 'Aspartate Aminotransferase (SGOT)', 'ATS', 'American Thoracic Society', 'AUC', 'Area under the concentration-time curve', 'BfS', 'Federal Office of Radiation Protection (Germany)', 'BID', 'Twice daily', 'BRCP', 'Breast cancer resistance protein', 'BUN', 'Blood urea nitrogen', 'CAT', 'COPD Assessment Test', 'CD', 'Cluster of differentiation', 'CFR', 'Code of Federal Regulations (United States)', 'CI', 'Confidence Interval', 'CID', 'Clinically important deterioration', 'CIL', 'Clinical Investigation Leader', 'Cmax', 'Maximum observed concentration', 'CONSORT', 'Consolidated standards of reporting trials', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'CRF', 'Case Report Form', 'CT', 'Computed Tomography', 'CV', 'Cardiovascular', 'CXCR', 'CXC Chemokine Receptor', 'CXR', 'Chest X-Ray', 'dL', 'Deciliter', 'DNA', 'Deoxyribonucleic acid', 'DNX', 'Danirixin', 'DRE', 'Disease Related Event', 'E0', 'Effect at zero concentration', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic Case Report Form', 'ED50', 'Dose causing 50% of the maximum achievable response', '55']"
168,page_169,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'EMA', 'European Medicines Agency', 'Emax', 'Maximum response achievable', 'eMDI', 'Electronic metered dose inhaler', 'EW', 'Early Withdrawal', 'FDA', 'Food and Drug Administation (United States)', 'FEV1', 'Forced Expiratory Volume in one second', 'FVC', 'Forced Vital Capacity', 'FSH', 'Follicle Stimulation Hormone', 'GCP', 'Good Clinical Practice', 'GCSP', 'Global Clinical Safety and Pharmacovigilance', 'GGT', 'Gamma glutamyltransferase', 'GOLD', 'Global Initiative for Chronic Obstructive Lung Disease', 'GSK', 'GlaxoSmithKline', 'HBsAG', 'Hepatitis B surface antigen', 'HCRU', 'Healthcare Resource Utilization', 'hCG', 'Human chorionic gonadotrophin', 'HDPE', 'High density polyethylene', 'Hep B', 'Hepatitis B', 'Hep C', 'Hepatitis C', 'hsCRP', 'High sensitivity C-reactive protein', 'HIV', 'Human immunodeficiency virus', 'HPLC', 'High performance liquid chromatography', 'IB', ""Investigator's Brochure"", 'ICF', 'Informed Consent Form', 'International Conference on Harmonization of Technical', 'ICH', 'Requirements for Registration of Pharmaceuticals for', 'Human Use', 'ICS', 'Inhaled corticosteroid', 'IDMC', 'Independent Data Monitoring Committee', 'IEC', 'Independent Ethics Committee', 'IgG', 'Immunoglobulin G', 'IgM', 'Immunoglobulin M', 'INR', 'International normalized ratio', 'IP', 'Investigational Product', 'IRB', 'Institutional Review Board', 'ITT', 'Intent to treat', '56']"
169,page_170,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'IUD', 'Intrauterine device', 'IUS', 'Intrauterine hormone releasing system', 'IVIVT', 'In vitro In vivo Translation', 'IWRS', 'Interactive Web Response System', 'kg', 'Kilogram', 'L', 'Liter', 'LABA', 'Long acting ß2 receptor agonist', 'LAMA', 'Long acting muscarinic receptor antagonist', 'LH', 'Leutinizing Hormone', 'MCV', 'Mean corpuscular volume', 'MCH', 'Mean corpuscular hemoglobin', 'MCHC', 'Mean corpuscular hemoglobin count', 'MDI', 'Metered dose inhaler', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mg', 'Milligrams', 'mL', 'Millititer', 'MM', 'Medical monitor', 'MSDS', 'Material Safety Data Sheet', 'msec', 'Millisecond', 'NOAEL', 'No observed adverse effect level', 'O2', 'Oxygen', 'PK', 'Pharmacokinetics', 'PR', 'PR interval; duration in milliseconds from the beginning', 'of the P wave to onset of ventricular depolarization (R)', 'PRO', 'Patient Reported Outcome', 'PTS', 'Platform Technology and Science', 'QRS interval; duration in milliseconds of the QRS', 'QRS', 'complex', 'QT interval; duraction in milliseconds between the start', 'QT', 'of the Q wave and the end of the T wave', 'QTcF', 'QT interval corrected for heart rate (Friderica formula)', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cells', 'RNA', 'Ribonucleic acid', 'SABA', 'Short-acting ß2 Receptor Agonist', 'SAE', 'Serious Adverse Event', 'SAMA', 'Short-acting Muscarinic Receptor Agonist', '57']"
170,page_171,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'SGRQ', ""St George's Respiratory Questionnaire"", 'SGRQ-C', 'SGRQ-C for COPD patients', 'SRM', 'Study Reference Manual', 'SRT', 'Safety Review Team', 'SOA', 'Schedule of Activities', 'SUSAR', 'Suspected unexpected serious adverse reaction', 't¹/2', 'Terminal phase half-life', 'tmax', 'Time to reach Cmax', 'TPR', 'Third Party Resourcing', 'ULN', 'Upper limit of normal', 'g', 'Microgram', 'VT', 'Ventricular tachycardia', 'WBC', 'White blood cells', 'WOCBP', 'Women of child bearing potential', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'CAT', 'Combivent', 'Duoneb', '58']"
171,page_172,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.2.', 'Appendix 2: Clinical Laboratory Tests', 'The tests detailed in Table 5 (Protocol-Required Safety Laboratory', 'Assessments) will be performed by the central laboratory, except as noted.', 'Local laboratory results are only required in the event that the central laboratory', 'results are not available in time for either study treatment administration and/or', 'response evaluation. If a local sample is required, it is important that the sample', 'for central analysis is obtained at the same time. Additionally, if the local', 'laboratory results are used to make either a study treatment decision or response', 'evaluation, the results must be entered into the CRF.', 'Protocol-specific requirements for inclusion or exclusion of participants are', 'detailed in Section 6.', 'Additional tests may be performed at any time during the study as determined', 'necessary by the investigator or required by local regulations.', 'Table 5', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Specific gravity', 'Urinalysis', 'pH, glucose, protein, blood, ketones by dipstick', '59']"
172,page_173,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody²', 'All study-required laboratory assessments will be performed by a central', 'laboratory', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Laboratory results that could unblind the study will not be reported to investigative sites', 'or other blinded personnel until the study has been unblinded.', '60']"
173,page_174,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.3.', 'Appendix 3: Study Governance Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with:', 'Consensus ethical principles derived from international guidelines', 'including the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical', 'Guidelines', 'Applicable ICH Good Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other', 'relevant documents (eg, advertisements) must be submitted to an IRB/IEC by', 'the investigator and reviewed and approved by the IRB/IEC before the study is', 'initiated.', 'Any amendments to the protocol will require IEC/IRB approval before', 'implementation of changes made to the study design, except for changes', 'necessary to eliminate an immediate hazard to study participants.', 'The investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC', 'annually or more frequently in accordance with the requirements, policies,', 'and procedures established by the IRB/EC', 'Notifying the IRB/IEC of SAE or other significant safety findings as', 'required by IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 CFR, ICH guidelines, the IRB/IEC, European', 'regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', 'Financial Disclosure', 'Investigators and sub-investigators will provide the sponsor with sufficient, accurate', 'financial information as requested to allow the sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate regulatory authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study.', '61']"
174,page_175,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Informed Consent Process', 'The investigator or his/her representative will explain the nature of the study to', 'the participant or his/her legally authorized representative and answer all', 'questions regarding the study.', 'Participants must be informed that their participation is voluntary. Participants', 'or their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', ""A copy of the ICF(s) must be provided to the participant or the participant's"", 'legally authorized representative.', 'Participants who are rescreened are required to sign a new ICF.', 'The ICF may contain a separate section that addresses the use of remaining', 'mandatory samples for optional exploratory research in accordance with SOP-', 'GSKF-410. The investigator or authorized designee will explain to each', 'participant the objectives of the exploratory research. Participants will be told', 'that they are free to refuse to participate and may withdraw their consent at any', 'time and for any reason during the storage period. A separate signature will be', ""required to document a participant's agreement to allow any remaining"", 'specimens to be used for exploratory research. Participants who decline to', 'participate will not provide this separate signature.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', '62']"
175,page_176,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Committees Structure', 'A study charter will be created to describe important governance aspects while the', 'study is being conducted.', 'The SRT will include the Safety Development Leader, GCSP scientist, MM, CIL', 'and study statistician but will extend to other functions as requied. The SRT will', 'provide a proactive, aggregate and holistic evaluation of the safety data of', 'danirixin. Further details are included in the SRT charter.', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with', 'International Committee of Medical Journal Editors authorship requirements.', 'Dissemination of Clinical Study Data', 'This study will be registered and study information from this protocol will be', 'posted on publicly available clinical trial registers before enrolment of study', 'participants begins.', 'The results summary of this study will be posted to the GSK Clinical Study', 'Register and other publicly available clinical trial registers within 8 months of', 'the primary study completion date.', 'A manuscript reporting the study results will be submitted to a peer reviewed', ""journal within 18 months of the last participant's last visit."", 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic', 'CRF unless transmitted to the sponsor or designee electronically (eg, laboratory', 'data). The investigator is responsible for verifying that data entries are accurate', 'and correct by physically or electronically signing the CRF.', 'The investigator must maintain accurate documentation (source data) that', 'supports the information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', '63']"
176,page_177,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the CRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the investigator for 25 years after study completion', 'unless local regulations or institutional policies require a longer retention period.', 'No records may be destroyed during the retention period without the written', 'approval of the sponsor. No records may be transferred to another location or', 'party without written notification to the sponsor.', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', ""investigator's site."", 'Data reported on the CRF or entered in the eCRF that are transcribed from', 'source documents must be consistent with the source documents or the', 'discrepancies must be explained. The investigator may need to request previous', 'medical records or transfer records, depending on the study. Also, current', 'medical records must be available.', 'Definition of what constitutes source data can be found in the SRM.', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed.', 'The investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the sponsor or investigator may include', 'but are not limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', ""IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines"", 'Inadequate recruitment of participants by the investigator', 'Discontinuation of further study treatment development', '64']"
177,page_178,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', 'Definition of AE', 'AE Definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of a study treatment, whether or not considered related to the', 'study treatment.', 'NOTE: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study treatment.', 'Events Meeting the AE Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)', 'or other safety assessments (eg, ECG, radiological scans, vital signs measurements),', 'including those that worsen from baseline, considered clinically significant in the', 'medical and scientific judgment of the investigator (ie, not related to progression of', 'underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study treatment administration even', 'though it may have been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'treatment or a concomitant medication. Overdose per se will not be reported as an', 'AE/SAE unless it is an intentional overdose taken with possible suicidal/self-', 'harming intent. Such overdoses should be reported regardless of sequelae.', '""Lack of efficacy"" or ""failure of expected pharmacological action"" per se will not be', 'reported as an AE or SAE. Such instances will be captured in the efficacy', 'assessments. However, the signs, symptoms, and/or clinical sequelae resulting from', 'lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE', 'or SAE.', 'The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be', 'reported as AE or SAE if they fulfill the definition of an AE or SAE. Also, ""lack of', 'efficacy"" or ""failure of expected pharmacological action"" constitutes an AE or SAE.', '65']"
178,page_179,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Events NOT Meeting the AE Definition', 'Any clinically significant abnormal laboratory findings or other abnormal safety', 'assessments which are associated with the underlying disease, unless judged by the', ""investigator to be more severe than expected for the participant's condition."", 'The disease/disorder being studied or expected progression, signs, or symptoms of', 'the disease/disorder being studied, unless more severe than expected for the', ""participant's condition."", 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that', 'leads to the procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or', 'convenience admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Definition of SAE', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious', 'conditions are met (eg, hospitalization for signs/symptoms of the disease under study,', 'death due to progression of disease).', 'A SAE is defined as any untoward medical occurrence that, at any dose:', 'a) Results in death', 'b) Is life-threatening', 'The term ""life-threatening\' in the definition of \'serious\' refers to an event in which the', 'participant was at risk of death at the time of the event. It does not refer to an event,', 'which hypothetically might have caused death, if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization', 'In general, hospitalization signifies that the participant has been detained (usually', 'involving at least an overnight stay) at the hospital or emergency ward for observation', ""and/or treatment that would not have been appropriate in the physician's office or"", 'outpatient setting. Complications that occur during hospitalization are AE. If a', 'complication prolongs hospitalization or fulfills any other serious criteria, the event is', 'serious. When in doubt as to whether ""hospitalization"" occurred or was necessary, the AE', 'should be considered serious.', 'Hospitalization for elective treatment of a pre-existing condition that did not worsen from', 'baseline is not considered an AE.', 'Results in persistent disability/incapacity', ""The term disability means a substantial disruption of a person's ability to conduct"", '66']"
179,page_180,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,', 'and accidental trauma (eg, sprained ankle) which may interfere with or prevent', 'everyday life functions but do not constitute a substantial disruption.', 'Is a congenital anomaly/birth defect', 'Other situations:', 'Medical or scientific judgment should be exercised in deciding whether SAE', 'reporting is appropriate in other situations such as important medical events that may', 'not be immediately life-threatening or result in death or hospitalization but may', 'jeopardize the participant or may require medical or surgical intervention to prevent', 'one of the other outcomes listed in the above definition. These events should usually', 'be considered serious.', 'Examples of such events include invasive or malignant cancers, intensive treatment', 'in an emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', 'Definition of Cardiovascular Events', 'Cardiovascular Events (CV) Definition:', 'Investigators will be required to fill out the specific CV event page of the CRF for the', 'following AEs and SAEs:', 'Myocardial infarction/unstable angina', 'Congestive heart failure', 'Arrhythmias', 'Valvulopathy', 'Pulmonary hypertension', 'Cerebrovascular events/stroke and transient ischemic attack', 'Peripheral arterial thromboembolism', 'Deep venous thrombosis/pulmonary embolism', 'Revascularization', '67']"
180,page_181,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Recording AE and SAE', 'AE and SAE Recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (eg, hospital progress notes, laboratory, and diagnostics reports)', 'related to the event.', 'The investigator will then record all relevant AE/SAE information in the CRF', ""It is not acceptable for the investigator to send photocopies of the participant's"", 'medical records to GSK in lieu of completion of the GSK (/AE/SAE CRF page.', 'There may be instances when copies of medical records for certain cases are', 'requested by GSK. In this case, all participant identifiers, with the exception of the', 'participant number, will be redacted on the copies of the medical records before', 'submission to GSK.', 'The investigator will attempt to establish a diagnosis of the event based on signs,', 'symptoms, and/or other clinical information. Whenever possible, the diagnosis (not', 'the individual signs/symptoms) will be documented as the AE/SAE.', 'Assessment of Intensity', 'The investigator will make an assessment of intensity for each AE and SAE reported', 'during the study and assign it to 1 of the following categories:', 'Mild: An event that is easily tolerated by the participant, causing minimal discomfort', 'and not interfering with everyday activities.', 'Moderate: An event that causes sufficient discomfort and interferes with normal', 'everyday activities.', 'Severe: An event that prevents normal everyday activities. An AE that is assessed as', 'severe should not be confused with an SAE. Severe is a category utilized for rating', 'the intensity of an event; and both AE and SAE can be assessed as severe.', 'An event is defined as ""serious\' when it meets at least 1 of the predefined outcomes', 'as described in the definition of an SAE, NOT when it is rated as severe.', 'Assessment of Causality', 'The investigator is obligated to assess the relationship between study treatment and', 'each occurrence of each AE/SAE.', 'A ""reasonable possibility"" of a relationship conveys that there are facts, evidence,', 'and/or arguments to suggest a causal relationship, rather than a relationship cannot', 'be ruled out.', 'The investigator will use clinical judgment to determine the relationship.', '68']"
181,page_182,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other', 'risk factors, as well as the temporal relationship of the event to study treatment', 'administration will be considered and investigated.', ""The investigator will also consult the Investigator's Brochure (IB) and/or Product"", 'Information, for marketed products, in his/her assessment.', 'For each AE/SAE, the investigator must document in the medical notes that he/she', 'has reviewed the AE/SAE and has provided an assessment of causality.', 'There may be situations in which an SAE has occurred and the investigator has', 'minimal information to include in the initial report to GSK. However, it is very', 'important that the investigator always make an assessment of causality for', 'every event before the initial transmission of the SAE data to GSK.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information and send an SAE follow-up report with the updated causality', 'assessment.', 'The causality assessment is one of the criteria used when determining regulatory', 'reporting requirements.', 'Follow-up of AE and SAE', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as medically indicated or as requested by GSK to', 'elucidate the nature and/or causality of the AE or SAE as fully as possible. This may', 'include additional laboratory tests or investigations, histopathological examinations,', 'or consultation with other health care professionals.', 'If a participant dies during participation in the study or during a recognized follow-', 'up period, the investigator will provide GSK with a copy of any post-mortem', 'findings including histopathology.', 'New or updated information will be recorded in the originally completed CRF.', 'The investigator will submit any updated SAE data to GSK within 24 hours of', 'receipt of the information.', 'Reporting of SAE to GSK', 'SAE Reporting to GSK via Electronic Data Collection Tool', 'The primary mechanism for reporting SAE to GSK will be the electronic data', 'collection tool.', 'If the electronic system is unavailable for more than 24 hours, then the site will use', 'the paper SAE data collection tool (see next section).', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', '69']"
182,page_183,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'After the study is completed at a given site, the electronic data collection tool will be', 'taken off-line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated', 'data on a previously reported SAE after the electronic data collection tool has been', 'taken off-line, then the site can report this information on a paper SAE form (see', 'next section) or to the medical monitor/SAE coordinator by telephone.', 'Contacts for SAE reporting can be found in the SRM.', '70']"
183,page_184,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient and confirmatory testing with additional FSH and', 'estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine or serum pregnancy test', 'Additional pregnancy testing will be performed at approximately monthly intervals', 'during the study treatment period, after the last dose of study treatment and as', 'required locally.', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected', '71']"
184,page_185,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Pregnancy testing, with a high sensitivity test will be performed using the test kit', 'provided by the central laboratory and approved by the sponsor and in accordance', 'with instructions provided in the test kit package insert.', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', 'Investigator will not routinely attempt to collect pregnancy information on any male', ""participant's female partner(s) who becomes pregnant while the male participant is"", 'participating in this study; however, voluntary reports of such incidents will be', 'captured through the GSK standard reporting mechanism. This applies only to male', 'participants who receive double-blind study treatment.', ""If pregnancy information for a male participant's female partner(s) is voluntarily"", 'reported, after obtaining the necessary signed informed consent from the pregnant', 'female partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', ""24 hours of learning of a participant's pregnancy."", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the investigator, will be reported to GSK', 'as described in Appendix 4. While the investigator is not obligated to actively seek', '72']"
185,page_186,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'this information in former study participants, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female participant who becomes pregnant while participating will discontinue', 'study treatment and be withdrawn from the study.', '73']"
186,page_187,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.6.', 'Appendix 6: Genetics', 'USE/ANALYSIS OF DNA', ""Genetic variation may impact a participant's response to therapy, susceptibility,"", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a blood sample will be collected for DNA analysis.', 'DNA samples will be used for research related to danirixin or COPD and related', 'diseases. They may also be used to develop tests/assays including diagnostic tests)', 'related danirixin treatment, and COPD (and related diseases). Genetic research may', 'consist of the analysis of one or more candidate genes or the analysis of genetic', 'markers throughout the genome (as appropriate).', 'DNA samples will be analyzed if it is hypothesized that this may help further', 'understand the clinical data.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to danirixin or study treatments of this class. The results of', 'genetic analyses may be reported in the clinical study report or in a separate study', 'summary.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on danirixin (or study treatments of this', 'class) or COPD (and related diseases) continues but no longer than 15 years or other', 'period as per local requirements.', '74']"
187,page_188,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', 'Phase II liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event etiology', 'Phase II liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria', 'ALT-absolute', 'ALT 5xULN', 'ALT Increase', 'ALT: 3xULN persists for >4 weeks', 'Bilirubin1, 2', 'ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin)', 'INR²', 'ALT > 3xULN and INR>1.5, if INR measured', 'Cannot', 'ALT: 3xULN and cannot be monitored weekly for 4 weeks', 'Monitor', 'Symptomatic³', 'ALT 3xULN associated with symptoms (new or worsening) believed', 'to be related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Obtain INR and recheck with each', 'liver chemistry assessment until the', 'Complete the liver event CRF and complete', 'transaminases values show', 'an SAE data collection tool if the event also', 'downward trend', 'meets the criteria for an SAE²', 'Obtain blood sample for', 'Perform liver chemistry event follow up', 'pharmacokinetic (PK) analysis, up', 'assessments', 'to 72 h after last dose5', 'Monitor the participant until liver', 'chemistries resolve, stabilize, or return to', 'Serum creatine phosphokinase', 'within baseline (see MONITORING', '(CPK) and lactate dehydrogenase', '(LDH).', 'below)', 'Fractionate bilirubin, if total', 'Do not restart/rechallenge participant', 'bilirubin 2xULN', 'with study treatment unless allowed per', 'protocol and GSK Medical Governance', 'Obtain complete blood count with', 'approval is granted (see below)', 'differential to assess eosinophilia', 'If restart/rechallenge not allowed per', 'Record the appearance or', 'protocol or not granted, permanently', 'worsening of clinical symptoms of', '75']"
188,page_189,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'discontinue study treatment and continue', 'liver injury, or hypersensitivity, on', 'participant in the study for any protocol', 'the AE report form', 'specified follow up assessments', 'Record use of concomitant', 'medications on the concomitant', 'MONITORING:', 'medications report form including', 'acetaminophen, herbal remedies,', 'For bilirubin or INR criteria:', 'other over the counter medications.', 'Repeat liver chemistries (include ALT,', 'Record alcohol use on the liver', 'AST, alkaline phosphatase, bilirubin) and', 'event alcohol intake case report', 'perform liver event follow up assessments', 'form (CRF) page', 'within 24 hrs', 'Monitor participants twice weekly until', 'liver chemistries resolve, stabilize or return', 'to within baseline', 'For bilirubin or INR criteria:', 'A specialist or hepatology consultation is', 'Anti-nuclear antibody, anti-smooth', 'recommended', 'muscle antibody, Type 1 anti-liver', 'kidney microsomal antibodies, and', 'For All other criteria:', 'quantitative total immunoglobulin', 'Repeat liver chemistries (include ALT,', 'G (IgG) or gamma globulins.', 'AST, alkaline phosphatase, bilirubin) and', 'Serum acetaminophen adduct high', 'perform liver event follow up assessments', 'performance liquid chromatography', 'within 24-72 hrs', '(HPLC) assay (quantifies potential', 'Monitor participants weekly until liver', 'acetaminophen contribution to liver', 'chemistries resolve, stabilize or return to', 'injury in participants with definite', 'within baseline', 'or likely acetaminophen use in the', 'preceding week [James, 2009].', 'Liver imaging (ultrasound,', 'magnetic resonance, or', 'computerised tomography) and /or', 'liver biopsy to evaluate liver', 'disease complete Liver Imaging', 'and/or Liver Biopsy CRF pages.', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that participant if ALT 3xULN and bilirubin 2xULN..', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT > 3xULN and INR>1.5, if INR', ""measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding"", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM);', 'Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable,', 'obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody', '76']"
189,page_190,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '5. PK sample may not be required for participants known to be receiving placebo or non-GSK comparator', 'treatments.) Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the', ""participant's best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot"", 'be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and', 'shipping are in the SRM.', 'Phase II liver chemistry increased monitoring criteria with continued therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'Notify the GSK medical monitor within 24 hours of', 'ALT >3xULN and <5xULN and bilirubin', 'learning of the abnormality to discuss participant', '<2xULN, without symptoms believed to', 'safety.', 'be related to liver injury or', 'Participant can continue study treatment', 'hypersensitivity, and who can be', 'monitored weekly for 4 weeks', 'Participant must return weekly for repeat liver', 'chemistries (ALT, AST, alkaline phosphatase,', 'bilirubin) until they resolve, stabilise or return to', 'within baseline', 'If at any time participant meets the liver chemistry', 'stopping criteria, proceed as described above', 'If, after 4 weeks of monitoring, ALT <3xULN and', 'bilirubin <2xULN, monitor participants twice monthly', 'until liver chemistries normalize or return to within', 'baseline.', 'Reference', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', '77']"
190,page_191,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.8.', 'Appendix 8: Medical Device Incidents: Definition and', 'Procedures for Recording, Evaluating, Follow-up, and', 'Reporting', 'Definition and Documentation of Medical Device Incidents', 'Definitions of a Medical Device Incident', 'The detection and documentation procedures described in this protocol apply to all GSK', 'medical devices provided for use in the study (see Section 7.1.1) for the list of GSK', 'medical devices).', 'Medical Device Incident Definition', 'A medical device incident is any malfunction or deterioration in the characteristics', 'and/or performance of a device as well as any inadequacy in the labeling or the', 'instructions for use which, directly or indirectly, might lead to or might have led to', 'the death of a participant/user/other person or to a serious deterioration in his/her', 'state of health.', 'Not all incidents lead to death or serious deterioration in health. The nonoccurrence', 'of such a result might have been due to other fortunate circumstances or to the', 'intervention of health care personnel.', 'It is sufficient that:', 'An incident associated with a device happened and', 'The incident was such that, if it occurred again, might lead to death or a serious', 'deterioration in health.', 'A serious deterioration in state of health can include any of the following:', 'Life-threatening illness', 'Permanent impairment of body function or permanent damage to body structure', 'Condition necessitating medical or surgical intervention to prevent one of the', 'above', 'Fetal distress, fetal death, or any congenital abnormality or birth defects', '78']"
191,page_192,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Examples of incidents', 'A participant, user, caregiver, or healthcare professional is injured as a result of a', 'medical device failure or its misuse.', ""A participant's study treatment is interrupted or compromised by a medical device"", 'failure.', 'A misdiagnosis due to medical device failure leads to inappropriate treatment.', ""A participant's health deteriorates due to medical device failure."", 'Documenting Medical Device Incidents', 'Medical Device Incident Documenting', 'Any medical device incident occurring during the study will be documented in the', ""participant's medical records, in accordance with the investigator's normal clinical"", 'practice, and on the appropriate form.', 'For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE', 'CRF page will be completed as described in Appendix 4.', 'The form will be completed as thoroughly as possible and signed by the investigator', 'before transmittal to the GSK.', 'It is very important that the investigator provides his/her assessment of causality', '(relationship to the medical device provided by GSK) at the time of the initial report', 'and describes any corrective or remedial actions taken to prevent recurrence of the', 'incident.', 'A remedial action is any action other than routine maintenance or servicing of a', 'medical device where such action is necessary to prevent recurrence of an incident.', 'This includes any amendment to the device design to prevent recurrence.', '79']"
192,page_193,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.9.', 'Appendix 9: Neutrophil Safety and Study Treatment Restart', 'Neutrophil Stopping Criteria: Absolute neutrophil count (ANC) < 0.5 X 109 /L', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Record the appearance or', 'worsening of any clinical', 'Report the event to GSK within 24 hours', 'symptoms on the AE report form¹', 'Complete an SAE data collection tool if the', 'event also meets the criteria for an SAE', 'Obtain blood sample for', 'pharmacokinetic (PK) analysis', 'Monitor the participant until neutrophil', 'within 12 hours after last dose²', 'count stabilizes or returns to within', 'Record use of concomitant', 'baseline (see MONITORING below)', 'medications on the concomitant', 'Do not restart participant with study', 'medications report form', 'treatment unless allowed per protocol and', 'GSK Medical Governance approval is', 'granted (see RESTART below)', 'MONITORING:', 'Treatment of any suspected infections¹', 'Repeat CBC within 24 hrs', 'Monitor CBC daily until neutrophil count', 'resolves, stabilizes or returns to within', 'baseline', 'RESTART', 'Restart of study medication must be', 'Check the CBC within 24-48 hours', 'approved by the GSK Medical Monitor', 'after re-starting study medication,', 'Restart may be attempted ONLY if all', 'monitor twice weekly for two', 'three criteria are met:', 'weeks, and monthly thereafter.', 'The neutrophil count is 1.5 X 109/L', 'If the ANC drops below 1.0 X', 'for at least 48 hours', '109/L on restart, the participant', 'At least 7 days have elapsed since the', 'should be permanently', 'suspension of study treatment', 'discontinued from study treatment', 'No sign or symptom of associated', 'and withdrawn from the study.', 'infection has been identified', '80']"
193,page_194,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '1. New or worsening symptoms believed to be related to neutropenia such as (but not limited', 'to): sudden onset of fever or malaise, stomatitis, odynophagia, periodontal infection, skin', 'abscesses, signs or symptoms of sinusitis and otitis, symptoms of pneumonia (eg, cough,', 'dyspnea), perirectal pain and irritation, hypotension or signs of septic shock.', '2. Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is', ""unclear, provide the participant's best approximation. If the date/time of the last dose cannot"", 'be approximated OR a PK sample cannot be collected in the time period indicated above, do', 'not obtain a PK sample. Instructions for sample handling and shipping are in the SRM.', '81']"
194,page_195,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.10.', 'Appendix 10: Country-specific requirements', 'No country specific requirements', '82']"
195,page_196,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.11.', 'Appendix 11 Protocol Amendment History', 'Amendment 1', 'Table 1', 'Schedule of activities', 'Original text:', 'FU', 'Up to', '28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'EW', 'Visit1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', 'days', 'post', 'last', 'dose', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'up to', '0/', '2/', '4/', '8/', '12/', '16/', '20/', '24', '32', '40', '52/', '-7 days', 'D1', 'D14', 'D28', 'D56', 'D84', 'D112', 'D140', '/1168', 'D224', 'D280', 'D364', 'Assessment', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'window', 'Urine or', 'serum', 'X', 'Pregnancy', 'testg', 'HIV,', 'Hepatitis B', 'and C', 'screeninge', 'AE review', 'SAE review', 'Revised text:', 'FU', 'Up to', '28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'EW', 'Visit1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', 'days', 'post', 'last', 'dose', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'up to', '0/', '2/', '4/', '8/', '12/', '16/', '20/', '24', '32', '40/', '52/', '-28 days', 'D1', 'D14', 'D28', 'D56', 'D84', 'D112', 'D140', '/1168', 'D224', 'D280', 'D364', 'Assessment', '+3d', '+3d', '+3d', '3d', '+3d', '3d', '3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'window', 'HIV,', 'Hepatitis B', 'X', 'and C', 'screeninge', 'AE review', 'X', 'X', '83']"
196,page_197,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'SAE review', 'X', 'X', 'Section 5.1', 'Overall Design', 'Original text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days - -7 to', '1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Placebo (n=50)', '7 days', 'Follow-up2', 'Screening¹', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2 Follow-up visit to occur within 28days of last dose of study medication', 'Amended text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -28', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', '84']"
197,page_198,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Up to 28', 'Placebo (n=50)', 'days', 'Follow-up2', 'Screening', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', 'Section 6.1', 'Inclusion Criteria', 'Original text:', '2', 'Male or female', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'Female participants:', 'A female participant is eligible to participate if she is not pregnant (see Section 12.5;', 'Appendix 5), not breastfeeding, and at least one of the following conditions applies:', 'i.', 'Not a woman of childbearing potential (WOCBP) as defined in Section 12.5', '(Appendix 5)', 'OR', '85']"
198,page_199,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'ii. A WOCBP who agrees to follow the contraceptive guidance in Section 12.5', '(Appendix 5) during the treatment period and for at least 60 hours after the', 'last dose of study treatment.', 'Revised text:', '3', 'Male or female', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', 'Section 12.2 Appendix 2:', 'Original text:', 'Table 7', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', '86']"
199,page_200,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'required for', 'phosphatase', 'screening)', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as', 'needed for women of childbearing potential)2', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody³', 'All study-required laboratory assessments will be performed by a central', 'laboratory, with the exception of urine testing', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2. Local urine hCG testing will be standard for the protocol unless serum testing is required by local', 'regulation or IRB/IEC.', '3.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', '87']"
200,page_201,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text:', 'Table 8', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody²', 'All study-required laboratory assessments will be performed by a central', 'laboratory', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', '88']"
201,page_202,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Section 12.5 Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Original text:', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level', 'in the postmenopausal range may be used to confirm a postmenopausal', 'state in women not using hormonal contraception or hormonal', 'replacement therapy (HRT). However, in the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient.', 'Females on HRT and whose menopausal status is in doubt will be', 'required to use one of the non-hormonal highly effective contraception', 'methods if they wish to continue their HRT during the study. Otherwise,', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', '89']"
202,page_203,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Female participants', 'Female participants of childbearing potential are eligible to participate if they agree to', 'use a highly effective method of contraception consistently and correctly as described in', 'Table 6.', 'Table 9', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '90']"
203,page_204,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text:', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level', 'in the postmenopausal range may be used to confirm a postmenopausal', 'state in women not using hormonal contraception or hormonal', 'replacement therapy (HRT). However, in the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient and confirmatory', 'testing with additional FSH and estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be', 'required to use one of the non-hormonal highly effective contraception', 'methods if they wish to continue their HRT during the study. Otherwise,', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', '91']"
204,page_205,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Table 10', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent', 'a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '92']"
205,page_206,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Amendment 2', 'Original text:', '3.3.1 Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', '93']"
206,page_207,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'No adverse events related to testicular', 'effects have been observed in clinical', 'studies to date.', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count 0.5', 'X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', '94']"
207,page_208,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', 'study in patients with Influenza (GSK Study', '201682, GlaxoSmithKline Document No.', '2014N205875_00), decreased neutrophil', 'counts have been observed in participants', 'receiving either placebo or danirixin; no', 'instances of danirixin-related neutropenia', 'have been reported in clinical studies to', 'date. In healthy participants, the data are', 'confounded by the observation of low', 'neutrophil counts before dosing or at', 'follow-up, and were not dose-related, while', 'in patients with influenza, neutrophil counts', 'recovered while receiving danirixin,', 'coincident with resolution of the viral', 'infection. There have been no reports of', 'neutrophil count decreases below the lower', 'limit of normal in patients with COPD who', 'were treated with danirixin for one year.', 'These data support the conclusion that a', 'causal association of neutropenia with', 'danirixin cannot be definitively established.', '95']"
208,page_209,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Male participants with female partners of', 'child-bearing potential must comply with', 'the contraception requirements.', 'Study Procedures', 'None', 'Other', 'Not applicable', '96']"
209,page_210,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Amended text:', '3.3.1 Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', 'No adverse events related to testicular', 'effects have been observed in clinical', '97']"
210,page_211,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'studies to date.', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count < 0.5 X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', '98']"
211,page_212,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'study in patients with Influenza (GSK Study', '201682, GlaxoSmithKline Document No.', '2014N205875_00) decreased neutrophil', 'counts have been observed in participants', 'receiving either placebo or danirixin; no', 'instances of danirixin-related neutropenia', 'have been reported in clinical studies to', 'date. In healthy participants, the data are', 'confounded by the observation of low', 'neutrophil counts before dosing or at', 'follow-up, and were not dose-related, while', 'in patients with influenza, neutrophil counts', 'recovered while receiving danirixin,', 'coincident with resolution of the viral', 'infection. There have been no reports of', 'neutrophil count decreases below the lower', 'limit of normal in patients with COPD who', 'were treated with danirixin for one year.', 'These data support the conclusion that a', 'causal association of neutropenia with', 'danirixin cannot be definitively established.', '99']"
212,page_213,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Study Procedures', 'None', 'Other', 'Not applicable', '100']"
213,page_214,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Section 6.1', 'Inclusion Criteria', 'Original text:', 'Sex', '4.', 'Male or female', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', 'Revised text:', '5.', 'Male or female', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', '7.1.1 Medical Devices', 'Original text:', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices are', 'provided in the SRM.', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', 'Revised text:', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', '101']"
214,page_215,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Mobile spirometers (MicroDiary, manusfactured by and purchased from CareFusion) are', 'also being provided by GSK for this study. These devices allow participants to conduct', 'spirometry assessments at home. The MicroDiary has US FDA 510(k) clearance to', 'market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices and', 'mobile spirometers are provided in the SRM.', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '9.2.8 Medical Device Incidents (Including Malfunctions)', 'Original text:', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use. In order to fulfill regulatory reporting obligations', 'worldwide, the investigator is responsible for the detection and documentation of events', 'meeting the definitions of incident or malfunction that occur during the study with such', 'devices.', 'Revised text:', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use and measuring spirometry at home. In order to fulfill', 'regulatory reporting obligations worldwide, the investigator is responsible for the', 'detection and documentation of events meeting the definitions of incident or malfunction', 'that occur during the study with such devices.', '12.5 Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Original text:', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', '102']"
215,page_216,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Table 6', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent', 'a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '103']"
216,page_217,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Revised text:', 'Text deleted.', '12.5 Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Original text:', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', ""Investigator will attempt to collect pregnancy information on any male participant's"", 'female partner of a male study participant who becomes pregnant while participating', 'in this study. This applies only to participants who receive study treatment.', 'After obtaining the necessary signed informed consent from the pregnant female', 'partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure.', 'Revised text:', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', 'Investigator will not routinely attempt to collect pregnancy information on any', ""male participant's female partner(s) who becomes pregnant while the male"", 'participant is participating in this study; however, voluntary reports of such', 'incidents will be captured through the GSK standard reporting mechanism. This', 'applies only to male participants who receive double-blind study treatment.', ""If pregnancy information for a male participant's female partner(s) is voluntarily"", 'reported, after obtaining the necessary signed informed consent from the pregnant', 'female partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', '104']"
217,page_218,"['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Generally, follow-up will be no longer than 6 to 8 weeks following the', 'estimateddelivery date. Any termination of the pregnancy will be reported', 'regardless of fetal status (presence or absence of anomalies) or indication for', 'procedure', '105']"
218,page_219,"['2016N293064 0', 'CONFIDENTIAL', '2018N394263_00', 'GlaxoSmithKline group of companies', '205864', 'TITLE PAGE', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluation the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Protocol Number: 205864 Amendment 1', 'Short Title: Danirixin Pilot Study for Disease Progression', 'Compound Number: GSK1325756', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information will be provided in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s): IND: 108168', 'Approval Date: 17-MAY-2017', 'Copyright 2017 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']"
219,page_220,"['2018N394263_00', '2016N293064_ 01', 'CONFIDENTIAL', '-', '205864', 'SPONSOR SIGNATORY:', 'PPD', '17-May + 2017', 'PPD', 'Aili Lazaar, MD', 'Date', 'Clinical Development Director', 'Respiratory Therapy Area Unit', 'PPD', '2']"
220,page_221,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 1', '17-May-2017', 'Original Protocol', '21-Mar-2017', 'Amendment 1 17-May-2017', 'Overall Rationale for the Amendment: This amendment excludes the enrolment of', 'women of childbearing potential and clarifies the testing required for determination of', 'post menopausal status in specific situations.', 'Section #', 'Description of Change', 'Brief Rationale', 'and Name', 'Table 1 -', 'Remove pregnancy testing', 'Not required as no longer enrolling', 'Schedule of', 'WOCBP', 'Activities', 'Added missing check', 'marks', 'Error in original protocol', 'Updated screening period', 'Required to allow for screening lab', 'tests', 'Section 6.1', 'Update to only allow females to', 'To remove additional burden on female', 'Inclusion', 'participate if they are not women of', 'subjects of childbearing potential requiring', 'Criteria', 'childbearing potential (WOCBP)', 'additional visits for pregnancy testing only.', 'Section 12.2', 'Update Table 6 - Protocol-', 'Removed pregnancy testing based on the', '- Appendix 2', 'Required Safety Laboratory', 'exclusion of WOCBP', 'Clinical', 'Assessments to remove pregnancy', 'Laboratory', 'testing', 'Tests', 'Section 12.5', 'Adding clarification on', 'Current wording in template is not', '- Appendix 5', 'determination of post', 'clear on testing required', 'Contraceptive', 'menopausal state in the', 'absence of 12 months of', 'Clarification of wording', 'Guidance and', 'Collection of', 'amenorrhea', 'Pregnancy', 'Updated wording to be in', 'Information', 'line with exclusion of', 'WOCBP', '3']"
221,page_222,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '3', '1. SYNOPSIS', '7', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '9', '3.', 'INTRODUCTION', '12', '3.1.', 'Study Rationale', '12', '3.2.', 'Background', '13', '3.3.', 'Benefit/Risk Assessment', '14', '3.3.1.', 'Risk Assessment', '15', '3.3.2.', 'Benefit Assessment', '19', '3.3.3.', 'Overall Benefit:Risk Conclusion', '19', '4. OBJECTIVES AND ENDPOINTS', '20', '5.', 'STUDY DESIGN', '21', '5.1.', 'Overall Design', '21', '5.2.', 'Number of Participants', '21', '5.3.', 'Participant and Study Completion', '22', '5.4.', 'Scientific Rationale for Study Design', '22', '5.5.', 'Dose Justification', '22', '6.', 'STUDY POPULATION', '23', '6.1.', 'Inclusion Criteria', '23', '6.2.', 'Exclusion Criteria', '24', '6.3.', 'Lifestyle Restrictions', '26', '6.3.1.', 'Meals and Dietary Restrictions', '26', '6.3.2.', 'Activity', '27', '6.4.', 'Screen Failures', '27', '7. TREATMENTS', '27', '7.1.', 'Treatments Administered', '28', '7.1.1.', 'Medical Devices', '28', '7.2.', 'Dose Modification', '29', '7.3.', 'Method of Treatment Assignment', '29', '7.4.', 'Blinding', '29', '7.5.', 'Preparation/Handling/Storage/Accountability', '29', '7.6.', 'Treatment Compliance', '30', '7.7.', 'Concomitant Therapy', '30', '7.8.', 'Treatment after the End of the Study', '32', '8.', 'DISCONTINUATION CRITERIA', '32', '8.1.', 'Discontinuation of Study Treatment', '32', '8.1.1.', 'Liver Chemistry Stopping Criteria', '32', '8.1.2.', 'QTc Stopping Criteria', '33', '8.1.3.', 'Neutrophil Stopping Criteria', '34', '8.1.4.', 'Temporary Discontinuation', '34', '8.1.5.', 'Study Treatment Restart', '34', '4']"
222,page_223,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '8.2.', 'Withdrawal from the Study', '34', '8.3.', 'Lost to Follow Up', '35', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', '36', '9.1.', 'Efficacy Assessments', '36', '9.1.1.', 'FEV1', '36', '9.1.1.1.', 'Clinic Spirometry', '36', '9.1.1.2.', 'Mobile Spirometry', '36', '9.1.2.', 'SGRQ-C', '36', '9.1.3.', 'CAT', '37', '9.1.4.', 'COPD Exacerbations', '37', '9.1.5.', 'Patient Global Rating of Severity and Global Rating of', 'Change in Disease Severity', '37', '9.2.', 'Adverse Events', '38', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '38', '9.2.2.', 'Method of Detecting AEs and SAEs', '38', '9.2.3.', 'Follow-up of AEs and SAEs', '38', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '39', '9.2.5.', 'Cardiovascular and Death Events', '39', '9.2.6.', 'Disease-Related Events and/or Disease-Related', 'Outcomes Not Qualifying as SAEs', '39', '9.2.7.', 'Pregnancy', '40', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', '40', '9.2.8.1.', 'Time Period for Detecting Medical Device', 'Incidents', '40', '9.2.8.2.', 'Follow-up of Medical Device Incidents', '41', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents', 'to Sponsor', '41', '9.2.8.4.', 'Regulatory Reporting Requirements for', 'Medical Device Incidents', '41', '9.3.', 'Treatment of Overdose', '42', '9.4.', 'Safety Assessments', '42', '9.4.1.', 'Physical Examinations', '42', '9.4.2.', 'Vital Signs', '42', '9.4.3.', 'Electrocardiograms', '43', '9.4.4.', 'Clinical Safety Laboratory Assessments', '43', '9.4.5.', 'Pneumonia', '43', '9.5.', 'Pharmacokinetics', '44', '9.6.', 'Pharmacodynamics', '44', '9.7.', 'Genetics', '44', '9.8.', 'Biomarkers', '44', '9.9.', 'Health Economics OR Medical Resource Utilization and Health', 'Economics', '45', '10. STATISTICAL CONSIDERATIONS', '45', '10.1.', 'Sample Size Determination', '45', '10.2. Randomization', '48', '10.3.', 'Populations for Analyses', '48', '10.4.', 'Statistical Analyses', '48', '10.4.1.', 'Efficacy Analyses', '48', '10.4.2.', 'Safety Analyses', '51', '5']"
223,page_224,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.4.3.', 'Other Analyses', '51', '10.4.4.', 'Interim Analyses', '51', '11. REFERENCES', '52', '12. APPENDICES', '55', '12.1. Appendix 1: Abbreviations and Trademarks', '55', '12.2.', 'Appendix 2: Clinical Laboratory Tests', '59', '12.3.', 'Appendix 3: Study Governance Considerations', '61', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '65', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', '71', '12.6.', 'Appendix 6: Genetics', '75', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', '76', '12.8.', 'Appendix 8: Medical Device Incidents: Definition and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '79', '12.9. Appendix 9: Neutrophil Safety and Study Treatment Restart', '81', '12.10. Appendix 10: Country-specific requirements', '83', '12.11. Appendix 11 Protocol Amendment History', '84', '6']"
224,page_225,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '1.', 'SYNOPSIS', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Short Title: Danirixin Pilot Study for Disease Progression in COPD', 'Rationale: This is a pilot study to investigate the effect of danirixin hydrobromide (HBr)', '35mg tablets on lung function and health related quality of life (HRQoL) in participants', 'with mild to moderate airflow obstruction and a demonstrated history of decline in FEV1.', 'This study aims to assess whether danirixin has the potential to impact disease', 'progression in participants with COPD and with a demonstrated history of disease', 'progression measured by lung function.', 'Objectives and Endpoints:', 'Objective', 'Endpoint', 'Primary', 'Rate of decline in FEV1', 'To assess whether danirixin HBr 35mg', 'tablets impact disease progression', ""Change from baseline in St. George's"", 'compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'Secondary', 'To further characterize the safety of', 'Adverse events', 'danirixin HBr 35mg tablets compared', 'Vital Signs', 'with placebo in participants with mild', 'ECG', 'to moderate airflow limitation', 'Clinical Laboratory Assessments', '(hematology, clinical chemistry,', 'urinalysis)', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared with placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Overall Design:', 'This is a Phase 2 study to investigate the potential impact of danirixin HBr 35mg tablets', 'compared with placebo on disease progression in participants with mild to moderate', '7']"
225,page_226,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'airflow obstruction. The study will also assess the enrichment strategy of enrolling', 'participants identified from the COPDGene study. These participants have been', 'identified by COPDGene investigators based on data collected over the initial 5 year', 'period. The participants were identified based on a Random Forest analysis and a', 'demonstrated decline of at least 20mL/yr over the initial 5 year period.', 'Number of Participants:', 'Approximately 130 participants will be screened to enrol 100 participants in this study. It', 'is anticipated that approximately 85 participants will complete the 52 weeks of treatment', '(assuming a 15% drop out rate).', 'Treatment Groups and Duration:', 'Participants will receive either placebo or danirixin 35mg tablets (as hydrobromide', 'hemihydrate salt) twice daily for 52 weeks (12months).', '8']"
226,page_227,"['2016N293064_01', 'CONFIDENTIAL', '2018N394263_00', '205864', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', 'Table 1', 'Schedule of activities', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'days', 'Visit1a', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Eligibility', 'Informed Consent', 'X', 'Genetics Informed Consentb', 'X', 'Demography', 'X', 'Inclusion and Exclusion Criteria', 'X', 'Smoking Statusc', 'X', 'Smoking Historyc', 'X', 'Medical Historyd', 'X', 'Full physical', 'Chest X-ray (historical within 1 year', 'acceptable)', 'HIV, Hepatitis B and C screeninge', 'Additional Eligibility and In Study Assessments', 'Verify Eligibility', 'X', 'Brief physical', 'X', 'Laboratory assessments (clinical chemistry,', 'including liver chemistries), hematology,', 'X', 'X', 'X', 'urinalysis', 'Additional Liver chemistries only', 'X', 'X', 'X', 'X', '12 lead ECG', 'X', 'X', 'X', 'Vital Signs', 'X', 'X', '9']"
227,page_228,"['2016N293064_01', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'Visit1a', 'days', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Office spirometry (centralized)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Home spirometry - (weekly)', 'X', 'Randomization', 'Dispense study medication', 'Dispense log pad and provide training', 'X', 'Dispense MDI sensors and provide training', 'Study Treatment', 'Study Treatment Compliance (ediary)', 'Collect IP', 'Collect MDI sensors', 'X', 'Collect log pad', 'AE review', 'SAE review', 'Concomitant medication review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Clinical Outcomes Assessments', 'COPD exacerbation review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Rescue medication Use', 'SGRQ-C', 'X', 'X', 'COPD Assessment Test (CAT)', 'Participant Global Impression of COPD', 'severity', 'Participant Impression of change in COPD', 'severity', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '10']"
228,page_229,"['2016N293064_01', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'Visit1a', 'days', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-28 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Genetic, Pharmacokinetic and Biomarker Blood Collections', 'Blood sample for Genetics', 'Blood sample for CRP', 'Blood sample for exploratory biomarkers', 'a', 'Informed consent may be signed prior to screening visit in the case that any changes in medications are necessary', 'b', 'Agreeing to genetic sample consent is not required for study participation', 'C', 'Smoking status/history assessed at screening; smoking status re-checked at Visit 2', 'd', 'Includes substance usage, past and present medical conditions and family history of premature CV disease', 'e', 'Hepatitis B (HBsAg) and Hepatitis C (HepC antibody) testing is required. If testing otherwise performed within 3 months prior to the first dose of study treatment, testing at', 'screening is not required. Hepatitis C RNA testing is optional; however a confirmatory negative Hepatitis C RNA test must be obtained, to be able to enrol participants with', 'positive Hepatitis C antibody due to prior resolved disease.', 'f', ""Participant's clinical status should be reviewed"", 'The timing and number of planned study assessments, including safety and biomarker assessments may be altered during the course of the study based on newly available data to', 'ensure appropriate data collection. Any changes in the timing or addition of time points for any planned study assess must be documented and approved by the relevant study team', 'member and then archived in the sponsor and site study files, but will not constitute a protocol amendment. The IRB/IEC will be informed of any safety issues that require alteration of', 'the safety monitoring scheme or amendment of the ICF.', '11']"
229,page_230,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.', 'INTRODUCTION', 'The inflammation associated with COPD is characterized by a prominent infiltration of', 'neutrophils in lung tissue and the airways. Neutrophils and other inflammatory cells are', 'recruited to the lung in response to various chemotactic factors, including chemokines.', 'Specifically, there is a large body of evidence that the CXCR2 chemokine receptor plays', 'a pivotal role in neutrophil recruitment to the lung. For neutrophils, chemokine binding', 'to the CXCR2 results in chemotaxis and cell activation, ultimately resulting in the release', 'of a number of inflammatory mediators and proteases that are thought to contribute to the', 'progressive fibrosis, airway stenosis, and destruction of the lung parenchyma', 'characteristic of COPD.', 'Selective antagonism of the interaction between CXCR2 and its ligands is a potential', 'strategy for reducing the inflammation in COPD [Chapman, 2009]. A reduction in tissue', 'and airway neutrophilia is expected to result in downstream effects on mucus', 'hypersecretion, lung inflammation, and tissue destruction that are hypothesized to', 'underlie the development and worsening of respiratory symptoms and decline in lung', 'function that occurs in COPD.', 'Molecules with CXCR2 antagonist activity have been shown to reduce the influx of', 'neutrophils into the lungs in healthy participants (e.g. ozone or LPS challenge models)', 'and to reduce sputum and tissue neutrophils in the lungs of patients with severe,', 'neutrophilic asthma, COPD and bronchiectasis in association with improvements in', ""measures of disease activity in some, but not all, studies O'Byrne, 2016; Holz, 2010;"", 'Watz, 2016; Lazaar, 2011; Nair, 2012; Rennard, 2015]. Overall, the results of the', 'reported clinical studies with CXCR2 antagonists suggest that careful selection of the', 'target patient population is important to achieving clinical benefit.', 'Danirixin is a selective CXCR2 antagonist being developed as a potential anti-', 'inflammatory agent for the treatment of COPD and other inflammatory diseases and', 'influenza. Danirixin has demonstrated potent antagonism of CXCR2 activity both in', 'vitro and in vivo in preclinical studies GlaxoSmithKline Document Number', 'YM2010/00163/07]', 'Clinical pharmacology studies in healthy volunteers demonstrated the pharmacodynamic', 'activity of danirixin (inhibition of ex vivo CXCL1-induced CD11b expression on', 'peripheral blood neutrophils). Danirixin has also been tested in a Phase IIa study in', 'symptomatic participants with mild to moderate COPD at risk for exacerbation', '[GlaxoSmithKline Document Number 2013N180289 03 Study ID 200163]. In study', '200163, twice daily dosing with danirixin free base (75 mg bid) or placebo given on top', 'of standard of care inhaled maintenance treatments was tested for one year. Analyses of', 'clinical endpoints from study 200163 demonstrated that danirixin, compared to placebo,', 'reduced respiratory symptoms as measured with E-RS:COPD [Miller, 2016].', '3.1.', 'Study Rationale', 'This protocol describes a pilot study to investigate the effect of danirixin HBr 35mg', 'tablets on lung function and health related quality of life (HRQoL) in participants with', '12']"
230,page_231,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'mild to moderate airflow obstruction identified from the COPDGene cohort. Study', 'participants will continue with their standard of care inhaled medications (i.e. long acting', 'bronchodilators with or without inhaled corticosteroids) while receiving study treatment.', 'Specifically, this study aims to assess whether or not danirixin has the potential to impact', 'disease progression in participants with a COPD progression score indicating they are', 'likely to decline based on 5 year data from COPDGene and support the conduct of a', 'larger Phase III study for disease progression. In addition to lung function and HRQoL,', 'this study will assess moderate/severe COPD exacerbations, health status (CAT), and', 'rescue medication use.', '3.2.', 'Background', 'COPD is a major cause of disability, morbidity, and mortality, resulting in millions of', 'deaths annually worldwide contributing significantly to health care costs [Mathers, 2006;', 'Lopez-Campos, 2016; Vastava, 2015; GOLD, 2016]. The morbidity and mortality of', 'COPD are continuing to increase and worldwide and, by the year 2020, COPD is', 'expected to be the third leading cause of death and fifth leading cause of disability', '[Mathers, 2006; Lopez-Campos, 2016]. The airflow limitation that characterizes COPD', 'is primarily due to small airways disease and parenchymal destruction associated with an', 'excessive inflammatory response in the lung, mainly caused by cigarette smoking [Celli,', '2004]. COPD is characterized by symptoms of chronic and, in many patients,', 'progressive breathlessness (or dyspnea), cough and sputum production. Many COPD', 'patients also suffer from periodic worsening of their COPD symptoms that is beyond the', 'typical day to day variation [Hurst, 2010]. These episodes of worsening symptoms', '(COPD exacerbations) account for a significant proportion of COPD-related and total', 'health care costs. Despite several available therapies that have been shown to reduce', 'COPD exacerbations and respiratory symptoms, many COPD patients continue to', 'experience a high burden of respiratory symptoms and COPD exacerbations resulting in a', 'continuing unmet medical need [Vestbo, 2016]. Additionally, there is growing', 'recognition that a high percentage of COPD patients with mild airflow limitation as well', 'as smokers with preserved lung function suffer from a high burden of symptoms and', 'COPD exacerbations with a subsequent impact on health status [Woodruff, 2016].', 'Therapies that effectively further reduce COPD exacerbations and improve respiratory', 'symptoms could have a substantial impact on healthcare utilization and most importantly', ""result in an improvement in COPD patients' quality of life."", 'The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the', 'treatment and management of patients with COPD recommend that the management of', 'current respiratory symptoms and subsequent worsening of symptoms resulting in COPD', 'exacerbations should be an important component of COPD patient management [GOLD,', '2016].', 'Danirixin is being evaluated as an addition to standard of care inhaled therapies (i.e. long', 'acting bronchodilators and long acting bronchodilator/corticosteroid combination', 'therapies) and is targeting those COPD patients that continue to have a burden of', 'respiratory symptoms and COPD exacerbations despite management with currently', 'available COPD treatments.', '13']"
231,page_232,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.', 'Benefit/Risk Assessment', 'More detailed information about the potential benefits and risks of danirixin may be', ""found in the danirixin Investigator's Brochure [GlaxoSmithKline Document Number"", 'YM2010/00163/07].', '14']"
232,page_233,"['2016N293064_01', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.1.', 'Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', 'No adverse events related to testicular', 'effects have been observed in clinical', 'studies to date.', '15']"
233,page_234,"['2016N293064_01', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count < 0.5 X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', 'study in patients with Influenza (GSK Study', '16']"
234,page_235,"['2016N293064_01', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', '201682, GlaxoSmithKline Document No.', '2014N205875_00) decreased neutrophil', 'counts have been observed in participants', 'receiving either placebo or danirixin; no', 'instances of danirixin-related neutropenia', 'have been reported in clinical studies to', 'date. In healthy participants, the data are', 'confounded by the observation of low', 'neutrophil counts before dosing or at', 'follow-up, and were not dose-related, while', 'in patients with influenza, neutrophil counts', 'recovered while receiving danirixin,', 'coincident with resolution of the viral', 'infection. There have been no reports of', 'neutrophil count decreases below the lower', 'limit of normal in patients with COPD who', 'were treated with danirixin for one year.', 'These data support the conclusion that a', 'causal association of neutropenia with', 'danirixin cannot be definitively established.', '17']"
235,page_236,"['2016N293064_01', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Male participants with female partners of', 'child-bearing potential must comply with', 'the contraception requirements.', 'Study Procedures', 'None', 'Other', 'Not applicable', '18']"
236,page_237,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.2.', 'Benefit Assessment', 'All participants will undergo a thorough medical assessment during the study.', 'Participants will have frequent study clinic visits for the evaluation of their', 'disease symptoms. During these visits, participants will have spirometry, ECG,', 'vital signs monitoring, and physical examinations. Monitoring for worsening of', 'their disease will also take place.', 'Participants may benefit from the knowledge that they are contributing to the', 'process of developing a new treatment in an area of unmet need, even if not', 'directly beneficial for them', 'All participants will continue with changes to their medications, where medically', 'appropriate, to receive established standard of care.', '3.3.3.', 'Overall Benefit:I Risk Conclusion', 'Danirixin has demonstrated potent antagonism of CXCR2 activity both in vitro and in', 'vivo in preclinical and clinical studies. Its potency and duration of action supports its', 'potential use as an oral, anti-inflammatory agent in the treatment of COPD with', 'anticipated potential for bringing benefit to a serious condition that affects the lives of', 'millions and contributes to significant morbidity and mortality.', 'In clinical trials completed to date danirixin has been well-tolerated and most adverse', 'events (AEs) were mild to moderate in intensity The most commonly observed AEs have', 'been nasopharyngitis, headache and diarrhea following administration of danirixin or', 'placebo. There have been no treatment related clinically significant changes in vital signs', 'or ECG at any dose of danirixin.', 'Taking into account the measures taken to minimize risks to participants in this study, the', 'potential risks identified in association with danirixin are justified by the anticipated', 'benefits that may be afforded to participants with COPD.', '19']"
237,page_238,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '4.', 'OBJECTIVES AND ENDPOINTS', 'Objectives', 'Enpoints', 'Primary', 'To assess whether danirixin HBr', 'Rate of decline in FEV1', '35mg tablets impacts disease', ""Change from baseline in St. George's"", 'progression compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'To further characterize the safety of', 'Adverse events (AE), clinical', 'danirixin HBr 35mg tablets', 'laboratory values, vital signs,', 'compared with placebo in', 'electrocardiogram (ECG), and/or', 'participants with mild to moderate', 'other safety biomarkers', 'airflow limitation', 'Secondary', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared to placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Exploratory', 'To characterize the effect of', 'Blood/serum/plasma biomarkers that', 'danirixin on lung matrix', 'are indicative of extracellular matrix', 'destruction/remodelling and', 'turnover/remodelling (e.g. elastin and', 'inflammation', 'collagen neo-epitopes) and', 'inflammation (e.g. CRP)', 'Further characterize efficacy of', 'danirixin', 'Global assessment of COPD severity', '20']"
238,page_239,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.', 'STUDY DESIGN', '5.1.', 'Overall Design', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -28', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Upto 28', 'Placebo (n=50)', 'days', 'Follow-up2', 'Screening', 'R', 'Danirixin, 35mg', '(n=50)', ': If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2 Follow-up visit to occur within 28days of last dose of study medication', '5.2.', 'Number of Participants', 'Approximately 130 participants will be screened to achieve 100 randomized in this study.', 'It is anticipated that approximately 85 participants will complete the 12 months of', 'treatment (assuming a 15% drop out rate).', 'For the analysis of study assessments, several analysis populations are defined in Section', '10.3.', '21']"
239,page_240,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.3.', 'Participant and Study Completion', 'A participant is considered to have completed the study if he/she has completed all', 'planned study visits including the last study visit and the last scheduled procedure shown', 'in the Schedule of Activities (Table 1).', 'The end of the study is defined as the date of the last visit of the last participant in the', 'study.', '5.4.', 'Scientific Rationale for Study Design', 'This study will use a multicenter, randomized, parallel-group design. This is a well', 'established design to evaluate the efficacy and safety of an investigational drug. With the', 'use of an enriched population, it is anticipated that one year of treatment will be sufficient', 'to detect a trend in altering disease progression. Danirixin has already been clinically', 'investigated over one year treatment duration (GlaxoSmithKline Document Number', '2013N180289_03 Study ID 200163).', 'The data from this study will provide useful information in determining whether or not to', 'progress to a Phase III study to explore an indication for slowing disease progression.', '5.5.', 'Dose Justification', 'One dose of danirixin is proposed for this study, 35mg tablets BID. This dose was', 'selected based on integrating information on:', 'Dose-exposure-biomarker response using inhibition of ex vivo CXCL1-induced', 'CD11b expression on peripheral blood neutrophils over the dose range of 0-400mg', '(free base tablet) in healthy volunteers (GSK Study No. CX3 112483).', 'Evidence of reduced respiratory symptoms and improvement in health status in mild', 'to moderate COPD participants from interim data in the Phase IIa study (GSK Study', 'No. 200163).', 'Relative bioavailability study comparing danirixin free base vs HBr (GSK Study No.', '201037).', 'In the previous clinical studies, danirixin was administered as a free base tablet, whereas', 'the danirixin formulation to be used in this study will be a hydrobromide salt tablet.', 'The hydrobromide tablet has approximately twice the bioavailability of the free base', 'tablet in healthy elderly participants (GlaxoSmithKline Document Number', '2015N248339 00 Study ID 201037). Thus the danirixin (hydrobromide tablet) 35mg', 'BID dose for investigation in this study is expected to provide steady-state systemic', 'exposure approximately equivalent to the 75mg BID (free base tablet) used in Study', '200163. Predicted steady-state exposures and multiples of blood ex vivo CXCL1-induced', 'CD11b pharmacology at the proposed danirixin doses are presented in Table 2.', '22']"
240,page_241,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Table 2', 'Predicted steady state systemic exposure and multiples of blood ex', 'vivo CXCL1-induced pharmacology following twice daily of', 'administration of danirixin', 'Dose', 'Predicted# steady-state median (5th 95th', 'Cavg', 'Cmin', '(mg)', 'percentile)', 'multiple of', 'multiple of', 'AUC(0-24)', 'Cavg', 'Cmin', 'IC50*', 'IC50*', 'steady-state', '(ng/mL)', '(ng/mL)', '(ug.h/mL)', '35', '9.59', '399', '192', '5.1', '2.4', '(4.70, 19.3)', '(196,806)', '(47.6, 630)', '#Model derived based on PK data in healthy elderly participants from GSK Study No. 201037', '(GlaxoSmithKline Document Number. 2015N248339_00).', '*Model predicted population mean IC50=78.5 ng/mL (95% CI: 37.3, 120), sigmoidal Emax model of DNX', 'PK-ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils in healthy participants.', '6.', 'STUDY POPULATION', 'This study will identify specific patients most likely to decline from the well established', 'COPDGene cohort [NCT00608764] This study will be an ancillary study within', 'COPDGene investigating the enrichment strategy for assessing disease progression.', 'These potential participants have been identified by COPDGene investigators based on', 'data collected over the initial 5 year period. The participants were identified based on a', 'Random Forest analysis and a demonstrated decline of at least 20mL/yr over the initial 5', 'year period. Once participants are identified from the COPDGene dataset, the following', 'criteria will be verified at initial study visit following signing of consent.', 'Prospective approval of protocol deviations to recruitment and enrolment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '6.1.', 'Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria', 'apply:', 'Age', '1. Participant must be 40 to 76 years of age inclusive, at the time of signing the', 'informed consent.', 'Type of Participant and Disease Characteristics', '2.', 'At the screening visit, the subject must have an FEV1 >40% of the predicted normal.', '3.', 'Participants with a prior history of asthma are eligible if they have a current', 'diagnosis of COPD', '23']"
241,page_242,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Weight', '4.', 'Body weight 45 kg', 'Sex', '5.', 'Male or female', 'a.', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'b. Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', 'Informed Consent', '6. Capable of giving signed informed consent as described in Section 12.3 (Appendix 3)', 'which includes compliance with the requirements and restrictions listed in the', 'informed consent form (ICF) and in this protocol.', '6.2.', 'Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', 'Medical Conditions', '1. Diagnosis of other clinically relevant lung disease (other than COPD), e.g.', 'sarcoidosis, tuberculosis, pulmonary fibrosis, severe bronchiectasis or lung cancer', '2. COPD due to alpha-1-antitrypsin deficiency', '3. Pulse oximetry < 88% at rest at screening. Participants should be tested while', 'breathing room air. However, participants living at high altitudes (above 5000 ft or', '1500 m above sea level) who are receiving supplemental oxygen can be included', 'provided they are receiving the equivalent of < 4L/min and screening oximetry is', 'measured while on their usual settings.', '4. Less than 14 days have elapsed from completion of a course of antibiotics or oral', 'corticosteroids for a recent COPD exacerbation', '5. Participants with a peripheral blood neutrophil count < 1 X 109/L', '6. Diagnosis of pneumonia (chest X-ray or CT confirmed) within the 3 months prior to', 'screening', '7. Chest X-ray (posterior with lateral) or CT scan reveals evidence of a clinically', 'significant abnormality not believed to be due to the presence of COPD (historic data', 'up to 1 year may be used).', '24']"
242,page_243,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '8. History or current evidence of clinically significant renal disease, diabetes', 'mellitus/metabolic syndrome, hypertension, or any other clinically significant', 'cardiovascular, neurological, immunological, endocrine, or haematological', 'abnormality that is uncontrolled on permitted therapies. Significant is defined as any', 'disease that, in the opinion of the Investigator, would put the safety of the participants', 'at risk through study participation, or which would affect the safety analysis or other', 'analysis if the disease/condition exacerbated during the study.', '9. History of sensitivity to any of the study medications, or components thereof or a', 'history of drug or other allergy that, in the opinion of the investigator of GSK medical', 'monitor, contraindicates their participation.', '10. Current of chronic history of liver disease, or know hepatic or biliary abnormalities', ""(with the exception of Gilbert's syndrome or asymptomatic gallstones)."", '11. Abnormal and clinically significant 12-lead ECG finding. The investigator will', 'determine the clinical significance of each abnormal ECG finding in relation to the', ""subject's medical history and exclude participants who would be at undue risk by"", 'participating in the trial. An abnormal and clinically significant finding that would', 'preclude a subject from entering the trial is defined as a 12-lead tracing that is', 'interpreted as, but not limited to, any of the following:', '- AF with rapid ventricular rate > 120 bpm;', '- sustained or non-sustained VT', '-', 'second degree heat block Mobitz type II and third degree heart block (unless', 'pacemaker or defibrillator has been implanted)', '- QTcF 500 msec in patients with QRS < 120 msec and QTcF > 530 msec in', 'patients with QRS 120 msec', '12. Previous lung surgery (e.g. lobectomy, pneumonectomy) or lung volume reduction', 'procedure.', 'Prior/Concomitant Therapy', '13. Current or expected chronic use of macrolide antibiotics during the study period for', 'the prevention of COPD exacerbations. Examples of chronic use include, but are not', 'limited to, daily or two to three times per week use for at least 3 months.', '14. Oral or injectable CYP3A4 or BRCP (breast cancer resistance protein) substrates with', 'a narrow therapeutic index (CYP3A4 substrates include, but are not limited to,', 'alfenatil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,', 'quinidine, sirolimus, tacrolimus, and theophylline; BCRP substrates include, but are', 'not limited to, topotecan.) The Investigator should consult with the Medical Monitor', 'if necessary.', '15. Current or expected use of phosphodiesterase-4 inhibitors (e.g. roflumilast).', 'Participants currently receiving roflumilast may be included if they are able to', 'discontinue use from 30 days prior to screening through the completion of the follow', 'up visit.', '25']"
243,page_244,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Prior/Concurrent Clinical Study Experience', '16. Participation in a previous clinical trial and has received an investigational product', 'within any of the following time periods prior to the first dosing day in the current', 'study: 30 days, 5 half lives, or twice the duration of the biological effect of the', 'investigational product (whichever is longer).', '17. Participation in a previous clinical trial with danirixin within 1 year prior to the first', 'dosing day in the current study', '18. Exposure to more than four investigational products within 1 year prior to the first', 'dosing day in the current study.', 'Diagnostic assessments', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN); bilirubin > 1.5xULN', '(isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct', 'bilirubin <35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Other Exclusions', '22. Pulmonary rehabilitation: Participants who have taken part in the acute phase of a', 'pulmonary rehabilitation program within 4 weeks prior to screening or participants', 'who plan to enter the acute phase of a pulmonary rehabilitation program during the', 'study. Participants who are in the maintenance phase of a pulmonary rehabilitation', 'program are not excluded.', '23. A history of allergy or hypersensitivity to any of the ingredients in the study', 'treatment.', '24. A known or suspected history of alcohol or drug abuse within the 2 years prior to', 'screening.', '25. Inability to read: in the opinion of the Investigator, any participant who is unable to', 'read and/or would not be able to complete study related materials.', '26. Affiliation with the study site: study investigators, sub-investigators, study', 'coordinators, employees of a study investigator, sub-investigator or study site, or', 'immediate family member of any of the above that are involved with the study.', '6.3.', 'Lifestyle Restrictions', '6.3.1.', 'Meals and Dietary Restrictions', 'No meal or dietary restrictions are required for participation in this study. Danirixin must', 'be taken with food. Specific dosing instructions will be provided in the Study Reference', 'Manual (SRM) and will be provided to all study participants.', '26']"
244,page_245,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '6.3.2.', 'Activity', 'Participants should abstain from strenuous exercise for 24 hours before each blood', 'collection for clinical laboratory tests.', '6.4.', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study', 'but are not subsequently randomized in the study. A minimal set of screen failure', 'information is required to ensure transparent reporting of screen failure participants to', 'meet the Consolidated Standards of Reporting Trials (CONSORT) publishing', 'requirements and to respond to queries from regulatory authorities. Minimal information', 'includes demography, screen failure details, eligibility criteria and any serious adverse', 'events (SAEs).', 'Individuals who do not meet the criteria for participation in this study (screen failure)', 'may not be rescreened unless discussed with the medical monitor.', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment(s), marketed product(s),', 'placebo, or medical device(s) intended to be administered to a study participant according', 'to the study protocol.', '27']"
245,page_246,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.1.', 'Treatments Administered', 'Study Treatment Name:', 'Danirixin', 'Placebo', '(GSK1325756H, the', 'hydrobromide', 'hemihydrate salt)', 'Dosage formulation:', 'White Film coated', 'White Film coated', 'tablets (oval shaped).', 'tablets (oval shaped).', 'Refer to', ""Refer to Investigator's"", 'Brochure for', ""Investigator's"", 'Brochure for', 'presentation and', 'presentation and', 'excipients', 'excipients', 'Unit dose strength(s)/Dosage level(s):', '35mg tablets (of free', 'N/A', 'base equivalent)', 'Route of Administration', 'Oral', 'Oral', 'Dosing instructions:', 'One tablet to be', 'One tablet to be taken', 'taken twice daily', 'twice daily with food', 'with food', 'Packaging and Labeling', 'Study Treatment will', 'Study Treatment will', 'be provided in a', 'be provided in a HDPE', 'HDPE bottle with', 'bottle with desiccant.', 'desiccant. Each', 'Each bottle will be', 'bottle will be labeled', 'labeled as required per', 'as required per', 'country requirement.', 'country requirement.', 'Manufacturer', 'GSK', 'GSK', '7.1.1.', 'Medical Devices', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices are', 'provided in the SRM.', '28']"
246,page_247,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '7.2.', 'Dose Modification', 'No individual participant dose modifications or adjustments are allowed.', '7.3.', 'Method of Treatment Assignment', 'This study will use an Interactive Web Response System (IWRS). All', 'participants will be centrally randomized using the IWRS. Before the study is', 'initiated, the log in information and directions for the IWRS will be provided to', 'each site.', 'Participant randomization will be stratified by smoking status (i.e. current', 'smoker or former smoker).', 'Study treatment will be dispensed to participants at the study visits summarized', 'in the SOA.', 'Returned study treatment should not be re-dispensed to any participant.', '7.4.', 'Blinding', 'This will be a double-blind study. Study participants, all study site staff, and all members', 'of the GSK study team will be blinded to individual participant treatment assignment.', ""A participant will be withdrawn if the participant's treatment code is unblinded by the"", 'investigator or treating physician. The primary reason for discontinuation (the event or', 'condition which led to the unblinding) will be recorded in the CRF.', ""GSK's Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the"", 'treatment assignment for any participant with an SAE. If the SAE requires that an', 'expedited regulatory report be sent to one or more regulatory agencies, a copy of the', ""report, identifying the participant's treatment assignment, may be sent to investigators in"", 'accordance with local regulations and/or GSK policy.', '7.5.', 'Preparation/Handling/Storage/Accountability', 'The investigator or designee must confirm and document appropriate temperature', 'conditions have been maintained during transit for all study treatment received', 'and any discrepancies are reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study', 'treatments must be stored in a secure, environmentally controlled, and monitored', '29']"
247,page_248,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '(manual or automated) area in accordance with the labeled storage conditions', 'with access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (ie, receipt, reconciliation, and final disposition of records).', 'Further guidance and information for the final disposition of unused study', 'treatment are provided in the SRM.', 'Precaution will be taken to avoid direct contact with the study treatment. Under', 'normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. In the case of unintentional', 'occupational exposure notify the monitor, Medical Monitor and/or GSK study', 'contact.', 'A Material Safety Data Sheet MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '7.6.', 'Treatment Compliance', 'When participants are dosed at the site, they will receive study treatment directly', 'from the investigator or designee, under medical supervision. The date and time of', 'each dose administered in the clinic will be recorded in the source documents. The', 'dose of study treatment and study participant identification will be confirmed at the', 'time of dosing by a member of the study site staff other than the person', 'administering the study treatment.', 'When participants self-administer study treatment(s) at home, compliance with study', 'treatment administration will be assessed through querying the participant during the', 'site visits and documented in the source documents and CRF. In addition,', 'participants will be asked to confirm study administration each day in the daily', 'ediary.', 'Study participants who are not compliant with study treatment administration', 'requirements should be re-educated on the importance of treatment compliance.', 'Every effort should be made to keep participants in the study. Participants who', 'continue to be non-compliant after several attempts to re-educate may be', 'discontinued after consultation with the GSK study team.', '7.7.', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) that the participant is receiving at the time of', 'enrolment or receives during the study must be recorded along with:', 'reason for use', 'dates of administration including start and end dates', '30']"
248,page_249,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'dosage information including dose and frequency', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', 'The following COPD medications are permitted during the study, at the discretion of the', 'GSK Medical Monitor and/or Investigator:', 'Inhaled COPD maintenance medications (e.g. long acting bronchodilator', 'medications (i.e. LAMA, LABA) and long-acting bronchodilator combination', 'therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled steroid', 'combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)', 'Short courses of oral corticosteroids and/or antibiotics (including macrolides)', 'are permitted for the acute treatment of exacerbations of COPD and should not', 'exceed 21 days. This use must be recorded as an HCRU exacerbation event.', 'The following medications are prohibited from the screening visit until after completion', 'of the follow up visit:', 'Chronic use of macrolide antibiotics for the prevention of COPD exacerbations.', 'Examples of chronic use include daily or two-three times per week for at least', '3', 'months.', 'Oral or injectable CYP3A4 or BCRP substrates with narrow therapeutic index', '(CYP3A4 substrates include, but are not limited to, alfentanil, cyclosporine,', 'dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus,', 'tacrolimus, and theophylline; BCRP substrates include, but are not limited to,', 'topotecan.', 'Phosphodiesterase-4 inhibitors (e.g. roflumilast)', 'Broad spectrum phosphodiesterase inhibitors (e.g. theophylline)', 'GSK will not supply rescue medication. Participants may continue to use and should', 'obtain rescue medication(s) through via their usual route. The following rescue', 'medications may be used:', 'Short acting beta agonists (SABA)(e.g., albuterol/salbutamol)', 'Short acting muscarinic antagonists (SAMA)(e.g., ipratropium)', 'Short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb,', 'Combivent)', 'The use of rescue medications is allowable at any time during the study. Participants', 'should record in the daily e-diary the number of puffs of rescue medication(s) over each', '24 hour period. Data from the MDI sensor device will be electronically captured and', 'transmitted to GSK.', 'Annual influenza vaccine is recommended for patients with COPD but is not required for', 'participation in this study. Influenza vaccination is permitted during the study and should', '31']"
249,page_250,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'be based on applicable local or national guidelines. Pneumococcal vaccine may also be', 'administered, when indicated, based on applicable local or national guidelines.', 'Additional vaccinations may be administered when indicated. Any vaccination', 'administered during the study should be recorded as a concomitant therapy.', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', 'study care of the participant.', 'GSK will not provide post-study treatment. There are no plans to provide the study', 'treatment for compassionate use following study completion.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', '8.1.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to assure', 'participant safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance). These protocol guidelines are in alignment', 'with FDA premarketing clinical liver safety guidance [FDA, 2009].', 'Discontinuation of study treatment for abnormal liver tests should be considered by the', 'investigator when a participant meets one of the conditions outlined in the algorithm', 'below or if the investigator believes that it is in the best interest of the participant.', '32']"
250,page_251,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If subject to be monitored weekly mustrefer to Liver Safety Required Actions and Follow up', 'Assessments section in the Appendix', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin>2x', 'Yes', 'No', 'ULN (>35%', 'ALT23xULN', 'ALT>3xULN', 'ALT>3xULN', 'direct)', 'Plus', 'Yes', 'No', 'No', 'No', 'but able to', 'Yes', 'persist for', 'ALT>3xULN', 'orplus', 'Symptoms of', 'ALT>5xULN', 'monitor', '4 weeks or', 'INR>1.5, if', 'liverinjury', 'weekly for', 'stopping', 'measured*', 'or', '4 weeks', 'criteria', 'Possible', 'hypersensitivity', 'met', ""Hy's Law"", 'Yes', 'Yes', 'No', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', ""Reportas an SAE if possible Hy's Law case:ALTa3xULNan Bilirubin>2xULN (>35% direct) or"", 'INR>1.5, if measured*', '*INR value not applicable to subjects on anticoagulants', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Appendix 7: Liver Safety: Required Actions and Follow-up Assessments).', '8.1.2.', 'QTc Stopping Criteria', 'The same QT correction formula must be used for each individual participant to', 'determine eligibility for and discontinuation from the study. This formula may', 'not be changed or substituted once the participant has been enrolled.', 'For example, if a participant is eligible for the protocol based on QTcB, then', 'QTcB must be used for discontinuation of this individual participant as well.', ""Once the QT correction formula has been chosen for a participant's eligibility,"", 'the same formula must continue to be used for that participant for all QTc data', 'being collected for data analysis. Safety ECGs and other non-protocol specified', 'ECGs are an exception.', 'The QTc should be based on single or averaged QTc values of triplicate', 'electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period.', 'A participant who meets either bulleted criteria based on the average of triplicate ECG', 'readings will be withdrawn from study treatment:', 'QTc > 500 msec OR Uncorrected QT > 600 msec', 'Change from baseline of QTc > 60 msec', '33']"
251,page_252,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'For patients with underlying bundle branch block, follow the discontinuation criteria', 'listed below:', 'Baseline QTc with Bundle Branch Block', 'Discontinuation QTc with Bundle', 'Branch Block', '< 450 msec', '> 500 msec', '450 - 480 msec', '> 530 msec', 'See the SoA (Table 1) for data to be collected at the time of treatment discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.1.3.', 'Neutrophil Stopping Criteria', 'A participant with a peripheral blood neutrophil count < 0.5 X 109/L that is confirmed on', 'repeat testing will be instructed to suspend dosing. The neutrophil count should be', 'monitored daily until it returns to within the baseline value, as detailed in Appendix 9.', '8.1.4.', 'Temporary Discontinuation', 'Temporary discontinuation of study treatment is allowed for up to 14 days when', 'medically necessary, e.g. for hospitalization for a COPD exacerbation, other medical', 'condition requiring hospitalization, or reduction in peripheral blood neutrophil counts <', '0.5 X 109/L. Temporary discontinuation for any other reason should be discussed with', 'the GSK Medical Monitor.', '8.1.5.', 'Study Treatment Restart', 'Study treatment restart after liver chemistry stopping criteria are met by any participant in', 'this study is not allowed. Refer to Appendix 7 (Section 12.7) for full guidance for', 'required actions and follow-up assessments to undertake if liver stopping criteria are met.', 'Study treatment restart after neutrophil stopping criteria are met can be considered once', 'the neutrophil count has returned to within baseline and provided that no more than 14', 'days have elapsed since study medication was halted. The Investigator must obtain', 'approval from the GSK Medical Monitor prior to restarting study treatment. See', 'Appendix 9 for the procedure to be followed for study treatment restart after neutrophil', 'stopping criteria are met.', '8.2.', 'Withdrawal from the Study', 'A participant may withdraw from the study at any time at his/her own request,', 'or may be withdrawn at any time at the discretion of the investigator for safety,', 'behavioural, compliance or administrative reasons.', '34']"
252,page_253,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If the participant withdraws consent for disclosure of future information, the', 'sponsor may retain and continue to use any data collected before such a', 'withdrawal of consent.', 'If a participant withdraws from the study, he/she may request destruction of any', 'samples taken and not tested, and the investigator must document this in the site', 'study records.', 'Refer to the SoA for data to be collected at the time of study discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.3.', 'Lost to Follow Up', 'A participant will be considered lost to follow-up if he or she repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'The following actions must be taken if a participant fails to return to the clinic for a', 'required study visit:', 'The site must attempt to contact the participant and reschedule the missed visit', 'as soon as possible and counsel the participant on the importance of maintaining', 'the assigned visit schedule and ascertain whether or not the participant wishes to', 'and/or should continue in the study.', 'Before a participant is deemed lost to follow up, the investigator or designee', 'must make every effort to regain contact with the participant (where possible, 3', ""telephone calls and, if necessary, a certified letter to the participant's last known"", 'mailing address or local equivalent methods). These contact attempts should be', ""documented in the participant's medical record."", 'Should the participant continue to be unreachable, he/she will be considered to', 'have withdrawn from the study with a primary reason of lost to follow-up.', '35']"
253,page_254,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA (Table 1)', 'Protocol waivers or exemptions are not allowed', 'Immediate safety concerns should be discussed with the sponsor immediately', 'upon occurrence or awareness to determine if the participant should continue or', 'discontinue study treatment.', 'Adherence to the study design requirements, including those specified in the', 'SoA, is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that', 'potential participants meet all eligibility criteria. The investigator will maintain a', 'screening log to record details of all participants screened and to confirm', 'eligibility or record reasons for screening failure, as applicable.', ""Procedures conducted as part of the participant's routine clinical management"", '(e.g., blood count) and obtained before signing of ICF may be utilized for', 'screening or baseline purposes provided the procedure met the protocol-', 'specified criteria and was performed within the time frame defined in the SoA.', 'The maximum amount of blood collected from each participant over the', 'duration of the study, including any extra assessments that may be required, will', 'not exceed 500 mL.', 'Repeat or unscheduled samples may be taken for safety reasons or for technical', 'issues with the samples.', '9.1.', 'Efficacy Assessments', '9.1.1.', 'FEV1', '9.1.1.1.', 'Clinic Spirometry', 'Spirometry using FEV and FVC measurements (FEV%, and FVC% and FEV1/FVC will', 'be calculated) will be performed in triplicate at time points listed in the SoA (Table 1).', 'Spirometry assessments should be performed in accordance with ATS/ERS guidelines as', 'outlined in the SRM.', '9.1.1.2.', 'Mobile Spirometry', 'Spirometry will also be performed weekly by the participants using a mobile spirometer', 'at home. Details will be outlined in the SRM.', '9.1.2.', 'SGRQ-C', ""The St. George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease"", 'specific tool (SGRQ-C) is a disease-specific questionnaire designed to measure the', ""impact of respiratory disease and its treatment on a COPD patient's HRQoL [Meguro,"", '2007]. As well as producing an overall summary score, scores for the individual domains', 'of symptoms, activity and impacts are also produced. The SGRQ-C has been used in', '36']"
254,page_255,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'numerous previous studies of COPD participants and has been translated and validated', 'for use in most major languages. The SGRQ-C is derived from the original SGRQ and', 'produces SGRQ scores equivalent to the original SGRQ instrument [Jones, 1992].', '9.1.3.', 'CAT', 'The COPD Assessment Test is a short and simple patient completed questionnaire which', 'has been developed for use in routine clinical practice to measure the health status of', 'patients with COPD. The CAT is an 8-item questionnaire suitable for completion by all', 'patients diagnosed with COPD [Jones, 2009; Jones, 2012]. When completing the', 'questionnaire, participants rate their experience on a 6-point scale, ranging from 0', '(maximum impairment) to 5 (no impairment) with a scoring range of 0-40. Higher scores', 'indicate greater disease impact.', '9.1.4.', 'COPD Exacerbations', 'An exacerbation of COPD is defined by a worsening of symptoms requiring additional', 'treatment or hospitalization.', 'Details of an exacerbation should be recorded in the exacerbation page of the eCRF.', 'Exacerbations will not be reported according to the standard process for expedited', 'reporting of SAEs to GSK (even though the event may meet the definition of an SAE) as', 'they are considered Disease Related Events (DREs). Only when the event is, in the', ""Investigator's opinion, of greater intensity, or duration than expected for the individual"", 'participant, or the Investigator considers that there is a reasonable possibility that the', 'event is related to study treatment should it be reported as an SAE (See Section 9.2).', '(Pneumonia must be recorded in the AE or SAE section of the eCRF and on the', 'pneumonia page of the eCRF (See Section 9.4.5)).', 'All medications used for the treatment of exacerbations must be recorded in the source', 'documents and the exacerbation page of the eCRF. If necessary the PI or other health', ""care personnel may stop the participant's study treatment temporarily in order to treat the"", 'COPD exacerbation. The reason for temporarily stopping study treatment and duration', 'should be recorded in the eCRF.', 'The date of onset and the date of resolution will be recorded in the source documents and', ""the eCRF based on the Investigator's judgement."", '9.1.5.', 'Patient Global Rating of Severity and Global Rating of Change in', 'Disease Severity', 'Participants will complete the Global Rating of COPD Severity at randomisation and', 'final study visit or IP Discontinuation Visit. This single global question will ask', 'participants to rate their severity of COPD on a four point scale (mild, moderate, severe,', 'very severe).', 'Participants will complete a Global Rating of Change in COPD (overall disease) question', 'at every visit following randomization (or Early Withdrawal (EW) Visit). Response', '37']"
255,page_256,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'options will be on a 7 point Likert scale ranging from much better to much worse. Asking', 'at each Visit allows for early detection of response as well as continued response.', '9.2.', 'Adverse Events', 'The definitions of an AE or SAE can be found in Appendix 4 (Section 12.4).', 'The investigator and any designees are responsible for detecting, documenting, and', 'reporting events that meet the definition of an AE or SAE and remain responsible for', 'following up AEs that are serious, considered related to the study treatment or the study,', 'or that caused the participant to discontinue the study treatment (see Section 8).', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', 'All SAEs will be collected from the time the informed consent is signed by the', 'participant until the follow up visit at the time points specified in the SoA', '(Table 1).', 'All AEs will be collected from the start of study treatment (randomization visit)', 'until the follow-up visit at the time points specified in the SoA (Table 1).', 'Medical occurrences that begin before the start of study treatment but after', 'obtaining informed consent will be recorded on the Medical History/Current', 'Medical Conditions section of the case report form (CRF) not the AE section.', 'All SAEs must be reported immediately and not more than 24 hrs to the sponsor,', 'as indicated in Appendix 4 (Section 12.4). The investigator will submit any', 'updated SAE data to the sponsor within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'participants. However, if the investigator learns of any SAE, including a death,', 'at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study treatment or study', 'participation, the investigator must promptly notify the sponsor.', 'The method of recording, evaluating, and assessing causality of AEs and SAEs', 'and the procedures for completing and transmitting SAE reports are provided in', 'Appendix 4 (Section 12.4).', '9.2.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AE and/or SAE. Open-ended and', 'non-leading verbal questioning of the participant is the preferred method to inquire about', 'AE occurrence.', '9.2.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All SAEs will be followed until the event is', '38']"
256,page_257,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'resolved, stabilized, otherwise explained, or the participant is lost to follow-up (as', 'defined in Section 8.3). Further information on follow-up procedures is given in', 'Appendix 4.', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to the sponsor of a SAE is essential so', 'that legal obligations and ethical responsibilities towards the safety of', 'participants and the safety of a study treatment under clinical investigation are', 'met.', 'The sponsor has a legal responsibility to notify both the local regulatory', 'authority and other regulatory agencies about the safety of a study treatment', 'under clinical investigation. The sponsor will comply with country-specific', 'regulatory requirements relating to safety reporting to the regulatory authority,', 'Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and', 'investigators.', 'Investigator safety reports must be prepared for suspected unexpected serious', 'adverse reactions (SUSAR) according to local regulatory requirements and', 'sponsor policy and forwarded to investigators as necessary.', 'An investigator who receives an investigator safety report describing a SAE or', 'other specific safety information e.g., summary or listing of SAE) from the', ""sponsor will review and then file it along with the Investigator's Brochure and"", 'will notify the IRB/IEC, if appropriate according to local requirements.', '9.2.5.', 'Cardiovascular and Death Events', 'For any cardiovascular events detailed in Section 12.4 (Appendix 4) and all deaths,', 'whether or not they are considered SAEs, specific Cardiovascular (CV) and Death', 'sections of the CRF will be required to be completed. These sections include questions', 'regarding cardiovascular (including sudden cardiac death) and non-cardiovascular death.', 'The CV CRFs are presented as queries in response to reporting of certain CV MedDRA', 'terms. The CV information should be recorded in the specific cardiovascular section of', 'the CRF within one week of receipt of a CV Event data query prompting its completion.', '9.2.6.', 'Disease-Related Events and/or Disease-Related Outcomes Not', 'Qualifying as SAEs', 'The following disease related events (DREs) are common in participants with COPD and', 'can be serious/life threatening:', 'COPD exacerbations', 'Because these events are typically associated with the disease under study, they will not', 'be reported according to the standard process for expedited reporting of SAEs to GSK', '(even though the event may meet the definition of an SAE). These events will be', ""recorded on the DRE page in the participant's CRF within 72 hours after the investigator"", '39']"
257,page_258,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'becomes aware of the event. These DREs will be monitored by the Safety Review Team', '(SRT) on a routine basis as described in Section 12.3 (Appendix 3).', 'NOTE: However, if either of the following conditions applies, then the event must be', 'recorded and reported as an SAE (instead of a DRE):', ""The event is, in the investigator's opinion, of greater intensity, frequency, or"", 'duration than expected for the individual participant, or', 'The investigator considers that there is a reasonable possibility that the event', 'was related to treatment with the investigational product', '9.2.7.', 'Pregnancy', 'Details of all pregnancies in female participants and female partners of male', 'participants will be collected after the start of study treatment and until 60 hours after', 'the last dose of study treatment.', 'If a pregnancy is reported, the investigator should inform GSK within 24 hours of', 'learning of the pregnancy and should follow the procedures outlined in Section 12.5', '(Appendix 5).', 'Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAEs.', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use. In order to fulfill regulatory reporting obligations', 'worldwide, the investigator is responsible for the detection and documentation of events', 'meeting the definitions of incident or malfunction that occur during the study with such', 'devices.', 'The definition of a Medical Device Incident can be found in Section 12.8 (Appendix 8).', 'NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes', 'outlined in Section 9.2 and Section 12.4 (Appendix 4).', '9.2.8.1.', 'Time Period for Detecting Medical Device Incidents', 'Medical device incidents or malfunctions of the device that result in an incident', 'will be detected, documented, and reported during all periods of the study in', 'which the medical device is used.', 'If the investigator learns of any incident at any time after a participant has been', 'discharged from the study, and such incident is considered reasonably related to', 'a medical device provided for the study, the investigator will promptly notify the', 'sponsor.', '40']"
258,page_259,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'The method of documenting Medical Device Incidents is provided in Section', '12.8 (Appendix 8).', '9.2.8.2.', 'Follow-up of Medical Device Incidents', 'All medical device incidents involving an AE will be followed and reported in', 'the same manner as other AEs (see Section 9.2). This applies to all participants,', 'including those who discontinue study treatment or the study.', 'The investigator is responsible for ensuring that follow-up includes any', 'supplemental investigations as indicated to elucidate the nature and/or causality', 'of the incident.', 'New or updated information will be recorded on the originally completed form', 'with all changes signed and dated by the investigator.', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents to Sponsor', 'Medical device incidents will be reported to the sponsor within 24 hours after', 'the investigator determines that the event meets the protocol definition of a', 'medical device incident.', 'Complete the Medical Device Incident Form for each participant who has a', 'medical device incident with GSK medical devices provided for use during the', 'study period. All of the header information in the form must be completed', 'before sending to GSK. Original documents should be filed in the site study', 'file. A copy of the form must also be sent to the GKS study monitor. Contact', 'details will be included in the SRM. A copy of the form must also be sent to the', 'GSK study monitor. Contact details will be included in the SRM. For incidents', 'fulfilling the definition of an AE or SAE, the appropriate pages of the CRF must', 'be completed. If there is an SAE, the completed CRF pages should be sent', 'together with the Medical Device Incident From. If the participant is withdrawn', 'due to a medical device incident, ensure the Study Conclusion page is', 'completed.', 'The same individual will be the contact for the receipt of medical device reports', 'and SAEs.', '9.2.8.4.', 'Regulatory Reporting Requirements for Medical Device Incidents', 'The investigator will promptly report all incidents occurring with any medical', 'device provided for use in the study in order for the sponsor to fulfill the legal', 'responsibility to notify appropriate regulatory authorities and other entities about', 'certain safety information relating to medical devices being used in clinical', 'studies.', 'The investigator, or responsible person according to local requirements (e.g., the', 'head of the medical institution), will comply with the applicable local regulatory', 'requirements relating to the reporting of incidents to the IRB/IEC.', '41']"
259,page_260,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.3.', 'Treatment of Overdose', 'For this study, any dose of study treatment 4 tablets in a day will be considered an', 'overdose.', 'GSK does not recommend specific treatment for an overdose.', 'In the event of an overdose, the investigator/treating physician should:', '1. Contact the Medical Monitor immediately.', '2. Closely monitor the participant for AE/SAE and laboratory abnormalities until study', 'treatment can no longer be detected systemically (at least 3 days).', '3. Obtain a plasma sample for PK analysis as soon as possible from the date of the last', 'dose of study treatment if requested by the Medical Monitor (determined on a case-', 'by-case basis).', '4. Document the quantity of the excess dose as well as the duration of the overdosing in', 'the CRF.', 'Decisions regarding dose interruptions or modifications will be made by the investigator', 'in consultation with the Medical Monitor based on the clinical evaluation of the', 'participant.', '9.4.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SoA.', '9.4.1.', 'Physical Examinations', 'A complete physical examination will include, at a minimum, assessments of the', 'skin, cardiovascular, respiratory, gastrointestinal and neurological systems.', 'Height and weight will also be measured and recorded.', 'A brief physical examination will include, at a minimum, assessments of the', 'skin, lungs, cardiovascular system, and abdomen (liver and spleen).', 'Investigators should pay special attention to clinical signs related to previous', 'serious illnesses.', '9.4.2.', 'Vital Signs', 'Vital signs will be measured in a semi-supine position after 5 minutes rest and will', 'include systolic and diastolic blood pressure, pulse, and respiratory rate. Three readings', 'of blood pressure and pulse will be taken. The first reading should be rejected. The', 'second and third readings should be averaged to give the measurement to be recorded in', 'the CRF. A single measurement of respiratory rate is adequate.', '42']"
260,page_261,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.4.3.', 'Electrocardiograms', 'For participant screening and pre-dose on Day 1, triplicate ECG measurements should be', 'collected. For all subsequent ECG assessments, single measurements are to be collected.', '12-lead ECG will be obtained as outlined in the SoA using an ECG machine that', 'automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.', 'Refer to Section 8.1.2 for QTc withdrawal criteria and additional QTc readings that may', 'be necessary.', 'At each time point at which triplicate ECG are required, 3 individual ECG tracings', 'should be obtained as closely as possible in succession, but no more than 2 minutes apart.', 'The full set of triplicates should be completed in less than 10 minutes.', '9.4.4.', 'Clinical Safety Laboratory Assessments', 'Refer to Section 12.2 (Appendix 2) for the list of clinical laboratory tests to be performed', 'and to the SoA for the timing and frequency.', 'The investigator must review the laboratory report, document this review, and record', 'any clinically relevant changes occurring during the study in the AE section of the', 'CRF. The laboratory reports must be filed with the source documents. Clinically', 'significant abnormal laboratory findings are those which are not associated with the', 'underlying disease, unless judged by the investigator to be more severe than', ""expected for the participant's condition."", 'All laboratory tests with values considered abnormal and clinically significant during', 'participation in the study or within 3 days after the last dose of study treatment', 'should be repeated until the values return to normal or baseline or are no longer', 'considered significantly abnormal by the investigator or medical monitor.', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the investigator, the etiology should be identified and the sponsor', 'notified.', 'All protocol-required laboratory assessments, as defined in Section 12.2, must be', 'conducted in accordance with the laboratory manual and the SoA (Table 1).', 'If laboratory values from non-protocol specified laboratory assessments performed at', ""the institution's local laboratory require a change in participant management or are"", 'considered clinically significant by the investigator (e.g., SAE or AE), then the', 'results must be recorded in the CRF.', '9.4.5.', 'Pneumonia', 'All suspected pneumonias will require confirmation as defined by the presence or new', 'infiltrate(s) on chest x-ray AND at least 2 of the following signs and symptoms:', 'Increased cough', 'Increased sputum purulence (colour) or production', 'Auscultatory findings of adventitious sounds (e.g. egophony, bronchial breath', 'sounds, rales, etc.)', '43']"
261,page_262,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Dyspnea or tachypnea', 'Fever (oral temperature > 37.5 °C)', 'Elevated white blood cell count (WBC) (> 10 X 109/L or > 15% immature', 'forms)', 'Hypoxemia (Hb O2 saturation < 88% or at least 2% lower than baseline value)', 'All pneumonias must be captured on the AE/SAE page of the eCRF and on the', 'pneumonia page of the eCRF.', 'The Investigator and site staff should remain vigilant for the possible development of', 'pneumonia in participants as the clinical features of such infections overlap with the', 'symptoms of COPD exacerbations. For all suspected cases of pneumonia, Investigators', 'are strongly encouraged to confirm the diagnosis (this includes obtaining a chest x-ray)', 'and to initiate appropriate therapy as promptly as possible. Any microbiology or virology', 'tests performed to determine etiology should be reported on the pneumonia eCRF page.', 'All diagnoses of pneumonia (radiographically confirmed or unconfirmed) must be', 'reported as an AE or SAE (if applicable).', '9.5.', 'Pharmacokinetics', 'Pharmacokinetic parameters are not evaluated in this study.', '9.6.', 'Pharmacodynamics', 'Pharmacodynamic parameters are not evaluated in this study.', '9.7.', 'Genetics', 'A 6 mL whole blood sample for DNA isolation will be collected from participants who', 'have consented to participate in the genetics analysis component of the study.', 'Participation in the genetics analysis is optional. Participants who do not wish to', 'participate in the genetic research may still participate in the study.', 'See Section 12.6 (Appendix 6) for Information regarding genetic research. Details on', 'procedures for collection and shipment and destruction of these samples can be found in', 'the SRM.', '9.8.', 'Biomarkers', 'Collection of samples for biomarker research is also part of this study. The following', 'samples for biomarker research will be collected from all participants in this study as', 'specified in the SoA:', 'peripheral venous blood samples for the preparation of serum and plasma', 'Samples will be tested for biomarkers that are indicative of inflammation (i.e. CRP),', 'extracellular matrix turnover and remodelling to evaluate their association with the', '44']"
262,page_263,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'observed clinical responses or to help understand the underlying biological responses to', 'danirixin.', ""In addition, with the participant's consent, samples will be stored and may be used to"", 'investigate additional biomarkers thought to play a role in COPD disease progression or', 'to evaluate their association with observed clinical responses to danirixin', 'Samples also may be used for research to develop methods or support identification of', 'prognostic/diagnostic biomarkers associated with clinical outcomes in COPD and related', 'diseases.', '9.9.', 'Health Economics OR Medical Resource Utilization and', 'Health Economics', 'Health Economics/Medical Resource Utilization and Health Economics parameters are', 'not evaluated in this study.', '10.', 'STATISTICAL CONSIDERATIONS', 'The objective of this study is to investigate the effect of danirixin HBr 35mg tablets on', 'COPD disease progression. There are no formal hypothesis tests associated with this', 'objective and no formal significance tests. The information acquired from this study will', 'primarily be used to assess whether or not danirixin impacts disease progression and to', 'quantify the effect that danirixin has on disease progression, specifically change in lung', 'function as measured by FEV1 decline and change in health-related quality of life as', 'measured by SGRQ total score to further support disease understanding and future', 'studies.', '10.1.', 'Sample Size Determination', 'Sample size is based primarily on feasibility for this study. Since there is much', 'uncertainty around the magnitude of the difference in the decline in FEV1 and change in', 'SGRQ along with the between-subject variability for the specific patient population, the', 'proposed sample size is unavoidably imprecise. Sample size may be adjusted using the', 'predictions of final study outcome based on simulations and possible interim analyses. It', 'is anticipated that screening 130 participants will allow for approximately 100', 'participants to enrol.', 'In order to observe the effect of different sample sizes, various simulations were done to', 'assess the impact of sample sizes of 50, 100, 150 and 200 with a 1:1 allocation to each', 'treatment group [Table 3]. The assumed variability for rate of decline in FEV1 and', 'change in SGRQ is 25 and 10, respectively. The correlation between rate of decline in', 'FEV1 and change in SGRQ is assumed to be -0.2. [Nagai, 2015]', '45']"
263,page_264,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Table 3', 'Assumptions used for the Simulations', 'Treatment Effect Assumptions', 'Variability Assumptions', 'Sample Size', '(ÔFEV1, ÔSGRQ)', '(OFEV1, OSGRQ)', 'Null', '(0,0)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 1', '(5,-1)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 2', '(5,0)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 3', '(0,-1)', '(25,10)', 'N={50,100,150,200}', 'Data from a bivariate normal distribution were simulated under the four different', 'treatment effect assumptions for samples sizes of 50, 100, 150, and 200. The samples', 'from the posterior probability distribution from the MCMC approximation were divided', 'into four regions based on OFEVI and ôSGRQ treatment effect cut-off values; SFEV1>0 and', 'ÔSGRQ <0, SFEV1>0 and ÔSGRQ>0, SFEVI<0 and SSGRQ0, and SFEVI<0 and SSGRQ>0 Based', 'on a 70% threshold, the proportion of the 1000 simulations meeting the requirement', '& SSGRQ50) > 70% were considered a success based on the joint definition', '[Figure 2, Table 4]. & SSGRQ<0) < 70%, success could further be defined', 'based on each endpoint independently where P(OFEVI > 0) > 80% or P(6SGRQ 0) > 80%.', 'Figure 2', 'Total Probability of Success', '90', 'Alt 1: (5,-1)', '80', 'Alt 2: (5,0)', 'Alt 3: (0,-1)', 'Null: (0,0)', '02', '60', '50', 'of', '30', '50', '100', '150', '200', 'Sample Size', 'Table 4', 'Total Probability of Success (Figure 2)', 'N=50', 'N=100', 'N=150', 'N=200', '(5,-1)', '57.4', '68.5', '75.1', '81.4', '(5,0)', '52.5', '62.6', '67.8', '74.5', '(0,-1)', '42.6', '46.2', '48.9', '53.0', '(0,0)', '34.9', '33.9', '33.3', '31.5', '46']"
264,page_265,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 3', 'Half Width of the 95% Confidence Interval of OFEV1 Point Estimate', 'DL', '13.8', '2L', '00', '9.7', '8.0', '8', '6.9', '6', '50', '100', '150', '200', 'Sample Size', 'Figure 4', 'Half Width of the 95% Confidence Interval of 5SGRQ Point Estimate', '6', '5.5', '5', '&', '3,9', 'm', '3.2', '2.7', '2', '50', '100', '150', '200', 'Sample Size', 'Based on the simulations, under the assumption of an expected treatment difference of', '(5,-1) which is the most probable scenario, the marginal increase for the total probability', 'of success is greatest when increasing the sample size from 50 to 100 (Figure 2). The half', 'widths of the 95% CI of the point estimate of the marginal treatment differences for FEV1', '(Figure 3) and SGRQ (Figure 4) have the greatest reduction from a sample size of 50 to', '100. A sample size of 100 will allow for an adequate level of confidence in the study', 'success while also considering the precision of the treatment effect differences.', '47']"
265,page_266,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.2.', 'Randomization', 'Participants will be randomized equally (1:1) to the two treatment arms of placebo and 35', 'mg danirixin HBr. Randomization will be stratified by smoking status (current VS.', 'former).', '10.3.', 'Populations for Analyses', 'For purposes of analysis, the following populations are defined:', 'Population', 'Description', 'All Participants', 'This population will comprise all participants screened and', 'for whom a record exists on the study database and will be', 'used for the tabulation and listing of reasons for withdrawal', 'before randomization and listings of AEs and SAEs for', 'nonrandomized participants.', 'Intent To Treat (ITT)', 'This population will comprise all participants randomized to', 'treatment and who received at least one dose of study', 'medication. This will constitute the primary population for all', 'analyses of efficacy and safety. Outcomes will be reported', 'according to the randomized treatment allocation.', 'Per-Protocol (PP)', 'This population will comprise of all patients in the ITT', 'Population', 'population who are not major protocol violators.', 'Safety', 'All randomized participants who take at least 1 dose of study', 'treatment. Participants will be analyzed according to the', 'treatment they actually received.', '10.4.', 'Statistical Analyses', 'Treatment comparisons using all endpoints will be made using appropriate statistical', 'techniques. Analysis methods for key endpoints are described below. Main analysis will', 'use ITT unless noted. Further details on all analyses will be described in the reporting and', 'analysis plan (RAP).', '10.4.1.', 'Efficacy Analyses', 'The total probability of success will be defined as a combination of a joint and', 'conditional statement. The joint probability of success will be defined as the probability', 'of the difference in the rate of decline in FEV1 between danirixin and placebo is greater', 'than or equal to 0 and the difference in the change in SGRQ total score from baseline', 'between danirixin and placebo is less than or equal to 0 is greater than 70%. If the joint', 'probability of success is less than 70%, success can further be defined based on each', 'endpoint independently, where either the difference in the rate of decline in FEV1 is', '48']"
266,page_267,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'greater than or equal to 0 is greater than 80% or the difference in the change in SGRQ', 'total score is less than or equal to 0 is greater than 80%.', 'Total PoS = P(SFEV, SSGRQ 0) 70%', '+ P (OFEV1 SSGRQ 0) < 70%', '+P (SSGRQ 0 & SSGRQ 0) < 70%', 'Endpoint', 'Statistical Analysis Methods', 'Primary', 'Rate of decline in FEV1 and change from baseline in SGRQ total score', 'Exploratory', 'Will be described in detail in the RAP', '49']"
267,page_268,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Lung Function Decline: Rate of Decline of FEV1 (mL/yr)', 'The rate of decline of FEV1 will be derived from a repeated measures random', 'coefficients model. Post-baseline FEV1 will be modelled including terms for age, sex,', 'smoking status, FEV1 at baseline, and BMI along with treatment group, time and', 'treatment by time interaction as fixed effects. Subject will be a random effect. Time will', 'be defined as the number of days since start of treatment. Only FEV values measured', 'after baseline will be used in the model. Based on the results of previous studies, the', 'study team will determine the time point at which post-baseline spirometry assessments', 'will be included in the model to account for the initial treatment response. The estimate', 'of the rate of FEV1 decline will be the slope of the parameter estimate of the treatment by', 'time interaction term in the model. Contrasts will be calculated for the difference in', 'treatment by time interaction between danirixin and placebo treatment groups to estimate', 'the treatment difference.', 'FEV1 = Treatment group + age + sex +smoking status+FEV1_BL+BMI+ time', '+', '-', 'treatment*time', 'The rate of decline for each subject, the estimate of the slope parameter of the treatment', 'by time interaction term, will be used as a co-primary endpoint for the joint analysis', 'using both FEV1 and SGRQ.', 'HRQoL: SGRQ', 'A co-primary endpoint of interest is change in SGRQ total score (derived from SGRQ-C)', 'from baseline. Change in SGRQ total scores from baseline will be derived using a mixed', 'model with repeated measures (MMRM) including fixed effects of treatment group, age,', 'sex, smoking status, BMI, baseline SGRQ score, time as a categorical variable and a', 'treatment by time interaction term. Subject will be a random effect. Estimated treatment', 'differences at the end of one year will be obtained. The difference of the least square', 'mean change from baseline at 12 months will be derived. The adjusted SGRQ total score', 'change from baseline will used as the other co-primary endpoint for the joint analysis', 'using both FEV1 and SGRQ.', 'Joint Analysis', 'The joint analysis will use the ITT population with all available FEV1 rate of decline and', 'change in SGRQ data.', 'The rate of decline (the slope parameter from the random coefficients model) of FEV1,', 'along with the change in SGRQ from the MMRM model will be extracted for each', 'subject. These values will then be used to obtain MCMC approximations of the joint', 'posterior distribution of the treatment differences between FEV1 decline and change in', 'SGRQ between the danirixin and placebo groups. Based on the samples from the', 'posterior distribution, the proportion of samples falling within certain treatment', 'difference regions will be calculated and the probability of success will be derived.', '50']"
268,page_269,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.4.2.', 'Safety Analyses', 'All safety endpoints will be tabulated or plotted by treatment group and will be', 'performed on the Safety Population. Further details will be described in the RAP.', '10.4.3.', 'Other Analyses', 'Exploratory biomarker analyses will be described in the RAP.', '10.4.4.', 'Interim Analyses', 'Conducting an interim analysis or futility assessment may not be practical due to an', 'expected fast recruitment period. By the time enough data will accumulate for any', 'meaningful interim analysis to support changes to the study design, recruitment of all', 'study participants will have concluded. However, if recruitment takes a longer than', 'anticipated, an interim analysis to reassess the variability assumptions, estimate the', 'probability of success at the end of study, and confirm the directionality of the endpoints', 'may be conducted.', 'The RAP will describe the potential interim analyses in greater detail.', '51']"
269,page_270,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '11.', 'REFERENCES', 'Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD.', 'Eur Respir J. 2004;23:932-946.', 'Chapman RW, Philips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2', 'antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009; 121:55-68.', 'FDA. Guidance for Industry. Center for Drug Evaluation and Research, United States', 'Food and Drug Administration; 2009. Drug-induced liver injury: premarketing clinical', 'evaluation.', 'GlaxoSmithKline Document Number 2013N180289 ( 03 Study ID 200163. A two part,', 'phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability,', 'pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin', '(GSK1325756) in symptomatic COPD subjects with mild to moderate airflow limitation', 'at risk for exacerbations. Report Date 05-Aug-2015.', 'GlaxoSmithKline Document Number 2014N205875 00 Study ID 201682. A', 'randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and', 'clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with', 'acute, uncomplicated influenza. Report Date 21-Nov-2014.', 'GlaxoSmithKline Document Number 2015N248339 00 Study ID 201037. A single', 'centre, open-label, 5-period, cross over, randomized study in healthy elderly subjects to', 'evaluate the relative bioavailability of hydrobromide salt and free base immediate release', 'tablet formulations of danirixin in the fed state, and to evaluate the effect of food and', 'gastric acid secretion suppression on danirixin pharmacokinetics following administration', 'of hydrobromide salt tablets. Report Date 01-Jun-2016.', ""GlaxoSmithKline Document Number YM2010/00163/07. Danirixin Investigator's"", 'Brochure, Version 09. Report Date 14-Apr-2016.', 'GOLD. From the Global Strateby for the Diagnosis, Management and Prevention of', 'COPD, Global Initiative for Chronic Obstructive Lung Disease. Global Initiative for', 'Chronic Obstructive Lung Disease, Available from: http://www.copdgold.org; 2016.', 'Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni I P, et al. SCH527123,', 'a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur', 'Respir J. 2010;35:564-570.', 'Hurst JA, Vestbo J, Anzueto A, Locantore N, Mullerova, Tal-Singer R, et al.', 'Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med.', '2010;363:1128-1138.', 'Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first', 'validation of the COPD Assessment Test (CAT). Eur Respir J. 2009;34:648-654.', '52']"
270,page_271,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R et al. Tests of the', 'responsiveness of the chronic obstructive pulmonary disease (COPD) assessment test', '(CAT) following acute exacerbation and pulmonary rehabilitation. Chest. 2012;142:134-', '140.', 'Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health', ""status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev"", 'Respir Dis. 1992;145:1321-1327.', 'Lazaar AL, Sweeney LE, MacDonald AJ et al. SB-656933, a novel CXCR2 selective', 'antagnoist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation', 'in humans. Br J Clin Pharmacol. 2011;72:282-293.', 'Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology.', '2016;21:14-23.', 'Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002', 'to 2030. PLoS Med. 2006;3:e442.', 'Meguro M, Barley EA, Spencer S et al. Development and validation of an improved', 'COPD-specific version of the St. George Respiratory Questionnaire. Chest.', '2007;132:456-463.', 'Miller B, Tal-Singer R, Lazaar A, Leidy N, Watz H, Collins D, et al. Assessing', 'symptoms in COPD: use of the E-RS daily digital diary in early drug development. Eur', 'Respir J.2016;48(S60):PA1047.', 'Nagai, K., Makita, H., Suzuki, M., Shimizu, K., Konno, S., Ito, Y. M., & Nishimura, M.', 'Differential changes in quality of life components over 5 years in chronic obstructive', 'pulmonary disease patients. International Journal of Chronic Obstructive Pulmonary', 'Disease. 2015; 10: 745-757.', 'Nair P, Gaga M, Zervas E et al. Safety and efficacy of a CXCR2 antagnoist in patients', 'with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical', 'trial. Clin Exp Allergy. 2012;42:1097-2103', ""O'Byrne PM, Metev H, Puu M et al. Efficacy and safety of a CXCR2 antagonist,"", 'AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind,', 'placebo-controlled trial. Lancet Respir Med. 2016;4:797-806.', 'Rennard SI, Dale DC, Donohue JF et al. CXCR2 antagonist MK-7123 - a phase 2 proof-', 'of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med.', '2015;191:1001-1011.', 'Vastava S, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and', 'economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoecon.', '2015;33:467-488.', '53']"
271,page_272,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindate S, et al.', 'Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J', 'Med. 2016;375:1253-1260.', 'Watz H, Kirsten A, Pedersen F, Goldmann T, Stellmacher F, Uddin M, et al. Neutrophils', 'in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist', 'AZD5069 - an explorative study in neutrophilic asthma. Eur Respir J.', '2016;48(S60): PA4892.', 'Woodruff PG, Barr RG, Bleecker F, Christenson SA, Couper D, Curtis JL, et al. Clinical', 'significance of symptoms in smokers with preserved pulmonary function. N Engl J Med.', '2016;374:1811-1821.', '54']"
272,page_273,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.', 'APPENDICES', '12.1.', 'Appendix 1: Abbreviations and Trademarks', 'List of Abbreviations', 'AE', 'Adverse Event', 'ALT', 'Alanine Aminotransferase (SGPT)', 'AST', 'Aspartate Aminotransferase (SGOT)', 'ATS', 'American Thoracic Society', 'AUC', 'Area under the concentration-time curve', 'BfS', 'Federal Office of Radiation Protection (Germany)', 'BID', 'Twice daily', 'BRCP', 'Breast cancer resistance protein', 'BUN', 'Blood urea nitrogen', 'CAT', 'COPD Assessment Test', 'CD', 'Cluster of differentiation', 'CFR', 'Code of Federal Regulations (United States)', 'CI', 'Confidence Interval', 'CID', 'Clinically important deterioration', 'CIL', 'Clinical Investigation Leader', 'Cmax', 'Maximum observed concentration', 'CONSORT', 'Consolidated standards of reporting trials', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'CRF', 'Case Report Form', 'CT', 'Computed Tomography', 'CV', 'Cardiovascular', 'CXCR', 'CXC Chemokine Receptor', 'CXR', 'Chest X-Ray', 'dL', 'Deciliter', 'DNA', 'Deoxyribonucleic acid', 'DNX', 'Danirixin', 'DRE', 'Disease Related Event', 'E0', 'Effect at zero concentration', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic Case Report Form', 'ED50', 'Dose causing 50% of the maximum achievable', 'response', '55']"
273,page_274,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'EMA', 'European Medicines Agency', 'Emax', 'Maximum response achievable', 'eMDI', 'Electronic metered dose inhaler', 'EW', 'Early Withdrawal', 'FDA', 'Food and Drug Administation (United States)', 'FEV1', 'Forced Expiratory Volume in one second', 'FVC', 'Forced Vital Capacity', 'FSH', 'Follicle Stimulation Hormone', 'GCP', 'Good Clinical Practice', 'GCSP', 'Global Clinical Safety and Pharmacovigilance', 'GGT', 'Gamma glutamyltransferase', 'GOLD', 'Global Initiative for Chronic Obstructive Lung', 'Disease', 'GSK', 'GlaxoSmithKline', 'HBsAG', 'Hepatitis B surface antigen', 'HCRU', 'Healthcare Resource Utilization', 'hCG', 'Human chorionic gonadotrophin', 'HDPE', 'High density polyethylene', 'Hep B', 'Hepatitis B', 'Hep C', 'Hepatitis C', 'hsCRP', 'High sensitivity C-reactive protein', 'HIV', 'Human immunodeficiency virus', 'HPLC', 'High performance liquid chromatography', 'IB', ""Investigator's Brochure"", 'ICF', 'Informed Consent Form', 'International Conference on Harmonization of', 'ICH', 'Technical Requirements for Registration of', 'Pharmaceuticals for Human Use', 'ICS', 'Inhaled corticosteroid', 'IDMC', 'Independent Data Monitoring Committee', 'IEC', 'Independent Ethics Committee', 'IgG', 'Immunoglobulin G', 'IgM', 'Immunoglobulin M', 'INR', 'International normalized ratio', 'IP', 'Investigational Product', 'IRB', 'Institutional Review Board', 'ITT', 'Intent to treat', '56']"
274,page_275,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'IUD', 'Intrauterine device', 'IUS', 'Intrauterine hormone releasing system', 'IVIVT', 'In vitro In vivo Translation', 'IWRS', 'Interactive Web Response System', 'kg', 'Kilogram', 'L', 'Liter', 'LABA', 'Long acting ß2 receptor agonist', 'LAMA', 'Long acting muscarinic receptor antagonist', 'LH', 'Leutinizing Hormone', 'MCV', 'Mean corpuscular volume', 'MCH', 'Mean corpuscular hemoglobin', 'MCHC', 'Mean corpuscular hemoglobin count', 'MDI', 'Metered dose inhaler', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mg', 'Milligrams', 'mL', 'Milliliter', 'MM', 'Medical monitor', 'MSDS', 'Material Safety Data Sheet', 'msec', 'Millisecond', 'NOAEL', 'No observed adverse effect level', 'O2', 'Oxygen', 'PK', 'Pharmacokinetics', 'PR interval; duration in milliseconds from the', 'PR', 'beginning of the P wave to onset of ventricular', 'depolarization (R)', 'PRO', 'Patient Reported Outcome', 'PTS', 'Platform Technology and Science', 'QRS interval; duration in milliseconds of the QRS', 'QRS', 'complex', 'QT interval; duraction in milliseconds between the', 'QT', 'start of the Q wave and the end of the T wave', 'QTcF', 'QT interval corrected for heart rate (Friderica', 'formula)', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cells', 'RNA', 'Ribonucleic acid', 'SABA', 'Short-acting ß2 Receptor Agonist', 'SAE', 'Serious Adverse Event', '57']"
275,page_276,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'SAMA', 'Short-acting Muscarinic Receptor Agonist', 'SGRQ', ""St George's Respiratory Questionnaire"", 'SGRQ-C', 'SGRQ-C for COPD patients', 'SRM', 'Study Reference Manual', 'SRT', 'Safety Review Team', 'SOA', 'Schedule of Activities', 'SUSAR', 'Suspected unexpected serious adverse reaction', 't¹/2', 'Terminal phase half-life', 'tmax', 'Time to reach Cmax', 'TPR', 'Third Party Resourcing', 'ULN', 'Upper limit of normal', 'g', 'Microgram', 'VT', 'Ventricular tachycardia', 'WBC', 'White blood cells', 'WOCBP', 'Women of child bearing potential', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'CAT', 'Combivent', 'Duoneb', '58']"
276,page_277,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.2.', 'Appendix 2: Clinical Laboratory Tests', 'The tests detailed in Table 5 (Protocol-Required Safety Laboratory', 'Assessments) will be performed by the central laboratory, except as noted.', 'Local laboratory results are only required in the event that the central laboratory', 'results are not available in time for either study treatment administration and/or', 'response evaluation. If a local sample is required, it is important that the sample', 'for central analysis is obtained at the same time. Additionally, if the local', 'laboratory results are used to make either a study treatment decision or response', 'evaluation, the results must be entered into the CRF.', 'Protocol-specific requirements for inclusion or exclusion of participants are', 'detailed in Section 6.', 'Additional tests may be performed at any time during the study as determined', 'necessary by the investigator or required by local regulations.', 'Table 5', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Specific gravity', 'Urinalysis', '59']"
277,page_278,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody²', 'All study-required laboratory assessments will be performed by a central', 'laboratory', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Laboratory results that could unblind the study will not be reported to investigative sites', 'or other blinded personnel until the study has been unblinded.', '60']"
278,page_279,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.3.', 'Appendix 3: Study Governance Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with:', 'Consensus ethical principles derived from international guidelines', 'including the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical', 'Guidelines', 'Applicable ICH Good Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other', 'relevant documents (eg, advertisements) must be submitted to an IRB/IEC by', 'the investigator and reviewed and approved by the IRB/IEC before the study is', 'initiated.', 'Any amendments to the protocol will require IEC/IRB approval before', 'implementation of changes made to the study design, except for changes', 'necessary to eliminate an immediate hazard to study participants.', 'The investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC', 'annually or more frequently in accordance with the requirements, policies,', 'and procedures established by the IRB/EC', 'Notifying the IRB/IEC of SAE or other significant safety findings as', 'required by IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 CFR, ICH guidelines, the IRB/IEC, European', 'regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', 'Financial Disclosure', 'Investigators and sub-investigators will provide the sponsor with sufficient, accurate', 'financial information as requested to allow the sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate regulatory authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study.', '61']"
279,page_280,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Informed Consent Process', 'The investigator or his/her representative will explain the nature of the study to', 'the participant or his/her legally authorized representative and answer all', 'questions regarding the study.', 'Participants must be informed that their participation is voluntary. Participants', 'or their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', ""A copy of the ICF(s) must be provided to the participant or the participant's"", 'legally authorized representative.', 'Participants who are rescreened are required to sign a new ICF.', 'The ICF may contain a separate section that addresses the use of remaining', 'mandatory samples for optional exploratory research in accordance with SOP-', 'GSKF-410. The investigator or authorized designee will explain to each', 'participant the objectives of the exploratory research. Participants will be told that', 'they are free to refuse to participate and may withdraw their consent at any time', 'and for any reason during the storage period. A separate signature will be required', ""to document a participant's agreement to allow any remaining specimens to be"", 'used for exploratory research. Participants who decline to participate will not', 'provide this separate signature.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', '62']"
280,page_281,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Committees Structure', 'A study charter will be created to describe important governance aspects while', 'the study is being conducted.', 'The SRT will include the Safety Development Leader, GCSP scientist, MM, CIL', 'and study statistician but will extend to other functions as requied. The SRT will', 'provide a proactive, aggregate and holistic evaluation of the safety data of', 'danirixin. Further details are included in the SRT charter.', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with', 'International Committee of Medical Journal Editors authorship requirements.', 'Dissemination of Clinical Study Data', 'This study will be registered and study information from this protocol will be', 'posted on publicly available clinical trial registers before enrolment of study', 'participants begins.', 'The results summary of this study will be posted to the GSK Clinical Study', 'Register and other publicly available clinical trial registers within 8 months of', 'the primary study completion date.', 'A manuscript reporting the study results will be submitted to a peer reviewed', ""journal within 18 months of the last participant's last visit."", 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic', 'CRF unless transmitted to the sponsor or designee electronically (eg, laboratory', 'data). The investigator is responsible for verifying that data entries are accurate', 'and correct by physically or electronically signing the CRF.', 'The investigator must maintain accurate documentation (source data) that', 'supports the information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', '63']"
281,page_282,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the CRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the investigator for 25 years after study completion', 'unless local regulations or institutional policies require a longer retention period.', 'No records may be destroyed during the retention period without the written', 'approval of the sponsor. No records may be transferred to another location or', 'party without written notification to the sponsor.', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', ""investigator's site."", 'Data reported on the CRF or entered in the eCRF that are transcribed from', 'source documents must be consistent with the source documents or the', 'discrepancies must be explained. The investigator may need to request previous', 'medical records or transfer records, depending on the study. Also, current', 'medical records must be available.', 'Definition of what constitutes source data can be found in the SRM.', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed.', 'The investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the sponsor or investigator may include', 'but are not limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', ""IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines"", 'Inadequate recruitment of participants by the investigator', 'Discontinuation of further study treatment development', '64']"
282,page_283,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', 'Definition of AE', 'AE Definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of a study treatment, whether or not considered related to the', 'study treatment.', 'NOTE: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study treatment.', 'Events Meeting the AE Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)', 'or other safety assessments (eg, ECG, radiological scans, vital signs measurements),', 'including those that worsen from baseline, considered clinically significant in the', 'medical and scientific judgment of the investigator (ie, not related to progression of', 'underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study treatment administration even', 'though it may have been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'treatment or a concomitant medication. Overdose per se will not be reported as an', 'AE/SAE unless it is an intentional overdose taken with possible suicidal/self-', 'harming intent. Such overdoses should be reported regardless of sequelae.', '""Lack of efficacy"" or ""failure of expected pharmacological action"" per se will not be', 'reported as an AE or SAE. Such instances will be captured in the efficacy', 'assessments. However, the signs, symptoms, and/or clinical sequelae resulting from', 'lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE', 'or SAE.', 'The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be', 'reported as AE or SAE if they fulfill the definition of an AE or SAE. Also, ""lack of', 'efficacy"" or ""failure of expected pharmacological action"" constitutes an AE or SAE.', '65']"
283,page_284,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Events NOT Meeting the AE Definition', 'Any clinically significant abnormal laboratory findings or other abnormal safety', 'assessments which are associated with the underlying disease, unless judged by the', ""investigator to be more severe than expected for the participant's condition."", 'The disease/disorder being studied or expected progression, signs, or symptoms of', 'the disease/disorder being studied, unless more severe than expected for the', ""participant's condition."", 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that', 'leads to the procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or', 'convenience admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Definition of SAE', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious', 'conditions are met (eg, hospitalization for signs/symptoms of the disease under study,', 'death due to progression of disease).', 'A SAE is defined as any untoward medical occurrence that, at any dose:', 'a.', 'Results in death', 'b.', 'Is life-threatening', 'The term ""life-threatening\' in the definition of \'serious\' refers to an event in which the', 'participant was at risk of death at the time of the event. It does not refer to an event,', 'which hypothetically might have caused death, if it were more severe.', 'c. Requires inpatient hospitalization or prolongation of existing hospitalization', 'In general, hospitalization signifies that the participant has been detained (usually', 'involving at least an overnight stay) at the hospital or emergency ward for observation', ""and/or treatment that would not have been appropriate in the physician's office or"", 'outpatient setting. Complications that occur during hospitalization are AE. If a', 'complication prolongs hospitalization or fulfills any other serious criteria, the event is', 'serious. When in doubt as to whether ""hospitalization"" occurred or was necessary, the AE', 'should be considered serious.', 'Hospitalization for elective treatment of a pre-existing condition that did not worsen from', 'baseline is not considered an AE.', 'd. Results in persistent disability/incapacity', ""The term disability means a substantial disruption of a person's ability to conduct"", '66']"
284,page_285,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,', 'and accidental trauma (eg, sprained ankle) which may interfere with or prevent', 'everyday life functions but do not constitute a substantial disruption.', 'e.', 'Is a congenital anomaly/birth defect', 'f.', 'Other situations:', 'Medical or scientific judgment should be exercised in deciding whether SAE', 'reporting is appropriate in other situations such as important medical events that may', 'not be immediately life-threatening or result in death or hospitalization but may', 'jeopardize the participant or may require medical or surgical intervention to prevent', 'one of the other outcomes listed in the above definition. These events should usually', 'be considered serious.', 'Examples of such events include invasive or malignant cancers, intensive treatment', 'in an emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', 'Definition of Cardiovascular Events', 'Cardiovascular Events (CV) Definition:', 'Investigators will be required to fill out the specific CV event page of the CRF for the', 'following AEs and SAEs:', 'Myocardial infarction/unstable angina', 'Congestive heart failure', 'Arrhythmias', 'Valvulopathy', 'Pulmonary hypertension', 'Cerebrovascular events/stroke and transient ischemic attack', 'Peripheral arterial thromboembolism', 'Deep venous thrombosis/pulmonary embolism', 'Revascularization', '67']"
285,page_286,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Recording AE and SAE', 'AE and SAE Recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (eg, hospital progress notes, laboratory, and diagnostics reports)', 'related to the event.', 'The investigator will then record all relevant AE/SAE information in the CRF', ""It is not acceptable for the investigator to send photocopies of the participant's"", 'medical records to GSK in lieu of completion of the GSK (/AE/SAE CRF page.', 'There may be instances when copies of medical records for certain cases are', 'requested by GSK. In this case, all participant identifiers, with the exception of the', 'participant number, will be redacted on the copies of the medical records before', 'submission to GSK.', 'The investigator will attempt to establish a diagnosis of the event based on signs,', 'symptoms, and/or other clinical information. Whenever possible, the diagnosis (not', 'the individual signs/symptoms) will be documented as the AE/SAE.', 'Assessment of Intensity', 'The investigator will make an assessment of intensity for each AE and SAE reported', 'during the study and assign it to 1 of the following categories:', 'Mild: An event that is easily tolerated by the participant, causing minimal discomfort', 'and not interfering with everyday activities.', 'Moderate: An event that causes sufficient discomfort and interferes with normal', 'everyday activities.', 'Severe: An event that prevents normal everyday activities. An AE that is assessed as', 'severe should not be confused with an SAE. Severe is a category utilized for rating', 'the intensity of an event; and both AE and SAE can be assessed as severe.', 'An event is defined as ""serious\' when it meets at least 1 of the predefined outcomes', 'as described in the definition of an SAE, NOT when it is rated as severe.', 'Assessment of Causality', 'The investigator is obligated to assess the relationship between study treatment and', 'each occurrence of each AE/SAE.', 'A ""reasonable possibility"" of a relationship conveys that there are facts, evidence,', 'and/or arguments to suggest a causal relationship, rather than a relationship cannot', 'be ruled out.', 'The investigator will use clinical judgment to determine the relationship.', '68']"
286,page_287,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other', 'risk factors, as well as the temporal relationship of the event to study treatment', 'administration will be considered and investigated.', ""The investigator will also consult the Investigator's Brochure (IB) and/or Product"", 'Information, for marketed products, in his/her assessment.', 'For each AE/SAE, the investigator must document in the medical notes that he/she', 'has reviewed the AE/SAE and has provided an assessment of causality.', 'There may be situations in which an SAE has occurred and the investigator has', 'minimal information to include in the initial report to GSK. However, it is very', 'important that the investigator always make an assessment of causality for', 'every event before the initial transmission of the SAE data to GSK.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information and send an SAE follow-up report with the updated causality', 'assessment.', 'The causality assessment is one of the criteria used when determining regulatory', 'reporting requirements.', 'Follow-up of AE and SAE', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as medically indicated or as requested by GSK to', 'elucidate the nature and/or causality of the AE or SAE as fully as possible. This may', 'include additional laboratory tests or investigations, histopathological examinations,', 'or consultation with other health care professionals.', 'If a participant dies during participation in the study or during a recognized follow-', 'up period, the investigator will provide GSK with a copy of any post-mortem', 'findings including histopathology.', 'New or updated information will be recorded in the originally completed CRF.', 'The investigator will submit any updated SAE data to GSK within 24 hours of', 'receipt of the information.', 'Reporting of SAE to GSK', 'SAE Reporting to GSK via Electronic Data Collection Tool', 'The primary mechanism for reporting SAE to GSK will be the electronic data', 'collection tool.', 'If the electronic system is unavailable for more than 24 hours, then the site will use', 'the paper SAE data collection tool (see next section).', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', '69']"
287,page_288,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'After the study is completed at a given site, the electronic data collection tool will be', 'taken off-line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated', 'data on a previously reported SAE after the electronic data collection tool has been', 'taken off-line, then the site can report this information on a paper SAE form (see', 'next section) or to the medical monitor/SAE coordinator by telephone.', 'Contacts for SAE reporting can be found in the SRM.', '70']"
288,page_289,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2.', 'Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3.', 'Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient and confirmatory testing with additional FSH and', 'estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred', 'lifestyle (abstinent on a long term and persistent basis) and agree to remain', 'abstinent', '71']"
289,page_290,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Table 6', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent', 'a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '72']"
290,page_291,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'NOTES:', 'a.', 'Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent', 'with local regulations regarding the use of contraceptive methods for participants in clinical studies.', 'b.', 'Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of', 'the contraceptive method. In this case two highly effective methods of contraception should be utilized during the', 'treatment period and for at least 60 hours after the last dose of study treatment', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine or serum pregnancy test', 'Additional pregnancy testing will be performed at approximately monthly intervals', 'during the study treatment period, after the last dose of study treatment and as', 'required locally.', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected', 'Pregnancy testing, with a high sensitivity test will be performed using the test kit', 'provided by the central laboratory and approved by the sponsor and in accordance', 'with instructions provided in the test kit package insert.', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', ""Investigator will attempt to collect pregnancy information on any male participant's"", 'female partner of a male study participant who becomes pregnant while participating', 'in this study. This applies only to participants who receive study treatment.', 'After obtaining the necessary signed informed consent from the pregnant female', 'partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure.', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', ""24 hours of learning of a participant's pregnancy."", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', '73']"
291,page_292,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the investigator, will be reported to GSK', 'as described in Appendix 4. While the investigator is not obligated to actively seek', 'this information in former study participants, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female participant who becomes pregnant while participating will discontinue', 'study treatment and be withdrawn from the study.', '74']"
292,page_293,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.6.', 'Appendix 6: Genetics', 'USE/ANALYSIS OF DNA', ""Genetic variation may impact a participant's response to therapy, susceptibility,"", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a blood sample will be collected for DNA analysis.', 'DNA samples will be used for research related to danirixin or COPD and related', 'diseases. They may also be used to develop tests/assays including diagnostic tests)', 'related danirixin treatment, and COPD (and related diseases). Genetic research may', 'consist of the analysis of one or more candidate genes or the analysis of genetic', 'markers throughout the genome (as appropriate).', 'DNA samples will be analyzed if it is hypothesized that this may help further', 'understand the clinical data.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to danirixin or study treatments of this class. The results of', 'genetic analyses may be reported in the clinical study report or in a separate study', 'summary.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on danirixin (or study treatments of this', 'class) or COPD (and related diseases) continues but no longer than 15 years or other', 'period as per local requirements.', '75']"
293,page_294,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', 'Phase II liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event etiology', 'Phase II liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria', 'ALT-absolute', 'ALT 5xULN', 'ALT Increase', 'ALT: 3xULN persists for >4 weeks', 'Bilirubin1, 2', 'ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin)', 'INR²', 'ALT > 3xULN and INR>1.5, if INR measured', 'Cannot', 'ALT: 3xULN and cannot be monitored weekly for 4 weeks', 'Monitor', 'Symptomatic³', 'ALT 3xULN associated with symptoms (new or worsening) believed', 'to be related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Obtain INR and recheck with each', 'liver chemistry assessment until the', 'Complete the liver event CRF and complete', 'transaminases values show', 'an SAE data collection tool if the event also', 'downward trend', 'meets the criteria for an SAE²', 'Obtain blood sample for', 'Perform liver chemistry event follow up', 'pharmacokinetic (PK) analysis, up', 'assessments', 'to 72 h after last dose5', 'Monitor the participant until liver', 'chemistries resolve, stabilize, or return to', 'Serum creatine phosphokinase', 'within baseline (see MONITORING', '(CPK) and lactate dehydrogenase', '(LDH).', 'below)', 'Fractionate bilirubin, if total', 'Do not restart/rechallenge participant', 'bilirubin 2xULN', 'with study treatment unless allowed per', 'protocol and GSK Medical Governance', 'Obtain complete blood count with', 'approval is granted (see below)', 'differential to assess eosinophilia', 'If restart/rechallenge not allowed per', 'Record the appearance or', 'protocol or not granted, permanently', 'worsening of clinical symptoms of', '76']"
294,page_295,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'discontinue study treatment and continue', 'liver injury, or hypersensitivity, on', 'participant in the study for any protocol', 'the AE report form', 'specified follow up assessments', 'Record use of concomitant', 'medications on the concomitant', 'MONITORING:', 'medications report form including', 'acetaminophen, herbal remedies,', 'For bilirubin or INR criteria:', 'other over the counter medications.', 'Repeat liver chemistries (include ALT,', 'Record alcohol use on the liver', 'AST, alkaline phosphatase, bilirubin) and', 'event alcohol intake case report', 'perform liver event follow up assessments', 'form (CRF) page', 'within 24 hrs', 'Monitor participants twice weekly until', 'liver chemistries resolve, stabilize or return', 'to within baseline', 'For bilirubin or INR criteria:', 'A specialist or hepatology consultation is', 'Anti-nuclear antibody, anti-smooth', 'recommended', 'muscle antibody, Type 1 anti-liver', 'kidney microsomal antibodies, and', 'For All other criteria:', 'quantitative total immunoglobulin', 'Repeat liver chemistries (include ALT,', 'G (IgG) or gamma globulins.', 'AST, alkaline phosphatase, bilirubin) and', 'Serum acetaminophen adduct high', 'perform liver event follow up assessments', 'performance liquid chromatography', 'within 24-72 hrs', '(HPLC) assay (quantifies potential', 'Monitor participants weekly until liver', 'acetaminophen contribution to liver', 'chemistries resolve, stabilize or return to', 'injury in participants with definite', 'within baseline', 'or likely acetaminophen use in the', 'preceding week [James, 2009].', 'Liver imaging (ultrasound,', 'magnetic resonance, or', 'computerised tomography) and /or', 'liver biopsy to evaluate liver', 'disease complete Liver Imaging', 'and/or Liver Biopsy CRF pages.', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that participant if ALT 3xULN and bilirubin 2xULN..', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT > 3xULN and INR>1.5, if INR', ""measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding"", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM);', 'Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable,', 'obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody', '77']"
295,page_296,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '5. PK sample may not be required for participants known to be receiving placebo or non-GSK comparator', 'treatments.) Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the', ""participant's best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot"", 'be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and', 'shipping are in the SRM.', 'Phase II liver chemistry increased monitoring criteria with continued therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'Notify the GSK medical monitor within 24 hours of', 'ALT >3xULN and <5xULN and bilirubin', 'learning of the abnormality to discuss participant', '<2xULN, without symptoms believed to', 'safety.', 'be related to liver injury or', 'Participant can continue study treatment', 'hypersensitivity, and who can be', 'monitored weekly for 4 weeks', 'Participant must return weekly for repeat liver', 'chemistries (ALT, AST, alkaline phosphatase,', 'bilirubin) until they resolve, stabilise or return to', 'within baseline', 'If at any time participant meets the liver chemistry', 'stopping criteria, proceed as described above', 'If, after 4 weeks of monitoring, ALT <3xULN and', 'bilirubin <2xULN, monitor participants twice monthly', 'until liver chemistries normalize or return to within', 'baseline.', 'Reference', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', '78']"
296,page_297,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.8.', 'Appendix 8: Medical Device Incidents: Definition and', 'Procedures for Recording, Evaluating, Follow-up, and', 'Reporting', 'Definition and Documentation of Medical Device Incidents', 'Definitions of a Medical Device Incident', 'The detection and documentation procedures described in this protocol apply to all GSK', 'medical devices provided for use in the study (see Section 7.1.1) for the list of GSK', 'medical devices).', 'Medical Device Incident Definition', 'A medical device incident is any malfunction or deterioration in the characteristics', 'and/or performance of a device as well as any inadequacy in the labeling or the', 'instructions for use which, directly or indirectly, might lead to or might have led to', 'the death of a participant/user/other person or to a serious deterioration in his/her', 'state of health.', 'Not all incidents lead to death or serious deterioration in health. The nonoccurrence', 'of such a result might have been due to other fortunate circumstances or to the', 'intervention of health care personnel.', 'It is sufficient that:', 'An incident associated with a device happened and', 'The incident was such that, if it occurred again, might lead to death or a serious', 'deterioration in health.', 'A serious deterioration in state of health can include any of the following:', 'Life-threatening illness', 'Permanent impairment of body function or permanent damage to body structure', 'Condition necessitating medical or surgical intervention to prevent one of the', 'above', 'Fetal distress, fetal death, or any congenital abnormality or birth defects', '79']"
297,page_298,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Examples of incidents', 'A participant, user, caregiver, or healthcare professional is injured as a result of a', 'medical device failure or its misuse.', ""A participant's study treatment is interrupted or compromised by a medical device"", 'failure.', 'A misdiagnosis due to medical device failure leads to inappropriate treatment.', ""A participant's health deteriorates due to medical device failure."", 'Documenting Medical Device Incidents', 'Medical Device Incident Documenting', 'Any medical device incident occurring during the study will be documented in the', ""participant's medical records, in accordance with the investigator's normal clinical"", 'practice, and on the appropriate form.', 'For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE', 'CRF page will be completed as described in Appendix 4.', 'The form will be completed as thoroughly as possible and signed by the investigator', 'before transmittal to the GSK.', 'It is very important that the investigator provides his/her assessment of causality', '(relationship to the medical device provided by GSK) at the time of the initial report', 'and describes any corrective or remedial actions taken to prevent recurrence of the', 'incident.', 'A remedial action is any action other than routine maintenance or servicing of a', 'medical device where such action is necessary to prevent recurrence of an incident.', 'This includes any amendment to the device design to prevent recurrence.', '80']"
298,page_299,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.9.', 'Appendix 9: Neutrophil Safety and Study Treatment Restart', 'Neutrophil Stopping Criteria: Absolute neutrophil count (ANC) < 0.5 X 109 /L', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Record the appearance or', 'worsening of any clinical', 'Report the event to GSK within 24 hours', 'symptoms on the AE report form¹', 'Complete an SAE data collection tool if the', 'event also meets the criteria for an SAE', 'Obtain blood sample for', 'pharmacokinetic (PK) analysis', 'Monitor the participant until neutrophil', 'within 12 hours after last dose²', 'count stabilizes or returns to within', 'Record use of concomitant', 'baseline (see MONITORING below)', 'medications on the concomitant', 'Do not restart participant with study', 'medications report form', 'treatment unless allowed per protocol and', 'GSK Medical Governance approval is', 'granted (see RESTART below)', 'MONITORING:', 'Treatment of any suspected infections¹', 'Repeat CBC within 24 hrs', 'Monitor CBC daily until neutrophil count', 'resolves, stabilizes or returns to within', 'baseline', 'RESTART', 'Restart of study medication must be', 'Check the CBC within 24-48 hours', 'approved by the GSK Medical Monitor', 'after re-starting study medication,', 'Restart may be attempted ONLY if all', 'monitor twice weekly for two', 'three criteria are met:', 'weeks, and monthly thereafter.', 'The neutrophil count is > 1.5 X 109/L', 'If the ANC drops below 1.0 X', 'for at least 48 hours', '109/L on restart, the participant', 'At least 7 days have elapsed since the', 'should be permanently', 'suspension of study treatment', 'discontinued from study treatment', 'No sign or symptom of associated', 'and withdrawn from the study.', 'infection has been identified', '81']"
299,page_300,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '1. New or worsening symptoms believed to be related to neutropenia such as (but not limited', 'to): sudden onset of fever or malaise, stomatitis, odynophagia, periodontal infection, skin', 'abscesses, signs or symptoms of sinusitis and otitis, symptoms of pneumonia (eg, cough,', 'dyspnea), perirectal pain and irritation, hypotension or signs of septic shock.', '2. Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is', ""unclear, provide the participant's best approximation. If the date/time of the last dose cannot"", 'be approximated OR a PK sample cannot be collected in the time period indicated above, do', 'not obtain a PK sample. Instructions for sample handling and shipping are in the SRM.', '82']"
300,page_301,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.10.', 'Appendix 10: Country-specific requirements', 'No country specific requirements', '83']"
301,page_302,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.11.', 'Appendix 11 Protocol Amendment History', 'Table 1', 'Schedule of activities', 'Original text:', 'FU', 'Up to', '28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'EW', 'Visit1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', 'days', 'post', 'last', 'dose', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'up to', '0/', '2/', '4/', '8/', '12/', '16', '20 /', '24', '32', '40/', '52 /', '-7 days', 'D1', 'D14', 'D28', 'D56', 'D84', 'D112', 'D140', 'D168', 'D224', 'D280', 'D364', 'Assessment', '+3d', '+3d', '+3d', '3d', '3d', '+3d', '3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'window', 'Urine or', 'serum', 'X', 'Pregnancy', 'testg', 'HIV,', 'Hepatitis B', 'and C', 'screeninge', 'AE review', 'SAE review', 'Revised text:', 'FU', 'Up to', '28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit', 'EW', 'Visit1a', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', 'days', 'post', 'last', 'dose', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'up to', '0/', '2/', '4/', '8/', '12/', '16/', '20/', '24', '32', '40/', '52/', '-28 days', 'D1', 'D14', 'D28', 'D56', 'D84', 'D112', 'D140', 'D168', 'D224', 'D280', 'D364', 'Assessment', '+3d', '+3d', '+3d', '+3d', '3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'window', 'HIV,', 'Hepatitis B', 'X', 'and C', 'screeninge', 'AE review', 'SAE review', '84']"
302,page_303,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Section 5.1', 'Overall Design', 'Original text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days - -7 to', '1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Placebo (n=50)', '7 days', 'Follow-up²', 'Screening¹', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', 'Amended text:', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days -28', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', '85']"
303,page_304,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 1', 'Study Schematic', '52 weeks', 'Up to 28', 'Placebo (n=50)', 'days', 'Follow-up2', 'Screening', 'R', 'Danirixin, 35mg', '(n=50)', ': If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2 Follow-up visit to occur within 28days of last dose of study medication', 'Section 6.1', 'Inclusion Criteria', 'Original text:', '2. Male or female', 'g.', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'h. Female participants:', 'A female participant is eligible to participate if she is not pregnant (see Section 12.5;', 'Appendix 5), not breastfeeding, and at least one of the following conditions applies:', 'i. Not a woman of childbearing potential (WOCBP) as defined in Section 12.5', '(Appendix 5)', 'OR', 'ii. A WOCBP who agrees to follow the contraceptive guidance in Section 12.5', '(Appendix 5) during the treatment period and for at least 60 hours after the', 'last dose of study treatment.', '86']"
304,page_305,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Revised text:', '3. Male or female', 'i.', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'j. Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', '87']"
305,page_306,"['2016N293064_01', 'CONFIDENTIAL', '2018N394263_00', '-', '205864', 'Section 12.2 Appendix 2:', 'Original text:', 'Table 7', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as', 'needed for women of childbearing potential²²', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody³', 'All study-required laboratory assessments will be performed by a central', 'laboratory, with the exception of urine testing', '88']"
306,page_307,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2.', 'Local urine hCG testing will be standard for the protocol unless serum testing is required by local', 'regulation or IRB/IEC.', '3.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Amended text:', 'Table 8', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', '89']"
307,page_308,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'Screening', 'childbearing potential only)', 'Tests', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody²', 'All study-required laboratory assessments will be performed by a central', 'laboratory', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Section 12.5 Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Original text:', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level', 'in the postmenopausal range may be used to confirm a postmenopausal', 'state in women not using hormonal contraception or hormonal', 'replacement therapy (HRT). However, in the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient.', 'Females on HRT and whose menopausal status is in doubt will be', 'required to use one of the non-hormonal highly effective contraception', 'methods if they wish to continue their HRT during the study. Otherwise,', '90']"
308,page_309,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred', 'lifestyle (abstinent on a long term and persistent basis) and agree to remain', 'abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Female participants', 'Female participants of childbearing potential are eligible to participate if they agree to', 'use a highly effective method of contraception consistently and correctly as described in', 'Table 6.', 'Table 9', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', '91']"
309,page_310,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', 'Amended text:', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's review of participant's"", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female:', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level', 'in the postmenopausal range may be used to confirm a postmenopausal', 'state in women not using hormonal contraception or hormonal', 'replacement therapy (HRT). However, in the absence of 12 months of', 'amenorrhea, a single FSH measurement is insufficient and confirmatory', 'testing with additional FSH and estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be', 'required to use one of the non-hormonal highly effective contraception', 'methods if they wish to continue their HRT during the study. Otherwise,', 'they must discontinue HRT to allow confirmation of postmenopausal', 'status before study enrollment.', '92']"
310,page_311,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred', 'lifestyle (abstinent on a long term and persistent basis) and agree to remain', 'abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Table 10', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', '93']"
311,page_312,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '94']"
312,page_313,"['2016N293064 0', 'CONFIDENTIAL', '2018N394263_00', 'GlaxoSmithKline group of companies', '205864', 'TITLE PAGE', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Protocol Number: 205864', 'Short Title: Danirixin Pilot Study for Disease Progression in COPD', 'Compound Number: GSK1325756', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information will be provided in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s): IND: 108168', 'Approval Date: 21-MAR-2017', 'Copyright 2017 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']"
313,page_314,"['2018N394263_00', '2016N293064_00', 'CONFIDENTIAL', '-', '205864', 'SPONSOR SIGNATORY:', 'PPD', '21-Mar-2017', 'Aili L. Lazaar, MD', 'PPD', 'Date', 'Clinical Development Director,', 'Respiratory Therapy Area Unit', 'PPD', '2']"
314,page_315,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'TABLE OF CONTENTS', 'PAGE', '1. SYNOPSIS', '6', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '8', '3. INTRODUCTION', '11', '3.1.', 'Study Rationale', '11', '3.2.', 'Background', '12', '3.3.', 'Benefit/Risk Assessment', '13', '3.3.1.', 'Risk Assessment', '14', '3.3.2.', 'Benefit Assessment', '18', '3.3.3.', 'Overall Benefit:Risk Conclusion', '18', '4.', 'OBJECTIVES AND ENDPOINTS', '19', '5.', 'STUDY DESIGN', '20', '5.1.', 'Overall Design', '20', '5.2.', 'Number of Participants', '20', '5.3.', 'Participant and Study Completion', '21', '5.4.', 'Scientific Rationale for Study Design', '21', '5.5.', 'Dose Justification', '21', '6.', 'STUDY POPULATION', '22', '6.1.', 'Inclusion Criteria', '22', '6.2.', 'Exclusion Criteria', '23', '6.3.', 'Lifestyle Restrictions', '26', '6.3.1.', 'Meals and Dietary Restrictions', '26', '6.3.2.', 'Activity', '26', '6.4.', 'Screen Failures', '26', '7. TREATMENTS', '26', '7.1.', 'Treatments Administered', '27', '7.1.1.', 'Medical Devices', '27', '7.2.', 'Dose Modification', '28', '7.3.', 'Method of Treatment Assignment', '28', '7.4.', 'Blinding', '28', '7.5.', 'Preparation/Handling/Storage/Accountability', '28', '7.6.', 'Treatment Compliance', '29', '7.7.', 'Concomitant Therapy', '29', '7.8.', 'Treatment after the End of the Study', '31', '8.', 'DISCONTINUATION CRITERIA', '31', '8.1.', 'Discontinuation of Study Treatment', '31', '8.1.1.', 'Liver Chemistry Stopping Criteria', '31', '8.1.2.', 'QTc Stopping Criteria', '32', '8.1.3.', 'Neutrophil Stopping Criteria', '33', '8.1.4.', 'Temporary Discontinuation', '33', '8.1.5.', 'Study Treatment Restart', '33', '8.2.', 'Withdrawal from the Study', '33', '8.3.', 'Lost to Follow Up', '34', '3']"
315,page_316,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '9. STUDY ASSESSMENTS AND PROCEDURES', '35', '9.1.', 'Efficacy Assessments', '35', '9.1.1.', 'FEV1', '35', '9.1.1.1.', 'Clinic Spirometry', '35', '9.1.1.2.', 'Mobile Spirometry', '35', '9.1.2.', 'SGRQ-C', '35', '9.1.3.', 'CAT', '36', '9.1.4.', 'COPD Exacerbations', '36', '9.1.5.', 'Patient Global Rating of Severity and Global Rating of', 'Change in Disease Severity', '36', '9.2.', 'Adverse Events', '37', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '37', '9.2.2.', 'Method of Detecting AEs and SAEs', '37', '9.2.3.', 'Follow-up of AEs and SAEs', '37', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '38', '9.2.5.', 'Cardiovascular and Death Events', '38', '9.2.6.', 'Disease-Related Events and/or Disease-Related', 'Outcomes Not Qualifying as SAEs', '38', '9.2.7.', 'Pregnancy', '39', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', '39', '9.2.8.1.', 'Time Period for Detecting Medical Device', 'Incidents', '39', '9.2.8.2.', 'Follow-up of Medical Device Incidents', '40', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents', 'to Sponsor', '40', '9.2.8.4.', 'Regulatory Reporting Requirements for', 'Medical Device Incidents', '40', '9.3.', 'Treatment of Overdose', '41', '9.4.', 'Safety Assessments', '41', '9.4.1.', 'Physical Examinations', '41', '9.4.2.', 'Vital Signs', '41', '9.4.3.', 'Electrocardiograms', '42', '9.4.4.', 'Clinical Safety Laboratory Assessments', '42', '9.4.5.', 'Pneumonia', '42', '9.5.', 'Pharmacokinetics', '43', '9.6.', 'Pharmacodynamics', '43', '9.7.', 'Genetics', '43', '9.8.', 'Biomarkers', '43', '9.9.', 'Health Economics OR Medical Resource Utilization and Health', 'Economics', '44', '10. STATISTICAL CONSIDERATIONS', '44', '10.1. Sample Size Determination', '44', '10.2. Randomization', '47', '10.3. Populations for Analyses', '47', '10.4.', 'Statistical Analyses', '47', '10.4.1.', 'Efficacy Analyses', '47', '10.4.2.', 'Safety Analyses', '50', '10.4.3.', 'Other Analyses', '50', '10.4.4.', 'Interim Analyses', '50', '4']"
316,page_317,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '11. REFERENCES', '51', '12. APPENDICES', '54', '12.1. Appendix 1: Abbreviations and Trademarks', '54', '12.2.', 'Appendix 2: Clinical Laboratory Tests', '58', '12.3.', 'Appendix 3: Study Governance Considerations', '60', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '64', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', '70', '12.6.', 'Appendix 6: Genetics', '74', '12.7. Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', '75', '12.8. Appendix 8: Medical Device Incidents: Definition and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '78', '12.9. Appendix 9: Neutrophil Safety and Study Treatment Restart', '80', '12.10. Appendix 10: Country-specific requirements', '82', '5']"
317,page_318,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '1.', 'SYNOPSIS', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Short Title: Danirixin Pilot Study for Disease Progression in COPD', 'Rationale: This is a pilot study to investigate the effect of danirixin hydrobromide (HBr)', '35mg tablets on lung function and health related quality of life (HRQoL) in participants', 'with mild to moderate airflow obstruction and a demonstrated history of decline in FEV1.', 'This study aims to assess whether danirixin has the potential to impact disease', 'progression in participants with COPD and with a demonstrated history of disease', 'progression measured by lung function.', 'Objectives and Endpoints:', 'Objective', 'Endpoint', 'Primary', 'Rate of decline in FEV1', 'To assess whether danirixin HBr 35mg', 'tablets impact disease progression', ""Change from baseline in St. George's"", 'compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'Secondary', 'To further characterize the safety of', 'Adverse events', 'danirixin HBr 35mg tablets compared', 'Vital Signs', 'with placebo in participants with mild', 'ECG', 'to moderate airflow limitation', 'Clinical Laboratory Assessments', '(hematology, clinical chemistry,', 'urinalysis)', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared with placebo', 'Change from baseline in FEV,', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Overall Design:', 'This is a Phase 2 study to investigate the potential impact of danirixin HBr 35mg tablets', 'compared with placebo on disease progression in participants with mild to moderate', '6']"
318,page_319,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'airflow obstruction. The study will also assess the enrichment strategy of enrolling', 'participants identified from the COPDGene study. These participants have been', 'identified by COPDGene investigators based on data collected over the initial 5 year', 'period. The participants were identified based on a Random Forest analysis and a', 'demonstrated decline of at least 20mL/yr over the initial 5 year period.', 'Number of Participants:', 'Approximately 130 participants will be screened to enrol 100 participants in this study. It', 'is anticipated that approximately 85 participants will complete the 52 weeks of treatment', '(assuming a 15% drop out rate).', 'Treatment Groups and Duration:', 'Participants will receive either placebo or danirixin 35mg tablets (as hydrobromide', 'hemihydrate salt) twice daily for 52 weeks (12months).', '7']"
319,page_320,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', 'Table 1', 'Schedule of activities', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'days', 'Visit1a', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-7 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Eligibility', 'Informed Consent', 'X', 'Genetics Informed Consentb', 'X', 'Demography', 'X', 'Inclusion and Exclusion Criteria', 'X', 'Smoking Statusc', 'X', 'Smoking Historyc', 'X', 'Medical Historyd', 'X', 'Full physical', 'Chest X-ray (historical within 1 year', 'acceptable)', 'HIV, Hepatitis B and C screeninge', 'Additional Eligibility and In Study Assessments', 'Verify Eligibility', 'X', 'Brief physical', 'X', 'Urine or serum Pregnancy testg', 'Laboratory assessments (clinical chemistry,', 'including liver chemistries), hematology,', 'X', 'X', 'X', 'urinalysis', 'Additional Liver chemistries only', 'X', 'X', '12 lead ECG', 'X', '8']"
320,page_321,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'days', 'Visit1a', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-7 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Vital Signs', 'X', 'X', 'X', 'X', 'X', 'Office spirometry (centralized)', 'X', 'Home spirometry - (weekly)', 'X', 'Randomization', 'Dispense study medication', 'Dispense log pad and provide training', 'Dispense MDI sensors and provide training', 'Study Treatment', 'Study Treatment Compliance (ediary)', 'Collect IP', 'Collect MDI sensors', 'Collect log pad', 'AE review', 'SAE review', 'Concomitant medication review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Clinical Outcomes Assessments', 'COPD exacerbation review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Rescue medication Use', 'SGRQ-C', 'COPD Assessment Test (CAT)', 'Participant Global Impression of COPD', 'X', 'severity', 'Participant Impression of change in COPD', 'severity', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '9']"
321,page_322,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_0', '205864', 'FU', 'Up to 28', 'Screening/', 'Visit', 'Visit', 'Visit', 'Visit', 'Visit 2', 'Visit 3', 'Visit 5', 'Visit 8', 'Visit 9', 'Visit 11', 'Visit 12', 'EW', 'days', 'Visit1a', '4', '6', '7', '10', 'post last', 'dose', 'Week', 'Week', 'up to', 'Week 2/', 'Week 4/', 'Week 8/', 'Week 12/', 'Week 16', 'Week 20', 'Week 32', 'Week 40', 'Week 52', '0/', '24', '-7 days', 'D14', 'D28', 'D56', 'D84', '/ D112', '/ D140', '/D224', '/ D280', '/ D364', 'D1', '/1168', 'Assessment window', '+3d', '3d', '+3d', '+3d', '+3d', '3d', '+3d', '+3d', '+6d', '+6d', '+6d', '+6d', 'Genetic, Pharmacokinetic and Biomarker Blood Collections', 'Blood sample for Genetics', 'Blood sample for CRP', 'Blood sample for exploratory biomarkers', 'X', 'a', 'Informed consent may be signed prior to screening visit in the case that any changes in medications are necessary', 'b', 'Agreeing to genetic sample consent is not required for study participation', 'C', 'Smoking status/history assessed at screening; smoking status re-checked at Visit 2', 'd', 'Includes substance usage, past and present medical conditions and family history of premature CV disease', 'e', 'Hepatitis B (HBsAg) and Hepatitis C (HepC antibody) testing is required. If testing otherwise performed within 3 months prior to the first dose of study treatment, testing at', 'screening is not required. Hepatitis C RNA testing is optional; however a confirmatory negative Hepatitis C RNA test must be obtained, to be able to enrol participants with', 'positive Hepatitis C antibody due to prior resolved disease.', 'f', ""Participant's clinical status should be reviewed"", 'g', 'Pregnancy testing is only required for women of child bearing potential (WOCBP). A positive urine pregnancy test requires confirmation with a serum pregnancy test.', 'The timing and number of planned study assessments, including safety and biomarker assessments may be altered during the course of the study based on newly available data to', 'ensure appropriate data collection. Any changes in the timing or addition of time points for any planned study assess must be documented and approved by the relevant study team', 'member and then archived in the sponsor and site study files, but will not constitute a protocol amendment. The IRB/IEC will be informed of any safety issues that require alteration of', 'the safety monitoring scheme or amendment of the ICF.', '10']"
322,page_323,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.', 'INTRODUCTION', 'The inflammation associated with COPD is characterized by a prominent infiltration of', 'neutrophils in lung tissue and the airways. Neutrophils and other inflammatory cells are', 'recruited to the lung in response to various chemotactic factors, including chemokines.', 'Specifically, there is a large body of evidence that the CXCR2 chemokine receptor plays', 'a pivotal role in neutrophil recruitment to the lung. For neutrophils, chemokine binding', 'to the CXCR2 results in chemotaxis and cell activation, ultimately resulting in the release', 'of a number of inflammatory mediators and proteases that are thought to contribute to the', 'progressive fibrosis, airway stenosis, and destruction of the lung parenchyma', 'characteristic of COPD.', 'Selective antagonism of the interaction between CXCR2 and its ligands is a potential', 'strategy for reducing the inflammation in COPD [Chapman, 2009]. A reduction in tissue', 'and airway neutrophilia is expected to result in downstream effects on mucus', 'hypersecretion, lung inflammation, and tissue destruction that are hypothesized to', 'underlie the development and worsening of respiratory symptoms and decline in lung', 'function that occurs in COPD.', 'Molecules with CXCR2 antagonist activity have been shown to reduce the influx of', 'neutrophils into the lungs in healthy participants (e.g. ozone or LPS challenge models)', 'and to reduce sputum and tissue neutrophils in the lungs of patients with severe,', 'neutrophilic asthma, COPD and bronchiectasis in association with improvements in', ""measures of disease activity in some, but not all, studies O'Byrne, 2016; Holz, 2010;"", 'Watz, 2016; Lazaar, 2011; Nair, 2012; Rennard, 2015]. Overall, the results of the', 'reported clinical studies with CXCR2 antagonists suggest that careful selection of the', 'target patient population is important to achieving clinical benefit.', 'Danirixin is a selective CXCR2 antagonist being developed as a potential anti-', 'inflammatory agent for the treatment of COPD and other inflammatory diseases and', 'influenza. Danirixin has demonstrated potent antagonism of CXCR2 activity both in', 'vitro and in vivo in preclinical studies [GlaxoSmithKline Document Number', 'YM2010/00163/07].', 'Clinical pharmacology studies in healthy volunteers demonstrated the pharmacodynamic', 'activity of danirixin (inhibition of ex vivo CXCL1-induced CD11b expression on', 'peripheral blood neutrophils). Danirixin has also been tested in a Phase IIa study in', 'symptomatic participants with mild to moderate COPD at risk for exacerbation', '[GlaxoSmithKline Document Number 2013N180289 ( 03 Study ID 200163]. In study', '200163, twice daily dosing with danirixin free base (75 mg bid) or placebo given on top', 'of standard of care inhaled maintenance treatments was tested for one year. Analyses of', 'clinical endpoints from study 200163 demonstrated that danirixin, compared to placebo,', 'reduced respiratory symptoms as measured with E-RS:COPD [Miller, 2016].', '3.1.', 'Study Rationale', 'This protocol describes a pilot study to investigate the effect of danirixin HBr 35mg', 'tablets on lung function and health related quality of life (HRQoL) in participants with', '11']"
323,page_324,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'mild to moderate airflow obstruction identified from the COPDGene cohort. Study', 'participants will continue with their standard of care inhaled medications (i.e. long acting', 'bronchodilators with or without inhaled corticosteroids) while receiving study treatment.', 'Specifically, this study aims to assess whether or not danirixin has the potential to impact', 'disease progression in participants with a COPD progression score indicating they are', 'likely to decline based on 5 year data from COPDGene and support the conduct of a', 'larger Phase III study for disease progression. In addition to lung function and HRQoL,', 'this study will assess moderate/severe COPD exacerbations, health status (CAT), and', 'rescue medication use.', '3.2.', 'Background', 'COPD is a major cause of disability, morbidity, and mortality, resulting in millions of', 'deaths annually worldwide contributing significantly to health care costs [Mathers, 2006;', 'Lopez-Campos, 2016; Vastava, 2015; GOLD, 2016]. The morbidity and mortality of', 'COPD are continuing to increase and worldwide and, by the year 2020, COPD is', 'expected to be the third leading cause of death and fifth leading cause of disability', '[Mathers, 2006; Lopez-Campos, 2016]. The airflow limitation that characterizes COPD', 'is primarily due to small airways disease and parenchymal destruction associated with an', 'excessive inflammatory response in the lung, mainly caused by cigarette smoking [Celli,', '2004]. COPD is characterized by symptoms of chronic and, in many patients,', 'progressive breathlessness (or dyspnea), cough and sputum production. Many COPD', 'patients also suffer from periodic worsening of their COPD symptoms that is beyond the', 'typical day to day variation [Hurst, 2010]. These episodes of worsening symptoms', '(COPD exacerbations) account for a significant proportion of COPD-related and total', 'health care costs. Despite several available therapies that have been shown to reduce', 'COPD exacerbations and respiratory symptoms, many COPD patients continue to', 'experience a high burden of respiratory symptoms and COPD exacerbations resulting in a', 'continuing unmet medical need [Vestbo, 2016]. Additionally, there is growing', 'recognition that a high percentage of COPD patients with mild airflow limitation as well', 'as smokers with preserved lung function suffer from a high burden of symptoms and', 'COPD exacerbations with a subsequent impact on health status [Woodruff, 2016].', 'Therapies that effectively further reduce COPD exacerbations and improve respiratory', 'symptoms could have a substantial impact on healthcare utilization and most importantly', ""result in an improvement in COPD patients' quality of life."", 'The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the', 'treatment and management of patients with COPD recommend that the management of', 'current respiratory symptoms and subsequent worsening of symptoms resulting in COPD', 'exacerbations should be an important component of COPD patient management [GOLD,', '2016].', 'Danirixin is being evaluated as an addition to standard of care inhaled therapies (i.e. long', 'acting bronchodilators and long acting bronchodilator/corticosteroid combination', 'therapies) and is targeting those COPD patients that continue to have a burden of', 'respiratory symptoms and COPD exacerbations despite management with currently', 'available COPD treatments.', '12']"
324,page_325,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.', 'Benefit/Risk Assessment', 'More detailed information about the potential benefits and risks of danirixin may be', ""found in the danirixin Investigator's Brochure [GlaxoSmithKline Document Number"", 'YM2010/00163/07].', '13']"
325,page_326,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.1.', 'Risk Assessment', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Testicular effects and male fertility', 'The most sensitive species is the rat.', 'Standard safety monitoring will be', 'Testicular effects present at doses >150', 'employed.', 'mg/kg/day in the rat include spermatid', 'degeneration, seminiferous tubular', 'The potential risk of testicular injury has', 'degeneration and secondary epididymal', 'been conveyed in the informed consent.', 'changes, including oligo/aspermia and/or', 'epididymal intratubular cellular debris. The', 'PK modelling predicts that in a participant', 'no observed adverse effect level (NOAEL)', 'receiving 35 mg BID of the HBr salt, the', 'in this study, based on the microscopic', 'risk of exposure exceeding the 2-fold', 'findings in the testis, was 50 mg/kg/day for', 'margin for AUC(0-24) for the NOAEL of', 'male rats. The systemic exposure margins', 'testicular effects is low.', 'for the NOAEL for testicular effects in the', 'rat is 7.3-fold for an oral clinical dose of 50', 'mg BID free base tablet.', 'The testicular effects seen in the rat have', 'also been shown to directly impact on male', 'fertility and the NOAEL for these', 'reproductive effects was 100 mg/kg/day.', 'Refer to IB Section 4.4 for full details', 'No adverse events related to testicular', 'effects have been observed in clinical', 'studies to date.', '14']"
326,page_327,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Impairment of host defense.', 'Host defense has not been studied directly', 'Monitoring of neutrophil count.', 'in nonclinical studies. However, data in', 'nonclinical species have not identified an', 'Stopping criteria: in participants with a', 'increased risk of infection with danirixin.', 'confirmed absolute neutrophil count < 0.5 X', 'Nonclinical studies in mice and ferrets with', '109/L product will be discontinued and', 'two CXCR2 antagonists in the same', 'neutrophil count will be monitored until', 'chemical class as danirixin have not shown', 'return to normal. Participants may be', 'an increase in infections in challenge', 'restarted on study treatment as detailed in', 'models (e.g., influenza viral load).', 'Appendix 9.', 'Secondary bacterial infections after viral', 'infection have not been directly evaluated in', 'Ongoing assessment of AE/SAEs related to', 'nonclinical studies.', 'infection.', 'The data from clinical studies including', 'Closely monitor, collect information on and', 'healthy participants, COPD and influenza', 'characterize infection events such as', 'patients thus far show no evidence that', 'pneumonia, and use adjudication as', 'participants taking danirixin have an', 'appropriate.', 'increased infection rate compared with', 'participants taking placebo.', 'Neutropenia has been reported in clinical', 'trials of other CXCR2 antagonists. No', 'instances of neutropenia have been reported', 'in nonclinical studies with danirixin. In', 'healthy volunteer studies and a phase 2a', 'study in patients with Influenza (GSK Study', '15']"
327,page_328,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756]', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', '201682, GlaxoSmithKline Document No.', '2014N205875_00) decreased neutrophil', 'counts have been observed in participants', 'receiving either placebo or danirixin; no', 'instances of danirixin-related neutropenia', 'have been reported in clinical studies to', 'date. In healthy participants, the data are', 'confounded by the observation of low', 'neutrophil counts before dosing or at', 'follow-up, and were not dose-related, while', 'in patients with influenza, neutrophil counts', 'recovered while receiving danirixin,', 'coincident with resolution of the viral', 'infection. There have been no reports of', 'neutrophil count decreases below the lower', 'limit of normal in patients with COPD who', 'were treated with danirixin for one year.', 'These data support the conclusion that a', 'causal association of neutropenia with', 'danirixin cannot be definitively established.', '16']"
328,page_329,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Investigational Product (IP) [Danirixin, GSK1325756', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Reproductive toxicology (Embryofetal', 'In a rat embryofetal development study, an', 'As danirixin HBr has shown the potential to', 'development)', 'oral dose of 300 mg/kg/day resulted in fetal', 'cause fetal malformations, danirixin or', 'skeletal variations in the skull (reductions in', 'danirixin HBr must not be administered to', 'ossification). There were no test article-', 'pregnant women or nursing mothers.', 'related effects on numbers of corpora lutea,', 'Women of childbearing potential should', 'implantations, embryofetal survival,', 'only be included in clinical trials with the', 'placental morphology, gravid uterine', 'use of appropriate precautions against', 'weight, sex ratio, fetal body weight, or fetal', 'pregnancy.', 'morphology (external and visceral).', 'Male participants with female partners of', 'child-bearing potential must comply with', 'the contraception requirements.', 'Study Procedures', 'None', 'Other', 'Not applicable', '17']"
329,page_330,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.3.2.', 'Benefit Assessment', 'All participants will undergo a thorough medical assessment during the study.', 'Participants will have frequent study clinic visits for the evaluation of their', 'disease symptoms. During these visits, participants will have spirometry, ECG,', 'vital signs monitoring, and physical examinations. Monitoring for worsening of', 'their disease will also take place.', 'Participants may benefit from the knowledge that they are contributing to the', 'process of developing a new treatment in an area of unmet need, even if not', 'directly beneficial for them', 'All participants will continue with changes to their medications, where medically', 'appropriate, to receive established standard of care.', '3.3.3.', 'Overall Benefit:I Risk Conclusion', 'Danirixin has demonstrated potent antagonism of CXCR2 activity both in vitro and in', 'vivo in preclinical and clinical studies. Its potency and duration of action supports its', 'potential use as an oral, anti-inflammatory agent in the treatment of COPD with', 'anticipated potential for bringing benefit to a serious condition that affects the lives of', 'millions and contributes to significant morbidity and mortality.', 'In clinical trials completed to date danirixin has been well-tolerated and most adverse', 'events (AEs) were mild to moderate in intensity The most commonly observed AEs have', 'been nasopharyngitis, headache and diarrhea following administration of danirixin or', 'placebo. There have been no treatment related clinically significant changes in vital signs', 'or ECG at any dose of danirixin.', 'Taking into account the measures taken to minimize risks to participants in this study, the', 'potential risks identified in association with danirixin are justified by the anticipated', 'benefits that may be afforded to participants with COPD.', '18']"
330,page_331,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '4.', 'OBJECTIVES AND ENDPOINTS', 'Objectives', 'Endpoints', 'Primary', 'To assess whether danirixin HBr', 'Rate of decline in FEV1', '35mg tablets impacts disease', ""Change from baseline in St. George's"", 'progression compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'To further characterize the safety of', 'Adverse events (AE), clinical', 'danirixin HBr 35mg tablets', 'laboratory values, vital signs,', 'compared with placebo in', 'electrocardiogram (ECG), and/or', 'participants with mild to moderate', 'other safety biomarkers', 'airflow limitation', 'Secondary', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared to placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Exploratory', 'To characterize the effect of', 'Blood/serum/plasma biomarkers that', 'danirixin on lung matrix', 'are indicative of extracellular matrix', 'destruction/remodelling and', 'turnover/remodelling (e.g. elastin and', 'inflammation', 'collagen neo-epitopes) and', 'inflammation (e.g. CRP)', 'Further characterize efficacy of', 'danirixin', 'Global assessment of COPD severity', '19']"
331,page_332,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.', 'STUDY DESIGN', '5.1.', 'Overall Design', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days - -7 to', '1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', '52 weeks', 'Placebo (n=50)', '7 days', 'Follow-up2', 'Screening¹', 'R', 'Danirixin, 35mg', '(n=50)', '1 If changes to medication are required, consent must be signed prior to any changes being made and may', 'occur prior to the Screening Visit', '2 Follow-up visit to occur within 28days of last dose of study medication', '5.2.', 'Number of Participants', 'Approximately 130 participants will be screened to achieve 100 randomized in this study.', 'It is anticipated that approximately 85 participants will complete the 12 months of', 'treatment (assuming a 15% drop out rate).', 'For the analysis of study assessments, several analysis populations are defined in Section', '10.3.', '20']"
332,page_333,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.3.', 'Participant and Study Completion', 'A participant is considered to have completed the study if he/she has completed all', 'planned study visits including the last study visit and the last scheduled procedure shown', 'in the Schedule of Activities (Table 1).', 'The end of the study is defined as the date of the last visit of the last participant in the', 'study.', '5.4.', 'Scientific Rationale for Study Design', 'This study will use a multicenter, randomized, parallel-group design. This is a well', 'established design to evaluate the efficacy and safety of an investigational drug. With the', 'use of an enriched population, it is anticipated that one year of treatment will be sufficient', 'to detect a trend in altering disease progression. Danirixin has already been clinically', 'investigated over one year treatment duration (GlaxoSmithKline Document Number', '2013N180289 03 Study ID 200163).', 'The data from this study will provide useful information in determining whether or not to', 'progress to a Phase III study to explore an indication for slowing disease progression.', '5.5.', 'Dose Justification', 'One dose of danirixin is proposed for this study, 35mg tablets BID. This dose was', 'selected based on integrating information on:', 'Dose-exposure-biomarker response using inhibition of ex vivo CXCL1-induced', 'CD11b expression on peripheral blood neutrophils over the dose range of 0-400mg', '(free base tablet) in healthy volunteers (GSK Study No. CX3 112483).', 'Evidence of reduced respiratory symptoms and improvement in health status in mild', 'to moderate COPD participants from interim data in the Phase IIa study (GSK Study', 'No. 200163).', 'Relative bioavailability study comparing danirixin free base VS HBr (GSK Study No.', '201037).', 'In the previous clinical studies, danirixin was administered as a free base tablet, whereas', 'the danirixin formulation to be used in this study will be a hydrobromide salt tablet.', 'The hydrobromide tablet has approximately twice the bioavailability of the free base', 'tablet in healthy elderly participants (GlaxoSmithKline Document Number', '2015N248339 00 Study ID 201037). Thus the danirixin (hydrobromide tablet) 35mg', 'BID dose for investigation in this study is expected to provide steady-state systemic', 'exposure approximately equivalent to the 75mg BID (free base tablet) used in Study', '200163. Predicted steady-state exposures and multiples of blood ex vivo CXCL1-induced', 'CD11b pharmacology at the proposed danirixin doses are presented in Table 2.', '21']"
333,page_334,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Table 2', 'Predicted steady state systemic exposure and multiples of blood ex', 'vivo CXCL1-induced pharmacology following twice daily of', 'administration of danirixin', 'Dose', 'Predicted# steady-state median (5th,95th', 'Cavg', 'Cmin', '(mg)', 'percentile)', 'multiple of', 'multiple of', 'AUC(0-24)', 'Cavg', 'Cmin', 'IC50*', 'IC50*', 'steady-state', '(ng/mL)', '(ng/mL)', '(ug.h/mL)', '35', '9.59', '399', '192', '5.1', '2.4', '(4.70, 19.3)', '(196,806)', '(47.6, 630)', '#Model derived based on PK data in healthy elderly participants from GSK Study No. 201037', '(GlaxoSmithKline Document Number. 2015N248339_00).', '*Model predicted population mean IC50=78.5 ng/mL (95% CI: 37.3, 120), sigmoidal Emax model of DNX', 'PK-ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils in healthy participants.', '6.', 'STUDY POPULATION', 'This study will identify specific patients most likely to decline from the well established', 'COPDGene cohort [NCT00608764]. This study will be an ancillary study within', 'COPDGene investigating the enrichment strategy for assessing disease progression.', 'These potential participants have been identified by COPDGene investigators based on', 'data collected over the initial 5 year period. The participants were identified based on a', 'Random Forest analysis and a demonstrated decline of at least 20mL/yr over the initial 5', 'year period. Once participants are identified from the COPDGene dataset, the following', 'criteria will be verified at initial study visit following signing of consent.', 'Prospective approval of protocol deviations to recruitment and enrolment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '6.1.', 'Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria', 'apply:', 'Age', '1. Participant must be 40 to 76 years of age inclusive, at the time of signing the', 'informed consent.', 'Type of Participant and Disease Characteristics', '2.', 'At the screening visit, the subject must have an FEV1 >40% of the predicted normal.', '3. Participants with a prior history of asthma are eligible if they have a current diagnosis', 'of COPD', '22']"
334,page_335,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Weight', '4. Body weight 45 kg', 'Sex', '5. Male or female', 'a.', 'Male participants:', 'A male participant must agree to use contraception as detailed in Appendix 5 of this', 'protocol during the treatment period and for at least 60 hours after the last dose of', 'study treatment, corresponding to approximately 6 half-lives (which is the time', 'needed to eliminate any teratogenic study treatment) and to refrain from donating', 'sperm during this period.', 'b. Female participants:', 'A female participant is eligible to participate if she is not pregnant (see Section 12.5;', 'Appendix 5), not breastfeeding, and at least one of the following conditions applies:', '(i)', 'Not a woman of childbearing potential (WOCBP) as defined in Section 12.5', '(Appendix 5)', 'OR', '(ii)', 'A WOCBP who agrees to follow the contraceptive guidance in Section 12.5', '(Appendix 5) during the treatment period and for at least 60 hours after the', 'last dose of study treatment.', 'Informed Consent', '6.', 'Capable of giving signed informed consent as described in Section 12.3 (Appendix', '3) which includes compliance with the requirements and restrictions listed in the', 'informed consent form (ICF) and in this protocol.', '6.2.', 'Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', 'Medical Conditions', '1. Diagnosis of other clinically relevant lung disease (other than COPD), e.g.', 'sarcoidosis, tuberculosis, pulmonary fibrosis, severe bronchiectasis or lung cancer', '2. COPD due to alpha-l-antitrypsin deficiency', '3. Pulse oximetry < 88% at rest at screening. Participants should be tested while', 'breathing room air. However, participants living at high altitudes (above 5000 ft or', '1500 m above sea level) who are receiving supplemental oxygen can be included', 'provided they are receiving the equivalent of < 4L/min and screening oximetry is', 'measured while on their usual settings.', '4. Less than 14 days have elapsed from completion of a course of antibiotics or oral', 'corticosteroids for a recent COPD exacerbation', '23']"
335,page_336,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '5. Participants with a peripheral blood neutrophil count < 1 X 109/L', '6. Diagnosis of pneumonia (chest X-ray or CT confirmed) within the 3 months prior to', 'screening', '7. Chest X-ray (posterior with lateral) or CT scan reveals evidence of a clinically', 'significant abnormality not believed to be due to the presence of COPD (historic data', 'up to 1 year may be used).', '8. History or current evidence of clinically significant renal disease, diabetes', 'mellitus/metabolic syndrome, hypertension, or any other clinically significant', 'cardiovascular, neurological, immunological, endocrine, or haematological', 'abnormality that is uncontrolled on permitted therapies. Significant is defined as any', 'disease that, in the opinion of the Investigator, would put the safety of the participants', 'at risk through study participation, or which would affect the safety analysis or other', 'analysis if the disease/condition exacerbated during the study.', '9. History of sensitivity to any of the study medications, or components thereof or a', 'history of drug or other allergy that, in the opinion of the investigator of GSK medical', 'monitor, contraindicates their participation.', '10. Current of chronic history of liver disease, or know hepatic or biliary abnormalities', ""(with the exception of Gilbert's syndrome or asymptomatic gallstones)."", '11. Abnormal and clinically significant 12-lead ECG finding. The investigator will', 'determine the clinical significance of each abnormal ECG finding in relation to the', ""subject's medical history and exclude participants who would be at undue risk by"", 'participating in the trial. An abnormal and clinically significant finding that would', 'preclude a subject from entering the trial is defined as a 12-lead tracing that is', 'interpreted as, but not limited to, any of the following:', '- AF with rapid ventricular rate > 120 bpm;', '- sustained or non-sustained VT', '-', 'second degree heat block Mobitz type II and third degree heart block (unless', 'pacemaker or defibrillator has been implanted)', '- QTcF 500 msec in patients with QRS < 120 msec and QTcF 530 msec in', 'patients with QRS 120 msec', '12. Previous lung surgery (e.g. lobectomy, pneumonectomy) or lung volume reduction', 'procedure.', 'Prior/Concomitant Therapy', '13. Current or expected chronic use of macrolide antibiotics during the study period for', 'the prevention of COPD exacerbations. Examples of chronic use include, but are not', 'limited to, daily or two to three times per week use for at least 3 months.', '14. Oral or injectable CYP3A4 or BRCP (breast cancer resistance protein) substrates with', 'a narrow therapeutic index (CYP3A4 substrates include, but are not limited to,', 'alfenatil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,', 'quinidine, sirolimus, tacrolimus, and theophylline; BCRP substrates include, but are', '24']"
336,page_337,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'not limited to, topotecan.) The Investigator should consult with the Medical Monitor', 'if necessary.', '15. Current or expected use of phosphodiesterase-4 inhibitors (e.g. roflumilast).', 'Participants currently receiving roflumilast may be included if they are able to', 'discontinue use from 30 days prior to screening through the completion of the follow', 'up visit.', 'Prior/Concurrent Clinical Study Experience', '16. Participation in a previous clinical trial and has received an investigational product', 'within any of the following time periods prior to the first dosing day in the current', 'study: 30 days, 5 half lives, or twice the duration of the biological effect of the', 'investigational product (whichever is longer).', '17. Participation in a previous clinical trial with danirixin within 1 year prior to the first', 'dosing day in the current study', '18. Exposure to more than four investigational products within 1 year prior to the first', 'dosing day in the current study.', 'Diagnostic assessments', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN); bilirubin > 1.5xULN', '(isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct', 'bilirubin <35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Other Exclusions', '22. Pulmonary rehabilitation: Participants who have taken part in the acute phase of a', 'pulmonary rehabilitation program within 4 weeks prior to screening or participants', 'who plan to enter the acute phase of a pulmonary rehabilitation program during the', 'study. Participants who are in the maintenance phase of a pulmonary rehabilitation', 'program are not excluded.', '23. A history of allergy or hypersensitivity to any of the ingredients in the study', 'treatment.', '24. A known or suspected history of alcohol or drug abuse within the 2 years prior to', 'screening.', '25. Inability to read: in the opinion of the Investigator, any participant who is unable to', 'read and/or would not be able to complete study related materials.', '26. Affiliation with the study site: study investigators, sub-investigators, study', 'coordinators, employees of a study investigator, sub-investigator or study site, or', 'immediate family member of any of the above that are involved with the study.', '25']"
337,page_338,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '6.3.', 'Lifestyle Restrictions', '6.3.1.', 'Meals and Dietary Restrictions', 'No meal or dietary restrictions are required for participation in this study. Danirixin must', 'be taken with food. Specific dosing instructions will be provided in the Study Reference', 'Manual (SRM) and will be provided to all study participants.', '6.3.2.', 'Activity', 'Participants should abstain from strenuous exercise for 24 hours before each blood', 'collection for clinical laboratory tests.', '6.4.', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study', 'but are not subsequently randomized in the study. A minimal set of screen failure', 'information is required to ensure transparent reporting of screen failure participants to', 'meet the Consolidated Standards of Reporting Trials (CONSORT) publishing', 'requirements and to respond to queries from regulatory authorities. Minimal information', 'includes demography, screen failure details, eligibility criteria and any serious adverse', 'events (SAEs).', 'Individuals who do not meet the criteria for participation in this study (screen failure)', 'may not be rescreened unless discussed with the medical monitor.', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment(s), marketed product(s),', 'placebo, or medical device(s) intended to be administered to a study participant according', 'to the study protocol.', '26']"
338,page_339,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.1.', 'Treatments Administered', 'Study Treatment Name:', 'Danirixin', 'Placebo', '(GSK1325756H, the', 'hydrobromide', 'hemihydrate salt)', 'Dosage formulation:', 'White Film coated', 'White Film coated', 'tablets (oval shaped).', 'tablets (oval shaped).', 'Refer to', ""Refer to Investigator's"", 'Brochure for', ""Investigator's"", 'Brochure for', 'presentation and', 'presentation and', 'excipients', 'excipients', 'Unit dose strength(s)/Dosage level(s):', '35mg tablets (of free', 'N/A', 'base equivalent)', 'Route of Administration', 'Oral', 'Oral', 'Dosing instructions:', 'One tablet to be', 'One tablet to be taken', 'taken twice daily', 'twice daily with food', 'with food', 'Packaging and Labeling', 'Study Treatment will', 'Study Treatment will', 'be provided in a', 'be provided in a HDPE', 'HDPE bottle with', 'bottle with desiccant.', 'desiccant. Each', 'Each bottle will be', 'bottle will be labeled', 'labeled as required per', 'as required per', 'country requirement.', 'country requirement.', 'Manufacturer', 'GSK', 'GSK', '7.1.1.', 'Medical Devices', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices are', 'provided in the SRM.', '27']"
339,page_340,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '7.2.', 'Dose Modification', 'No individual participant dose modifications or adjustments are allowed.', '7.3.', 'Method of Treatment Assignment', 'This study will use an Interactive Web Response System (IWRS). All', 'participants will be centrally randomized using the IWRS. Before the study is', 'initiated, the log in information and directions for the IWRS will be provided to', 'each site.', 'Participant randomization will be stratified by smoking status (i.e. current', 'smoker or former smoker).', 'Study treatment will be dispensed to participants at the study visits summarized', 'in the SOA.', 'Returned study treatment should not be re-dispensed to any participant.', '7.4.', 'Blinding', 'This will be a double-blind study. Study participants, all study site staff, and all members', 'of the GSK study team will be blinded to individual participant treatment assignment.', ""A participant will be withdrawn if the participant's treatment code is unblinded by the"", 'investigator or treating physician. The primary reason for discontinuation (the event or', 'condition which led to the unblinding) will be recorded in the CRF.', ""GSK's Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the"", 'treatment assignment for any participant with an SAE. If the SAE requires that an', 'expedited regulatory report be sent to one or more regulatory agencies, a copy of the', ""report, identifying the participant's treatment assignment, may be sent to investigators in"", 'accordance with local regulations and/or GSK policy.', '7.5.', 'Preparation/Handling/Storage/Accountability', 'The investigator or designee must confirm and document appropriate temperature', 'conditions have been maintained during transit for all study treatment received', 'and any discrepancies are reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study', 'treatments must be stored in a secure, environmentally controlled, and monitored', '28']"
340,page_341,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '(manual or automated) area in accordance with the labeled storage conditions', 'with access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (ie, receipt, reconciliation, and final disposition of records).', 'Further guidance and information for the final disposition of unused study', 'treatment are provided in the SRM.', 'Precaution will be taken to avoid direct contact with the study treatment. Under', 'normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. In the case of unintentional', 'occupational exposure notify the monitor, Medical Monitor and/or GSK study', 'contact.', 'A Material Safety Data Sheet MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '7.6.', 'Treatment Compliance', 'When participants are dosed at the site, they will receive study treatment directly', 'from the investigator or designee, under medical supervision. The date and time of', 'each dose administered in the clinic will be recorded in the source documents. The', 'dose of study treatment and study participant identification will be confirmed at the', 'time of dosing by a member of the study site staff other than the person', 'administering the study treatment.', 'When participants self-administer study treatment(s) at home, compliance with study', 'treatment administration will be assessed through querying the participant during the', 'site visits and documented in the source documents and CRF. In addition,', 'participants will be asked to confirm study administration each day in the daily', 'ediary.', 'Study participants who are not compliant with study treatment administration', 'requirements should be re-educated on the importance of treatment compliance.', 'Every effort should be made to keep participants in the study. Participants who', 'continue to be non-compliant after several attempts to re-educate may be', 'discontinued after consultation with the GSK study team.', '7.7.', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) that the participant is receiving at the time of', 'enrolment or receives during the study must be recorded along with:', 'reason for use', 'dates of administration including start and end dates', '29']"
341,page_342,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'dosage information including dose and frequency', 'The Medical Monitor should be contacted if there are any questions regarding', 'concomitant or prior therapy.', 'The following COPD medications are permitted during the study, at the discretion of the', 'GSK Medical Monitor and/or Investigator:', 'Inhaled COPD maintenance medications (e.g. long acting bronchodilator', 'medications (i.e. LAMA, LABA) and long-acting bronchodilator combination', 'therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled steroid', 'combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)', 'Short courses of oral corticosteroids and/or antibiotics (including macrolides)', 'are permitted for the acute treatment of exacerbations of COPD and should not', 'exceed 21 days. This use must be recorded as an HCRU exacerbation event.', 'The following medications are prohibited from the screening visit until after completion', 'of the follow up visit:', 'Chronic use of macrolide antibiotics for the prevention of COPD exacerbations.', 'Examples of chronic use include daily or two-three times per week for at least', '3', 'months.', 'Oral or injectable CYP3A4 or BCRP substrates with narrow therapeutic index', '(CYP3A4 substrates include, but are not limited to, alfentanil, cyclosporine,', 'dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus,', 'tacrolimus, and theophylline; BCRP substrates include, but are not limited to,', 'topotecan.', 'Phosphodiesterase-4 inhibitors (e.g. roflumilast)', 'Broad spectrum phosphodiesterase inhibitors (e.g. theophylline)', 'GSK will not supply rescue medication. Participants may continue to use and should', 'obtain rescue medication(s) through via their usual route. The following rescue', 'medications may be used:', 'Short acting beta agonists (SABA)(e.g., albuterol/salbutamol)', 'Short acting muscarinic antagonists (SAMA)(e.g., ipratropium)', 'Short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb,', 'Combivent)', 'The use of rescue medications is allowable at any time during the study. Participants', 'should record in the daily e-diary the number of puffs of rescue medication(s) over each', '24 hour period. Data from the MDI sensor device will be electronically captured and', 'transmitted to GSK.', 'Annual influenza vaccine is recommended for patients with COPD but is not required for', 'participation in this study. Influenza vaccination is permitted during the study and should', '30']"
342,page_343,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'be based on applicable local or national guidelines. Pneumococcal vaccine may also be', 'administered, when indicated, based on applicable local or national guidelines.', 'Additional vaccinations may be administered when indicated. Any vaccination', 'administered during the study should be recorded as a concomitant therapy.', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', 'study care of the participant.', 'GSK will not provide post-study treatment. There are no plans to provide the study', 'treatment for compassionate use following study completion.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', '8.1.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to assure', 'participant safety and evaluate liver event etiology (in alignment with the FDA', 'premarketing clinical liver safety guidance). These protocol guidelines are in alignment', 'with FDA premarketing clinical liver safety guidance [FDA, 2009].', 'Discontinuation of study treatment for abnormal liver tests should be considered by the', 'investigator when a participant meets one of the conditions outlined in the algorithm', 'below or if the investigator believes that it is in the best interest of the participant.', '31']"
343,page_344,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If subject to be monitored weekly mustrefer to Liver Safety Required Actions and Follow up', 'Assessments section in the Appendix', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin>2x', 'Yes', 'No', 'ULN (>35%', 'ALT23xULN', 'ALT>3xULN', 'ALT>3xULN', 'direct)', 'Plus', 'Yes', 'No', 'ALT>3xULN', 'orplus', 'No', 'No', 'but able to', 'Yes', 'persist for', 'Symptoms of', 'ALT25xULN', 'monitor', '4 weeks or', 'INR>1.5, if', 'liverinjury', 'weekly for', 'stopping', 'measured*', 'or', '4 weeks', 'criteria', 'Possible', 'hypersensitivity', 'met', ""Hy's Law"", 'Yes', 'Yes', 'No', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', ""Reportas an SAE if possible Hy's Law case:ALT>3xULNan Bilirubin>2xULN (>35% direct) or"", 'INR>1.5, if measured*', '*INR value not applicable to subjects on anticoagulants', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Appendix 7: Liver Safety: Required Actions and Follow-up Assessments).', '8.1.2.', 'QTc Stopping Criteria', 'The same QT correction formula must be used for each individual participant to', 'determine eligibility for and discontinuation from the study. This formula may', 'not be changed or substituted once the participant has been enrolled.', 'For example, if a participant is eligible for the protocol based on QTcB, then', 'QTcB must be used for discontinuation of this individual participant as well.', ""Once the QT correction formula has been chosen for a participant's eligibility,"", 'the same formula must continue to be used for that participant for all QTc data', 'being collected for data analysis. Safety ECGs and other non-protocol specified', 'ECGs are an exception.', 'The QTc should be based on single or averaged QTc values of triplicate', 'electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period.', 'A participant who meets either bulleted criteria based on the average of triplicate ECG', 'readings will be withdrawn from study treatment:', 'QTc > 500 msec OR Uncorrected QT > 600 msec', 'Change from baseline of QTc > 60 msec', '32']"
344,page_345,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'For patients with underlying bundle branch block, follow the discontinuation criteria', 'listed below:', 'Baseline QTc with Bundle Branch Block', 'Discontinuation QTc with Bundle', 'Branch Block', '< 450 msec', '> 500 msec', '450 - 480 msec', '> 530 msec', 'See the SoA (Table 1) for data to be collected at the time of treatment discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.1.3.', 'Neutrophil Stopping Criteria', 'A participant with a peripheral blood neutrophil count < 0.5 X 109/L that is confirmed on', 'repeat testing will be instructed to suspend dosing. The neutrophil count should be', 'monitored daily until it returns to within the baseline value, as detailed in Appendix 9.', '8.1.4.', 'Temporary Discontinuation', 'Temporary discontinuation of study treatment is allowed for up to 14 days when', 'medically necessary, e.g. for hospitalization for a COPD exacerbation, other medical', 'condition requiring hospitalization, or reduction in peripheral blood neutrophil counts', '0.5 X 109/L. Temporary discontinuation for any other reason should be discussed with', 'the GSK Medical Monitor.', '8.1.5.', 'Study Treatment Restart', 'Study treatment restart after liver chemistry stopping criteria are met by any participant in', 'this study is not allowed. Refer to Appendix 7 (Section 12.7) for full guidance for', 'required actions and follow-up assessments to undertake if liver stopping criteria are met.', 'Study treatment restart after neutrophil stopping criteria are met can be considered once', 'the neutrophil count has returned to within baseline and provided that no more than 14', 'days have elapsed since study medication was halted. The Investigator must obtain', 'approval from the GSK Medical Monitor prior to restarting study treatment. See', 'Appendix 9 for the procedure to be followed for study treatment restart after neutrophil', 'stopping criteria are met.', '8.2.', 'Withdrawal from the Study', 'A participant may withdraw from the study at any time at his/her own request,', 'or may be withdrawn at any time at the discretion of the investigator for safety,', 'behavioural, compliance or administrative reasons.', '33']"
345,page_346,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'If the participant withdraws consent for disclosure of future information, the', 'sponsor may retain and continue to use any data collected before such a', 'withdrawal of consent.', 'If a participant withdraws from the study, he/she may request destruction of any', 'samples taken and not tested, and the investigator must document this in the site', 'study records.', 'Refer to the SoA for data to be collected at the time of study discontinuation and', 'follow-up and for any further evaluations that need to be completed.', '8.3.', 'Lost to Follow Up', 'A participant will be considered lost to follow-up if he or she repeatedly fails to return for', 'scheduled visits and is unable to be contacted by the study site.', 'The following actions must be taken if a participant fails to return to the clinic for a', 'required study visit:', 'The site must attempt to contact the participant and reschedule the missed visit', 'as soon as possible and counsel the participant on the importance of maintaining', 'the assigned visit schedule and ascertain whether or not the participant wishes to', 'and/or should continue in the study.', 'Before a participant is deemed lost to follow up, the investigator or designee', 'must make every effort to regain contact with the participant (where possible, 3', ""telephone calls and, if necessary, a certified letter to the participant's last known"", 'mailing address or local equivalent methods). These contact attempts should be', ""documented in the participant's medical record."", 'Should the participant continue to be unreachable, he/she will be considered', 'to', 'have withdrawn from the study with a primary reason of lost to follow-up.', '34']"
346,page_347,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA (Table 1)', 'Protocol waivers or exemptions are not allowed', 'Immediate safety concerns should be discussed with the sponsor immediately', 'upon occurrence or awareness to determine if the participant should continue or', 'discontinue study treatment.', 'Adherence to the study design requirements, including those specified in the', 'SoA, is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that', 'potential participants meet all eligibility criteria. The investigator will maintain a', 'screening log to record details of all participants screened and to confirm', 'eligibility or record reasons for screening failure, as applicable.', ""Procedures conducted as part of the participant's routine clinical management"", '(e.g., blood count) and obtained before signing of ICF may be utilized for', 'screening or baseline purposes provided the procedure met the protocol-', 'specified criteria and was performed within the time frame defined in the SoA.', 'The maximum amount of blood collected from each participant over the', 'duration of the study, including any extra assessments that may be required, will', 'not exceed 500 mL.', 'Repeat or unscheduled samples may be taken for safety reasons or for technical', 'issues with the samples.', '9.1.', 'Efficacy Assessments', '9.1.1.', 'FEV1', '9.1.1.1.', 'Clinic Spirometry', 'Spirometry using FEV 1 and FVC measurements (FEV%, and FVC% and FEV1/FVC will', 'be calculated) will be performed in triplicate at time points listed in the SoA (Table 1).', 'Spirometry assessments should be performed in accordance with ATS/ERS guidelines as', 'outlined in the SRM.', '9.1.1.2.', 'Mobile Spirometry', 'Spirometry will also be performed weekly by the participants using a mobile spirometer', 'at home. Details will be outlined in the SRM.', '9.1.2.', 'SGRQ-C', ""The St. George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease"", 'specific tool (SGRQ-C) is a disease-specific questionnaire designed to measure the', ""impact of respiratory disease and its treatment on a COPD patient's HRQoL [Meguro,"", '2007]. As well as producing an overall summary score, scores for the individual domains', 'of symptoms, activity and impacts are also produced. The SGRQ-C has been used in', '35']"
347,page_348,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'numerous previous studies of COPD participants and has been translated and validated', 'for use in most major languages. The SGRQ-C is derived from the original SGRQ and', 'produces SGRQ scores equivalent to the original SGRQ instrument [Jones, 1992].', '9.1.3.', 'CAT', 'The COPD Assessment Test is a short and simple patient completed questionnaire which', 'has been developed for use in routine clinical practice to measure the health status of', 'patients with COPD. The CAT is an 8-item questionnaire suitable for completion by all', 'patients diagnosed with COPD [Jones, 2009; Jones, 2012]. When completing the', 'questionnaire, participants rate their experience on a 6-point scale, ranging from 0', '(maximum impairment) to 5 (no impairment) with a scoring range of 0-40. Higher scores', 'indicate greater disease impact.', '9.1.4.', 'COPD Exacerbations', 'An exacerbation of COPD is defined by a worsening of symptoms requiring additional', 'treatment or hospitalization.', 'Details of an exacerbation should be recorded in the exacerbation page of the eCRF.', 'Exacerbations will not be reported according to the standard process for expedited', 'reporting of SAEs to GSK (even though the event may meet the definition of an SAE) as', 'they are considered Disease Related Events (DREs). Only when the event is, in the', ""Investigator's opinion, of greater intensity, or duration than expected for the individual"", 'participant, or the Investigator considers that there is a reasonable possibility that the', 'event is related to study treatment should it be reported as an SAE (See Section 9.2).', '(Pneumonia must be recorded in the AE or SAE section of the eCRF and on the', 'pneumonia page of the eCRF (See Section 9.4.5)).', 'All medications used for the treatment of exacerbations must be recorded in the source', 'documents and the exacerbation page of the eCRF. If necessary the PI or other health', ""care personnel may stop the participant's study treatment temporarily in order to treat the"", 'COPD exacerbation. The reason for temporarily stopping study treatment and duration', 'should be recorded in the eCRF.', 'The date of onset and the date of resolution will be recorded in the source documents and', ""the eCRF based on the Investigator's judgement."", '9.1.5.', 'Patient Global Rating of Severity and Global Rating of Change in', 'Disease Severity', 'Participants will complete the Global Rating of COPD Severity at randomisation and', 'final study visit or IP Discontinuation Visit. This single global question will ask', 'participants to rate their severity of COPD on a four point scale (mild, moderate, severe,', 'very severe).', 'Participants will complete a Global Rating of Change in COPD (overall disease) question', 'at every visit following randomization (or Early Withdrawal (EW) Visit). Response', '36']"
348,page_349,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'options will be on a 7 point Likert scale ranging from much better to much worse. Asking', 'at each Visit allows for early detection of response as well as continued response.', '9.2.', 'Adverse Events', 'The definitions of an AE or SAE can be found in Appendix 4 (Section 12.4).', 'The investigator and any designees are responsible for detecting, documenting, and', 'reporting events that meet the definition of an AE or SAE and remain responsible for', 'following up AEs that are serious, considered related to the study treatment or the study,', 'or that caused the participant to discontinue the study treatment (see Section 8).', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', 'All SAEs will be collected from the time the informed consent is signed by the', 'participant until the follow up visit at the time points specified in the SoA', '(Table 1).', 'All AEs will be collected from the start of study treatment (randomization visit)', 'until the follow-up visit at the time points specified in the SoA (Table 1).', 'Medical occurrences that begin before the start of study treatment but after', 'obtaining informed consent will be recorded on the Medical History/Current', 'Medical Conditions section of the case report form (CRF) not the AE section.', 'All SAEs must be reported immediately and not more than 24 hrs to the sponsor,', 'as indicated in Appendix 4 (Section 12.4). The investigator will submit any', 'updated SAE data to the sponsor within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'participants. However, if the investigator learns of any SAE, including a death,', 'at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study treatment or study', 'participation, the investigator must promptly notify the sponsor.', 'The method of recording, evaluating, and assessing causality of AEs and SAEs', 'and the procedures for completing and transmitting SAE reports are provided in', 'Appendix 4 (Section 12.4).', '9.2.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AE and/or SAE. Open-ended and', 'non-leading verbal questioning of the participant is the preferred method to inquire about', 'AE occurrence.', '9.2.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All SAEs will be followed until the event is', '37']"
349,page_350,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'resolved, stabilized, otherwise explained, or the participant is lost to follow-up (as', 'defined in Section 8.3). Further information on follow-up procedures is given in', 'Appendix 4.', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to the sponsor of a SAE is essential so', 'that legal obligations and ethical responsibilities towards the safety of', 'participants and the safety of a study treatment under clinical investigation are', 'met.', 'The sponsor has a legal responsibility to notify both the local regulatory', 'authority and other regulatory agencies about the safety of a study treatment', 'under clinical investigation. The sponsor will comply with country-specific', 'regulatory requirements relating to safety reporting to the regulatory authority,', 'Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and', 'investigators.', 'Investigator safety reports must be prepared for suspected unexpected serious', 'adverse reactions (SUSAR) according to local regulatory requirements and', 'sponsor policy and forwarded to investigators as necessary.', 'An investigator who receives an investigator safety report describing a SAE or', 'other specific safety information e.g., summary or listing of SAE) from the', ""sponsor will review and then file it along with the Investigator's Brochure and"", 'will notify the IRB/IEC, if appropriate according to local requirements.', '9.2.5.', 'Cardiovascular and Death Events', 'For any cardiovascular events detailed in Section 12.4 (Appendix 4) and all deaths,', 'whether or not they are considered SAEs, specific Cardiovascular (CV) and Death', 'sections of the CRF will be required to be completed. These sections include questions', 'regarding cardiovascular (including sudden cardiac death) and non-cardiovascular death.', 'The CV CRFs are presented as queries in response to reporting of certain CV MedDRA', 'terms. The CV information should be recorded in the specific cardiovascular section of', 'the CRF within one week of receipt of a CV Event data query prompting its completion.', '9.2.6.', 'Disease-Related Events and/or Disease-Related Outcomes Not', 'Qualifying as SAEs', 'The following disease related events (DREs) are common in participants with COPD and', 'can be serious/life threatening:', 'COPD exacerbations', 'Because these events are typically associated with the disease under study, they will not', 'be reported according to the standard process for expedited reporting of SAEs to GSK', '(even though the event may meet the definition of an SAE) These events will be', ""recorded on the DRE page in the participant's CRF within 72 hours after the investigator"", '38']"
350,page_351,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'becomes aware of the event. These DREs will be monitored by the Safety Review Team', '(SRT) on a routine basis as described in Section 12.3 (Appendix 3).', 'NOTE: However, if either of the following conditions applies, then the event must be', 'recorded and reported as an SAE (instead of a DRE):', ""The event is, in the investigator's opinion, of greater intensity, frequency, or"", 'duration than expected for the individual participant, or', 'The investigator considers that there is a reasonable possibility that the event', 'was related to treatment with the investigational product', '9.2.7.', 'Pregnancy', 'Details of all pregnancies in female participants and female partners of male', 'participants will be collected after the start of study treatment and until 60 hours after', 'the last dose of study treatment.', 'If a pregnancy is reported, the investigator should inform GSK within 24 hours of', 'learning of the pregnancy and should follow the procedures outlined in Section 12.5', '(Appendix 5).', 'Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAEs.', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use. In order to fulfill regulatory reporting obligations', 'worldwide, the investigator is responsible for the detection and documentation of events', 'meeting the definitions of incident or malfunction that occur during the study with such', 'devices.', 'The definition of a Medical Device Incident can be found in Section 12.8 (Appendix 8).', 'NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes', 'outlined in Section 9.2 and Section 12.4 (Appendix 4).', '9.2.8.1.', 'Time Period for Detecting Medical Device Incidents', 'Medical device incidents or malfunctions of the device that result in an incident', 'will be detected, documented, and reported during all periods of the study in', 'which the medical device is used.', 'If the investigator learns of any incident at any time after a participant has been', 'discharged from the study, and such incident is considered reasonably related to', 'a medical device provided for the study, the investigator will promptly notify the', 'sponsor.', '39']"
351,page_352,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'The method of documenting Medical Device Incidents is provided in Section', '12.8 (Appendix 8).', '9.2.8.2.', 'Follow-up of Medical Device Incidents', 'All medical device incidents involving an AE will be followed and reported in', 'the same manner as other AEs (see Section 9.2). This applies to all participants,', 'including those who discontinue study treatment or the study.', 'The investigator is responsible for ensuring that follow-up includes any', 'supplemental investigations as indicated to elucidate the nature and/or causality', 'of the incident.', 'New or updated information will be recorded on the originally completed form', 'with all changes signed and dated by the investigator.', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents to Sponsor', 'Medical device incidents will be reported to the sponsor within 24 hours after', 'the investigator determines that the event meets the protocol definition of a', 'medical device incident.', 'Complete the Medical Device Incident Form for each participant who has a', 'medical device incident with GSK medical devices provided for use during the', 'study period. All of the header information in the form must be completed', 'before sending to GSK. Original documents should be filed in the site study', 'file. A copy of the form must also be sent to the GKS study monitor. Contact', 'details will be included in the SRM. A copy of the form must also be sent to the', 'GSK study monitor. Contact details will be included in the SRM. For incidents', 'fulfilling the definition of an AE or SAE, the appropriate pages of the CRF must', 'be completed. If there is an SAE, the completed CRF pages should be sent', 'together with the Medical Device Incident From. If the participant is withdrawn', 'due to a medical device incident, ensure the Study Conclusion page is', 'completed.', 'The same individual will be the contact for the receipt of medical device reports', 'and SAEs.', '9.2.8.4.', 'Regulatory Reporting Requirements for Medical Device Incidents', 'The investigator will promptly report all incidents occurring with any medical', 'device provided for use in the study in order for the sponsor to fulfill the legal', 'responsibility to notify appropriate regulatory authorities and other entities about', 'certain safety information relating to medical devices being used in clinical', 'studies.', 'The investigator, or responsible person according to local requirements (e.g., the', 'head of the medical institution), will comply with the applicable local regulatory', 'requirements relating to the reporting of incidents to the IRB/IEC.', '40']"
352,page_353,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.3.', 'Treatment of Overdose', 'For this study, any dose of study treatment 4 tablets in a day will be considered an', 'overdose.', 'GSK does not recommend specific treatment for an overdose.', 'In the event of an overdose, the investigator/treating physician should:', '1. Contact the Medical Monitor immediately.', '2. Closely monitor the participant for AE/SAE and laboratory abnormalities until study', 'treatment can no longer be detected systemically (at least 3 days).', '3. Obtain a plasma sample for PK analysis as soon as possible from the date of the last', 'dose of study treatment if requested by the Medical Monitor (determined on a case-', 'by-case basis).', '4. Document the quantity of the excess dose as well as the duration of the overdosing in', 'the CRF.', 'Decisions regarding dose interruptions or modifications will be made by the investigator', 'in consultation with the Medical Monitor based on the clinical evaluation of the', 'participant.', '9.4.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SoA.', '9.4.1.', 'Physical Examinations', 'A complete physical examination will include, at a minimum, assessments of the', 'skin, cardiovascular, respiratory, gastrointestinal and neurological systems.', 'Height and weight will also be measured and recorded.', 'A brief physical examination will include, at a minimum, assessments of the', 'skin, lungs, cardiovascular system, and abdomen (liver and spleen).', 'Investigators should pay special attention to clinical signs related to previous', 'serious illnesses.', '9.4.2.', 'Vital Signs', 'Vital signs will be measured in a semi-supine position after 5 minutes rest and will', 'include systolic and diastolic blood pressure, pulse, and respiratory rate. Three readings', 'of blood pressure and pulse will be taken. The first reading should be rejected. The', 'second and third readings should be averaged to give the measurement to be recorded in', 'the CRF. A single measurement of respiratory rate is adequate.', '41']"
353,page_354,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.4.3.', 'Electrocardiograms', 'For participant screening and pre-dose on Day 1, triplicate ECG measurements should be', 'collected. For all subsequent ECG assessments, single measurements are to be collected.', '12-lead ECG will be obtained as outlined in the SoA using an ECG machine that', 'automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.', 'Refer to Section 8.1.2 for QTc withdrawal criteria and additional QTc readings that may', 'be necessary.', 'At each time point at which triplicate ECG are required, 3 individual ECG tracings', 'should be obtained as closely as possible in succession, but no more than 2 minutes apart.', 'The full set of triplicates should be completed in less than 10 minutes.', '9.4.4.', 'Clinical Safety Laboratory Assessments', 'Refer to Section 12.2 (Appendix 2) for the list of clinical laboratory tests to be performed', 'and to the SoA for the timing and frequency.', 'The investigator must review the laboratory report, document this review, and record', 'any clinically relevant changes occurring during the study in the AE section of the', 'CRF. The laboratory reports must be filed with the source documents. Clinically', 'significant abnormal laboratory findings are those which are not associated with the', 'underlying disease, unless judged by the investigator to be more severe than', ""expected for the participant's condition."", 'All laboratory tests with values considered abnormal and clinically significant during', 'participation in the study or within 3 days after the last dose of study treatment', 'should be repeated until the values return to normal or baseline or are no longer', 'considered significantly abnormal by the investigator or medical monitor.', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the investigator, the etiology should be identified and the sponsor', 'notified.', 'All protocol-required laboratory assessments, as defined in Section 12.2, must be', 'conducted in accordance with the laboratory manual and the SoA (Table 1).', 'If laboratory values from non-protocol specified laboratory assessments performed at', ""the institution's local laboratory require a change in participant management or are"", 'considered clinically significant by the investigator (e.g., SAE or AE), then the', 'results must be recorded in the CRF.', '9.4.5.', 'Pneumonia', 'All suspected pneumonias will require confirmation as defined by the presence or new', 'infiltrate(s) on chest x-ray AND at least 2 of the following signs and symptoms:', 'Increased cough', 'Increased sputum purulence (colour) or production', 'Auscultatory findings of adventitious sounds (e.g. egophony, bronchial breath', 'sounds, rales, etc.)', '42']"
354,page_355,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Dyspnea or tachypnea', 'Fever (oral temperature > 37.5 °C)', 'Elevated white blood cell count (WBC) (> 10 X 109/L or > 15% immature', 'forms)', 'Hypoxemia (Hb O2 saturation < 88% or at least 2% lower than baseline value)', 'All pneumonias must be captured on the AE/SAE page of the eCRF and on the', 'pneumonia page of the eCRF.', 'The Investigator and site staff should remain vigilant for the possible development of', 'pneumonia in participants as the clinical features of such infections overlap with the', 'symptoms of COPD exacerbations. For all suspected cases of pneumonia, Investigators', 'are strongly encouraged to confirm the diagnosis (this includes obtaining a chest x-ray)', 'and to initiate appropriate therapy as promptly as possible. Any microbiology or virology', 'tests performed to determine etiology should be reported on the pneumonia eCRF page.', 'All diagnoses of pneumonia (radiographically confirmed or unconfirmed) must be', 'reported as an AE or SAE (if applicable).', '9.5.', 'Pharmacokinetics', 'Pharmacokinetic parameters are not evaluated in this study.', '9.6.', 'Pharmacodynamics', 'Pharmacodynamic parameters are not evaluated in this study.', '9.7.', 'Genetics', 'A 6 mL whole blood sample for DNA isolation will be collected from participants who', 'have consented to participate in the genetics analysis component of the study.', 'Participation in the genetics analysis is optional. Participants who do not wish to', 'participate in the genetic research may still participate in the study.', 'See Section 12.6 (Appendix 6) for Information regarding genetic research. Details on', 'procedures for collection and shipment and destruction of these samples can be found in', 'the SRM.', '9.8.', 'Biomarkers', 'Collection of samples for biomarker research is also part of this study. The following', 'samples for biomarker research will be collected from all participants in this study as', 'specified in the SoA:', 'peripheral venous blood samples for the preparation of serum and plasma', 'Samples will be tested for biomarkers that are indicative of inflammation (i.e. CRP),', 'extracellular matrix turnover and remodelling to evaluate their association with the', '43']"
355,page_356,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'observed clinical responses or to help understand the underlying biological responses to', 'danirixin.', ""In addition, with the participant's consent, samples will be stored and may be used to"", 'investigate additional biomarkers thought to play a role in COPD disease progression or', 'to evaluate their association with observed clinical responses to danirixin', 'Samples also may be used for research to develop methods or support identification of', 'prognostic/diagnostic biomarkers associated with clinical outcomes in COPD and related', 'diseases.', '9.9.', 'Health Economics OR Medical Resource Utilization and', 'Health Economics', 'Health Economics/Medical Resource Utilization and Health Economics parameters are', 'not evaluated in this study.', '10.', 'STATISTICAL CONSIDERATIONS', 'The objective of this study is to investigate the effect of danirixin HBr 35mg tablets on', 'COPD disease progression. There are no formal hypothesis tests associated with this', 'objective and no formal significance tests. The information acquired from this study will', 'primarily be used to assess whether or not danirixin impacts disease progression and to', 'quantify the effect that danirixin has on disease progression, specifically change in lung', 'function as measured by FEV1 decline and change in health-related quality of life as', 'measured by SGRQ total score to further support disease understanding and future', 'studies.', '10.1.', 'Sample Size Determination', 'Sample size is based primarily on feasibility for this study. Since there is much', 'uncertainty around the magnitude of the difference in the decline in FEV1 and change in', 'SGRQ along with the between-subject variability for the specific patient population, the', 'proposed sample size is unavoidably imprecise. Sample size may be adjusted using the', 'predictions of final study outcome based on simulations and possible interim analyses. It', 'is anticipated that screening 130 participants will allow for approximately 100', 'participants to enrol.', 'In order to observe the effect of different sample sizes, various simulations were done to', 'assess the impact of sample sizes of 50, 100, 150 and 200 with a 1:1 allocation to each', 'treatment group [Table 3]. The assumed variability for rate of decline in FEV1 and', 'change in SGRQ is 25 and 10, respectively. The correlation between rate of decline in', 'FEV1 and change in SGRQ is assumed to be -0.2. [Nagai, 2015]', '44']"
356,page_357,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Table 3', 'Assumptions used for the Simulations', 'Treatment Effect Assumptions', 'Variability Assumptions', 'Sample Size', '(ÔFEV1, ÔSGRQ)', '(OFEV1, OSGRO)', 'Null', '(0,0)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 1', '(5,-1)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 2', '(5,0)', '(25,10)', 'N=(50,100,150,200)', 'Alternate 3', '(0,-1)', '(25,10)', 'N=(50,100,150,200}', 'Data from a bivariate normal distribution were simulated under the four different', 'treatment effect assumptions for samples sizes of 50, 100, 150, and 200. The samples', 'from the posterior probability distribution from the MCMC approximation were divided', 'into four regions based on OFEVI and ÔSGRQ treatment effect cut-off values; SFEVI>O and', 'ÔSGRQ <0, and ÔSGRQ>0, OFEV1° <0 and SSGRQ and OFEVI<C and SSGRO>O. Based', 'on a 70% threshold, the proportion of the 1000 simulations meeting the requirement', '& > 70% were considered a success based on the joint definition', '[Figure 2, Table 4]. If & ÔSGRQ<0) < 70%, success could further be defined', 'based on each endpoint independently where P(OFEV1 > 0) > 80% or P(6SGRQ 0) > 80%.', 'Figure 2', 'Total Probability of Success', '80', 'Alt 1: (5,-1)', '80', 'Alt 2: (5,0)', 'Alt 3: (0,-1)', 'Null: (0,0)', 'OF', '60', '50', '40', '30', '50', '100', '150', '200', 'Sample Size', 'Table 4', 'Total Probability of Success (Figure 2)', 'N=50', 'N=100', 'N=150', 'N=200', '(5,-1)', '57.4', '68.5', '75.1', '81.4', '(5,0)', '52.5', '62.6', '67.8', '74.5', '(0,-1)', '42.6', '46.2', '48.9', '53.0', '(0,0)', '34.9', '33.9', '33.3', '31.5', '45']"
357,page_358,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Figure 3', 'Half Width of the 95% Confidence Interval of OFEV1 Point Estimate', 'DL', '13.8', '2L', '00', '9.7', '8.0', '8', '6.9', '6', '50', '100', '150', '200', 'Sample Size', 'Figure 4', 'Half Width of the 95% Confidence Interval of 5SGRQ Point Estimate', '6', '5.5', '5', '&', '3,9', 'm', '3.2', '2.7', '2', '50', '100', '150', '200', 'Sample Size', 'Based on the simulations, under the assumption of an expected treatment difference of', '(5,-1) which is the most probable scenario, the marginal increase for the total probability', 'of success is greatest when increasing the sample size from 50 to 100 (Figure 2). The half', 'widths of the 95% CI of the point estimate of the marginal treatment differences for FEV1', '(Figure 3) and SGRQ (Figure 4) have the greatest reduction from a sample size of 50 to', '100. A sample size of 100 will allow for an adequate level of confidence in the study', 'success while also considering the precision of the treatment effect differences.', '46']"
358,page_359,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.2.', 'Randomization', 'Participants will be randomized equally (1:1) to the two treatment arms of placebo and 35', 'mg danirixin HBr. Randomization will be stratified by smoking status (current VS.', 'former).', '10.3.', 'Populations for Analyses', 'For purposes of analysis, the following populations are defined:', 'Population', 'Description', 'All Participants', 'This population will comprise all participants screened and', 'for whom a record exists on the study database and will be', 'used for the tabulation and listing of reasons for withdrawal', 'before randomization and listings of AEs and SAEs for', 'nonrandomized participants.', 'Intent To Treat (ITT)', 'This population will comprise all participants randomized to', 'treatment and who received at least one dose of study', 'medication. This will constitute the primary population for all', 'analyses of efficacy and safety. Outcomes will be reported', 'according to the randomized treatment allocation.', 'Per-Protocol (PP)', 'This population will comprise of all patients in the ITT', 'Population', 'population who are not major protocol violators.', 'Safety', 'All randomized participants who take at least 1 dose of study', 'treatment. Participants will be analyzed according to the', 'treatment they actually received.', '10.4.', 'Statistical Analyses', 'Treatment comparisons using all endpoints will be made using appropriate statistical', 'techniques. Analysis methods for key endpoints are described below. Main analysis will', 'use ITT unless noted. Further details on all analyses will be described in the reporting and', 'analysis plan (RAP).', '10.4.1.', 'Efficacy Analyses', 'The total probability of success will be defined as a combination of a joint and', 'conditional statement. The joint probability of success will be defined as the probability', 'of the difference in the rate of decline in FEV1 between danirixin and placebo is greater', 'than or equal to 0 and the difference in the change in SGRQ total score from baseline', 'between danirixin and placebo is less than or equal to 0 is greater than 70%. If the joint', 'probability of success is less than 70%, success can further be defined based on each', 'endpoint independently, where either the difference in the rate of decline in FEV1 is', '47']"
359,page_360,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'greater than or equal to 0 is greater than 80% or the difference in the change in SGRQ', 'total score is less than or equal to 0 is greater than 80%.', 'Total PoS = P(SFEV, SSGRQ 0) 70%', '+ P (OFEV1 SSGRQ 0) < 70%', '+P (65GRQ 0 & SSGRQ 0) < 70%', 'Endpoint', 'Statistical Analysis Methods', 'Primary', 'Rate of decline in FEV1 and change from baseline in SGRQ total score', 'Exploratory', 'Will be described in detail in the RAP', '48']"
360,page_361,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Lung Function Decline: Rate of Decline of FEV1 (mL/yr)', 'The rate of decline of FEV1 will be derived from a repeated measures random', 'coefficients model. Post-baseline FEV will be modelled including terms for age, sex,', 'smoking status, FEV1 at baseline, and BMI along with treatment group, time and', 'treatment by time interaction as fixed effects. Subject will be a random effect. Time will', 'be defined as the number of days since start of treatment. Only FEV values measured', 'after baseline will be used in the model. Based on the results of previous studies, the', 'study team will determine the time point at which post-baseline spirometry assessments', 'will be included in the model to account for the initial treatment response. The estimate', 'of the rate of FEV1 decline will be the slope of the parameter estimate of the treatment by', 'time interaction term in the model. Contrasts will be calculated for the difference in', 'treatment by time interaction between danirixin and placebo treatment groups to estimate', 'the treatment difference.', 'FEV1 = Treatment group + age + sex +smoking status+FEV1_BL+BMI+ time +', '-', 'treatment*time', 'The rate of decline for each subject, the estimate of the slope parameter of the treatment', 'by time interaction term, will be used as a co-primary endpoint for the joint analysis', 'using both FEV1 and SGRQ.', 'HRQoL: SGRQ', 'A co-primary endpoint of interest is change in SGRQ total score (derived from SGRQ-C)', 'from baseline. Change in SGRQ total scores from baseline will be derived using a mixed', 'model with repeated measures (MMRM) including fixed effects of treatment group, age,', 'sex, smoking status, BMI, baseline SGRQ score, time as a categorical variable and a', 'treatment by time interaction term. Subject will be a random effect. Estimated treatment', 'differences at the end of one year will be obtained. The difference of the least square', 'mean change from baseline at 12 months will be derived. The adjusted SGRQ total score', 'change from baseline will used as the other co-primary endpoint for the joint analysis', 'using both FEV1 and SGRQ.', 'Joint Analysis', 'The joint analysis will use the ITT population with all available FEV1 rate of decline and', 'change in SGRQ data.', 'The rate of decline (the slope parameter from the random coefficients model) of FEV1,', 'along with the change in SGRQ from the MMRM model will be extracted for each', 'subject. These values will then be used to obtain MCMC approximations of the joint', 'posterior distribution of the treatment differences between FEV1 decline and change in', 'SGRQ between the danirixin and placebo groups. Based on the samples from the', 'posterior distribution, the proportion of samples falling within certain treatment', 'difference regions will be calculated and the probability of success will be derived.', '49']"
361,page_362,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.4.2.', 'Safety Analyses', 'All safety endpoints will be tabulated or plotted by treatment group and will be', 'performed on the Safety Population. Further details will be described in the RAP.', '10.4.3.', 'Other Analyses', 'Exploratory biomarker analyses will be described in the RAP.', '10.4.4.', 'Interim Analyses', 'Conducting an interim analysis or futility assessment may not be practical due to an', 'expected fast recruitment period. By the time enough data will accumulate for any', 'meaningful interim analysis to support changes to the study design, recruitment of all', 'study participants will have concluded. However, if recruitment takes a longer than', 'anticipated, an interim analysis to reassess the variability assumptions, estimate the', 'probability of success at the end of study, and confirm the directionality of the endpoints', 'may be conducted.', 'The RAP will describe the potential interim analyses in greater detail.', '50']"
362,page_363,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '11.', 'REFERENCES', 'Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD.', 'Eur Respir J. 2004;23:932-946.', 'Chapman RW, Philips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2', 'antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009; (121:55-68.', 'FDA. Guidance for Industry. Center for Drug Evaluation and Research, United States', 'Food and Drug Administration; 2009. Drug-induced liver injury: premarketing clinical', 'evaluation.', 'GlaxoSmithKline Document Number 2013N180289 03 Study ID 200163. A two part,', 'phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability,', 'pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin', '(GSK1325756) in symptomatic COPD subjects with mild to moderate airflow limitation', 'at risk for exacerbations. Report Date 05-Aug-2015.', 'GlaxoSmithKline Document Number 2014N205875 00 Study ID 201682. A', 'randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and', 'clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with', 'acute, uncomplicated influenza. Report Date 21-Nov-2014.', 'GlaxoSmithKline Document Number 2015N248339 00 Study ID 201037. A single', 'centre, open-label, 5-period, cross over, randomized study in healthy elderly subjects to', 'evaluate the relative bioavailability of hydrobromide salt and free base immediate release', 'tablet formulations of danirixin in the fed state, and to evaluate the effect of food and', 'gastric acid secretion suppression on danirixin pharmacokinetics following administration', 'of hydrobromide salt tablets. Report Date 01-Jun-2016.', ""GlaxoSmithKline Document Number YM2010/00163/07. Danirixin Investigator's"", 'Brochure, Version 09. Report Date 14-Apr-2016.', 'GOLD. From the Global Strateby for the Diagnosis, Management and Prevention of', 'COPD, Global Initiative for Chronic Obstructive Lung Disease. Global Initiative for', 'Chronic Obstructive Lung Disease, Available from: http://www.copdgold.org; 2016.', 'Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, et al. SCH527123,', 'a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur', 'Respir J. 2010;35:564-570.', 'Hurst JA, Vestbo J, Anzueto A, Locantore N, Mullerova, Tal-Singer R, et al.', 'Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med.', '2010;363:1128-1138.', 'Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy NK. Development and first', 'validation of the COPD Assessment Test (CAT). Eur Respir J. 2009;34:648-654.', '51']"
363,page_364,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R et al. Tests of the', 'responsiveness of the chronic obstructive pulmonary disease (COPD) assessment test', '(CAT) following acute exacerbation and pulmonary rehabilitation. Chest. 2012;142:134-', '140.', 'Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health', ""status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev"", 'Respir Dis. 1992;145:1321-1327.', 'Lazaar AL, Sweeney LE, MacDonald AJ et al. SB-656933, a novel CXCR2 selective', 'antagnoist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation', 'in humans. Br J Clin Pharmacol. 2011;72:282-293.', 'Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology.', '2016;21:14-23.', 'Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002', 'to 2030. PLoS Med. 2006;3:e442.', 'Meguro M, Barley EA, Spencer S et al. Development and validation of an improved', 'COPD-specific version of the St. George Respiratory Questionnaire. Chest.', '2007;132:456-463.', 'Miller B, Tal-Singer R, Lazaar A, Leidy N, Watz H, Collins D, et al. Assessing', 'symptoms in COPD: use of the E-RS daily digital diary in early drug development. Eur', 'Respir J. 2016;48(S60): PA1047.', 'Nagai, K., Makita, H., Suzuki, M., Shimizu, K., Konno, S., Ito, Y. M., & Nishimura, M.', 'Differential changes in quality of life components over 5 years in chronic obstructive', 'pulmonary disease patients. International Journal of Chronic Obstructive Pulmonary', 'Disease. 2015; 10: 745-757.', 'Nair P, Gaga M, Zervas E et al. Safety and efficacy of a CXCR2 antagnoist in patients', 'with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical', 'trial. Clin Exp Allergy. 2012;42:1097-2103', ""O'Byrne PM, Metev H, Puu M et al. Efficacy and safety of a CXCR2 antagonist,"", 'AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind,', 'placebo-controlled trial. Lancet Respir Med. 2016;4:797-806.', 'Rennard SI, Dale DC, Donohue JF et al. CXCR2 antagonist MK-7123 - a phase 2 proof-', 'of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med.', '2015;191:1001-1011', 'Vastava S, Thakur D, Sharma S, Punekar YS. Systematic review of humanistic and', 'economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoecon.', '2015;33:467-488.', '52']"
364,page_365,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindate S, et al.', 'Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J', 'Med. 2016;375:1253-1260.', 'Watz H, Kirsten A, Pedersen F, Goldmann T, Stellmacher F, Uddin M, et al. Neutrophils', 'in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist', 'AZD5069 - an explorative study in neutrophilic asthma. Eur Respir J.', '2016;48(S60): PA4892.', 'Woodruff PG, Barr RG, Bleecker F, Christenson SA, Couper D, Curtis JL, et al. Clinical', 'significance of symptoms in smokers with preserved pulmonary function. N Engl J Med.', '2016;374:1811-1821.', '53']"
365,page_366,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.', 'APPENDICES', '12.1.', 'Appendix 1: Abbreviations and Trademarks', 'List of Abbreviations', 'AE', 'Adverse Event', 'ALT', 'Alanine Aminotransferase (SGPT)', 'AST', 'Aspartate Aminotransferase (SGOT)', 'ATS', 'American Thoracic Society', 'AUC', 'Area under the concentration-time curve', 'BfS', 'Federal Office of Radiation Protection (Germany)', 'BID', 'Twice daily', 'BRCP', 'Breast cancer resistance protein', 'BUN', 'Blood urea nitrogen', 'CAT', 'COPD Assessment Test', 'CD', 'Cluster of differentiation', 'CFR', 'Code of Federal Regulations (United States)', 'CI', 'Confidence Interval', 'CID', 'Clinically important deterioration', 'CIL', 'Clinical Investigation Leader', 'Cmax', 'Maximum observed concentration', 'CONSORT', 'Consolidated standards of reporting trials', 'COPD', 'Chronic Obstructive Pulmonary Disease', 'CRF', 'Case Report Form', 'CT', 'Computed Tomography', 'CV', 'Cardiovascular', 'CXCR', 'CXC Chemokine Receptor', 'CXR', 'Chest X-Ray', 'dL', 'Deciliter', 'DNA', 'Deoxyribonucleic acid', 'DNX', 'Danirixin', 'DRE', 'Disease Related Event', 'E0', 'Effect at zero concentration', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic Case Report Form', 'ED50', 'Dose causing 50% of the maximum achievable', 'response', '54']"
366,page_367,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'EMA', 'European Medicines Agency', 'Emax', 'Maximum response achievable', 'eMDI', 'Electronic metered dose inhaler', 'EW', 'Early Withdrawal', 'FDA', 'Food and Drug Administation (United States)', 'FEV1', 'Forced Expiratory Volume in one second', 'FVC', 'Forced Vital Capacity', 'FSH', 'Follicle Stimulation Hormone', 'GCP', 'Good Clinical Practice', 'GCSP', 'Global Clinical Safety and Pharmacovigilance', 'GGT', 'Gamma glutamyltransferase', 'GOLD', 'Global Initiative for Chronic Obstructive Lung', 'Disease', 'GSK', 'GlaxoSmithKline', 'HBsAG', 'Hepatitis B surface antigen', 'HCRU', 'Healthcare Resource Utilization', 'hCG', 'Human chorionic gonadotrophin', 'HDPE', 'High density polyethylene', 'Hep B', 'Hepatitis B', 'Hep C', 'Hepatitis C', 'hsCRP', 'High sensitivity C-reactive protein', 'HIV', 'Human immunodeficiency virus', 'HPLC', 'High performance liquid chromatography', 'IB', ""Investigator's Brochure"", 'ICF', 'Informed Consent Form', 'International Conference on Harmonization of', 'ICH', 'Technical Requirements for Registration of', 'Pharmaceuticals for Human Use', 'ICS', 'Inhaled corticosteroid', 'IDMC', 'Independent Data Monitoring Committee', 'IEC', 'Independent Ethics Committee', 'IgG', 'Immunoglobulin G', 'IgM', 'Immunoglobulin M', 'INR', 'International normalized ratio', 'IP', 'Investigational Product', 'IRB', 'Institutional Review Board', 'ITT', 'Intent to treat', '55']"
367,page_368,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'IUD', 'Intrauterine device', 'IUS', 'Intrauterine hormone releasing system', 'IVIVT', 'In vitro In vivo Translation', 'IWRS', 'Interactive Web Response System', 'kg', 'Kilogram', 'L', 'Liter', 'LABA', 'Long acting ß2 receptor agonist', 'LAMA', 'Long acting muscarinic receptor antagonist', 'LH', 'Leutinizing Hormone', 'MCV', 'Mean corpuscular volume', 'MCH', 'Mean corpuscular hemoglobin', 'MCHC', 'Mean corpuscular hemoglobin count', 'MDI', 'Metered dose inhaler', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mg', 'Milligrams', 'mL', 'Milliliter', 'MM', 'Medical monitor', 'MSDS', 'Material Safety Data Sheet', 'msec', 'Millisecond', 'NOAEL', 'No observed adverse effect level', 'O2', 'Oxygen', 'PK', 'Pharmacokinetics', 'PR interval; duration in milliseconds from the', 'PR', 'beginning of the P wave to onset of ventricular', 'depolarization (R)', 'PRO', 'Patient Reported Outcome', 'PTS', 'Platform Technology and Science', 'QRS interval; duration in milliseconds of the QRS', 'QRS', 'complex', 'QT interval; duraction in milliseconds between the', 'QT', 'start of the Q wave and the end of the T wave', 'QT interval corrected for heart rate (Friderica', 'QTcF', 'formula)', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cells', 'RNA', 'Ribonucleic acid', 'SABA', 'Short-acting ß2 Receptor Agonist', 'SAE', 'Serious Adverse Event', '56']"
368,page_369,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'SAMA', 'Short-acting Muscarinic Receptor Agonist', 'SGRQ', ""St George's Respiratory Questionnaire"", 'SGRQ-C', 'SGRQ-C for COPD patients', 'SRM', 'Study Reference Manual', 'SRT', 'Safety Review Team', 'SOA', 'Schedule of Activities', 'SUSAR', 'Suspected unexpected serious adverse reaction', 't¹/2', 'Terminal phase half-life', 'tmax', 'Time to reach Cmax', 'TPR', 'Third Party Resourcing', 'ULN', 'Upper limit of normal', 'g', 'Microgram', 'VT', 'Ventricular tachycardia', 'WBC', 'White blood cells', 'WOCBP', 'Women of child bearing potential', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'CAT', 'Combivent', 'Duoneb', '57']"
369,page_370,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.2.', 'Appendix 2: Clinical Laboratory Tests', 'The tests detailed in Table 5 (Protocol-Required Safety Laboratory', 'Assessments) will be performed by the central laboratory, except as noted.', 'Local laboratory results are only required in the event that the central laboratory', 'results are not available in time for either study treatment administration and/or', 'response evaluation. If a local sample is required, it is important that the sample', 'for central analysis is obtained at the same time. Additionally, if the local', 'laboratory results are used to make either a study treatment decision or response', 'evaluation, the results must be entered into the CRF.', 'Protocol-specific requirements for inclusion or exclusion of participants are', 'detailed in Section 6.', 'Additional tests may be performed at any time during the study as determined', 'necessary by the investigator or required by local regulations.', 'Table 5', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Specific gravity', 'Urinalysis', '58']"
370,page_371,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as', 'needed for women of childbearing potential)²', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody³', 'All study-required laboratory assessments will be performed by a central', 'laboratory, with the exception of urine testing', 'NOTES :', '1.', 'Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', ""(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or"", 'cirrhosis).', '2. Local urine hCG testing will be standard for the protocol unless serum testing is required by local', 'regulation or IRB/IEC.', '3.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Laboratory results that could unblind the study will not be reported to investigative sites', 'or other blinded personnel until the study has been unblinded.', '59']"
371,page_372,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.3.', 'Appendix 3: Study Governance Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with:', 'Consensus ethical principles derived from international guidelines', 'including the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical', 'Guidelines', 'Applicable ICH Good Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other', 'relevant documents (eg, advertisements) must be submitted to an IRB/IEC by', 'the investigator and reviewed and approved by the IRB/IEC before the study is', 'initiated.', 'Any amendments to the protocol will require IEC/IRB approval before', 'implementation of changes made to the study design, except for changes', 'necessary to eliminate an immediate hazard to study participants.', 'The investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC', 'annually or more frequently in accordance with the requirements, policies,', 'and procedures established by the IRB/EC', 'Notifying the IRB/IEC of SAE or other significant safety findings as', 'required by IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 CFR, ICH guidelines, the IRB/IEC, European', 'regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', 'Financial Disclosure', 'Investigators and sub-investigators will provide the sponsor with sufficient, accurate', 'financial information as requested to allow the sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate regulatory authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study.', '60']"
372,page_373,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Informed Consent Process', 'The investigator or his/her representative will explain the nature of the study to', 'the participant or his/her legally authorized representative and answer all', 'questions regarding the study.', 'Participants must be informed that their participation is voluntary. Participants', 'or their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', ""A copy of the ICF(s) must be provided to the participant or the participant's"", 'legally authorized representative.', 'Participants who are rescreened are required to sign a new ICF.', 'The ICF may contain a separate section that addresses the use of remaining', 'mandatory samples for optional exploratory research in accordance with SOP-', 'GSKF-410. The investigator or authorized designee will explain to each', 'participant the objectives of the exploratory research. Participants will be told that', 'they are free to refuse to participate and may withdraw their consent at any time', 'and for any reason during the storage period. A separate signature will be required', ""to document a participant's agreement to allow any remaining specimens to be"", 'used for exploratory research. Participants who decline to participate will not', 'provide this separate signature.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', '61']"
373,page_374,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Committees Structure', 'A study charter will be created to describe important governance aspects while the', 'study is being conducted.', 'The SRT will include the Safety Development Leader, GCSP scientist, MM, CIL', 'and study statistician but will extend to other functions as requied. The SRT will', 'provide a proactive, aggregate and holistic evaluation of the safety data of', 'danirixin. Further details are included in the SRT charter.', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with', 'International Committee of Medical Journal Editors authorship requirements.', 'Dissemination of Clinical Study Data', 'This study will be registered and study information from this protocol will be', 'posted on publicly available clinical trial registers before enrolment of study', 'participants begins.', 'The results summary of this study will be posted to the GSK Clinical Study', 'Register and other publicly available clinical trial registers within 8 months of', 'the primary study completion date.', 'A manuscript reporting the study results will be submitted to a peer reviewed', ""journal within 18 months of the last participant's last visit."", 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic', 'CRF unless transmitted to the sponsor or designee electronically (eg, laboratory', 'data). The investigator is responsible for verifying that data entries are accurate', 'and correct by physically or electronically signing the CRF.', 'The investigator must maintain accurate documentation (source data) that', 'supports the information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', '62']"
374,page_375,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the CRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the investigator for 25 years after study completion', 'unless local regulations or institutional policies require a longer retention period.', 'No records may be destroyed during the retention period without the written', 'approval of the sponsor. No records may be transferred to another location or', 'party without written notification to the sponsor.', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', ""investigator's site."", 'Data reported on the CRF or entered in the eCRF that are transcribed from', 'source documents must be consistent with the source documents or the', 'discrepancies must be explained. The investigator may need to request previous', 'medical records or transfer records, depending on the study. Also, current', 'medical records must be available.', 'Definition of what constitutes source data can be found in the SRM.', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed.', 'The investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the sponsor or investigator may include', 'but are not limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', ""IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines"", 'Inadequate recruitment of participants by the investigator', 'Discontinuation of further study treatment development', '63']"
375,page_376,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', 'Definition of AE', 'AE Definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of a study treatment, whether or not considered related to the', 'study treatment.', 'NOTE: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study treatment.', 'Events Meeting the AE Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)', 'or other safety assessments (eg, ECG, radiological scans, vital signs measurements),', 'including those that worsen from baseline, considered clinically significant in the', 'medical and scientific judgment of the investigator (ie, not related to progression of', 'underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study treatment administration even', 'though it may have been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'treatment or a concomitant medication. Overdose per se will not be reported as an', 'AE/SAE unless it is an intentional overdose taken with possible suicidal/self-', 'harming intent. Such overdoses should be reported regardless of sequelae.', '""Lack of efficacy"" or ""failure of expected pharmacological action"" per se will not be', 'reported as an AE or SAE. Such instances will be captured in the efficacy', 'assessments. However, the signs, symptoms, and/or clinical sequelae resulting from', 'lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE', 'or SAE.', 'The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be', 'reported as AE or SAE if they fulfill the definition of an AE or SAE. Also, ""lack of', 'efficacy"" or ""failure of expected pharmacological action"" constitutes an AE or SAE.', '64']"
376,page_377,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Events NOT Meeting the AE Definition', 'Any clinically significant abnormal laboratory findings or other abnormal safety', 'assessments which are associated with the underlying disease, unless judged by the', ""investigator to be more severe than expected for the participant's condition."", 'The disease/disorder being studied or expected progression, signs, or symptoms of', 'the disease/disorder being studied, unless more severe than expected for the', ""participant's condition."", 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that', 'leads to the procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or', 'convenience admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Definition of SAE', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious', 'conditions are met (eg, hospitalization for signs/symptoms of the disease under study,', 'death due to progression of disease).', 'A SAE is defined as any untoward medical occurrence that, at any dose:', 'a.', 'Results in death', 'b.', 'Is life-threatening', 'The term ""life-threatening\' in the definition of \'serious\' refers to an event in which the', 'participant was at risk of death at the time of the event. It does not refer to an event,', 'which hypothetically might have caused death, if it were more severe.', 'c. Requires inpatient hospitalization or prolongation of existing hospitalization', 'In general, hospitalization signifies that the participant has been detained (usually', 'involving at least an overnight stay) at the hospital or emergency ward for observation', ""and/or treatment that would not have been appropriate in the physician's office or"", 'outpatient setting. Complications that occur during hospitalization are AE. If a', 'complication prolongs hospitalization or fulfills any other serious criteria, the event is', 'serious. When in doubt as to whether ""hospitalization"" occurred or was necessary, the AE', 'should be considered serious.', 'Hospitalization for elective treatment of a pre-existing condition that did not worsen from', 'baseline is not considered an AE.', 'd. Results in persistent disability/incapacity', ""The term disability means a substantial disruption of a person's ability to conduct"", '65']"
377,page_378,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,', 'and accidental trauma (eg, sprained ankle) which may interfere with or prevent', 'everyday life functions but do not constitute a substantial disruption.', 'e.', 'Is a congenital anomaly/birth defect', 'f.', 'Other situations:', 'Medical or scientific judgment should be exercised in deciding whether SAE', 'reporting is appropriate in other situations such as important medical events that may', 'not be immediately life-threatening or result in death or hospitalization but may', 'jeopardize the participant or may require medical or surgical intervention to prevent', 'one of the other outcomes listed in the above definition. These events should usually', 'be considered serious.', 'Examples of such events include invasive or malignant cancers, intensive treatment', 'in an emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', 'Definition of Cardiovascular Events', 'Cardiovascular Events (CV) Definition:', 'Investigators will be required to fill out the specific CV event page of the CRF for the', 'following AEs and SAEs:', 'Myocardial infarction/unstable angina', 'Congestive heart failure', 'Arrhythmias', 'Valvulopathy', 'Pulmonary hypertension', 'Cerebrovascular events/stroke and transient ischemic attack', 'Peripheral arterial thromboembolism', 'Deep venous thrombosis/pulmonary embolism', 'Revascularization', '66']"
378,page_379,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Recording AE and SAE', 'AE and SAE Recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (eg, hospital progress notes, laboratory, and diagnostics reports)', 'related to the event.', 'The investigator will then record all relevant AE/SAE information in the CRF', ""It is not acceptable for the investigator to send photocopies of the participant's"", 'medical records to GSK in lieu of completion of the GSK/AE/SAE CRF page.', 'There may be instances when copies of medical records for certain cases are', 'requested by GSK. In this case, all participant identifiers, with the exception of the', 'participant number, will be redacted on the copies of the medical records before', 'submission to GSK.', 'The investigator will attempt to establish a diagnosis of the event based on signs,', 'symptoms, and/or other clinical information. Whenever possible, the diagnosis (not', 'the individual signs/symptoms) will be documented as the AE/SAE.', 'Assessment of Intensity', 'The investigator will make an assessment of intensity for each AE and SAE reported', 'during the study and assign it to 1 of the following categories:', 'Mild: An event that is easily tolerated by the participant, causing minimal discomfort', 'and not interfering with everyday activities.', 'Moderate: An event that causes sufficient discomfort and interferes with normal', 'everyday activities.', 'Severe: An event that prevents normal everyday activities. An AE that is assessed as', 'severe should not be confused with an SAE. Severe is a category utilized for rating', 'the intensity of an event; and both AE and SAE can be assessed as severe.', 'An event is defined as ""serious\' when it meets at least 1 of the predefined outcomes', 'as described in the definition of an SAE, NOT when it is rated as severe.', 'Assessment of Causality', 'The investigator is obligated to assess the relationship between study treatment and', 'each occurrence of each AE/SAE.', 'A ""reasonable possibility"" of a relationship conveys that there are facts, evidence,', 'and/or arguments to suggest a causal relationship, rather than a relationship cannot', 'be ruled out.', 'The investigator will use clinical judgment to determine the relationship.', '67']"
379,page_380,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Alternative causes, such as underlying disease(s), concomitant therapy, and other', 'risk factors, as well as the temporal relationship of the event to study treatment', 'administration will be considered and investigated.', ""The investigator will also consult the Investigator's Brochure (IB) and/or Product"", 'Information, for marketed products, in his/her assessment.', 'For each AE/SAE, the investigator must document in the medical notes that he/she', 'has reviewed the AE/SAE and has provided an assessment of causality.', 'There may be situations in which an SAE has occurred and the investigator has', 'minimal information to include in the initial report to GSK. However, it is very', 'important that the investigator always make an assessment of causality for', 'every event before the initial transmission of the SAE data to GSK.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information and send an SAE follow-up report with the updated causality', 'assessment.', 'The causality assessment is one of the criteria used when determining regulatory', 'reporting requirements.', 'Follow-up of AE and SAE', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as medically indicated or as requested by GSK to', 'elucidate the nature and/or causality of the AE or SAE as fully as possible. This may', 'include additional laboratory tests or investigations, histopathological examinations,', 'or consultation with other health care professionals.', 'If a participant dies during participation in the study or during a recognized follow-', 'up period, the investigator will provide GSK with a copy of any post-mortem', 'findings including histopathology.', 'New or updated information will be recorded in the originally completed CRF.', 'The investigator will submit any updated SAE data to GSK within 24 hours of', 'receipt of the information.', 'Reporting of SAE to GSK', 'SAE Reporting to GSK via Electronic Data Collection Tool', 'The primary mechanism for reporting SAE to GSK will be the electronic data', 'collection tool.', 'If the electronic system is unavailable for more than 24 hours, then the site will use', 'the paper SAE data collection tool (see next section).', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', '68']"
380,page_381,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'After the study is completed at a given site, the electronic data collection tool will be', 'taken off-line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated', 'data on a previously reported SAE after the electronic data collection tool has been', 'taken off-line, then the site can report this information on a paper SAE form (see', 'next section) or to the medical monitor/SAE coordinator by telephone.', 'Contacts for SAE reporting can be found in the SRM.', '69']"
381,page_382,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2.', 'Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', ""Note: Documentation can come from the site personnel's: review of participant's"", 'medical records, medical examination, or medical history interview.', '3.', 'Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred', 'lifestyle (abstinent on a long term and persistent basis) and agree to remain', 'abstinent', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', '70']"
382,page_383,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Female participants', 'Female participants of childbearing potential are eligible to participate if they agree to', 'use a highly effective method of contraception consistently and correctly as described in', 'Table 6.', 'Table 6', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '71']"
383,page_384,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'NOTES:', 'a.', 'Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent', 'with local regulations regarding the use of contraceptive methods for participants in clinical studies.', 'b.', 'Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of', 'the contraceptive method. In this case two highly effective methods of contraception should be utilized during the', 'treatment period and for at least 60 hours after the last dose of study treatment', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine or serum pregnancy test', 'Additional pregnancy testing will be performed at approximately monthly intervals', 'during the study treatment period, after the last dose of study treatment and as', 'required locally.', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected', 'Pregnancy testing, with a high sensitivity test will be performed using the test kit', 'provided by the central laboratory and approved by the sponsor and in accordance', 'with instructions provided in the test kit package insert.', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', ""Investigator will attempt to collect pregnancy information on any male participant's"", 'female partner of a male study participant who becomes pregnant while participating', 'in this study. This applies only to participants who receive study treatment.', 'After obtaining the necessary signed informed consent from the pregnant female', 'partner directly, the investigator will record pregnancy information on the', ""appropriate form and submit it to GSK within 24 hours of learning of the partner's"", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure.', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', ""24 hours of learning of a participant's pregnancy."", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', '72']"
384,page_385,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the investigator, will be reported to GSK', 'as described in Appendix 4. While the investigator is not obligated to actively seek', 'this information in former study participants, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female participant who becomes pregnant while participating will discontinue', 'study treatment and be withdrawn from the study.', '73']"
385,page_386,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.6.', 'Appendix 6: Genetics', 'USE/ANALYSIS OF DNA', ""Genetic variation may impact a participant's response to therapy, susceptibility,"", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a blood sample will be collected for DNA analysis.', 'DNA samples will be used for research related to danirixin or COPD and related', 'diseases. They may also be used to develop tests/assays including diagnostic tests)', 'related danirixin treatment, and COPD (and related diseases). Genetic research may', 'consist of the analysis of one or more candidate genes or the analysis of genetic', 'markers throughout the genome (as appropriate).', 'DNA samples will be analyzed if it is hypothesized that this may help further', 'understand the clinical data.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to danirixin or study treatments of this class. The results of', 'genetic analyses may be reported in the clinical study report or in a separate study', 'summary.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on danirixin (or study treatments of this', 'class) or COPD (and related diseases) continues but no longer than 15 years or other', 'period as per local requirements.', '74']"
386,page_387,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', 'Phase II liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event etiology', 'Phase II liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria', 'ALT-absolute', 'ALT 5xULN', 'ALT Increase', 'ALT: 3xULN persists for >4 weeks', 'Bilirubin 1,', '2', 'ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin)', 'INR²', 'ALT > 3xULN and INR>1.5, if INR measured', 'Cannot', 'ALT 3xULN and cannot be monitored weekly for 4 weeks', 'Monitor', 'Symptomatic3', 'ALT 3xULN associated with symptoms (new or worsening) believed', 'to be related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Obtain INR and recheck with each', 'liver chemistry assessment until the', 'Complete the liver event CRF and complete', 'transaminases values show', 'an SAE data collection tool if the event also', 'meets the criteria for an SAE²', 'downward trend', 'Obtain blood sample for', 'Perform liver chemistry event follow up', 'pharmacokinetic (PK) analysis, up', 'assessments', 'to 72 h after last dose5', 'Monitor the participant until liver', 'chemistries resolve, stabilize, or return to', 'Serum creatine phosphokinase', '(CPK) and lactate dehydrogenase', 'within baseline (see MONITORING', '(LDH).', 'below)', 'Fractionate bilirubin, if total', 'Do not restart/rechallenge participant', 'bilirubin > 2xULN', 'with study treatment unless allowed per', 'protocol and GSK Medical Governance', 'Obtain complete blood count with', 'approval is granted (see below)', 'differential to assess eosinophilia', 'If restart/rechallenge not allowed per', 'Record the appearance or', 'protocol or not granted, permanently', 'worsening of clinical symptoms of', '75']"
387,page_388,"['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'discontinue study treatment and continue', 'liver injury, or hypersensitivity, on', 'participant in the study for any protocol', 'the AE report form', 'specified follow up assessments', 'Record use of concomitant', 'medications on the concomitant', 'MONITORING:', 'medications report form including', 'acetaminophen, herbal remedies,', 'For bilirubin or INR criteria:', 'other over the counter medications.', 'Repeat liver chemistries (include ALT,', 'Record alcohol use on the liver', 'AST, alkaline phosphatase, bilirubin) and', 'event alcohol intake case report', 'perform liver event follow up assessments', 'form (CRF) page', 'within 24 hrs', 'Monitor participants twice weekly until', 'liver chemistries resolve, stabilize or return', 'to within baseline', 'For bilirubin or INR criteria:', 'A specialist or hepatology consultation is', 'Anti-nuclear antibody, anti-smooth', 'recommended', 'muscle antibody, Type 1 anti-liver', 'kidney microsomal antibodies, and', 'For All other criteria:', 'quantitative total immunoglobulin', 'Repeat liver chemistries (include ALT,', 'G (IgG) or gamma globulins.', 'AST, alkaline phosphatase, bilirubin) and', 'Serum acetaminophen adduct high', 'perform liver event follow up assessments', 'within 24-72 hrs', 'performance liquid chromatography', '(HPLC) assay (quantifies potential', 'Monitor participants weekly until liver', 'acetaminophen contribution to liver', 'chemistries resolve, stabilize or return to', 'injury in participants with definite', 'within baseline', 'or likely acetaminophen use in the', 'preceding week [James, 2009].', 'Liver imaging (ultrasound,', 'magnetic resonance, or', 'computerised tomography) and /or', 'liver biopsy to evaluate liver', 'disease complete Liver Imaging', 'and/or Liver Biopsy CRF pages.', '1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that participant if ALT 3xULN and bilirubin 2xULN..', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT > 3xULN and INR>1.5, if INR', ""measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding"", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM);', 'Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable,', 'obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody', '76']"
388,page_389,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '5. PK sample may not be required for participants known to be receiving placebo or non-GSK comparator', 'treatments.) Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the', ""participant's best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot"", 'be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and', 'shipping are in the SRM.', 'Phase II liver chemistry increased monitoring criteria with continued therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'Notify the GSK medical monitor within 24 hours of', 'ALT >3xULN and <5xULN and bilirubin', 'learning of the abnormality to discuss participant', '<2xULN, without symptoms believed to', 'safety.', 'be related to liver injury or', 'Participant can continue study treatment', 'hypersensitivity, and who can be', 'monitored weekly for 4 weeks', 'Participant must return weekly for repeat liver', 'chemistries (ALT, AST, alkaline phosphatase,', 'bilirubin) until they resolve, stabilise or return to', 'within baseline', 'If at any time participant meets the liver chemistry', 'stopping criteria, proceed as described above', 'If, after 4 weeks of monitoring, ALT <3xULN and', 'bilirubin <2xULN, monitor participants twice monthly', 'until liver chemistries normalize or return to within', 'baseline.', 'Reference', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', '77']"
389,page_390,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.8.', 'Appendix 8: Medical Device Incidents: Definition and', 'Procedures for Recording, Evaluating, Follow-up, and', 'Reporting', 'Definition and Documentation of Medical Device Incidents', 'Definitions of a Medical Device Incident', 'The detection and documentation procedures described in this protocol apply to all GSK', 'medical devices provided for use in the study (see Section 7.1.1) for the list of GSK', 'medical devices).', 'Medical Device Incident Definition', 'A medical device incident is any malfunction or deterioration in the characteristics', 'and/or performance of a device as well as any inadequacy in the labeling or the', 'instructions for use which, directly or indirectly, might lead to or might have led to', 'the death of a participant/user/other person or to a serious deterioration in his/her', 'state of health.', 'Not all incidents lead to death or serious deterioration in health. The nonoccurrence', 'of such a result might have been due to other fortunate circumstances or to the', 'intervention of health care personnel.', 'It is sufficient that:', 'An incident associated with a device happened and', 'The incident was such that, if it occurred again, might lead to death or a serious', 'deterioration in health.', 'A serious deterioration in state of health can include any of the following:', 'Life-threatening illness', 'Permanent impairment of body function or permanent damage to body structure', 'Condition necessitating medical or surgical intervention to prevent one of the', 'above', 'Fetal distress, fetal death, or any congenital abnormality or birth defects', '78']"
390,page_391,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Examples of incidents', 'A participant, user, caregiver, or healthcare professional is injured as a result of a', 'medical device failure or its misuse.', ""A participant's study treatment is interrupted or compromised by a medical device"", 'failure.', 'A misdiagnosis due to medical device failure leads to inappropriate treatment.', ""A participant's health deteriorates due to medical device failure."", 'Documenting Medical Device Incidents', 'Medical Device Incident Documenting', 'Any medical device incident occurring during the study will be documented in the', ""participant's medical records, in accordance with the investigator's normal clinical"", 'practice, and on the appropriate form.', 'For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE', 'CRF page will be completed as described in Appendix 4.', 'The form will be completed as thoroughly as possible and signed by the investigator', 'before transmittal to the GSK.', 'It is very important that the investigator provides his/her assessment of causality', '(relationship to the medical device provided by GSK) at the time of the initial report', 'and describes any corrective or remedial actions taken to prevent recurrence of the', 'incident.', 'A remedial action is any action other than routine maintenance or servicing of a', 'medical device where such action is necessary to prevent recurrence of an incident.', 'This includes any amendment to the device design to prevent recurrence.', '79']"
391,page_392,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.9.', 'Appendix 9: Neutrophil Safety and Study Treatment Restart', 'Neutrophil Stopping Criteria: Absolute neutrophil count (ANC) < 0.5 X 109 /L', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Record the appearance or', 'worsening of any clinical', 'Report the event to GSK within 24 hours', 'symptoms on the AE report form 1', 'Complete an SAE data collection tool if the', 'event also meets the criteria for an SAE', 'Obtain blood sample for', 'pharmacokinetic (PK) analysis', 'Monitor the participant until neutrophil', 'within 12 hours after last dose²', 'count stabilizes or returns to within', 'Record use of concomitant', 'baseline (see MONITORING below)', 'medications on the concomitant', 'Do not restart participant with study', 'medications report form', 'treatment unless allowed per protocol and', 'GSK Medical Governance approval is', 'granted (see RESTART below)', 'MONITORING:', 'Treatment of any suspected infections¹', 'Repeat CBC within 24 hrs', 'Monitor CBC daily until neutrophil count', 'resolves, stabilizes or returns to within', 'baseline', 'RESTART', 'Restart of study medication must be', 'Check the CBC within 24-48 hours', 'approved by the GSK Medical Monitor', 'after re-starting study medication,', 'Restart may be attempted ONLY if all', 'monitor twice weekly for two', 'three criteria are met:', 'weeks, and monthly thereafter.', 'The neutrophil count is > 1.5 X 109/L', 'If the ANC drops below 1.0 X', 'for at least 48 hours', '109/L on restart, the participant', 'At least 7 days have elapsed since the', 'should be permanently', 'suspension of study treatment', 'discontinued from study treatment', 'No sign or symptom of associated', 'and withdrawn from the study.', 'infection has been identified', '80']"
392,page_393,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '1. New or worsening symptoms believed to be related to neutropenia such as (but not limited', 'to): sudden onset of fever or malaise, stomatitis, odynophagia, periodontal infection, skin', 'abscesses, signs or symptoms of sinusitis and otitis, symptoms of pneumonia (eg, cough,', 'dyspnea), perirectal pain and irritation, hypotension or signs of septic shock.', '2. Record the date/time of the PK blood sample draw and the date/time of the last dose of study', 'treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is', ""unclear, provide the participant's best approximation. If the date/time of the last dose cannot"", 'be approximated OR a PK sample cannot be collected in the time period indicated above, do', 'not obtain a PK sample. Instructions for sample handling and shipping are in the SRM.', '81']"
393,page_394,"['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.10.', 'Appendix 10: Country-specific requirements', 'No country specific requirements', '82']"
